

(51) International Patent Classification:
C07K 14/705 (2006.01)(21) International Application Number:
PCT/US2016/051786(22) International Filing Date:
14 September 2016 (14.09.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/218,531	14 September 2015 (14.09.2015)	US
62/323,595	15 April 2016 (15.04.2016)	US
62/323,608	15 April 2016 (15.04.2016)	US
62/367,822	28 July 2016 (28.07.2016)	US
62/367,819	28 July 2016 (28.07.2016)	US

(71) Applicant: ALPINE IMMUNE SCIENCES, INC.
[US/US]; 600 Stewart Street, Suite 1503, Seattle, WA 98101 (US).

(72) Inventors: SWANSON, Ryan; 600 Stewart Street, Suite 1503, Seattle, WA 98101 (US). KORNACKER, Michael; 600 Stewart Street, Suite 1503, Seattle, WA 98101 (US).

(74) Agents: POTTER, Karen et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TUNABLE VARIANT IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND ENGINEERED CELL THERAPY




FIG. 2

(57) Abstract: Provided are transmembrane immunomodulatory proteins, nucleic acids encoding such proteins and cells engineered with the proteins. The transmembrane immunomodulatory proteins and engineered cells provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

TUNABLE VARIANT IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND ENGINEERED CELL THERAPY

Cross-Reference to Related Applications

[0001] This application claims priority from U.S. provisional application No.62/218,531 filed September 14, 2015, entitled “Tunable Variant Immunoglobulin Superfamily Domains and Engineered Cell Therapy,” U.S. provisional application No. 62/323,608 filed April 15, 2016, entitled “ICOS Ligand Variant Immunomodulatory Proteins and Uses Thereof, ” to U.S. provisional application No. 62/323,595 filed April 15, 2016, entitled “CD80 Variant Immunomodulatory Proteins and Uses Thereof, ” U.S. provisional application No. 62/367,822 filed July 28, 2016, entitled “CD155 Variant Immunomodulatory Proteins and Uses Thereof, ” and U.S. provisional application No. 62/367,819 filed July 28, 2016, entitled “CD112 Variant Immunomodulatory Proteins and Uses Thereof, ”the contents of each of which are incorporated by reference in their entirety.

Incorporation by Reference of Sequence Listing

[0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 761612000240SeqList.TXT, created September 10, 2016 which is 750,987 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety.

Field

[0003] The present invention relates to transmembrane immunomodulatory proteins (TIPs) and immune cells engineered to express such immunomodulatory proteins for modulating immune response in the treatment of cancer and immunological diseases.

Background

[0004] Modulation of the immune response by intervening in the processes that occur in the immunological synapse (IS) formed by and between antigen-presenting cells (APCs) or target cells and lymphocytes is of increasing medical interest. Currently, biologics used to enhance or suppress immune responses have generally been limited to immunoglobulins (e.g., anti-PD-1

mAbs) or soluble receptors (e.g., Fc-CTLA4). Soluble receptors suffer from a number of deficiencies. While useful for antagonizing interactions between proteins, soluble receptors often lack the ability to agonize such interactions. Antibodies have proven less limited in this regard and examples of both agonistic and antagonistic antibodies are known in the art. Nevertheless, both soluble receptors and antibodies lack important attributes that are critical to function in the IS. Mechanistically, cell surface proteins in the IS can involve the coordinated and often simultaneous interaction of multiple protein targets with a single protein to which they bind. IS interactions occur in close association with the junction of two cells, and a single protein in this structure can interact with both a protein on the same cell (cis) as well as a protein on the associated cell (trans), likely at the same time. Thus, there is a need for improved molecules for modulation of immune responses. Provided are embodiments that meet such needs.

Summary

[0005] Provided herein are transmembrane immunomodulatory proteins (TIP) containing (1) an ectodomain comprising at least one non-immunoglobulin affinity-modified immunoglobulin superfamily (IgSF) domain containing one or more amino acid substitution(s) in a wild-type IgSF domain, wherein the at least one affinity-modified IgSF domain specifically binds at least one cell surface cognate binding partner of the wild-type IgSF domain and (2) a transmembrane domain.

[0006] In some of any such embodiments, the at least one cell surface cognate binding partner is expressed on a mammalian cell. In some of any such embodiments, the mammalian cell is an antigen presenting cell (APC), a tumor cell, or a lymphocyte. In some embodiments, the lymphocyte is a T-cell. In some of any such embodiments, the mammalian cell is a mouse, rat, cynomolgus monkey, or human cell.

[0007] In some of any such embodiments, the at least one affinity modified IgSF domain has increased binding affinity to the at least one cell surface cognate binding partner compared with the reference wild-type IgSF domain. In some of any such embodiments, specific binding of the transmembrane immunomodulatory protein containing the at least one affinity-modified IgSF domain modulates immunological activity of the mammalian cell compared with the reference transmembrane domain containing the wild-type IgSF domain. In some of any such embodiments, specific binding of the transmembrane immunomodulatory protein containing the

at least one affinity-modified IgSF domain increases immunological activity of the mammalian cell compared with the reference transmembrane domain containing the wild-type IgSF domain. In some of any such embodiments, specific binding of the transmembrane immunomodulatory protein attenuates immunological activity of the mammalian cell compared with the reference transmembrane domain containing the wild-type IgSF domain.

[0008] In some of any such embodiments, the wild-type IgSF domain is from an IgSF family member of a family selected from Signal-Regulatory Protein (SIRP) Family, Triggering Receptor Expressed On Myeloid Cells Like (TREM) Family, Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM) Family, Sialic Acid Binding Ig-Like Lectin (SIGLEC) Family, Butyrophilin Family, B7 family, CD28 family, V-set and Immunoglobulin Domain Containing (VSIG) family, V-set transmembrane Domain (VSTM) family, Major Histocompatibility Complex (MHC) family, Signaling lymphocytic activation molecule (SLAM) family, Leukocyte immunoglobulin-like receptor (LIR), Nectin (Nec) family, Nectin-like (NECL) family, Poliovirus receptor related (PVR) family, Natural cytotoxicity triggering receptor (NCR) family, T cell immunoglobulin and mucin (TIM) family or Killer-cell immunoglobulin-like receptors (KIR) family. In some of any such embodiments, the wild-type IgSF domain is from an IgSF member selected from CD80, CD86, PD-L1, PD-L2, ICOS Ligand, B7-H3, B7-H4, CD28, CTLA4, PD-1, ICOS, BTLA, CD4, CD8-alpha, CD8-beta, LAG3, TIM-3, CEACAM1, TIGIT, PVR, PVRL2, CD226, CD2, CD160, CD200, CD200R or Nkp30. In some of any such embodiments, the wild-type IgSF domain is a human IgSF member.

[0009] In some of any such embodiments, the at least one affinity modified IgSF domain has at least 90% sequence identity to a wild-type IgSF domain or a specific binding fragment thereof contained in the sequence of amino acids set forth in any of SEQ ID NOS: 1-54. In some of any such embodiments, the transmembrane immunomodulatory protein has at least 90% sequence identity to the amino acid sequence selected from any of SEQ ID NOS: 393-419.

[0010] In some of any such embodiments, the at least one cell surface cognate binding partner is a stimulatory receptor expressed on a T-cell and the at least one affinity-modified IgSF domain has increased binding affinity to the stimulatory receptor compared to the affinity of the wild-type IgSF domain. In some embodiments, binding of the affinity-modified IgSF domain to the stimulatory receptor increases immunological activity of the T-cell.

[0011] In some of any such embodiments, provided is a transmembrane immunomodulatory protein (TIP) comprising: an ectodomain, wherein the ectodomain comprises at least one non-immunoglobulin affinity-modified immunoglobulin superfamily (IgSF) domain; and a transmembrane domain, wherein: the TIP is expressed on a first T-cell; the affinity-modified IgSF domain specifically binds at least one counter-structure expressed on a mammalian cell; the mammalian cell is an antigen presenting cell (APC), a tumor cell, or a second T-cell; and specific binding of the affinity-modified IgSF domain to a counter-structure modulates immunological activity of the mammalian cell. In some embodiments, the TIP comprises a first affinity-modified IgSF domain, wherein the counter-structure expressed on the mammalian cell is a stimulatory counter-structure expressed on the second T-cell; and the first affinity-modified IgSF domain specifically binds to the stimulatory counter-structure and increases immunomodulatory activity of the second T-cell.

[0012] In some cases, the stimulatory receptor is CD28, ICOS or CD226. In some of any such embodiments, the at least one affinity-modified IgSF domain is an affinity modified B7-1 IgSF domain and the stimulatory receptor is CD28. In some of any such embodiments, the at least one affinity-modified IgSF domain is an affinity modified ICOSL IgSF domain and the stimulatory receptor is ICOS. In some of any such embodiments, the affinity-modified IgSF domain is an affinity modified ICOSL IgSF domain and the stimulatory receptor is CD28. In some of any such embodiments, the at least one affinity-modified IgSF domain is an affinity-modified ICOSL IgSF domain that has increased binding affinity to at least one of: ICOS and CD28. In some of any such embodiments, the affinity modified IgSF domain is an affinity modified ICOSL IgV IgSF domain with increased binding affinity to both ICOS and CD28. In some of any such embodiments, the affinity-modified IgSF domain does not substantially specifically bind to CTLA-4 or exhibits decreased binding affinity to CTLA-4 compared to the wild-type IgSF domain.

[0013] In some of any such embodiments, the at least one affinity-modified IgSF domain specifically binds to no more than one cell surface cognate binding partner. In some of any such embodiments, the transmembrane immunomodulatory protein specifically binds to no more than one cell surface cognate binding partner. In some of any such embodiments, the at least one affinity-modified domain specifically binds to at least two cell surface cognate binding partners.

[0014] In some of any such embodiments, the first cell surface cognate binding partner is a stimulatory receptor expressed on a T cell; and the second cell surface cognate binding partner is an inhibitory ligand of an inhibitory receptor, wherein the inhibitory receptor is expressed on a T-cell.

[0015] In some of any such embodiments, binding of the affinity-modified domain to the inhibitory ligand competitively inhibits binding of the inhibitory ligand to the inhibitory receptor. In some embodiments, the inhibitory receptor is PD-1, CTLA-4, LAG-3, TIGIT, CD96, CD112R, BTLA, CD160 or TIM-3; or the ligand of the inhibitory receptor is PD-L1, PD-L2, B7-1, B7-2, HVEM, MHC class II, PVR, CEACAM-1 or GAL9. In some of any such embodiments, the affinity modified IgSF domain is an affinity modified B7-1 domain and the stimulatory receptor is CD28. In some of any such embodiments, the inhibitory ligand is PD-L1 and the inhibitory receptor is PD-1.

[0016] In some of any such embodiments, the affinity-modified IgSF domain exhibits decreased binding affinity to CTLA-4 compared to the wild-type IgSF domain for CTLA-4. In some of any such embodiments, the affinity-modified IgSF domain does not substantially specifically bind to CTLA-4. In some of any such embodiments, the affinity modified IgSF domain is an affinity modified CD155 IgSF domain or an affinity modified CD112 IgSF domain and the stimulatory receptor is CD226. In some of any such embodiments, the affinity-modified IgSF domain exhibits decreased binding affinity to TIGIT (T-cell immunoreceptor with Ig and ITIM domains) compared to the affinity of the wild-type IgSF domain.

[0017] In some of any such embodiments, the at least one affinity-modified IgSF domain specifically binds to a cell surface cognate binding partner that is a tumor specific antigen. In some embodiments, the tumor specific antigen is B7-H6.

[0018] In some of any such embodiments, the affinity-modified IgSF domain is an affinity modified Nkp30 IgSF domain. In some of any such embodiments, the at least one affinity-modified IgSF domain is a first affinity-modified IgSF domain and the ectodomain contains a second affinity-modified IgSF domain. In some embodiments, the first and second affinity-modified IgSF domain are different. In some of any such embodiments, the first affinity-modified IgSF domain and the second affinity-modified IgSF domain each contain one or more amino acid different substitutions in the same wild-type IgSF domain. In some of any such embodiments, the first affinity-modified IgSF domain and the second affinity-modified IgSF domain each contain one or more amino acid substitutions in a different wild-type IgSF domain.

[0019] In some of any such embodiments, the transmembrane immunomodulatory protein further contains an endodomain or cytoplasmic signaling domains. In some embodiments, the endodomain is the endodomain from the wild-type IgSF member containing the wild-type IgSF domain or is a functionally active portion thereof. In some embodiments, the transmembrane immunomodulatory protein is a chimeric receptor, wherein the endodomain is not the endodomain from the wild-type IgSF member containing the wild-type IgSF domain. In some of any such embodiments, the endodomain contains at least one ITAM (immunoreceptor tyrosine-based activation motif)-containing signaling domain. In some of any such embodiments, the endodomain contains a CD3-zeta signaling domain. In some of any such embodiments, the endodomain further contains at least one of: a CD28 costimulatory domain, an ICOS signaling domain, an OX40 signaling domain, and a 41BB signaling domain.

[0020] In some of any such embodiments, the wild-type IgSF domain is from an IgSF member that is an inhibitory receptor containing an ITIM signaling domain. In some embodiments, the inhibitory receptor is PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA and the at least one affinity-modified IgSF domain is an affinity-modified IgSF domain of PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA, respectively. In some of any such embodiments, the inhibitory receptor is PD-1 and the at least one affinity-modified IgSF domain is an affinity-modified IgSF of PD-1. In some of any such embodiments, the affinity-modified IgSF domain has increased binding affinity for a trans surface cognate binding partner compared to the wildtype IgSF domain, whereby the increased binding affinity competitively inhibits binding of the trans surface cognate binding partner to the inhibitory receptor.

[0021] In some of any such embodiments, the transmembrane immunomodulatory protein does not contain an endodomain, ITIM or cytoplasmic signaling domains.

[0022] In some of any such embodiments, the affinity modified IgSF domain differs by no more than ten amino acid substitutions from the wildtype IgSF domain. In some of any such embodiments, the affinity modified IgSF domain differs by no more than five amino acid substitutions from the wildtype IgSF domain.

[0023] In some of any such embodiments, the affinity-modified IgSF domain is or contains an affinity modified IgV domain, affinity modified IgC1 domain or an affinity modified IgC2 domain or is a specific binding fragment thereof containing the one or more amino acid substitutions. In some of any such embodiments, the ectodomain further contains one or more non-affinity modified IgSF domains.

[0024] In some of any such embodiments, the one or more non-affinity modified IgSF domains is from a wild-type IgSF member containing the wild-type IgSF domain. In some of any such embodiments, the transmembrane domain is the native transmembrane domain from the corresponding wild-type IgSF member. In some of any such embodiments, the transmembrane domain is not the native transmembrane domain from the corresponding wild-type IgSF member. In some embodiments, the transmembrane protein is a transmembrane protein derived from CD8.

[0025] In another aspect, the present invention relates to a recombinant nucleic acid encoding any of the transmembrane immunomodulatory proteins summarized above.

[0026] In another aspect, the present invention relates to a recombinant expression vector containing any of the nucleic acids summarized above.

[0027] In another aspect, the present invention relates to a recombinant expression vector containing a nucleic acid encoding any of the transmembrane immunomodulatory proteins summarized above.

[0028] In another aspect, the present invention relates to a recombinant host cell containing any of the expression vectors summarized above.

[0029] In another aspect, the present invention relates to a recombinant host cell containing a nucleic acid described above. In some of any such embodiments, the host cell is a mammalian host cell. In some of any such embodiments, the mammalian host cell is a human host cell.

[0030] In another aspect, the present invention relates to an engineered cell containing any of the transmembrane immunomodulatory proteins described above. In some of any such embodiments, the cell is an immune cell. In some of any such embodiments, the cell is a lymphocyte. In some embodiments, the lymphocyte is a T cell, a B cell or an NK cell. In some of any such embodiments, the cell is a T cell. In some of any such embodiments, the T cells is CD4+ or CD8+. In some of any such embodiments, the cell is an antigen presenting cell.

[0031] In some of any such embodiments, the engineered cell further contains a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR).

[0032] In another aspect, the present invention relates to a pharmaceutical composition containing any of the cells described above and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is sterile.

[0033] In some embodiments, provided herein is a method of modulating an immune response in a mammalian subject, involving administering a cell according to any one of the embodiments described above or a pharmaceutical composition according to any one of the embodiments described above to the subject. In some of any such embodiments, modulating the immune response treats a disease or disorder in the subject. In some of any such embodiments, the modulated immune response is increased. In some embodiments, the disease or disorder is a tumor. In some of any such embodiments, the disease or disorder is a cancer. In some of any such embodiments, the disease or disorder is melanoma, lung cancer, bladder cancer, or a hematological malignancy.

[0034] In some of any such embodiments, the modulated immune response is decreased. In some of any such embodiments, the disease or disorder is an inflammatory disease or condition. In some of any such embodiments, the disease or condition is Crohn's disease, ulcerative colitis, multiple sclerosis, asthma, rheumatoid arthritis, or psoriasis.

[0035] In some of any such embodiments, the subject is human. In some of any such embodiments, the cell is autologous to the subject. In some of any such embodiments, the cell is allogenic to the subject.

Brief Description of the Drawings

[0036] Fig. 1A depicts results of a competition binding assay for binding of biotinylated recombinant CD28 Fc fusion protein (rCD28.Fc) to immobilized CD80 variant A91G ECD-Fc fusion molecule in the presence of unlabeled recombinant human PD-L1-his, human CTLA-4-his or human-PD-L2-Fc fusion protein.

[0037] FIG. 1B depicts results of a competition binding assay for binding of biotinylated recombinant human PD-L1-his monomeric protein to immobilized CD80 variant A91G ECD-Fc fusion molecule in the presence of unlabeled recombinant human rCD28.Fc, human CTLA-4.Fc or human PD-L2.Fc

[0038] FIG. 2 depicts impedance results reflecting cytotoxic killing activity of cells engineered with an anti-CD19 chimeric antigen receptor (CAR) alone or with an exemplary transmembrane immunomodulatory TIP (CD80-TIP or ICOSL-TIP) or the corresponding CD80 or ICOSL wild-type transmembrane protein following co-culture with target antigen-expressing cells. Impedance was assessed using the Acea Real-Time Cell Analyzer (RTCA), which

measures the impedance variations in the culture media of a 96-well microelectronic plate (E-plate).

Detailed Description

[0039] Provided herein are transmembrane immunomodulatory proteins (TIPs) and cells, such as immune cells, engineered to express such TIPs. In some embodiments, the TIP contains an extracellular ligand binding domain that contains an affinity-modified IgSF domain and that is capable of binding to one or more protein ligands, and generally two or more protein ligands. In some embodiments, the protein ligands are cell surface proteins expressed by immune cells that engage with one or more other immune receptor, e.g. on lymphocytes, to induce inhibitory or activating signals. For example, the interaction of certain receptors on lymphocytes with their cognate cell surface ligands to form an immunological synapse (IS) between antigen-presenting cells (APCs) or target cells and lymphocytes can provide costimulatory or inhibitory signals that can regulate the immune system. In some aspects, TIP-engineered cells expressing a TIP provided herein can alter the interaction of cell surface protein ligands with their receptors to thereby modulate immune cells, such as T cell, activity. In some embodiments, the binding of the TIP to a ligand or ligands modulates, e.g. induces, enhances or suppresses, immunological immune responses of the immune cell in which it is expressed or a cell to which the TIP expressed on the cell specifically binds.

[0040] In some embodiments, under normal physiological conditions, the T cell-mediated immune response is initiated by antigen recognition by the T cell receptor (TCR) and is regulated by a balance of co-stimulatory and inhibitory signals (i.e., immune checkpoint proteins). The immune system relies on immune checkpoints to prevent autoimmunity (i.e., self-tolerance) and to protect tissues from excessive damage during an immune response, for example during an attack against a pathogenic infection. In some cases, however, these immunomodulatory proteins can be dysregulated in diseases and conditions, including tumors, as a mechanism for evading the immune system.

[0041] Thus, in some aspects, immunotherapy that alters immune cell activity, such as T cell activity, can treat certain diseases and conditions in which the immune response is dysregulated. Therapeutic approaches that seek to modulate interactions in the IS would benefit from the ability to bind multiple IS targets simultaneously and in a manner that is sensitive to temporal sequence and spatial orientation. Current therapeutic approaches fall short of this goal. Instead,

soluble receptors and antibodies typically bind no more than a single target protein at a time. This may be due to the absence of more than a single target species. Additionally, wild-type receptors and ligands possess low affinities for cognate binding partners, which preclude their use as soluble therapeutics.

[0042] Less trivially, however, soluble receptors and antibodies generally bind competitively (e.g., to no more than one target species at a time) and therefore lack the ability to simultaneously bind multiple targets. And while bispecific antibodies, as well as modalities comprising dual antigen binding regions, can bind to more than one target molecule simultaneously, the three-dimensional configuration typical of these modalities often precludes them intervening in key processes occurring in the IS in a manner consistent with their temporal and spatial requirements.

[0043] What is needed is an entirely new class of therapeutic molecules that have the specificity and affinity of antibodies or soluble receptors but, in addition, maintain the size, volume, and spatial orientation constraints required in the IS. Further, such therapeutics would have the ability to bind to their targets non-competitively as well as competitively. A molecule with these properties would therefore have novel function in the ability to integrate into multi-protein complexes at IS and generate the desired binding configuration and resulting biological activity.

[0044] To this end, emerging immuno-oncology therapeutic regimes need to safely break tumor-induced T cell tolerance. Current state-of-the-art immuno-therapeutics block PD-1 or CTLA4, central inhibitory molecules of the B7/CD28 family that are known to limit T cell effector function. While antagonistic antibodies against such single targets function to disrupt immune synapse checkpoint signaling complexes, they fall short of simultaneously activating T cells. Conversely, bispecific antibody approaches activate T cells, but fall short of simultaneously blocking inhibitory ligands that regulate the induced signal.

[0045] To address these shortcomings, provided are immunotherapies, such as cell therapies, that can modulate immune cell activities. In some embodiments, the provided immunotherapies can enhance immune cells signaling, such as T-cell activation signaling, and/or can block inhibitory regulation, which, in some cases, can occur simultaneously. In some embodiments, the provided immunotherapies relate to immunoglobulin superfamily (IgSF) components of the immune synapse that are known to have a dual role in both T-cell activation and blocking of inhibitory ligands. In some aspects, IgSF based-cell therapies engineered from immune system

ligands, such as human immune system ligands themselves are more likely to retain their ability to normally assemble into key pathways of the immune synapse and maintain normal interactions and regulatory functions in ways that antibodies or next-generation bi-specific reagents cannot. This is due to the relatively large size of antibodies as well as from the fact they are not natural components of the immune synapse. These unique features of human immune system ligands, and cells engineered to express affinity-modified variants of such ligands, promise to provide a new level of immunotherapeutic efficacy and safety. In particular aspects, the provided TIP-engineered cells provide an immunotherapy platform using affinity modified native immune ligands to generate immunotherapy biologics that bind with tunable affinities to one or more of their cognate immune receptors in the treatment of a variety of oncological and immunological indications.

[0046] All publications, including patents, patent applications scientific articles and databases, mentioned in this specification are herein incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, including patent, patent application, scientific article or database, were specifically and individually indicated to be incorporated by reference. If a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth herein prevails over the definition that is incorporated herein by reference.

[0047] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

I. DEFINITIONS

[0048] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[0049] The terms used throughout this specification are defined as follows unless otherwise limited in specific instances. As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms, acronyms, and abbreviations used

herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Unless indicated otherwise, abbreviations and symbols for chemical and biochemical names is per IUPAC-IUB nomenclature. Unless indicated otherwise, all numerical ranges are inclusive of the values defining the range as well as all integer values in-between.

[0050] The term “affinity modified” as used in the context of an immunoglobulin superfamily domain, means a mammalian immunoglobulin superfamily (IgSF) domain having an altered amino acid sequence (relative to the corresponding wild-type parental or unmodified IgSF domain) such that it has an increased or decreased binding affinity or avidity to at least one of its cognate binding partners (alternatively “counter-structures”) compared to the parental wild-type or unmodified (i.e., non-affinity modified) IgSF control domain. In some embodiments, the affinity-modified IgSF domain can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more amino acid differences, such as amino acid substitutions, in a wildtype or unmodified IgSF domain. An increase or decrease in binding affinity or avidity can be determined using well known binding assays such as flow cytometry. Larsen et al., American Journal of Transplantation, Vol 5: 443-453 (2005). See also, Linsley et al., Immunity, 1: 7930801 (1994). An increase in a protein’s binding affinity or avidity to its cognate binding partner(s) is to a value at least 10% greater than that of the wild-type IgSF domain control and in some embodiments, at least 20%, 30%, 40%, 50%, 100%, 200%, 300%, 500%, 1000%, 5000%, or 10000% greater than that of the wild-type IgSF domain control value. A decrease in a protein’s binding affinity or avidity to at least one of its cognate binding partner is to a value no greater than 90% of the control but no less than 10% of the wild-type IgSF domain control value, and in some embodiments no greater than 80%, 70%, 60%, 50%, 40%, 30%, or 20% but no less than 10% of the wild-type IgSF domain control value. An affinity-modified protein is altered in primary amino acid sequence by substitution, addition, or deletion of amino acid residues. The term “affinity modified IgSF domain” is not be construed as imposing any condition for any particular starting composition or method by which the affinity-modified IgSF domain was created. Thus, the affinity modified IgSF domains of the present invention are not limited to wild type IgSF domains that are then transformed to an affinity modified IgSF domain by any particular process of affinity modification. An affinity modified IgSF domain polypeptide can, for example, be generated starting from wild type mammalian IgSF domain sequence information, then modeled in silico

for binding to its cognate binding partner, and finally recombinantly or chemically synthesized to yield the affinity modified IgSF domain composition of matter. In but one alternative example, an affinity modified IgSF domain can be created by site-directed mutagenesis of a wild-type IgSF domain. Thus, affinity modified IgSF domain denotes a product and not necessarily a product produced by any given process. A variety of techniques including recombinant methods, chemical synthesis, or combinations thereof, may be employed.

[0051] The term “allogeneic” as used herein means a cell or tissue that is removed from one organism and then infused or adoptively transferred into a genetically dissimilar organism of the same species.

[0052] The term “autologous” as used herein means a cell or tissue that is removed from the same organism to which it is later infused or adoptively transferred. An autologous cell or tissue can be altered by, for example, recombinant DNA methodologies, such that it is no longer genetically identical to the native cell or native tissue which is removed from the organism. For example, a native autologous T-cell can be genetically engineered by recombinant DNA techniques to become an autologous engineered cell expressing a transmembrane immunomodulatory protein and/or chimeric antigen receptor (CAR), which in some cases involves engineering a T-cell or TIL (tumor infiltrating lymphocyte). The engineered cell can then be infused into a patient from which the native T-cell was isolated. In some embodiments, the organism is human or murine.

[0053] The terms “binding affinity,” and “binding avidity” as used herein means the specific binding affinity and specific binding avidity, respectively, of a protein for its cognate binding partner (i.e., its counter-structure) under specific binding conditions. In biochemical kinetics avidity refers to the accumulated strength of multiple affinities of individual non-covalent binding interactions, such as between an IgSF domain and its cognate binding partner (i.e., its counter-structure). As such, avidity is distinct from affinity, which describes the strength of a single interaction. An increase or attenuation in binding affinity of an affinity modified IgSF domain to its counter-structure is determined relative to the binding affinity of the unmodified IgSF domain (e.g., the native or wild-type IgSF domain). Methods for determining binding affinity or avidity are known in art. See, for example, Larsen et al., American Journal of Transplantation, Vol 5: 443-453 (2005).

[0054] The term “cell surface counter-structure” (alternatively “cognate cell surface binding partner”) as used herein is a counter-structure (alternatively is a cognate binding partner) expressed on a mammalian cell. Typically, the cell surface counter-structure is a transmembrane protein. In some embodiments, the cell surface counter-structure is a receptor.

[0055] The term “chimeric antigen receptor” or “CAR” as used herein refers to an artificial (i.e., man-made) transmembrane protein expressed on a mammalian cell comprising at least an ectodomain, a transmembrane, and an endodomain. Optionally, the CAR protein includes a “spacer” which covalently links the ectodomain to the transmembrane domain. A spacer is often a polypeptide linking the ectodomain to the transmembrane domain via peptide bonds. The CAR is typically expressed on a mammalian lymphocyte. In some embodiments, the CAR is expressed on a mammalian cell such as a T-cell or a tumor infiltrating lymphocyte (TIL). A CAR expressed on a T-cell is referred to herein as a CAR T-cell or “CAR-T.” In some embodiments the CAR-T is a T helper cell, a cytotoxic T-cell, a natural killer T-cell, a memory T-cell, a regulatory T-cell, or a gamma delta T-cell. When used clinically in, e.g. adoptive cell transfer, a CAR with antigen binding specificity to the patient's tumor is typically engineered to be expressed on a native lymphocyte obtained from the patient. The engineered lymphocyte expressing the CAR is then infused back into the patient. The lymphocyte is thus often an autologous T-cell although allogeneic T-cells are included within the scope of the invention. The ectodomain of a CAR comprises an antigen binding region, such as an antibody or antigen binding fragment thereof (e.g. scFv), that specifically binds under physiological conditions with an antigen, such as a tumor specific antigen. Upon specific binding a biochemical chain of events (i.e., signal transduction) results in modulation of the immunological activity of the cell on which the CAR is expressed. Thus, for example, upon specific binding by the antigen binding region of the CAR-T to its antigen can lead to changes in the immunological activity of the T-cell activity as reflected by changes in cytotoxicity, proliferation or cytokine production. Signal transduction upon CAR activation is achieved in some embodiments by the CD3-zeta chain (“CD3-z”) which is involved in signal transduction in native mammalian T-cells. CARs can further comprise multiple signaling domains such as CD28, ICOS, 41BB or OX40, to further modulate immunomodulatory response of the T-cell. CD3-z comprises a conserved motif known as an immunoreceptor tyrosine-based activation motif (ITAM) which is involved in T-cell receptor signal transduction.

[0056] The terms “cognate binding partner” or “counter-structure” in reference to a protein, such as an IgSF domain or an affinity modified IgSF domain, refers to at least one molecule (typically a native mammalian protein) to which the referenced protein specifically binds under specific binding conditions. In some aspects, an affinity modified IgSF domain specifically binds to the counter-structure of the corresponding native or wildtype IgSF domain but with increased or attenuated affinity. A species of ligand recognized and specifically binding to its cognate receptor under specific binding conditions is an example of a counter-structure or cognate binding partner of that receptor. A receptor, to which a native ligand recognizes and specifically binds to under specific binding conditions, is an example of a counter-structure of that ligand. In turn, the native ligand is the counter-structure of the receptor. For example, ICOSL specifically binds to CD28 and ICOS and thus these proteins are counter-structures of ICOSL. In another example, a tumor specific antigen and an affinity modified IgSF domain to which it specifically binds, are each counter-structures of the other. In the present invention a “cell surface molecular species” is a cognate binding partner of ligands of the immunological synapse (IS), expressed on and by cells, such as mammalian cells, forming the immunological synapse, for example immune cells.

[0057] The term “competitive binding” as used herein means that a protein is capable of specifically binding to at least two cognate binding partners but that specific binding of one cognate binding partner inhibits, such as prevents or precludes, simultaneous binding of the second cognate binding partner. Thus, in some cases, it is not possible for a protein to bind the two cognate binding partners at the same time. Generally, competitive binders contain the same or overlapping binding site for binding but this is not a requirement. In some embodiments, competitive binding causes a measurable inhibition (partial or complete) of specific binding of a protein to one of its cognate binding partner due to specific binding of a second cognate binding partner. A variety of methods are known to quantify competitive binding such as ELISA (enzyme linked immunosorbent assay) or Forte-Bio Octet experimental systems.

[0058] The term “conservative amino acid substitution” as used herein means an amino acid substitution in which an amino acid residue is substituted by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). Examples of groups of amino acids that have side chains with similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and

glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid; and 7) sulfur-containing side chains: cysteine and methionine. Conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.

[0059] The term, “corresponding to” with reference to positions of a protein, such as recitation that nucleotides or amino acid positions “correspond to” nucleotides or amino acid positions in a disclosed sequence, such as set forth in the Sequence listing, refers to nucleotides or amino acid positions identified upon alignment with the disclosed sequence based on structural sequence alignment or using a standard alignment algorithm, such as the GAP algorithm. By aligning the sequences, one skilled in the art can identify corresponding residues, for example, using conserved and identical amino acid residues as guides.

[0060] The term “cytokine” includes, e.g., but is not limited to, interleukins, interferons (IFN), chemokines, hematopoietic growth factors, tumor necrosis factors (TNF), and transforming growth factors. In general, these are small molecular weight proteins that regulate maturation, activation, proliferation, and differentiation of cells of the immune system.

[0061] The terms “derivatives” or “derivatized” refer to modification of an immunomodulatory protein by covalently linking it, directly or indirectly, so as to alter such characteristics as half-life, bioavailability, immunogenicity, solubility, toxicity, potency, or efficacy while retaining or enhancing its therapeutic benefit. Derivatives can be made by glycosylation, pegylation, lipidation, or Fc-fusion.

[0062] As used herein, “domain” (typically a sequence of three or more, generally 5 or 7 or more amino acids, such as 10 to 200 amino acid residues) refers to a portion of a molecule, such as a protein or encoding nucleic acid, that is structurally and/or functionally distinct from other portions of the molecule and is identifiable. For example, domains include those portions of a polypeptide chain that can form an independently folded structure within a protein made up of one or more structural motifs and/or that is recognized by virtue of a functional activity, such as binding activity. A protein can have one, or more than one, distinct domains. For example, a domain can be identified, defined or distinguished by homology of the primary sequence or structure to related family members, such as homology to motifs. In another example, a domain can be distinguished by its function, such as an ability to interact with a biomolecule, such as a cognate binding partner. A domain independently can exhibit a biological function or activity

such that the domain independently or fused to another molecule can perform an activity, such as, for example binding. A domain can be a linear sequence of amino acids or a non-linear sequence of amino acids. Many polypeptides contain a plurality of domains. Such domains are known, and can be identified by those of skill in the art. For exemplification herein, definitions are provided, but it is understood that it is well within the skill in the art to recognize particular domains by name. If needed appropriate software can be employed to identify domains. It is understood that reference to amino acids, including to a specific sequence set forth as a SEQ ID NO used to describe domain organization of an IgSF domain are for illustrative purposes and are not meant to limit the scope of the embodiments provided. It is understood that polypeptides and the description of domains thereof are theoretically derived based on homology analysis and alignments with similar molecules. Thus, the exact locus can vary, and is not necessarily the same for each protein. Hence, the specific IgSF domain, such as specific IgV domain or IgC domain, can be several amino acids (one, two, three or four) longer or shorter.

[0063] The term “ectodomain” as used herein refers to the region of a membrane protein, such as a transmembrane protein, that lies outside the vesicular membrane (e.g., the space outside of a cell). Ectodomains often interact with specific ligands or specific cell surface receptors, such as via a binding domain that specifically binds to the ligand or cell surface receptor. The ectodomain of a cellular transmembrane protein is alternately referred to as an extracellular domain.

[0064] The terms “effective amount” or “therapeutically effective amount” refer to a quantity and/or concentration of a therapeutic composition of the invention, such as composition containing engineered cells, that when administered ex vivo (by contact with a cell from a patient) or in vivo (by administration into a patient, such as by adoptive transfer) either alone (i.e., as a monotherapy) or in combination with additional therapeutic agents, yields a statistically significant inhibition of disease progression as, for example, by ameliorating or eliminating symptoms and/or the cause of the disease. An effective amount for treating an immune system disease or disorder may be an amount that relieves, lessens, or alleviates at least one symptom or biological response or effect associated with the disease or disorder, prevents progression of the disease or disorder, or improves physical functioning of the patient. In the case of cell therapy, the effective amount is an effective dose or number of cells administered to a patient. In some embodiments the patient is a human patient.

[0065] The term “endodomain” as used herein refers to the region found in some membrane proteins, such as transmembrane proteins, that extends into the interior space defined by the cell surface membrane. In mammalian cells, the endodomain is the cytoplasmic region of the membrane protein. In cells, the endodomain interacts with intracellular constituents and can be play a role in signal transduction and thus, in some cases, can be an intracellular signaling domain. The endodomain of a cellular transmembrane protein is alternately referred to as a cytoplasmic domain, which, in some cases, can be a cytoplasmic signaling domain.

[0066] The term “enhanced” or “increased” as used herein in the context of increasing immunological activity of a mammalian lymphocyte means to increase one or more activities of the lymphocyte. An increased activity can be one or more of an increase cell survival, cell proliferation, cytokine production, or T-cell cytotoxicity, such as by a statistically significant amount. In some embodiments, reference to increased immunological activity means to increase interferon gamma (IFN-gamma) production, such as by a statistically significant amount. Methods of assessing activities of lymphocytes are known in the art, including any assay as described herein. In some embodiments an enhancement can be an increase of at least 10%, 20%, 30%, 40%, 50%, 75%, 100%, 200%, 300%, 400%, or 500% greater than a non-zero control value.

[0067] The term “engineered cell” as used herein refers to a mammalian cell that has been genetically modified by human intervention such as by recombinant DNA methods or viral transduction. In some embodiments, the cell is an immune cells, such as a lymphocyte (e.g. T cell, B cell, NK cell) or an antigen presenting cell (e.g. dendritic cell). The cell can be a primary cell from a patient or can be a cell line. In the context of the present disclosure, an engineered cell comprises a transmembrane immunomodulatory protein (TIP) as described herein that is expressed on the cell and is engineered to modulate immunological activity of the engineered cell itself, or a mammalian cell to which an affinity modified IgSF domain of the TIP specifically binds. In some cases, the TIP is formatted as a chimeric receptor containing a heterologous cytoplasmic signaling domain or endodomain. Among provided TIP-engineered cells also are cells further containing an engineered T-cell receptor (TCR) or chimeric antigen receptor (CAR).

[0068] The term “engineered T-cell” as used herein refers to a T-cell such as a T helper cell, cytotoxic T-cell (alternatively, cytotoxic T lymphocyte or CTL), natural killer T-cell, regulatory T-cell, memory T-cell, or gamma delta T-cell, that has been genetically modified by human

intervention such as by recombinant DNA methods. An engineered T-cell comprises a transmembrane immunomodulatory protein (TIP) of the present invention that is expressed on the T-cell and is engineered to modulate immunological activity of the engineered T-cell itself, or a mammalian cell to which an affinity modified IgSF domain of the TIP expressed on the T-cell specifically binds.

[0069] The term "engineered T-cell receptor" or "engineered TCR" refers to a T-cell receptor (TCR) engineered to specifically bind with a desired affinity to a major histocompatibility complex (MHC)/peptide target antigen that is selected, cloned, and/or subsequently introduced into a population of T-cells, often used for adoptive immunotherapy. In contrast to engineered TCRs, CARs are engineered to bind target antigens in a MHC independent manner.

[0070] The term "expressed on" as used herein is used in reference to a protein expressed on the surface of a cell, such as a mammalian cell. Thus, the protein is expressed as a membrane protein. In some embodiments, the expressed protein is a transmembrane protein. In some embodiments, the protein is conjugated to a small molecule moiety such as a drug or detectable label. Proteins expressed on the surface of a cell can include cell-surface proteins such as cell surface receptors that are expressed on mammalian cells.

[0071] The term "host cell" refers to a cell that can be used to express a protein encoded by a recombinant expression vector. A host cell can be a prokaryote, for example, *E. coli*, or it can be a eukaryote, for example, a single-celled eukaryote (e.g., a yeast or other fungus), a plant cell (e.g., a tobacco or tomato plant cell), an animal cell (e.g., a human cell, a monkey cell, a hamster cell, a rat cell, a mouse cell, or an insect cell) or a hybridoma. Examples of host cells include Chinese hamster ovary (CHO) cells or their derivatives such as Veggie CHO and related cell lines which grow in serum-free media or CHO strain DX-B11, which is deficient in DHFR.

[0072] The term "immunological synapse" or "immune synapse" as used herein means the interface between a mammalian cell that expresses MHC I (major histocompatibility complex) or MHC II, such as an antigen-presenting cell or tumor cell, and a mammalian lymphocyte such as an effector T cell or Natural Killer (NK) cell.

[0073] The term "immunoglobulin" (abbreviated "Ig") as used herein is synonymous with the term "antibody" (abbreviated "Ab") and refers to a mammalian immunoglobulin protein including any of the five human classes: IgA (which includes subclasses IgA1 and IgA2), IgD, IgE, IgG (which includes subclasses IgG1, IgG2, IgG3, and IgG4), and IgM. The term is also

inclusive of immunoglobulins that are less than full-length, whether wholly or partially synthetic (e.g., recombinant or chemical synthesis) or naturally produced, such as antigen binding fragment (Fab), variable fragment (Fv) containing VH and VL, the single chain variable fragment (scFv) containing VH and VL linked together in one chain, as well as other antibody V region fragments, such as Fab', F(ab)2, F(ab')2, dsFv diabody, Fc, and Fd polypeptide fragments. Bispecific antibodies, homobispecific and heterobispecific, are included within the meaning of the term.

[0074] An Fc (fragment crystallizable) region or domain of an immunoglobulin molecule (also termed an Fc polypeptide) corresponds largely to the constant region of the immunoglobulin heavy chain, and is responsible for various functions, including the antibody's effector function(s). An immunoglobulin Fc fusion ("Fc-fusion") is a molecule comprising one or more polypeptides (or one or more small molecules) operably linked to an Fc region of an immunoglobulin. An Fc-fusion may comprise, for example, the Fc region of an antibody (which, in some cases, facilitates effector functions and pharmacokinetics) and the IgSF domain of a wild-type or affinity-modified immunoglobulin superfamily domain ("IgSF"), or other protein or fragment thereof. In some embodiments, the Fc is a variant Fc that exhibits reduced (e.g. reduced greater than 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) activity to facilitate an effector function. The IgSF domain mediates recognition of the cognate binding partner (comparable to that of antibody variable region of an antibody for an antigen). An immunoglobulin Fc region may be linked indirectly or directly to one or more polypeptides or small molecules (fusion partners). Various linkers are known in the art and can be used to link an Fc to a fusion partner to generate an Fc-fusion. An Fc-fusion protein of the invention typically comprises an immunoglobulin Fc region covalently linked, directly or indirectly, to at least one affinity modified IgSF domain. Fc-fusions of identical species can be dimerized to form Fc-fusion homodimers, or using non-identical species to form Fc-fusion heterodimers.

[0075] The term "immunoglobulin superfamily" or "IgSF" as used herein means the group of cell surface and soluble proteins that are involved in the recognition, binding, or adhesion processes of cells. Molecules are categorized as members of this superfamily based on shared structural features with immunoglobulins (i.e., antibodies); they all possess a domain known as an immunoglobulin domain or fold. Members of the IgSF include cell surface antigen receptors, co-receptors and co-stimulatory molecules of the immune system, molecules involved in antigen presentation to lymphocytes, cell adhesion molecules, certain cytokine receptors and

intracellular muscle proteins. They are commonly associated with roles in the immune system. Proteins in the immunological synapse are often members of the IgSF. IgSF can also be classified into “subfamilies” based on shared properties such as function. Such subfamilies typically consist of from 4 to 30 IgSF members.

[0076] The terms “IgSF domain” or “immunoglobulin domain” or “Ig domain” as used herein refers a structural domain of IgSF proteins. Ig domains are named after the immunoglobulin molecules. They contain about 70-110 amino acids and are categorized according to their size and function. Ig-domains possess a characteristic Ig-fold, which has a sandwich-like structure formed by two sheets of antiparallel beta strands. Interactions between hydrophobic amino acids on the inner side of the sandwich and highly conserved disulfide bonds formed between cysteine residues in the B and F strands, stabilize the Ig-fold. One end of the Ig domain has a section called the complementarity determining region that is important for the specificity of antibodies for their ligands. The Ig like domains can be classified (into classes) as: IgV, IgC1, IgC2, or IgI. Most Ig domains are either variable (IgV) or constant (IgC). IgV domains with 9 beta strands are generally longer than IgC domains with 7 beta strands. Ig domains of some members of the IgSF resemble IgV domains in the amino acid sequence, yet are similar in size to IgC domains. These are called IgC2 domains, while standard IgC domains are called IgC1 domains. T-cell receptor (TCR) chains contain two Ig domains in the extracellular portion; one IgV domain at the N-terminus and one IgC1 domain adjacent to the cell membrane.

[0077] The term “IgSF species” as used herein means an ensemble of IgSF member proteins with identical or substantially identical primary amino acid sequence. Each mammalian immunoglobulin superfamily (IgSF) member defines a unique identity of all IgSF species that belong to that IgSF member. Thus, each IgSF family member is unique from other IgSF family members and, accordingly, each species of a particular IgSF family member is unique from the species of another IgSF family member. Nevertheless, variation between molecules that are of the same IgSF species may occur owing to differences in post-translational modification such as glycosylation, phosphorylation, ubiquitination, nitrosylation, methylation, acetylation, and lipidation. Additionally, minor sequence differences within a single IgSF species owing to gene polymorphisms constitute another form of variation within a single IgSF species as do wild type truncated forms of IgSF species owing to, for example, proteolytic cleavage. A “cell surface IgSF species” is an IgSF species expressed on the surface of a cell, generally a mammalian cell.

[0078] The term “immunological activity” as used herein in the context of mammalian lymphocytes refers to one or more cell survival, cell proliferation, cytokine production (e.g. interferon-gamma), or T-cell cytotoxicity activities. Methods to assay the immunological activity of engineered cells, including to evaluate the activity of a transmembrane immunomodulatory protein, are known in the art and include, but are not limited to, the ability to expand T cells following antigen stimulation, sustain T cell expansion in the absence of re-stimulation, and anti-cancer activities in appropriate animal models. Assays also include assays to assess cytotoxicity, including a standard ⁵¹Cr-release assay (see e.g. Milone et al., (2009) *Molecular Therapy* 17: 1453-1464) or flow based cytotoxicity assays, or an impedance based cytotoxicity assay (Peper et al. (2014) *Journal of Immunological Methods*, 405:192-198). Assays to assess immunological activity of engineered cells can be compared to control non-engineered cells or to cells containing one or more other engineered recombinant receptor (e.g. antigen receptor) with a known activity.

[0079] An “immunomodulatory protein” is a protein that modulates immunological activity. By “modulation” or “modulating” an immune response is meant that immunological activity is either enhanced or suppressed. An immunomodulatory protein can be a single polypeptide chain or a multimer (dimers or higher order multimers) of at least two polypeptide chains covalently bonded to each other by, for example, interchain disulfide bonds. Thus, monomeric, dimeric, and higher order multimeric proteins are within the scope of the defined term. Multimeric proteins can be homomultimeric (of identical polypeptide chains) or heteromultimeric (of different polypeptide chains). Transmembrane immunomodulatory proteins are a type of immunomodulatory protein.

[0080] The term “increase” as used herein means to increase by a statistically significant amount. An increase can be at least 5%, 10%, 20%, 30%, 40%, 50%, 75%, 100%, or greater than a non-zero control value.

[0081] The term “lymphocyte” as used herein means any of three subtypes of white blood cell in a mammalian immune system. They include natural killer cells (NK cells) (which function in cell-mediated, cytotoxic innate immunity), T cells (for cell-mediated, cytotoxic adaptive immunity), and B cells (for humoral, antibody-driven adaptive immunity). T cells include T helper cells, cytotoxic T-cells, natural killer T-cells, memory T-cells, regulatory T-cells, or gamma delta T-cells. Innate lymphoid cells (ILC) are also included within the definition of lymphocyte.

[0082] An “inhibitory counter-structure” is a cell membrane protein, often a receptor, which when proximally bound near a separate activating receptor leads to an attenuation in the frequency, duration, magnitude, or intensity of the activating signaling cascade and phenotype mediated by the activating receptor. Examples of inhibitory receptors include PD-1, CTLA-4, LAG-3, TIGIT, CD96, CD112R, BTLA, CD160 and TIM-3. The term “stimulatory counter-structure” is a cell membrane protein, often a receptor, which when activated and signal transduction is thereby induced, leads to an increase in the frequency, duration, or intensity of the phenotype mediated by that receptor. Examples of stimulatory receptors include CD28, ICOS, and CD226.

[0083] The term “lymphocyte” as used herein means any of three subtypes of white blood cell in a mammalian immune system. They include natural killer cells (NK cells) (which function in cell-mediated, cytotoxic innate immunity), T cells (for cell-mediated, cytotoxic adaptive immunity), and B cells (for humoral, antibody-driven adaptive immunity). T cells include: T helper cells, cytotoxic T-cells, natural killer T-cells, memory T-cells, regulatory T-cells, or gamma delta T-cells. Innate lymphoid cells (ILC) are also included within the definition of lymphocyte.

[0084] The terms “mammal,” “subject,” or “patient” specifically includes reference to at least one of a: human, chimpanzee, rhesus monkey, cynomolgus monkey, dog, cat, mouse, or rat.

[0085] The term “membrane protein” as used herein means a protein that, under physiological conditions, is attached directly or indirectly to a lipid bilayer. A lipid bilayer that forms a membrane can be a biological membrane such as a eukaryotic (e.g., mammalian) cell membrane or an artificial (i.e., man-made) membrane such as that found on a liposome. Attachment of a membrane protein to the lipid bilayer can be by way of covalent attachment, or by way of non-covalent interactions such as hydrophobic or electrostatic interactions. A membrane protein can be an integral membrane protein or a peripheral membrane protein. Membrane proteins that are peripheral membrane proteins are non-covalently attached to the lipid bilayer or non-covalently attached to an integral membrane protein. A peripheral membrane protein forms a temporary attachment to the lipid bilayer such that under the range of conditions that are physiological in a mammal, peripheral membrane protein can associate and/or disassociate from the lipid bilayer. In contrast to peripheral membrane proteins, integral membrane proteins form a substantially permanent attachment to the membrane's lipid bilayer

such that under the range of conditions that are physiological in a mammal, integral membrane proteins do not disassociate from their attachment to the lipid bilayer. A membrane protein can form an attachment to the membrane by way of one layer of the lipid bilayer (monotopic), or attached by way of both layers of the membrane (polytopic). An integral membrane protein that interacts with only one lipid bilayer is an “integral monotopic protein”. An integral membrane protein that interacts with both lipid bilayers is an “integral polytopic protein” alternatively referred to herein as a “transmembrane protein”.

[0086] The terms “modulating” or “modulate” as used herein in the context of an immune response, such as a mammalian immune response, refer to any alteration, such as an increase or decrease, of an existing or potential immune responses that occurs as a result of administration of an immunomodulatory protein or as a result of administration of engineered cells expressing an immunomodulatory protein, such as a transmembrane immunomodulatory protein of the present invention. Such modulation includes any induction, or alteration in degree or extent, or suppression of immunological activity of an immune cell. Immune cells include B cells, T cells, NK (natural killer) cells, NK T cells, professional antigen-presenting cells (APCs), and non-professional antigen-presenting cells, and inflammatory cells (neutrophils, macrophages, monocytes, eosinophils, and basophils). Modulation includes any change imparted on an existing immune response, a developing immune response, a potential immune response, or the capacity to induce, regulate, influence, or respond to an immune response. Modulation includes any alteration in the expression and/or function of genes, proteins and/or other molecules in immune cells as part of an immune response. Modulation of an immune response or modulation of immunological activity includes, for example, the following: elimination, deletion, or sequestration of immune cells; proliferation, induction, survival or generation of immune cells that can modulate the functional capacity of other cells such as autoreactive lymphocytes, antigen presenting cells, or inflammatory cells; induction of an unresponsive state in immune cells (i.e., anergy); enhancing or suppressing the activity or function of immune cells, including but not limited to altering the pattern of proteins expressed by these cells. Examples include altered production and/or secretion of certain classes of molecules such as cytokines, chemokines, perforins, granzymes, growth factors, transcription factors, kinases, costimulatory molecules, or other cell surface receptors or any combination of these modulatory events. Modulation can be assessed, for example, by an alteration of an immunological activity of engineered cells, such as an alteration in cytotoxic activity of engineered cells or an alteration

in cytokine secretion of engineered cells relative to cells engineered with the wild-type IgSF protein.

[0087] The term “molecular species” as used herein means an ensemble of proteins with identical or substantially identical primary amino acid sequence. Each mammalian immunoglobulin superfamily (IgSF) member defines a collection of identical or substantially identical molecular species. Thus, for example, human CD80 is an IgSF member and each human CD80 molecule is a species of CD80. Variation between molecules that are of the same molecular species may occur owing to differences in post-translational modification such as glycosylation, phosphorylation, ubiquitination, nitrosylation, methylation, acetylation, and lipidation. Additionally, minor sequence differences within a single molecular species owing to gene polymorphisms constitute another form of variation within a single molecular species as do wild type truncated forms of a single molecular species owing to, for example, proteolytic cleavage. A “cell surface molecular species” is a molecular species expressed on the surface of a mammalian cell. Two or more different species of protein, each of which is present exclusively on one or exclusively the other (but not both) of the two mammalian cells forming the IS, are said to be in “cis” or “cis configuration” with each other. Two different species of protein, the first of which is exclusively present on one of the two mammalian cells forming the IS and the second of which is present exclusively on the second of the two mammalian cells forming the IS, are said to be in “trans” or “trans configuration.” Two different species of protein each of which is present on both of the two mammalian cells forming the IS are in both cis and trans configurations on these cells.

[0088] The term “non-competitive binding” as used herein means the ability of a protein to specifically bind simultaneously to at least two cognate binding partners. In some embodiments, the binding occurs under specific binding conditions. Thus, the protein is able to bind to at least two different cognate binding partners at the same time although the binding interaction need not be for the same duration such that, in some cases, the protein is specifically bound to only one of the cognate binding partners. In some embodiments, the simultaneous binding is such that binding of one cognate binding partner does not substantially inhibit simultaneous binding to a second cognate binding partner. In some embodiments, non-competitive binding means that binding a second cognate binding partner to its binding site on the protein does not displace the binding of a first cognate binding partner to its binding site on the protein. Methods of assessing non-competitive binding are well known in the art such as the method described in Perez de La

Lastra et al., Immunology, 1999 Apr; 96(4): 663–670. In some cases, in non-competitive interactions, the first cognate binding partner specifically binds at an interaction site that does not overlap with the interaction site of the second cognate binding partner such that binding of the second cognate binding partner does not directly interfere with the binding of the first cognate binding partner. Thus, any effect on binding of the cognate binding partner by the binding of the second cognate binding partner is through a mechanism other than direct interference with the binding of the first cognate binding partner. For example, in the context of enzyme-substrate interactions, a non-competitive inhibitor binds to a site other than the active site of the enzyme. Non-competitive binding encompasses uncompetitive binding interactions in which a second cognate binding partner specifically binds at an interaction site that does not overlap with the binding of the first cognate binding partner but binds to the second interaction site only when the first interaction site is occupied by the first cognate binding partner.

[0089] The terms “nucleic acid” and “polynucleotide” are used interchangeably to refer to a polymer of nucleic acid residues (e.g., deoxyribonucleotides or ribonucleotides) in either single- or double-stranded form. Unless specifically limited, the terms encompass nucleic acids containing known analogues of natural nucleotides and that have similar binding properties to it and are metabolized in a manner similar to naturally-occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary nucleotide sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues. The term nucleic acid or polynucleotide encompasses cDNA or mRNA encoded by a gene.

[0090] The term “pharmaceutical composition” refers to a composition suitable for pharmaceutical use in a mammalian subject, often a human. A pharmaceutical composition typically comprises an effective amount of an active agent (e.g., an immunomodulatory protein or engineered cells expressing a transmembrane immunomodulatory protein of the present invention) and a carrier, excipient, or diluent. The carrier, excipient, or diluent is typically a pharmaceutically acceptable carrier, excipient or diluent, respectively.

[0091] The terms “polypeptide” and “protein” are used interchangeably herein and refer to a molecular chain of two or more amino acids linked through peptide bonds. The terms do not refer to a specific length of the product. Thus, “peptides,” and “oligopeptides,” are included

within the definition of polypeptide. The terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. The terms also include molecules in which one or more amino acid analogs or non-canonical or unnatural amino acids are included as can be synthesized, or expressed recombinantly using known protein engineering techniques. In addition, proteins can be derivatized as described herein by well-known organic chemistry techniques.

[0092] The term “primary T-cell assay” as used herein refers to an in vitro assay to measure interferon-gamma (“IFN-gamma”) expression. A variety of such primary T-cell assays are known in the art such as that described in Example 6. In a preferred embodiment, the assay used is anti-CD3 coimmobilization assay. In this assay, primary T cells are stimulated by anti-CD3 immobilized with or without additional recombinant proteins. Culture supernatants are harvested at timepoints, usually 24-72 hours. In another embodiment, the assay used is a mixed lymphocyte reaction (MLR). In this assay, primary T cells are simulated with allogenic APC. Culture supernatants are harvested at timepoints, usually 24-72 hours. Human IFN-gamma levels are measured in culture supernatants by standard ELISA techniques. Commercial kits are available from vendors and the assay is performed according to manufacturer’s recommendation.

[0093] The term “purified” as applied to nucleic acids, such as encoding atransmembrane immunomodulatory proteins, or proteins (e.g. immunomodulatory proteins) generally denotes a nucleic acid or polypeptide that is substantially free from other components as determined by analytical techniques well known in the art (e.g., a purified polypeptide or polynucleotide forms a discrete band in an electrophoretic gel, chromatographic eluate, and/or a media subjected to density gradient centrifugation). For example, a nucleic acid or polypeptide that gives rise to essentially one band in an electrophoretic gel is “purified.” A purified nucleic acid, or protein is at least about 50% pure, usually at least about 75%, 80%, 85%, 90%, 95%, 96%, 99% or more pure (e.g., percent by weight or on a molar basis).

[0094] The term “recombinant” indicates that the material (e.g., a nucleic acid or a polypeptide) has been artificially (i.e., non-naturally) altered by human intervention. The alteration can be performed on the material within, or removed from, its natural environment or state. For example, a “recombinant nucleic acid” is one that is made by recombining nucleic acids, e.g., during cloning, affinity modification, DNA shuffling or other well-known molecular biological procedures. A “recombinant DNA molecule,” is comprised of segments of DNA

joined together by means of such molecular biological techniques. The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule (e.g., an immunomodulatory protein) which is expressed using a recombinant DNA molecule. A “recombinant host cell” is a cell that contains and/or expresses a recombinant nucleic acid or that is otherwise altered by genetic engineering, such as by introducing into the cell a nucleic acid molecule encoding a recombinant protein, such as a transmembrane immunomodulatory protein provided herein. Transcriptional control signals in eukaryotes comprise “promoter” and “enhancer” elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription. Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. The terms “in operable combination,” “in operable order” and “operably linked” as used herein refer to the linkage of nucleic acid sequences in such a manner or orientation that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced and/or transported.

[0095] The term “recombinant expression vector” as used herein refers to a DNA molecule containing a desired coding sequence (e.g., an immunomodulatory nucleic acid, a transmembrane immunomodulatory nucleic acid) and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular cell. Nucleic acid sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals. A secretory signal peptide sequence can also, optionally, be encoded by the recombinant expression vector, operably linked to the coding sequence so that the expressed protein can be secreted by the recombinant host cell, for more facile isolation of the fusion protein from the cell, if desired. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Among the vectors are viral vectors, such as lentiviral vectors.

[0096] The term “sequence identity” as used herein refers to the sequence identity between genes or proteins at the nucleotide or amino acid level, respectively. “Sequence identity” is a measure of identity between proteins at the amino acid level and a measure of identity between nucleic acids at nucleotide level. The protein sequence identity may be determined by comparing the amino acid sequence in a given position in each sequence when the sequences are aligned. Similarly, the nucleic acid sequence identity may be determined by comparing the nucleotide sequence in a given position in each sequence when the sequences are aligned. Methods for the alignment of sequences for comparison are well known in the art, such methods include GAP, BESTFIT, BLAST, FASTA and TFASTA. The BLAST algorithm calculates percent sequence identity and performs a statistical analysis of the similarity between the two sequences. The software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information (NCBI) website.

[0097] The term “soluble” as used herein in reference to proteins, means that the protein is not a membrane protein. In general, a soluble protein contains only the extracellular domain of an IgSF family member receptor, or a portion thereof containing an IgSF domain or domains or specific-binding fragments thereof.

[0098] The term “species” as used herein in the context of a nucleic acid sequence or a polypeptide sequence refers to an identical collection of such sequences. Slightly truncated sequences that differ (or encode a difference) from the full length species at the amino-terminus or carboxy-terminus by no more than 1, 2, or 3 amino acid residues are considered to be of a single species. Such microheterogeneities are a common feature of manufactured proteins.

[0099] The term “specifically binds” as used herein means the ability of a protein, under specific binding conditions, to bind to a target protein such that its affinity or avidity is at least 10 times as great, but optionally 50, 100, 250 or 500 times as great, or even at least 1000 times as great as the average affinity or avidity of the same protein to a collection of random peptides or polypeptides of sufficient statistical size. A specifically binding protein need not bind exclusively to a single target molecule (e.g., its cognate binding partner) but may specifically bind to a non-target molecule due to similarity in structural conformation between the target and non-target (e.g., paralogs or orthologs). Those of skill will recognize that specific binding to a molecule having the same function in a different species of animal (i.e., ortholog) or to a non-target molecule having a substantially similar epitope as the target molecule (e.g., paralog) is possible and does not detract from the specificity of binding which is determined relative to a

statistically valid collection of unique non-targets (e.g., random polypeptides). Thus, an affinity-modified polypeptide of the invention may specifically bind to more than one distinct species of target molecule due to cross-reactivity. Generally, such off-target specific binding is mitigated by reducing affinity or avidity for undesired targets. Solid-phase ELISA immunoassays or Biacore measurements can be used to determine specific binding between two proteins. Generally, interactions between two binding proteins have dissociation constants (K_d) less than 1×10^{-5} M, and often as low as 1×10^{-12} M. In certain aspects of the present disclosure, interactions between two binding proteins have dissociation constants of 1×10^{-6} M, 1×10^{-7} M, 1×10^{-8} M, 1×10^{-9} M, 1×10^{-10} M or 1×10^{-11} M.

[0100] The term “specific binding fragment” or “fragment” as used herein in reference to a mature (i.e., absent the signal peptide) wild-type IgSF domain, means a polypeptide that is shorter than the full-length mature IgSF domain and that specifically binds in vitro and/or in vivo to the wild-type IgSF domain’s native cognate binding partner. In some embodiments, the specific binding fragment is at least 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% the sequence length of the full-length mature wild-type sequence. The specific binding fragment can be altered in sequence to form an affinity modified IgSF domain of the invention. In some embodiments, the specific binding fragment modulates immunological activity of a lymphocyte. The term “suppress” or “attenuate” or “decrease” as used herein means to decrease by a statistically significant amount. In some embodiments suppression can be a decrease of at least 10%, and up to 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%.

[0101] The terms “surface expresses” or “surface expression” in reference to a mammalian cell expressing a polypeptide means that the polypeptide is expressed as a membrane protein. In some embodiments, the membrane protein is a transmembrane protein.

[0102] As used herein, “synthetic,” with reference to, for example, a synthetic nucleic acid molecule or a synthetic gene or a synthetic peptide refers to a nucleic acid molecule or polypeptide molecule that is produced by recombinant methods and/or by chemical synthesis methods.

[0103] The term “transmembrane protein” as used herein means a membrane protein that substantially or completely spans a lipid bilayer such as those lipid bilayers found in a biological membrane such as a mammalian cell, or in an artificial construct such as a liposome. The transmembrane protein comprises a transmembrane domain (“transmembrane domain”) by

which it is integrated into the lipid bilayer and by which the integration is thermodynamically stable under physiological conditions. Transmembrane domains are generally predictable from their amino acid sequence via any number of commercially available bioinformatics software applications on the basis of their elevated hydrophobicity relative to regions of the protein that interact with aqueous environments (e.g., cytosol, extracellular fluid). A transmembrane domain is often a hydrophobic alpha helix that spans the membrane. A transmembrane protein can pass through the both layers of the lipid bilayer once or multiple times. A transmembrane protein includes the provided transmembrane immunomodulatory proteins described herein. In addition to the transmembrane domain, a transmembrane immunomodulatory protein of the invention further comprises an ectodomain and, in some embodiments, an endodomain.

[0104] The terms “treating,” “treatment,” or “therapy” of a disease or disorder as used herein mean slowing, stopping or reversing the disease or disorders progression, as evidenced by decreasing, cessation or elimination of either clinical or diagnostic symptoms, by administration of an immunomodulatory protein or engineered cells expressing a transmembrane immunomodulatory protein of the present invention either alone or in combination with another compound as described herein. “Treating,” “treatment,” or “therapy” also means a decrease in the severity of symptoms in an acute or chronic disease or disorder or a decrease in the relapse rate as for example in the case of a relapsing or remitting autoimmune disease course or a decrease in inflammation in the case of an inflammatory aspect of an autoimmune disease. As used herein in the context of cancer, the terms “treatment” or, “inhibit,” “inhibiting” or “inhibition” of cancer refers to at least one of: a statistically significant decrease in the rate of tumor growth, a cessation of tumor growth, or a reduction in the size, mass, metabolic activity, or volume of the tumor, as measured by standard criteria such as, but not limited to, the Response Evaluation Criteria for Solid Tumors (RECIST), or a statistically significant increase in progression free survival (PFS) or overall survival (OS). “Preventing,” “prophylaxis,” or “prevention” of a disease or disorder as used in the context of this invention refers to the administration of an immunomodulatory protein or engineered cells expressing a transmembrane immunomodulatory protein of the present invention, either alone or in combination with another compound, to prevent the occurrence or onset of a disease or disorder or some or all of the symptoms of a disease or disorder or to lessen the likelihood of the onset of a disease or disorder.

[0105] The term “tumor specific antigen” or “TSA” as used herein refers to a an antigen that is present primarily on tumor cells of a mammalian subject but generally not found on normal cells of the mammalian subject. In some cases, a tumor specific antigen is a counter structure or cognate binding partner of an IgSF member. A tumor specific antigen need not be exclusive to tumor cells but the percentage of cells of a particular mammal that have the tumor specific antigen is sufficiently high or the levels of the tumor specific antigen on the surface of the tumor are sufficiently high such that it can be targeted by anti-tumor therapeutics and provide prevention or treatment of the mammal from the effects of the tumor. In some embodiments, in a random statistical sample of cells from a mammal with a tumor, at least 50% of the cells displaying a TSA are cancerous. In other embodiments, at least 60%, 70%, 80%, 85%, 90%, 95%, or 99% of the cells displaying a TSA are cancerous.

[0106] The term “wild-type” or “natural” or “native” as used herein is used in connection with biological materials such as nucleic acid molecules, proteins, IgSF members, host cells, and the like, refers to those which are found in nature and not modified by human intervention.

II. TRANSEMEMBRANE IMMUNOMODULATORY PROTEINS AND ENGINEERED CELLS

[0107] Provided herein are immunomodulatory proteins that are transmembrane proteins (“transmembrane immunomodulatory proteins”). Transmembrane immunomodulatory proteins, and engineered cells expressing such transmembrane immunomodulatory proteins, generally have therapeutic utility by modulating immunological activity in a mammal with a disease or disorder in which modulation of the immune system response is beneficial. A transmembrane immunomodulatory protein of the present invention comprises an ectodomain, a transmembrane, and in some embodiments, an endodomain, such as a cytoplasmic signaling domain.

A. Ectodomain

[0108] In some embodiments, the provided transmembrane immunomodulatory proteins include an ectodomain comprising at least one affinity modified IgSF domain compared to an IgSF domain of a wild-type mammalian IgSF member. The wild-type mammalian IgSF member excludes antibodies (i.e., immunoglobulins) such as those that are mammalian or may be of mammalian origin. Thus, the present invention relates to ectodomains that are non-immunoglobulin (i.e., non-antibody) IgSF domains. Wild-type mammalian IgSF family members that are not immunoglobulins (i.e. antibodies) are known in the art as are their nucleic

and amino acid sequences. Affinity-modified IgSF domains of a wild-type IgSF domain of all non-immunoglobulin mammalian IgSF family members are included as an ectodomain within the scope of the invention.

[0109] In some embodiments, transmembrane immunomodulatory proteins of the present invention in their various embodiments comprise at least one affinity modified mammalian IgSF domain, such as at least one affinity modified non-immunoglobulin mammalian IgSF domain. In some embodiments, the non-immunoglobulin IgSF family members, and the corresponding IgSF domains present therein, are of mouse, rat, cynomolgus monkey, or human origin. In some embodiments, the IgSF family members are members from at least or exactly one, two, three, four, five, or more IgSF subfamilies such as: Signal-Regulatory Protein (SIRP) Family, Triggering Receptor Expressed On Myeloid Cells Like (TREM) Family, Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM) Family, Sialic Acid Binding Ig-Like Lectin (SIGLEC) Family, Butyrophilin Family, B7 family, CD28 family, V-set and Immunoglobulin Domain Containing (VSIG) family, V-set transmembrane Domain (VSTM) family, Major Histocompatibility Complex (MHC) family, Signaling lymphocytic activation molecule (SLAM) family, Leukocyte immunoglobulin-like receptor (LIR), Nectin (Nec) family, Nectin-like (NECL) family, Poliovirus receptor related (PVR) family, Natural cytotoxicity triggering receptor (NCR) family, or Killer-cell immunoglobulin-like receptors (KIR) family. In some embodiments, the at least one IgSF domain is derived from an IgSF protein that is any of CD80(B7-1), CD86(B7-2), CD274 (PD-L1, B7-H1), PDCD1LG2(PD-L2, CD273), ICOSLG(B7RP1, CD275, ICOSL, B7-H2), CD276(B7-H3), VTCN1(B7-H4), CD28, CTLA4, PDCD1(PD-1), ICOS, BTLA(CD272), CD4, CD8A(CD8-alpha), CD8B(CD8-beta), LAG3, HAVCR2(TIM-3), CEACAM1, TIGIT, PVR(CD155), PVRL2(CD112), CD226, CD2, CD160, CD200, CD200R1(CD200R), and NC R3 (NKp30).

[0110] In some embodiments, the ectodomain of the transmembrane immunomodulatory protein contains at least one affinity modified IgSF domain. In some embodiments, the at least one affinity-modified IgSF domain is affinity modified compared to a corresponding IgSF domain of a non-immunoglobulin IgSF family member that is a mammalian IgSF member. In some embodiments, the mammalian IgSF member is one of the IgSF members or comprises an IgSF domain from one of the IgSF members as indicated in Table 1 including any mammalian orthologs thereof. Orthologs are genes in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same function in the course of

evolution. In some embodiments, the affinity modified IgSF domain is an affinity modified IgV or IgC domain, including IgC1 or IgC2 domain.

[0111] In some embodiments, the ectodomain of the transmembrane immunomodulatory protein of the present invention comprises the sequence of the extracellular domain of a wild-type mammalian non-immunoglobulin (i.e., non-antibody) IgSF family member but wherein at least one IgSF domain therein is affinity modified ("Type I" transmembrane immunomodulatory proteins). Additional domains present within the IgSF family can be affinity modified, such as at least two, three, four, or five IgSF domains and, in some embodiments, exactly two, three, four, or five IgSF domains. In some embodiments of a Type I transmembrane immunomodulatory protein of the invention, the mammalian IgSF member will be one of the IgSF members as indicated in Table 1 including any mammalian orthologs thereof

[0112] The first column of Table 1 provides the name and, optionally, the name of some possible synonyms for that particular IgSF member. The second column provides the protein identifier of the UniProtKB database, a publicly available database accessible via the internet at uniprot.org. The Universal Protein Resource (UniProt) is a comprehensive resource for protein sequence and annotation data. The UniProt databases include the UniProt Knowledgebase (UniProtKB). UniProt is a collaboration between the European Bioinformatics Institute (EMBL-EBI), the SIB Swiss Institute of Bioinformatics and the Protein Information Resource (PIR) and supported mainly by a grant from the U.S. National Institutes of Health (NIH). The third column provides the region where the indicated IgSF domain is located. The region is specified as a range where the domain is inclusive of the residues defining the range. Column 3 also indicates the IgSF domain class for the specified IgSF region. Column 4 provides the region where the indicated additional domains are located (signal peptide, S; extracellular domain, E; transmembrane domain, T; cytoplasmic domain, C). Column 5 indicates for some of the listed IgSF members, some of its cognate cell surface binding partners.

[0113] Typically, the affinity modified IgSF domain of the ectodomain of a transmembrane immunomodulatory protein of the provided embodiments is a human or murine affinity modified IgSF domain.

TABLE 1. IgSF members according to the present disclosure.

IgSF Member (Synonyms)	UniProtKB Protein Identifier	IgSF Region & Domain Class	Other Domains	Cognate Cell Surface Binding Partners	IgSF Member Amino Acid Sequence (SEQ ID NO)		
					Precursor (mature residues)	Mature	ECD
CD80 (B7-1)	NP_005182.1 P33681	35-138 or 37-138 IgV, 145-230 or 154-232 IgC	S: 1-34, E: 35-242, T: 243-263, C: 264-288	CD28, CTLA4, PD-L1	SEQ ID NO: 1 (35-288)	SEQ ID NO: 393	SEQ ID NO: 28
CD86 (B7-2)	P42081.2	33-131 IgV, 150-225 IgC2	S: 1-23, E: 24-247, T: 248-268, C: 269-329	CD28, CTLA4	SEQ ID NO: 2 (24-329)	SEQ ID NO: 394	SEQ ID NO: 29
CD274 (PD-L1, B7-H1)	Q9NZQ7.1	24-130 IgV, 133-225 IgC2	S: 1-18, E: 19-238, T: 239-259, C: 260-290	PD-1, B7-1	SEQ ID NO: 3 (19-290)	SEQ ID NO: 395	SEQ ID NO: 30
PDCD1LG2 (PD-L2, CD273)	Q9BQ51.2	21-118 IgV, 122-203 IgC2	S: 1-19, E: 20-220, T: 221-241, C: 242-273	PD-1, RGMb	SEQ ID NO: 4 (20-273)	SEQ ID NO: 396	SEQ ID NO: 31
ICOSLG (B7RP1, CD275, ICOSL, B7-H2)	O75144.2	19-129 IgV, 141-227 IgC2	S: 1-18, E: 19-256, T: 257-277, C: 278-302	ICOS, CD28, CTLA4	SEQ ID NO: 5 (19-302)	SEQ ID NO: 397	SEQ ID NO: 32
CD276 (B7-H3)	Q5ZPR3.1	29-139 IgV, 145-238 IgC2, 243-357 IgV, 367-453 IgC	S: 1-28, E: 29-466, T: 467-487, C: 488-534		SEQ ID NO: 6 (29-534)	SEQ ID NO: 398	SEQ ID NO: 33
VTCN1 (B7-H4)	Q7Z7D3.1	35-146 IgV, 153-241 IgV	S: 1-24, E: 25-259, T: 260-280, C: 281-282		SEQ ID NO: 7 (25-282)	SEQ ID NO: 399	SEQ ID NO: 34
CD28	P10747.1	28-137 IgV	S: 1-18, E: 19-152, T: 153-179, C: 180-220	B7-1, B7-2, B7RP1	SEQ ID NO: 8 (19-220)	SEQ ID NO: 400	SEQ ID NO: 35

TABLE 1. IgSF members according to the present disclosure.

IgSF Member (Synonyms)	UniProtKB Protein Identifier	IgSF Region & Domain Class	Other Domains	Cognate Cell Surface Binding Partners	IgSF Member Amino Acid Sequence (SEQ ID NO)		
					Precursor (mature residues)	Mature	ECD
CTLA4	P16410.3	39-140 IgV	S: 1-35, E: 36-161, T: 162-182, C: 183-223	B7-1, B7-2, B7RP1	SEQ ID NO: 9 (36-223)	SEQ ID NO: 401	SEQ ID NO: 36
PDCD1 (PD-1)	Q15116.3	35-145 IgV	S: 1-20, E: 21-170, T: 171-191, C: 192-288	PD-L1, PD-L2	SEQ ID NO: 10 (21-288)	SEQ ID NO: 402	SEQ ID NO: 37
ICOS	Q9Y6W8.1	30-132 IgV	S: 1-20, E: 21-140, T: 141-161, C: 162-199	B7RP1	SEQ ID NO: 11 (21-199)	SEQ ID NO: 403	SEQ ID NO: 38
BTLA (CD272)	Q7Z6A9.3	31-132 IgV	S: 1-30, E: 31-157, T: 158-178, C: 179-289	HVEM	SEQ ID NO: 12 (31-289)	SEQ ID NO: 404	SEQ ID NO: 39
CD4	P01730.1	26-125 IgV, 126-203 IgC2, 204-317 IgC2, 317-389 IgC2	S: 1-25, E: 26-396, T: 397-418, C: 419-458	MHC class II	SEQ ID NO: 13 (26-458)	SEQ ID NO: 405	SEQ ID NO: 40
CD8A (CD8-alpha)	P01732.1	22-135 IgV	S: 1-21, E: 22-182, T: 183-203, C: 204-235	MHC class I	SEQ ID NO: 14 (22-235)	SEQ ID NO: 406	SEQ ID NO: 41
CD8B (CD8-beta)	P10966.1	22-132 IgV	S: 1-21, E: 22-170, T: 171-191, C: 192-210	MHC class I	SEQ ID NO: 15 (22-210)	SEQ ID NO: 407	SEQ ID NO: 42
LAG3	P18627.5	37-167 IgV, 168-252 IgC2, 265-343 IgC2, 349-419 IgC2	S: 1-28, E: 29-450, T: 451-471, C: 472-525	MHC class II	SEQ ID NO: 16 (29-525)	SEQ ID NO: 408	SEQ ID NO: 43

TABLE 1. IgSF members according to the present disclosure.

IgSF Member (Synonyms)	UniProtKB Protein Identifier	IgSF Region & Domain Class	Other Domains	Cognate Cell Surface Binding Partners	IgSF Member Amino Acid Sequence (SEQ ID NO)		
					Precursor (mature residues)	Mature	ECD
HAVCR2 (TIM-3)	Q8TDQ0.3	22-124 IgV	S: 1-21, E: 22-202, T: 203-223, C: 224-301	CEACAM-1, phosphatidylserine, Galectin-9, HMGB1	SEQ ID NO: 17 (22-301)	SEQ ID NO: 409	SEQ ID NO: 44
CEACAM1	P13688.2	35-142 IgV, 145-232 IgC2, 237-317 IgC2, 323-413 IgC	S: 1-34, E: 35-428, T: 429-452, C: 453-526	TIM-3	SEQ ID NO: 18 (35-526)	SEQ ID NO: 410	SEQ ID NO: 45
TIGIT	Q495A1.1	22-124 IgV	S: 1-21, E: 22-141, T: 142-162, C: 163-244	CD155, CD112	SEQ ID NO: 19 (22-244)	SEQ ID NO: 411	SEQ ID NO: 46
PVR (CD155)	P15151.2	24-139 IgV, 145-237 IgC2, 244-328 IgC2	S: 1-20, E: 21-343, T: 344-367, C: 368-417	TIGIT, CD226, CD96, poliovirus	SEQ ID NO: 20 (21-417)	SEQ ID NO: 412	SEQ ID NO: 47
PVRL2 (CD112)	Q92692.1	32-156 IgV, 162-256 IgC2, 261-345 IgC2	S: 1-31, E: 32-360, T: 361-381, C: 382-538	TIGIT, CD226, CD112R	SEQ ID NO: 21 (32-538)	SEQ ID NO: 413	SEQ ID NO: 48
CD226	Q15762.2	19-126 IgC2, 135-239 IgC2	S: 1-18, E: 19-254, T: 255-275, C: 276-336	CD155, CD112	SEQ ID NO: 22 (19-336)	SEQ ID NO: 414	SEQ ID NO: 49
CD2	P06729.2	25-128 IgV, 129-209 IgC2	S: 1-24, E: 25-209, T: 210-235, C: 236-351	CD58	SEQ ID NO: 23 (25-351)	SEQ ID NO: 415	SEQ ID NO: 50
CD160	O95971.1	27-122 IgV	N/A	HVEM, MHC family of proteins	SEQ ID NO: 24 (27-159)	SEQ ID NO: 416	SEQ ID NO: 51
CD200	P41217.4	31-141 IgV, 142-232 IgC2	S: 1-30, E: 31-232, T: 233-259, C: 260-278	CD200R	SEQ ID NO: 25 (31-278)	SEQ ID NO: 417	SEQ ID NO: 52

TABLE 1. IgSF members according to the present disclosure.

IgSF Member (Synonyms)	UniProtKB Protein Identifier	IgSF Region & Domain Class	Other Domains	Cognate Cell Surface Binding Partners	IgSF Member Amino Acid Sequence (SEQ ID NO)		
					Precursor (mature residues)	Mature	ECD
CD200R1 (CD200R)	Q8TD46.2	53-139 IgV, 140-228 IgC2	S: 1-28, E: 29-243, T: 244-264, C: 265-325	CD200	SEQ ID NO: 26 (29-325)	SEQ ID NO: 418	SEQ ID NO: 53
NCR3 (NKp30)	O14931.1	19-126 IgC-like	S: 1-18, E: 19-135, T: 136-156, C: 157-201	B7-H6	SEQ ID NO: 27 (19-201)	SEQ ID NO: 419	SEQ ID NO: 54

[0114] In some embodiments, the ectodomain of the transmembrane immunomodulatory protein further contains at least one affinity modified domain and further contains at least one non-affinity modified IgSF domain (e.g. unmodified or wildtype IgSF domain). In some embodiments, the ectodomain of the transmembrane immunomodulatory protein contains at least two affinity modified domains. In some embodiments, the ectodomain of the transmembrane immunomodulatory protein can contain a plurality of non-affinity modified IgSF domains and/or affinity modified IgSF domains such as 1, 2, 3, 4, 5, or 6 non-affinity modified IgSF and/or affinity modified IgSF domains.

[0115] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein comprises a combination (a “non-wild-type combination”) and/or arrangement (a “non-wild type arrangement” or “non-wild-type permutation”) of an affinity modified and/or non-affinity modified IgSF domain sequences that are not found in wild-type IgSF family members (“Type II” immunomodulatory proteins). The sequences of the IgSF domains which are non-affinity modified (e.g., wild-type) or have been affinity modified can be mammalian, such as from mouse, rat, cynomolgus monkey, or human origin, or combinations thereof. In some embodiments, the sequence of the non-affinity modified domain is any IgSF domain set forth in Table 1. The number of such non-affinity modified or affinity modified IgSF domains present in these embodiments of a Type II immunomodulatory protein (whether non-wild type combinations or non-wild type arrangements) is at least 2, 3, 4, or 5 and in some embodiments exactly 2, 3, 4, or 5 IgSF domains.

[0116] In some embodiments, at least two of the affinity modified IgSF domains are identical affinity modified IgSF domains. In some embodiments, the affinity modified IgSF domains are non-identical (i.e., different) IgSF domains. Non-identical affinity modified IgSF domains specifically bind, under specific binding conditions, different cognate binding partners and are “non-identical” irrespective of whether or not the wild-type IgSF domains from which they are designed was the same. Thus, for example, a combination of at least two non-identical IgSF domains in the ectodomain of a transmembrane immunomodulatory protein of the present invention can comprise at least one IgSF domain sequence whose origin is from and unique to one IgSF family member and at least one of a second IgSF domain sequence whose origin is from and unique to another IgSF family member wherein the IgSF domains of the ectodomain of a transmembrane immunomodulatory protein are in affinity modified form. However, in alternative embodiments, the two non-identical IgSF domains originate from the same IgSF domain sequence but are affinity modified differently such that they specifically bind to different cognate binding partners. In some embodiments, the number of non-identical affinity modified IgSF domains present in the ectodomain of a transmembrane immunomodulatory protein of the invention is at least 2, 3, 4, or 5 and in some embodiments exactly 2, 3, 4, or 5 non-identical affinity modified IgSF domains. In some embodiments, the non-identical IgSF domains are combinations from at least two IgSF members indicated in Table 1, and in some embodiments at least three or four IgSF members of Table 1.

[0117] In other embodiments an ectodomain of a transmembrane immunomodulatory protein provided herein comprises at least two IgSF domains from a single IgSF member but in a non-wild-type arrangement. One illustrative example of a non-wild type arrangement or permutation is an immunomodulatory protein of the present invention comprising a non-wild type order of affinity modified IgSF domain sequences relative to those found in the wild-type mammalian IgSF family member whose IgSF domain sequences served as the source of the affinity modified IgSF domains. The mammalian wild-type IgSF member in the preceding embodiment specifically includes those listed in Table 1. Thus, in one example, if the wild-type family member comprises an IgC1 domain proximal to the transmembrane domain of a cell surface protein and an IgV domain distal to the transmembrane domain, then the ectodomain of a transmembrane immunomodulatory protein provided herein can comprise an IgV proximal and an IgC1 distal to the transmembrane domain albeit in affinity modified form. The presence, in an ectodomain of a transmembrane immunomodulatory protein, of both non-wild type

combinations and non-wild type arrangements of affinity modified IgSF domains is also within the scope of the present invention. A plurality of affinity modified IgSF domains in an ectodomain of a transmembrane immunomodulatory protein's polypeptide chain need not be covalently linked directly to one another. In some embodiments, an intervening span of one or more amino acid residues indirectly covalently bonds the affinity modified IgSF domains to each other. Such "peptide linkers" can be a single amino acid residue or greater in length.

[0118] In some embodiments, the affinity modified IgSF domain can be affinity modified to specifically bind to a single (e.g., 1) or multiple (e.g., 2, 3, 4, or more) counter-structures (also called a "cognate binding partner") expressed on a mammalian cell. Typically, the counter-structure is a native counter-structure of the wild-type IgSF domain that has been affinity modified. In some embodiments, the counter-structure is an IgSF member. In some embodiments the counter-structure is a non-IgSF family member. For example, in some embodiments the counter-structure of an affinity modified IgSF domain such as BTLA (B- and T-lymphocyte attenuation) is the non-IgSF member counter-structure HVEM (herpes virus entry mediator). BTLA-HVEM complexes negatively regulate T-cell immune responses. Each IgSF domain present in a transmembrane immunomodulatory protein can be affinity modified to independently increase or attenuate specific binding affinity or avidity to each of the single or multiple counter-structures to which it binds. By this method, specific binding to each of multiple counter-structures is independently tuned to a particular affinity or avidity.

[0119] In some embodiments, the counter-structure of an IgSF domain is at least one, and sometimes at least two or three of the counter-structures (cognate binding partners) of the wild-type IgSF domain, such as those listed in Table 1. The sequence of the IgSF domain, such as mammalian IgSF domain, is affinity modified by altering its sequence with at least one substitution, addition, or deletion. Alteration of the sequence can occur at the binding site for the counter-structure or at an allosteric site. In some embodiments, a nucleic acid encoding an IgSF domain, such as a mammalian IgSF domain, is affinity modified by substitution, addition, deletion, or combinations thereof, of specific and pre-determined nucleotide sites to yield a nucleic acid encoding an ectodomain of the transmembrane immunomodulatory protein of the invention. In some contrasting embodiments, a nucleic acid encoding an IgSF domain, such as a mammalian IgSF domain, is affinity modified by substitution, addition, deletion, or combinations thereof, at random sites within the nucleic acid. In some embodiments, a

combination of the two approaches (pre-determined and random) is utilized. In some embodiments, design of the affinity modified IgSF domains is performed in silico.

[0120] In some embodiments, the affinity modified IgSF domain of the ectodomain contains one or more amino acid substitutions (alternatively, “mutations” or “replacements”) relative to a wild-type or unmodified polypeptide or a portion thereof containing an immunoglobulin superfamily (IgSF) domain. In some embodiments, the IgSF domain is an IgV domain or an IgC domain or specific binding fragment of the IgV domain or the IgC domain. In some embodiments, the ectodomain of the transmembrane immunomodulatory protein comprises an affinity modified IgSF domain that contains an IgV domain or an IgC domain or specific binding fragments thereof in which the at least one of the amino acid substitutions is in the IgV domain or IgC domain or a specific binding fragment thereof. In some embodiments, by virtue of the altered binding activity or affinity, the IgV domain or IgC domain is an affinity-modified IgSF domain.

[0121] In some embodiments, the IgSF domain, such as a mammalian IgSF domain, is affinity modified in sequence with at least one but no more than a total of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof. In some embodiments, the IgSF domain, such as mammalian IgSF domain, is affinity modified in sequence with at least one but no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions. In some embodiments, the substitutions are conservative substitutions. In some embodiments, the substitutions are non-conservative. In some embodiments, the substitutions are a combination of conservative and non-conservative substitutions. In some embodiments, the modification in sequence is made at the binding site of the IgSF domain for its counter-structure.

[0122] In some embodiments, the wild-type or unmodified IgSF domain is a mammalian IgSF domain. In some embodiments, the wild-type or unmodified IgSF domain can be an IgSF domain that includes, but is not limited to, human, mouse, cynomolgus monkey, or rat. In some embodiments, the wild-type or unmodified IgSF domain is human.

[0123] In some embodiments, the wild-type or unmodified IgSF domain is or comprises an extracellular domain of an IgSF family member or a portion thereof containing an IgSF domain (e.g. IgV domain or IgC domain). In some cases, the extracellular domain of an unmodified or wild-type IgSF domain can comprise more than one IgSF domain, for example, an IgV domain and an IgC domain. However, the affinity modified IgSF domain need not comprise both the

IgV domain and the IgC domain. In some embodiments, the affinity modified IgSF domain comprises or consists essentially of the IgV domain or a specific binding fragment thereof. In some embodiments, the affinity modified IgSF domain comprises or consists essentially of the IgC domain or a specific binding fragment thereof. In some embodiments, the affinity modified IgSF domain comprises the IgV domain or a specific binding fragment thereof, and the IgC domain or a specific binding fragment thereof.

[0124] In some embodiments, the one or more amino acid substitutions of the affinity modified IgSF domain can be located in any one or more of the IgSF polypeptide domains. For example, in some embodiments, one or more amino acid substitutions are located in the extracellular domain of the IgSF polypeptide. In some embodiments, one or more amino acid substitutions are located in the IgV domain or specific binding fragment of the IgV domain. In some embodiments, one or more amino acid substitutions are located in the IgC domain or specific binding fragment of the IgC domain.

[0125] In some embodiments, the wild-type or unmodified IgSF domain is an IgSF domain or specific binding fragment thereof contained in the sequence of amino acids set forth in any of SEQ ID NOS:1-27 or contained in a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS:1-27. In some embodiments, the IgSF domain is an IgV domain or IgC domain contained therein or specific binding fragments thereof. Table 1 identifies the IgSF domains contained in each of SEQ ID NOS: 1-27.

[0126] In some embodiments, the unmodified or wild-type IgSF domain comprises the extracellular domain (ECD) or a portion comprising an IgSF domain (e.g. IgV domain or IgC domain) of an IgSF member, such as a mammalian IgSF member. In some embodiments, the unmodified or wild-type IgSF domain comprises (i) the sequence of amino acids set forth in any of SEQ ID NOS:28-54, (ii) a sequence of amino acids that has at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to any of SEQ ID NOS: 28-54, or (iii) is a specific binding fragment of (i) or (ii) comprising an IgV domain or an IgC domain.

[0127] In some embodiments, at least one IgSF domain, such as at least one mammalian IgSF domain, of a transmembrane immunomodulatory protein of the present invention is independently affinity modified in sequence to have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, or 80% sequence identity with the

corresponding wild-type IgSF domain or specific binding fragment thereof contained in a wild-type or unmodified IgSF protein, such as, but not limited to, those disclosed in Table 1 as SEQ ID NOS: 1-27.

[0128] In some embodiments, the affinity-modified IgSF domain of a transmembrane immunomodulatory protein provided herein is a specific binding fragment of a wild-type or unmodified IgSF domain contained in a wild-type or unmodified IgSF protein, such as but not limited to, those disclosed in Table 1 in SEQ ID NOS: 1-27. In some embodiments, the specific binding fragment can have an amino acid length of at least 50 amino acids, such as at least 60, 70, 80, 90, 100, or 110 amino acids. In some embodiments, the specific binding fragment of the IgV domain contains an amino acid sequence that is at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the length of the wild-type or unmodified IgV domain. In some embodiments, the specific binding fragment of the IgC domain comprises an amino acid sequence that is at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the length of the wild-type or unmodified IgC domain. In some embodiments, the specific binding fragment modulates immunological activity. In more specific embodiments, the specific binding fragment of an IgSF domain increases immunological activity. In alternative embodiments, the specific binding fragment decreases immunological activity.

[0129] In some embodiments, to determine the percent identity of two nucleic acid sequences or of two amino acids, the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions) x 100). In one embodiment the two sequences are the same length. One may manually align the sequences and count the number of identical nucleic acids or amino acids. Alternatively, alignment of two sequences for the determination of percent identity may be accomplished using a mathematical algorithm. Such an algorithm is incorporated into the NBLAST and XBLAST programs. BLAST nucleotide searches may be

performed with the NBLAST program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches may be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecule of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST may be utilized. Alternatively, PSI-Blast may be used to perform an iterated search which detects distant relationships between molecules. When utilizing the NBLAST, XBLAST, and Gapped BLAST programs, the default parameters of the respective programs may be used such as those available on the NCBI website. Alternatively, sequence identity may be calculated after the sequences have been aligned e.g. by the BLAST program in the NCBI database. Generally, the default settings with respect to e.g. “scoring matrix” and “gap penalty” may be used for alignment. In the context of the present invention, the BLASTN and PSI BLAST NCBI default settings may be employed.

[0130] The means by which the affinity-modified IgSF domains of the transmembrane immunomodulatory proteins are designed or created is not limited to any particular method. In some embodiments, however, wild-type IgSF domains are mutagenized (site specific, random, or combinations thereof) from wild-type IgSF genetic material and screened for altered binding according to the methods disclosed in the Examples. Methods of mutagenizing nucleic acids is known to those of skill in the art. In some embodiments, the affinity modified IgSF domains are synthesized de novo utilizing protein or nucleic acid sequences available at any number of publicly available databases and then subsequently screened. The National Center for Biotechnology Information provides such information and its website is publicly accessible via the internet as is the UniProtKB database as discussed previously.

[0131] In some embodiments, at least one non-affinity modified IgSF domain and/or one affinity modified IgSF domain present in the ectodomain of a transmembrane immunomodulatory protein provided herein specifically binds to at least one cell surface molecular species expressed on mammalian cells forming the immunological synapse (IS). In some embodiments, an ectodomain of a transmembrane immunomodulatory protein provided herein can comprise a plurality of non-affinity modified IgSF domains and/or affinity modified IgSF domains such as 1, 2, 3, 4, 5, or 6 non-affinity modified IgSF and/or affinity modified IgSF domains. One or more of these non-affinity modified IgSF domains and/or affinity modified IgSF domains can independently specifically bind to either one or both of the mammalian cells forming the IS.

[0132] Often, the cell surface molecular species to which the affinity modified IgSF domain of the ectodomain specifically binds will be the cognate binding partner of the wild type IgSF family member or wild type IgSF domain that has been affinity modified. In some embodiments, the cell surface molecular species is a mammalian IgSF member. In some embodiments, the cell surface molecular species is a human IgSF member. In some embodiments, the cell surface molecular species will be the cell surface cognate binding partners as indicated in Table 1. In some embodiments, the cell surface molecular species will be a viral protein, such as a poliovirus protein, on the cell surface of a mammalian cell such as a human cell.

[0133] In some embodiments, at least one non-affinity modified and/or affinity modified IgSF domain of the ectodomain of a transmembrane immunomodulatory protein provided herein binds to at least two or three cell surface molecular species present on mammalian cells forming the IS. The cell surface molecular species to which the non-affinity modified IgSF domains and/or the affinity modified IgSF domains of the ectodomain specifically bind to can exclusively be on one or the other of the two mammalian cells (i.e. in cis configuration) forming the IS or, alternatively, the cell surface molecular species can be present on both.

[0134] In some embodiments, the affinity modified IgSF domain specifically binds to at least two cell surface molecular species wherein one of the molecular species is present on one of the two mammalian cells forming the IS and the other molecular species is present on the second of the two mammalian cells forming the IS. In such embodiments, the cell surface molecular species is not necessarily present solely on one or the other of the two mammalian cells forming the IS (i.e., in a trans configuration) although in some embodiments it is. Thus, embodiments provided herein include those wherein each cell surface molecular species is exclusively on one or the other of the mammalian cells forming the IS (cis configuration) as well as those where the cell surface molecular species to which each affinity modified IgSF binds is present on both of the mammalian cells forming the IS (i.e., cis and trans configuration).

[0135] Those of skill will recognize that antigen presenting cells (APCs) and tumor cells form an immunological synapse with lymphocytes. Thus, in some embodiments at least one non-affinity modified IgSF domain and/or at least one affinity modified IgSF domain of the ectodomain of a transmembrane immunomodulatory protein specifically binds to only cell surface molecular species present on a cancer cell, wherein the cancer cell in conjunction with a lymphocyte forms the IS. In other embodiments, at least one non-affinity modified IgSF domain

and/or at least one affinity modified IgSF domain of the ectodomain of a transmembrane immunomodulatory protein specifically binds to only cell surface molecular species present on a lymphocyte, wherein the lymphocyte in conjunction with an APC or tumor cell forms the IS. In some embodiments, the non-affinity modified IgSF domain and/or affinity modified IgSF domain bind to cell surface molecular species present on both the target cell (or APC) and the lymphocyte forming the IS.

[0136] Embodiments of the invention include those in which an ectodomain of a transmembrane immunomodulatory protein provided herein comprises at least one affinity modified IgSF domain with an amino acid sequence that differs from a wild-type or unmodified IgSF domain (e.g. a mammalian IgSF domain) such that the binding affinity (or avidity if in a multimeric or other relevant structure) of the affinity-modified IgSF domain, under specific binding conditions, to at least one of its cognate binding partners is either increased or decreased relative to the unaltered wild-type or unmodified IgSF domain control. In some embodiments, an affinity modified IgSF domain has a binding affinity for a cognate binding partner that differs from that of a wild-type or unmodified IgSF control sequence as determined by, for example, solid-phase ELISA immunoassays, flow cytometry or Biacore assays. In some embodiments, the affinity modified IgSF domain has an increased binding affinity for one or more cognate binding partners, relative to a wild-type or unmodified IgSF domain. In some embodiments, the affinity modified IgSF domain has a decreased binding affinity for one or more cognate binding partners, relative to a wild-type or unmodified IgSF domain. In some embodiments, the cognate binding partner can be a mammalian protein, such as a human protein or a murine protein.

[0137] Binding affinities for each of the cognate binding partners are independent; that is, in some embodiments, an affinity modified IgSF domain has an increased binding affinity for one, two or three different cognate binding partners, and a decreased binding affinity for one, two or three of different cognate binding partners, relative to a wild-type or unmodified polypeptide.

[0138] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein provided herein comprises at least one affinity modified domain in which the binding affinity or avidity of the affinity modified IgSF domain is increased at least 10%, 20%, 30%, 40%, 50%, 100%, 200%, 300%, 400%, 500%, 1000%, 5000%, or 10,000% relative to the wild type or unmodified control IgSF domain. In some embodiments, the increase in binding affinity relative to the wild-type or unmodified IgSF domain is more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold or 50-fold.

[0139] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein provided herein comprises at least one affinity modified domain in which the binding affinity or avidity of the affinity modified IgSF domain is decreased at least 10%, and up to 20%, 30%, 40%, 50%, 60%, 70%, 80% or up to 90% relative to the wild type or unmodified control IgSF domain. In some embodiments, the decrease in binding affinity relative to the wild-type or unmodified IgSF domain is more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold 40-fold or 50-fold.

[0140] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein provided herein comprises at least one affinity modified domain in which its specific binding affinity to a cognate binding partner can be at least 1×10^{-5} M, 1×10^{-6} M, 1×10^{-7} M, 1×10^{-8} M, 1×10^{-9} M, 1×10^{-10} M or 1×10^{-11} M, or 1×10^{-12} M.

[0141] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein provided comprises at least two IgSF domains in which at least one of the IgSF domain is affinity modified while in some embodiments both are affinity modified, and wherein at least one of the affinity modified IgSF domains has increased affinity (or avidity) to its cognate binding partner and at least one affinity modified IgSF domain has a decreased affinity (or avidity) to its cognate binding partner. Functionally, and irrespective of whether specific binding to its cognate binding partner is increased or decreased, the transmembrane immunomodulatory protein comprising the ectodomain acts to enhance or suppress immunological activity of engineered immune cells, such as lymphocytes or antigen presenting cells, relative to engineered immune cells expressing the wild-type, parental molecule under the appropriate assay controls. In some embodiments, a transmembrane immunomodulatory protein comprising an ectodomain that comprises at least two affinity modified IgSF domains is one in which at least one of the affinity modified IgSF domains agonizes an activating receptor and at least one affinity modified IgSF domain acts to antagonize an inhibitory receptor. In some embodiments, an enhancement of immunological activity can be an increase of at least 10%, 20%, 30%, 40%, 50%, 75%, 100%, 200%, 300%, 400%, or 500% greater than a non-zero control value such as in a cytotoxic activity assay, an assay for assessing cellular cytokines or a cell proliferation assay. In some embodiments, suppression of immunological activity can be a decrease of at least 10%, and up to 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%..

[0142] The affinity modified IgSF domains of the transmembrane immunomodulatory proteins of the invention can in some embodiments specifically bind competitively to its counter-structure. In other embodiments the affinity modified IgSF domains of the present invention specifically bind non-competitively to its counter-structure.

[0143] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein provided herein contains an IgSF domain that otherwise binds to multiple cell surface molecular species but is affinity modified such that it substantially no longer specifically binds to one of its cognate cell surface molecular species. Thus, in these embodiments the specific binding to one of its cognate cell surface molecular species is reduced to specific binding of no more than 90% of the wild type level, such as no more than 80%, 70%, 60%, 50%, 40%, 30%, 20% or less. In some embodiments, the specific binding to one of its cognate cell surface molecular species is reduced to specific binding of no more than 10% of the wild type level and often no more than 7%, 5%, 3%, 1%, or no detectable or statistically significant specific binding.

[0144] In some embodiments, a specific binding site on a mammalian IgSF domain is inactivated or substantially inactivated with respect to at least one of the cell surface molecular species. Thus, for example, if a wild type IgSF domain specifically binds to exactly two cell surface molecular species then in some embodiments it is affinity modified to specifically bind to exactly one cell surface molecular species. And, if a wild type IgSF domain specifically binds to exactly three cell surface molecular species then in some embodiments it is affinity modified to specifically bind to exactly two cell surface molecular species. The IgSF domain that is affinity modified to substantially no longer specifically bind to one of its cognate cell surface molecular species can be an IgSF domain that otherwise specifically binds competitively or non-competitively to its cell surface molecular species. An illustrative example concerns native CD80 (B7-1) which specifically binds counter-structures: CD28, PD-L1, and CTLA4. In some embodiments, CD80 can be IgSF affinity modified to increase or attenuate its specific binding to CD28 and/or PD-L1 but not to specifically bind to any physiologically significant extent to CTLA4. The IgSF domain that is affinity modified to substantially no longer specifically bind to one of its cell surface counter-structures can be an IgSF domain that otherwise specifically binds competitively or non-competitively to its counter-structure. Those of skill will appreciate that a wild type IgSF domain that competitively binds to two cognate binding partners can nonetheless be inactivated with respect to exactly one of them if, for

example, their binding sites are not precisely coextensive but merely overlap such that specific binding of one inhibits binding of the other cognate binding partner and yet both competitive binding sites are distinct.

[0145] The non-affinity modified IgSF domains and/or affinity modified IgSF domains of the ectodomain of provided transmembrane immunomodulatory proteins provided can in some embodiments specifically bind competitively to its cognate cell surface molecular species. In other embodiments the non-affinity modified IgSF domains and/or affinity modified IgSF domains of the ectodomain of a transmembrane immunomodulatory protein provided herein specifically bind non-competitively to its cognate cell surface molecular species. Any number of the non-affinity modified IgSF domains and/or affinity modified IgSF domains present in the ectodomain of a transmembrane immunomodulatory protein provided herein can specifically bind competitively or non-competitively.

[0146] In some embodiments, the ectodomain of a transmembrane immunomodulatory protein provided herein comprises at least two non-affinity modified IgSF domains, or at least one non-affinity modified IgSF domain and at least one affinity modified IgSF domain, or at least two affinity modified IgSF domains wherein one IgSF domain specifically binds competitively and a second IgSF domain binds non-competitively to its cognate cell surface molecular species. More generally, the ectodomain of a transmembrane immunomodulatory protein provided herein can comprise 1, 2, 3, 4, 5, or 6 competitive or 1, 2, 3, 4, 5, or 6 non-competitive binding non-affinity modified IgSF and/or affinity modified IgSF domains or any combination thereof. Thus, the ectodomain of an immunomodulatory protein provided herein can have the number of non-competitive and competitive binding IgSF domains, respectively, of: 0 and 1, 0 and 2, 0 and 3, 0 and 4, 1 and 0, 1 and 1, 1 and 2, 1 and 3, 2 and 0, 2 and 1, 2 and 2, 2 and 3, 3 and 0, 3 and 1, 3 and 2, 3 and 3, 4 and 0, 4 and 1, and, 4 and 2.

[0147] In some embodiments in which the ectodomain contains a plurality of IgSF domain, the plurality of non-affinity modified and/or affinity modified IgSF domains of the ectodomain of the transmembrane immunomodulatory protein provided herein need not be covalently linked directly to one another. In some embodiments, an intervening span of one or more amino acid residues indirectly covalently bonds the non-affinity modified and/or affinity modified IgSF domains to each other. The linkage can be via the N-terminal to C-terminal residues.

[0148] In some embodiments, the linkage can be made via side chains of amino acid residues that are not located at the N-terminus or C-terminus of the non-affinity modified or affinity modified IgSF domain. Thus, linkages can be made via terminal or internal amino acid residues or combinations thereof.

[0149] The “peptide linkers” that link the non-affinity modified and/or affinity modified IgSF domains can be a single amino acid residue or greater in length. In some embodiments, the peptide linker has at least one amino acid residue but is no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues in length. In some embodiments, the linker is (in one-letter amino acid code): GGGGS (“4GS”) or multimers of the 4GS linker, such as repeats of 2, 3, 4, or 5 4GS linkers.

Exemplary Affinity Modified Domains and Ectodomains

[0150] In some embodiments, the ectodomain of a provided transmembrane immunomodulatory protein contains an affinity modified IgSF domain that has one or more amino acid substitutions in an IgSF domain of a wild-type or unmodified IgSF protein, such as set forth in Table 1 above. In some embodiments, the one or more amino acid substitutions are in the IgV domain or specific binding fragment thereof. In some embodiments, the one or more amino acid substitutions are in the IgC domain or specific binding fragment thereof. In some embodiments, one or more amino acid substitutions are in the IgV domain or a specific binding fragment thereof, and some of the one or more amino acid substitutions are in the IgC domain or a specific binding fragment thereof.

[0151] In some embodiments, the affinity modified IgSF domain of the ectodomain has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. The substitutions can be in the IgV domain or the IgC domain. In some embodiments, the affinity modified IgSF domain has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the IgV domain or specific binding fragment thereof. In some embodiments, the affinity modified IgSF domain has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the IgC domain or specific binding fragment thereof. In some embodiments, the affinity modified IgSF domain has at least about 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the wild-type or unmodified IgSF domain or specific binding fragment

thereof, such as an IgSF domain contained in the IgSF protein set forth in any of SEQ ID NOS: 1-27.

[0152] In some embodiments, the transmembrane immunomodulatory protein contains an ectodomain that includes at least one affinity modified IgSF domain containing one or more amino acid substitutions in a wild-type or unmodified IgSF domain of a B7 IgSF family member. In some embodiments, the B7 IgSF family member is CD80, CD86 or ICOS Ligand (ICOSL). In some embodiments, the affinity modified IgSF domain of the ectodomain has at least about 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the wild-type or unmodified IgSF domain or specific binding fragment thereof of CD80, CD86 or ICOS Ligand (ICOSL), such as the IgSF domain (e.g. IgV or IgC) contained in the IgSF protein set forth in any of SEQ ID NOS: 1, 2 or 5. Exemplary affinity modified IgSF domains of CD80 are set forth in Table 2. Exemplary affinity modified IgSF domains of ICOSL are set forth in Table 3. Exemplary affinity modified IgSF domains of CD86 are set forth in Table 4.

TABLE 2: Exemplary variant CD80 polypeptides		
Mutation(s)	ECD SEQ ID NO	IgV SEQ ID NO
Wild-type	28	152
L70Q/A91G	55	153
L70Q/A91G/T130A	56	
L70Q/A91G/I118A/T120S/T130A	57	
V4M/L70Q/A91G/T120S/T130A	58	154
L70Q/A91G/T120S/T130A	59	
V20L/L70Q/A91S/T120S/T130A	60	155
S44P/L70Q/A91G/T130A	61	156
L70Q/A91G/E117G/T120S/T130A	62	
A91G/T120S/T130A	63	157
L70R/A91G/T120S/T130A	64	158
L70Q/E81A/A91G/T120S/I127T/T130A	65	159
L70Q/Y87N/A91G/T130A	66	160
T28S/L70Q/A91G/E95K/T120S/T130A	67	161
N63S/L70Q/A91G/T120S/T130A	68	162
K36E/I67T/L70Q/A91G/T120S/T130A/N152T	69	163
E52G/L70Q/A91G/T120S/T130A	70	164
K37E/F59S/L70Q/A91G/T120S/T130A	71	165
A91G/S103P	72	
K89E/T130A	73	166
A91G	74	
D60V/A91G/T120S/T130A	75	167

K54M/A91G/T120S	76	168
M38T/L70Q/E77G/A91G/T120S/T130A/N152T	77	169
R29H/E52G/L70R/E88G/A91G/T130A	78	170
Y31H/T41G/L70Q/A91G/T120S/T130A	79	171
V68A/I110A	80	172
S66H/D90G/T110A/F116L	81	173
R29H/E52G/T120S/T130A	82	174
A91G/L102S	83	
I67T/L70Q/A91G/T120S	84	175
L70Q/A91G/T110A/T120S/T130A	85	
M38V/T41D/M43I/W50G/D76G/V83A/K89E/T120S/T130A	86	176
V22A/L70Q/S121P	87	177
A12V/S15F/Y31H/T41G/T130A/P137L/N152T	88	178
I67F/L70R/E88G/A91G/T120S/T130A	89	179
E24G/L25P/L70Q/T120S	90	180
A91G/F92L/F108L/T120S	91	181
R29D/Y31L/Q33H/K36G/M38I/T41A/M43R/M47T/E81V/L85R/K89N/A91T/F92P/K93V/R94L/I118T/N149S	92	182
R29D/Y31L/Q33H/K36G/M38I/T41A/M43R/M47T/E81V/L85R/K89N/A91T/F92P/K93V/R94L/N144S/N149S	93	
R29D/Y31L/Q33H/K36G/M38I/T41A/M42T/M43R/M47T/E81V/L85R/K89N/A91T/F92P/K93V/R94L/L148S/N149S	94	183
E24G/R29D/Y31L/Q33H/K36G/M38I/T41A/M43R/M47T/F59L/E81V/L85R/K89N/A91T/F92P/K93V/R94L/H96R/N149S/C182S	95	184
R29D/Y31L/Q33H/K36G/M38I/T41A/M43R/M47T/E81V/L85R/K89N/A91T/F92P/K93V/R94L/N149S	96	
R29V/M43Q/E81R/L85I/K89R/D90L/A91E/F92N/K93Q/R94G	97	185
T41I/A91G	98	186
K89R/D90K/A91G/F92Y/K93R/N122S/N177S	99	187
K89R/D90K/A91G/F92Y/K93R	100	
K36G/K37Q/M38I/F59L/E81V/L85R/K89N/A91T/F92P/K93V/R94L/E99G/T130A/N149S	101	188
E88D/K89R/D90K/A91G/F92Y/K93R	102	189
K36G/K37Q/M38I/L40M	103	190
K36G	104	191
R29H/Y31H/T41G/Y87N/E88G/K89E/D90N/A91G/P109S	105	192
A12T/H18L/N43V/F59L/E77K/P109S/I118T	106	193
R29V/Y31F/K36G/M38L/N43Q/E81R/V83I/L85I/K89R/D90L/A91E/F92N/K93Q/R94G	107	194
V68M/L70P/L72P/K86E	108	195

TABLE 3: Exemplary variant ICOSL polypeptides

Mutation(s)	ECD SEQ ID NO	IgV SEQ ID NO
Wild-type	32	196

N52S	109	197
N52H	110	198
N52D	111	199
N52Y/N57Y/F138L/L203P	112	200
N52H/N57Y/Q100P	113	201
N52S/Y146C/Y152C	114	
N52H/C198R	115	
N52H/C140D/T225A	116	
N52H/C198R/T225A	117	
N52H/K92R	118	202
N52H/S99G	119	203
N52Y	120	204
N57Y	121	205
N57Y/Q100P	122	206
N52S/S130G/Y152C	123	
N52S/Y152C	124	
N52S/C198R	125	
N52Y/N57Y/Y152C	126	
N52Y/N57Y/I29P/C198R	127	
N52H/L161P/C198R	128	
N52S/T113E	129	
S54A	130	207
N52D/S54P	131	208
N52K/L208P	132	209
N52S/Y152H	133	
N52D/V151A	134	
N52H/I143T	135	
N52S/L80P	136	210
F120S/Y152H/N201S	137	
N52S/R75Q/L203P	138	211
N52S/D158G	139	
N52D/Q133H	140	
N52S/N57Y/H94D/L96F/L98F/Q100R	141	212
N52S/N57Y/H94D/L96F/L98F/Q100R/G103E/F120S	142	213
N52S/G103E	239	240

TABLE 4: Exemplary variant CD86 polypeptides

Mutation(s)	ECD SEQ ID NO	IgC SEQ ID NO
Wild-type	29	220
Q35H/H90L/Q102H	148	221
Q35H	149	222
H90L	150	223
Q102H	151	224

[0153] In some embodiments, the transmembrane immunomodulatory protein contains an ectodomain that includes at least one affinity modified IgSF domain containing one or more amino acid substitutions in a wild-type or unmodified IgSF domain of a poliovirus receptor IgSF family member. In some embodiments, the poliovirus IgSF family member is CD155 (PVR) or CD122 (PRR-2). In some embodiments, the affinity modified IgSF domain of the ectodomain has at least about 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the wild-type or unmodified IgSF domain or specific binding fragment thereof of CD155 or CD112, such as an IgSF domain (e.g. IgV or IgC) contained in the IgSF protein set forth in any of SEQ ID NO:20 or 21. Exemplary affinity modified IgSF domains of CD155 are set forth in Table 5. Exemplary affinity modified IgSF domains of CD112 are set forth in Table 6.

TABLE 5: Exemplary variant CD155 polypeptides

Mutation(s)	ECD SEQ ID NO	IgV SEQ ID NO
Wild-type	47	241
P18S, P64S, F91S	242	264
P18S, F91S, L104P	243	265
L44P	244	266
A56V	245	267
P18L, L79V, F91S	246	268
P18S, F91S	247	269
P18T, F91S	248	270
P18T, S42P, F91S	249	271
G7E, P18T, Y30C, F91S	250	272
P18T, F91S, G111D	251	273
P18S, F91P	252	274
P18T, F91S, F108L	253	275
P18S, F91S	254	276
P18T, T45A, F91S	255	277
P18T, F91S, R94H	256	278
P18S, Y30C, F91S	257	279
A81V, L83P	258	280
L88P	259	281
R94H	260	282
A13E, P18S, A56V, F91S	261	283
P18T, F91S, V115A	262	284
P18T, Q60K	263	285

TABLE 6: Exemplary variant CD112 polypeptides		
Mutation(s)	ECD SEQ ID NO	IgV SEQ ID NO
Wild-type	48	286
Y33H, A112V, G117D	287	334
V19A, Y33H, S64G, S80G, G98S, N106Y, A112V	288	335
L32P, A112V	289	336
A95V, A112I	290	337
P28S, A112V	291	338
P27A, T38N, V101A, A112V	292	339
S118F	293	340
R12W, H48Y, F54S, S118F	294	341
R12W, Q79R, S118F	295	342
T113S, S118Y	296	343
S118Y	297	344
N106I, S118Y	298	345
N106I, S118F	299	346
A95T, L96P, S118Y	300	347
Y33H, P67S, N106Y, A112V	301	348
N106Y, A112V	302	349
T18S, Y33H, A112V	303	350
P9S, Y33H, N47S, A112V	304	351
P42S, P67H, A112V	305	352
P27L, L32P, P42S, A112V	306	353
G98D, A112V	307	354
Y33H, S35P, N106Y, A112V	308	355
L32P, P42S, T100A, A112V	309	356
P27S, P45S, N106I, A112V	310	357
Y33H, N47K, A112V	311	358
Y33H, N106Y, A112V	312	359
K78R, D84G, A112V, F114S	313	360
Y33H, N47K, F54L, A112V	314	361
Y33H, A112V	315	362
A95V, A112V	316	363
R12W, A112V	317	364
R12W, P27S, A112V	318	365
Y33H, V51M, A112V	319	366
Y33H, A112V, S118T	320	367
Y33H, V101A, A112V, P115S	321	368
H24R, T38N, D43G, A112V	322	369
A112V	323	370
P27A, A112V	324	371
A112V, S118T	325	372
R12W, A112V, M122I	326	373
Q83K, N106Y, A112V	327	374

R12W, P27S, A112V, S118T	328	375
P28S, Y33H, A112V	329	376
P27S, Q90R, A112V	330	377
L15V, P27A, A112V, S118T	331	378
Y33H, N106Y, T108I, A112V	332	379
Y33H, P56L, V75M, V101M, A112V	333	380

[0155] In some embodiments, the transmembrane immunomodulatory protein contains an ectodomain that includes an affinity modified IgSF domain containing one or more amino acid substitutions in a wild-type or unmodified IgSF domain of an NkP30 family member. In some embodiments, the affinity modified IgSF domain has at least about 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the wild-type or unmodified IgSF domain or specific binding fragment thereof of an NkP30 family member, such as the IgSF domain (e.g. IgC) contained in the IgSF protein set forth in SEQ ID NO: 27. Table 7 provides exemplary affinity modified NkP30 IgSF domains.

TABLE 7: Exemplary variant NKp30 polypeptides		
Mutation(s)	ECD SEQ ID NO	IgV SEQ ID NO
Wild-type	54	214
L30V/A60V/S64P/S86G	143	215
L30V	144	216
A60V	145	217
S64P	146	218
S86G	147	219

B. Transmembrane Domain

[0156] The transmembrane immunomodulatory proteins provided herein further contain a transmembrane domain linked to the ectodomain. In some embodiments, the transmembrane domain results in an encoded protein for cell surface expression on a cell. In some embodiments, the transmembrane domain is linked directly to the ectodomain. In some embodiments, the transmembrane domain is linked indirectly to the ectodomain via one or more linkers or spacers. In some embodiments, the transmembrane domain contains predominantly hydrophobic amino acid residues, such as leucine and valine.

[0157] In some embodiments, a full length transmembrane anchor domain can be used to ensure that the TIPs will be expressed on the surface of the engineered cell, such as engineered T cell. Conveniently, this could be from a particular native protein that is being affinity modified (e.g. CD80 or ICOSL or other native IgSF protein), and simply fused to the sequence of the first membrane proximal domain in a similar fashion as the native IgSF protein (e.g. CD80 or ICOSL). In some embodiments, the transmembrane immunomodulatory protein comprises a transmembrane domain of the corresponding wild-type or unmodified IgSF member, such as a transmembrane domain contained in the sequence of amino acids set forth in any of SEQ ID NOs:1-27 (see Table 1).

[0158] In some embodiments, the transmembrane domain is a non-native transmembrane domain that is not the transmembrane domain of the wild-type IgSF member. In some embodiments, the transmembrane domain is derived from a transmembrane domain from another non-IgSF family member polypeptide that is a membrane-bound or is a transmembrane protein. In some embodiments, a transmembrane anchor domain from another protein on T cells can be used. In some embodiments, the transmembrane domain is derived from CD8. In some embodiments, the transmembrane domain can further contain an extracellular portion of CD8 that serves as a spacer domain. An exemplary CD8 derived transmembrane domain is set forth in SEQ ID NO: 386 or a portion thereof containing the CD8 transmembrane domain. In some embodiments, the transmembrane domain is a synthetic transmembrane domain.

C. Endodomain

[0159] In some embodiments, the transmembrane immunomodulatory protein further contains an endodomain, such as a cytoplasmic signaling domain, linked to the transmembrane domain. In some embodiments, the cytoplasmic signaling domain induces cell signaling. In some embodiments, the endodomain of the transmembrane immunomodulatory protein comprises the cytoplasmic domain of the corresponding wild-type or unmodified polypeptide, such as a cytoplasmic domain contained in the sequence of amino acids set forth in any of SEQ ID NOS:1-27 (see Table 1).

[0160] In some embodiments, provided are CAR-related transmembrane immunomodulatory proteins in which the endodomain of a transmembrane immunomodulatory protein comprises a cytoplasmic signaling domain that comprises at least one ITAM (immunoreceptor tyrosine-based activation motif)-containing signaling domain. ITAM is a conserved motif found in a number of protein signaling domains involved in signal transduction

of immune cells, including in the CD3-zeta chain (“CD3-z”) involved in T-cell receptor signal transduction. In some embodiments, the endodomain comprises at CD3-zeta signaling domain. In some embodiments, the CD3-zeta signaling domain comprises the sequence of amino acids set forth in SEQ ID NO: 387 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% to SEQ ID NO:387 and retains the activity of T cell signaling. In some embodiments, the endodomain of a CAR-related transmembrane immunomodulatory protein can further comprise a costimulatory signaling domain to further modulate immunomodulatory responses of the T-cell. In some embodiments, the costimulatory signaling domain is CD28, ICOS, 41BB or OX40. In some embodiments, the provided CAR-related transmembrane immunomodulatory proteins have features of CARs to stimulate T cell signaling upon binding of an affinity modified IgSF domain to a cognate binding partner or counter structure. In some embodiments, upon specific binding by the affinity-modified IgSF domain to its counter structure can lead to changes in the immunological activity of the T-cell activity as reflected by changes in cytotoxicity, proliferation or cytokine production.

[0161] In some embodiments, a CAR-related transmembrane immunomodulatory protein comprises an antigen binding region that is engineered to specifically bind to a desired counter-structure. In some embodiments, an affinity modified IgSF domain specifically binds its native counter-structure. In some embodiments the counter-structure is an IgSF family member. In some embodiments, provided is a CAR-related transmembrane immunomodulatory protein that specifically binds to a tumor specific IgSF counter-structure. In some embodiments, the antigen binding region (ectodomain) is an affinity modified IgSF domain NKp30. In some embodiments, the affinity modified IgSF domain specifically binds the tumor specific antigen NKp30 ligand B7-H6 (see, Levin et al., The Journal of Immunology, 2009, 182, 134.20). In examples of such embodiments, the endodomain comprises at least one ITAM (immunoreceptor tyrosine-based activation motif) containing signaling domain, such as a CD3-zeta signaling domain. In some embodiments, the endodomain can further comprises at least one of: a CD28 costimulatory domain, an OX40 signaling domain, and a 41BB signaling domain.

[0162] In some embodiments, the transmembrane immunomodulatory protein does not contain an endodomain capable of mediating cytoplasmic signaling. In some embodiments, the transmembrane immunomodulatory protein lacks the signal transduction mechanism of the wild-type or unmodified polypeptide and therefore does not itself induce cell signaling. In some

embodiments, the transmembrane immunomodulatory protein lacks an intracellular (cytoplasmic) domain or a portion of the intracellular domain of the corresponding wild-type or unmodified polypeptide, such as a cytoplasmic signaling domain contained in the sequence of amino acids set forth in any of SEQ ID NOS:1-27 (see Table 1). In some embodiments, the transmembrane immunomodulatory protein does not contain an ITIM (immunoreceptor tyrosine-based inhibition motif), such as contained in certain inhibitory receptors, including inhibitory receptors of the IgSF family (e.g. PD-1 or TIGIT). Thus, in some embodiments, the transmembrane immunomodulatory protein only contains the ectodomain and the transmembrane domain, such as any as described.

D. Nucleic Acid Molecules and Vectors

[0163] Provided herein are isolated or recombinant nucleic acids collectively referred to as “nucleic acids” which encode any of the various provided embodiments of the transmembrane immunomodulatory polypeptides of the invention. Nucleic acids provided herein, including all described below, are useful in recombinant expression of the transmembrane immunomodulatory proteins, including for engineering cells. The nucleic acids provided herein can be in the form of RNA or in the form of DNA, and include mRNA, cRNA, recombinant or synthetic RNA and DNA, and cDNA. The nucleic acids of the invention are typically DNA molecules, and usually double-stranded DNA molecules. However, single-stranded DNA, single-stranded RNA, double-stranded RNA, and hybrid DNA/RNA nucleic acids or combinations thereof comprising any of the nucleotide sequences of the invention also are provided.

[0164] Also provided herein are expression vectors useful in engineering cells to express the transmembrane immunomodulatory proteins of the present invention. The immunomodulatory polypeptides provided herein can be introduced into cells using recombinant DNA techniques. To do so, a recombinant DNA molecule encoding a transmembrane immunomodulatory polypeptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidite method. Also, a combination of these techniques could be used. In some instances, a recombinant or synthetic nucleic acid may be generated through polymerase chain reaction (PCR).

[0165] In some embodiments, a full length DNA insert can be generated comprising an optional endodomain (i.e., cytoplasmic domain), a transmembrane anchor domain, an optional spacer domain, an optional epitope tag, and finally one or more extracellular affinity modified IgSF domains. This DNA insert can be cloned into an appropriate T cell transduction/transfection vector as is known to those of skill in the art. Also provided are vectors containing the nucleic acid molecules.

[0166] In some embodiments, the expression vectors are capable of expressing the transmembrane immunomodulatory proteins in an appropriate cell under conditions suited to expression of the protein. In some aspects, an expression vector comprises the DNA molecule that codes for the transmembrane immunomodulatory protein operatively linked to appropriate expression control sequences. Methods of affecting this operative linking, either before or after the DNA molecule is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation. In some embodiments, a nucleic acid of the invention further comprises nucleotide sequence that encodes a secretory or signal peptide operably linked to the nucleic acid encoding the transmembrane immunomodulatory protein.

[0167] In some embodiments, the resulting expression vector having the DNA molecule thereon is used to transform, such as transduce, an appropriate cell. The introduction can be performed using methods well known in the art. Exemplary methods include those for transfer of nucleic acids encoding the receptors, including via viral, e.g., retroviral or lentiviral, transduction, transposons, and electroporation. In some embodiments, the expression vector is a viral vector. In some embodiments, the nucleic acid is transferred into cells by lentiviral or retroviral transduction methods.

E. Exemplary Transmembrane Immunomodulatory Proteins and Encoding Nucleic Acid Molecules

[0168] Provided herein is a transmembrane immunomodulatory protein in accord with the above description that comprises a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 393-419 and contains an ectodomain comprising at least one affinity-modified IgSF domain as described and a transmembrane domain. In some embodiments, the transmembrane immunomodulatory protein can further comprise a cytoplasmic domain as

described. In some embodiments, the transmembrane immunomodulatory protein can further contain a signal peptide. In some embodiments, the signal peptide is the native signal peptide of the corresponding wild-type IgSF member (see e.g. Table 1).

[0169] Also provided herein is a nucleic acid molecule encoding a transmembrane immunomodulatory protein comprising a nucleotide sequence that encodes a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of SEQ ID NOS: 393-419 and contains an ectodomain comprising at least one affinity-modified IgSF domain as described, a transmembrane domain and, optionally, a cytoplasmic domain. In some embodiments, the nucleic acid molecule can further comprise a sequence of nucleotides encoding a signal peptide. In some embodiments, the signal peptide is the native signal peptide of the corresponding wild-type IgSF member (see e.g. Table 1).

[0170] Exemplary of a transmembrane immunomodulatory protein is a CD80 TIP comprising i) the sequence of amino acids set forth in SEQ ID NO:381 or ii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:381 and that comprises the affinity-modified domain of SEQ ID NO:381. Also provided is i) a sequence of nucleotides set forth in SEQ ID NO:382, ii) a sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 381 and that encodes a TIP that comprises the affinity-modified domain of SEQ ID NO:381, or iii) a sequence of i) or ii) having degenerate codons.

[0171] Exemplary of a transmembrane immunomodulatory protein is a ICOSL TIP comprising i) the sequence of amino acids set forth in SEQ ID NO:383 or ii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:381 and that comprises the affinity-modified domain of SEQ ID NO:383. Also provided is i) a sequence of nucleotides set forth in SEQ ID NO:384, ii) a sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 384 and that encodes a TIP that comprises the affinity-modified domain of SEQ ID NO:383, or iii) a sequence of i) or ii) having degenerate codons.

III. ENGINEERED CELLS

[0172] Provided herein are engineered cells expressing on their surface any of the provided transmembrane immunomodulatory polypeptide. In some embodiments, the transmembrane immunomodulatory protein is expressed on a lymphocyte such as a tumor infiltrating lymphocyte (TIL), T-cell or NK cell, or on a myeloid cell. In some embodiments, the engineered cells are antigen presenting cells (APCs). In some embodiments, the engineered cells are engineered mammalian T cells or engineered mammalian antigen presenting cells (APCs). In some embodiments, the engineered T-cells or APCs are human or murine cells.

[0173] In some embodiments, engineered T-cells include, but are not limited to, T helper cell, cytotoxic T-cell (alternatively, cytotoxic T lymphocyte or CTL), natural killer T-cell, regulatory T-cell, memory T-cell, or gamma delta T-cell. In some embodiments, the engineered T cells are CD4+ or CD8+. In addition to the signal of the MHC, engineered T-cells also require a co-stimulatory signal which in some embodiments is provided by the TIP as discussed previously.

[0174] In some embodiments, the engineered APCs include, for example, MHC II expressing APCs such as macrophages, B cells, and dendritic cells, as well as artificial APCs (aAPCs) including both cellular and acellular (e.g., biodegradable polymeric microparticles) aAPCs. Artificial APCs (aAPCs) are synthetic versions of APCs that can act in a similar manner to APCs in that they present antigens to T-cells as well as activate them. Antigen presentation is performed by the MHC (Class I or Class II). In some aspects, in engineered APCs such as aAPCs, the antigen that is loaded onto the MHC is, in some embodiments, a tumor specific antigen or a tumor associated antigen. The antigen loaded onto the MHC is recognized by a T-cell receptor (TCR) of a T cell, which, in some cases, can express one or more cognate binding partners or other molecule recognized by the affinity modified domain of the transmembrane immunomodulatory polypeptides provided herein. Materials which can be used to engineer an aAPC include: poly (glycolic acid), poly(lactic-co-glycolic acid), iron-oxide, liposomes, lipid bilayers, sepharose, and polystyrene.

[0175] In some embodiments, a transmembrane immunomodulatory protein provided herein is co-expressed or engineered into a cell that expresses an antigen-binding receptor, such as a recombinant receptor, such as a chimeric antigen receptor (CAR) or T cell receptor (TCR). In some embodiments, the engineered cell, such as an engineered T cell, recognizes a desired antigen associated with cancer, inflammatory and autoimmune disorders, or a viral infection. In

specific embodiments, the antigen-binding receptor contains an antigen-binding moiety that specifically binds a tumor specific antigen or a tumor associated antigen. In some embodiments, the engineered T-cell is a CAR (chimeric antigen receptor) T-cell that contains an antigen-binding domain (e.g. scFv) that specifically binds to an antigen, such as a tumor specific antigen or tumor associated antigen. In another embodiment, the engineered T-cell possesses a TCR, including a recombinant or engineered TCR. In some embodiments, the TCR can be a native TCR. Those of skill in the art will recognize that generally native mammalian T-cell receptors comprise an alpha and a beta chain (or a gamma and a delta chain) involved in antigen specific recognition and binding. In some embodiments, the TCR is an engineered TCR that is modified. In some embodiments, the TCR of an engineered T-cell specifically binds to a tumor associated or tumor specific antigen presented by an APC. Thus, in some embodiments, the TIP protein is expressed in an engineered T-cell receptor cell or and engineered chimeric antigen receptor cell. In such embodiments, the engineered cell co-expresses the TIP and the CAR or TCR.

[0176] In some embodiments, transmembrane immunomodulatory polypeptides can be incorporated into engineered cells, such as engineered T cells or engineered APCs, by a variety of strategies such as those employed for recombinant host cells. A variety of methods to introduce a DNA construct into primary T cells are known in the art. In some embodiments, viral transduction or plasmid electroporation are employed. In typical embodiments, the nucleic acid molecule encoding the transmembrane immunomodulatory protein, or the expression vector, comprises a signal peptide that localizes the expressed transmembrane immunomodulatory proteins to the cellular membrane. In some embodiments, a nucleic acid encoding a transmembrane immunomodulatory proteins of the invention is sub-cloned into a viral vector, such as a retroviral vector, which allows expression in the host mammalian cell. The expression vector can be introduced into a mammalian host cell and, under host cell culture conditions, the TIP is expressed.

[0177] In an exemplary example, primary T cells can be purified ex vivo (CD4 cells or CD8 cells or both) and stimulated with an activation protocol consisting of various TCR/CD28 agonists, such as anti-CD3/anti-CD28 coated beads. After a 2 or 3 day activation process, the DNA vector containing a TIP of the present invention can be stably introduced into the primary T cells through art standard lentiviral or retroviral transduction protocols or plasmid electroporation strategies. Cells can be monitored for TIP expression by, for example, flow

cytometry using anti-epitope tag or antibodies that cross-react with native parental molecule and affinity modified variant. T cells that express the TIP can be enriched through sorting with anti-epitope tag antibodies or enriched for high or low expression depending on the application.

[0178] Upon TIP expression the engineered T cell can be assayed for improved function by a variety of means. The engineered CAR or TCR co-expression can be validated to show that this part of the engineered T cell was not significantly impacted by the expression of the TIP construct. Once validated, standard in vitro cytotoxicity, proliferation, or cytokine assays can be used to assess the function of the engineered cells. Exemplary standard endpoints are percent lysis of the tumor line, proliferation of the engineered T-cell, or IFN-gamma protein expression in culture supernatants. An engineered construct which results in statistically significant increased lysis of tumor line, increased proliferation of the engineered T-cell, or increased IFN-gamma expression over the control construct can be selected for. Additionally, non-engineered cells, such as native primary or endogenous T-cells, could also be incorporated into the same in vitro assay to measure the ability of the TIP construct expressed on the engineered cells, such as engineered T-cells, to modulate activity, including, in some cases, to activate and generate effector function in bystander, native T-cells. Increased expression of activation markers such as CD69, CD44, or CD62L could be monitored on endogenous T cells, and increased proliferation and/or cytokine production could indicate desired activity of the TIP expressed on the engineered T cells.

[0179] In some embodiments, the similar assays can be used to compare the function of engineered T cells containing the CAR or TCR alone to those containing the CAR or TCR and a TIP construct. Typically, these in vitro assays are performed by plating various ratios of the engineered T cell and a “tumor” cell line containing the cognate CAR or TCR antigen together in culture. Standard endpoints are percent lysis of the tumor line, proliferation of the engineered T cell, or IFN-gamma production in culture supernatants. An engineered TIP construct which resulted in statistically significant increased lysis of tumor line, increased proliferation of the engineered T cell, or increased IFN-gamma production over the same TCR or CAR construct alone can be selected for. Engineered human T cells can be analyzed in immunocompromised mice, like the NSG strain, which lacks mouse T, NK and B cells. Engineered human T cells in which the CAR or TCR binds a target counter-structure on the xenograft and is co-expressed with the TIP affinity modified IgSF domain can be adoptively transferred in vivo at different cell numbers and ratios compared to the xenograft. For example, engraftment of CD19+ leukemia

tumor lines containing a luciferase/GFP vector can be monitored through bioluminescence or ex vivo by flow cytometry. In a common embodiment, the xenograft is introduced into the murine model, followed by the engineered T cells several days later. Engineered T cells containing the TIP can be assayed for increased survival, tumor clearance, or expanded engineered T cells numbers relative to engineered T cells containing the CAR or TCR alone. As in the in vitro assay, endogenous, native (i.e., non-engineered) human T cells could be co-adoptively transferred to look for successful epitope spreading in that population, resulting in better survival or tumor clearance.

Exemplary Functional Activities and Features

[0180] In some aspects, TIP-engineered cells, such as engineered lymphocytes (e.g. tumor infiltrating lymphocytes, T cells or NK cells) or myeloid cells (e.g. antigen presenting cells), exhibit one or more desirable features or activities.

[0181] In some embodiments, the affinity-modified IgSF domain, localized on the ectodomain of the TIP, specifically binds to at least one counter-structure expressed on a mammalian cell. In some embodiments, the mammalian cell is an autologous or allogeneic mouse, rat, cynomolgus monkey, or human cell. In some aspects, the mammalian cell can include such embodiments as an antigen presenting cell (APC), a tumor cell, or a T-cell. In some embodiments, the tumor cell is a mouse, rat, cynomolgus monkey, or human tumor cell. A TIP can comprise one or multiple (e.g., 2, 3, or 4) affinity modified IgSF domains. Thus, in some embodiments the TIP binds to no more than one counter-structure on the mammalian cell. In some embodiments, an affinity modified IgSF domain of a TIP specifically binds to no more than one counter-structure on the mammalian cell. Alternatively, in some embodiments, a TIP specifically binds to at least two, three or four, or exactly two, three, or four, counter-structures expressed on a mammalian cell. In some embodiments, the TIP specifically binds to no more than one cell surface counter-structure. Specific binding of the TIP affinity-modified IgSF domain to the counter-structure on a mammalian cell modulates immunological activity of the mammalian cell. Specific binding by and between an affinity modified IgSF domain and a mammalian cell counter-structure can be specific binding in cis arrangement (i.e., specific binding on the same cell) or in trans arrangement (i.e., specific binding on different cells) or in both cis and trans arrangement. Immunological activity of the cell can be increased as evidenced by increased, e.g., cell survival, cell proliferation, cytokine production, or T-cell

cytotoxicity. In alternative embodiments, the immunological activity of the cell is attenuated as evidenced by a decrease of cell survival, cell proliferation, cytokine production, or T-cell cytotoxicity.

[0182] In some embodiments, at least one affinity modified IgSF domain present in a transmembrane immunomodulatory protein specifically binds to at least one cell surface counter-structure expressed on a mammalian cell and in which modulation of immunological activity is desired. In some embodiments, the counter-structure to which the affinity modified IgSF domain specifically binds is the native counter-structure of the wild type IgSF family member or wild type IgSF domain that has been affinity modified. In some embodiments, the specific binding increases and/or attenuates activity a mammalian cell expressing a cognate binding partner to which the affinity modified IgSF domain exhibits improved binding. Thus, by increasing specific binding affinity, the provided transmembrane immunomodulatory proteins can either increase or attenuate immunological activity of a mammalian cell. In some embodiments, the specific binding modulates, such as increases, immunological activity of the engineered cell with the transmembrane immunomodulatory protein.

[0183] In some embodiments, the counter-structure expressed on the mammalian cell is a mammalian IgSF member. The mammalian cell is, in some embodiments, an antigen presenting cell (APC), a lymphocyte, or a tumor cell. In some embodiments, the lymphocyte is a tumor infiltrating lymphocyte (TIL), an engineered or native T-cell, or an engineered or native NK cell. In some embodiments, the counter-structure of the affinity modified IgSF domain is a native human IgSF member. In some embodiments, the counter-structure is a “cell surface cognate binding partner” as indicated in Table 1.

[0184] In some embodiments, a TIP comprising an affinity modified IgSF when expressed on an immune cell, e.g. a lymphocyte such as a T-cell, can specifically bind at least one counter-structure expressed on a second immune cells, e.g. a lymphocyte such as a T-cell. The counter-structure on the second immune cells, e.g. second T-cell, can be an inhibitory counter-structure or a stimulatory counter-structure. Exemplary counter-structures include cell surface receptors or ligands. Examples of inhibitory receptors/ligands include PD-1/PD-L1, PD-L2, CTLA-4/B7-1/B7-2, BTLA/HVEM, LAG3/MHC class II, TIGIT/PVR, and TIM-3/CEACAM-1/GAL9. Examples of stimulatory receptors/ligands include CD28/B7-1/B7-2, ICOS/ICOSL, and CD226/PVR.

[0185] In some embodiments, the TIP is expressed on a lymphocyte or an NK cell that is in trans arrangement to the mammalian cell on which is expressed the counter-structure to which it specifically binds. In alternate embodiments it is in cis arrangement. In some embodiments, the TIP specifically binds to counter-structures that are cis and trans. In a particular embodiment, the TIP is expressed on a T-cell and comprises an affinity modified IgSF domain that specifically binds to a counter-structure expressed on a T-cell. In some embodiments the first and second T-cells are separate T-cells and in this embodiment the TIP and counter-structure are in trans to each other. In some embodiments, the TIP and counter-structure are expressed on the same T-cell and are cis to each other. In some embodiments, the TIP and counter-structure to which it specifically binds can be both cis and trans. In some embodiments, at least one of the T-cells is a native T-cell or an engineered T-cell. In some embodiments, the engineered T-cell is a chimeric antigen receptor (CAR) T-cell or a T-cell receptor (TCR) engineered T-cell.

[0186] In some embodiments, a transmembrane immunomodulatory protein comprises an affinity modified IgSF domain with increased affinity to a cell surface receptor to stimulate an increase in receptor signal transduction. Stimulating an increase in receptor signaling can in some embodiments increase immunological activity of that cell if, for example, the receptor is a stimulatory receptor that works to mediate those effects. In some cases, the inflammatory activity of the cell in which receptor signaling is stimulated is increased. In some embodiments, the transmembrane immunomodulatory protein increases the activity of a stimulatory receptor. In such examples, an IgSF domain of a transmembrane immunomodulatory protein can be affinity modified to increase the specific binding affinity to the native counter-structure on a mammalian cell, which, in some cases, is a stimulatory receptor. In some embodiments, the stimulatory receptor is expressed on T cells. In certain embodiments, the affinity modified IgSF domain of the TIP, such as is expressed by a TIP-engineered cell (e.g. a first T cell), specifically binds to a stimulatory counter-structure expressed on a T cell (e.g. a second T cell) with increased affinity (relative to the non-affinity modified IgSF domain as a control). In certain embodiments, the affinity modified IgSF domain of the TIP specifically binds to a stimulatory counter-structure expressed on a T cell (e.g. second T cell) and increases immunomodulatory activity of the T-cell. In some embodiments, the affinity modified IgSF domain of a TIP binds to a stimulatory counter-structure on the T cell (e.g. second T-cell) with increased affinity and increases immunomodulatory activity of the T-cell.

[0187] In some embodiments, the stimulatory receptor is CD28, ICOS or CD226 and the transmembrane immunomodulatory protein is one that contains an ectodomain comprising an affinity-modified IgSF domain that exhibits increased binding affinity to one of CD28, ICOS or CD226 compared to a transmembrane protein containing a wild-type IgSF domain. In some embodiments, the affinity modified IgSF domain is an affinity modified domain of B7-1 (CD80). In some embodiments, an affinity modified CD80 (B7-1) IgSF domain of a TIP of the present invention is expressed on a first T-cell and is affinity modified to bind with increased affinity to the stimulatory counter-structure CD28 on the second T-cell. In some embodiments, the affinity modified IgSF domain is an affinity modified domain of ICOSL. In specific embodiments, the affinity modified IgSF domain is an affinity modified ICOSL (inducible costimulator ligand) domain and the stimulatory counter-structure is at least one of: ICOS (inducible costimulator) or CD28. In some embodiments, the ICOSL domain is affinity modified to specifically bind to both ICOS and CD28. In some embodiments, ICOSL is affinity modified to specifically bind to either ICOS or to CD28 but not both. In some embodiments, binding affinity to one of ICOS or CD28 is increased while binding affinity to the other is attenuated. In some embodiments, the affinity modified IgSF domain is an affinity modified CD155. In some embodiment, the affinity modified IgSF domain is an affinity modified CD112.

[0188] In some methods of the present invention, the transmembrane immunomodulatory protein attenuates the activity of an inhibitory receptor. In some cases, the increased binding affinity of the transmembrane immunomodulatory protein to a cognate cell surface molecule results in inhibition of specific binding between native counter-structures on mammalian cells. The greater affinity for that native counter-structure (relative to the competing affinity of the native IgSF member) attenuates specific binding affinity of native molecule to its counter-structure. Those of skill in the art will appreciate that antagonizing an inhibitory receptor signaling can in some embodiments attenuate immunological activity of that cell if, for example, the receptor is an inhibitory receptor that serves to cause those cellular effects.

[0189] Thus, in some embodiments, a TIP can be used to stimulate a cell on which the TIP is not expressed (i.e., the trans cell) while attenuating inhibition of the cell on which the TIP is expressed (the cis cell). For example, in some embodiments, the TIP comprises at least one affinity modified domain, and in some cases at least two affinity modified domains, that results in increased binding affinity to at least two cell surface cognate binding partners. In some

embodiments, a first cognate binding partner is a stimulatory receptor and the second cell surface cognate binding partner is an inhibitory ligand of an inhibitory receptor. In some embodiments, binding of the affinity-modified domain to the inhibitory ligand competitively inhibits binding of the inhibitory ligand to the inhibitory receptor. In some embodiments, the stimulatory receptor and inhibitory receptor can independently be expressed on immune cells, such as T cells or antigen presenting cells. In some embodiments the stimulatory receptor is expressed on lymphocytes, such as T cells. In some embodiments, the inhibitory receptor is expressed on the TIP-engineered cells, such as an engineered T-cell. In some embodiments, the inhibitory receptor is PD-1, CTLA-4, LAG-3, TIGIT, CD96, CD112R, BTLA, CD160 or TIM-3 and/or the ligand of the inhibitory receptor is PD-L1, PD-L2, B7-1, B7-2, HVEM, MHC class II, PVR, CEACAM-1 or GAL9 (see e.g. Table 1). In some embodiments, the inhibitory counter-structure (i.e. inhibitory ligand and inhibitory receptor) is PD-L1 or PD-1.

[0190] In some embodiments, a TIP can be used to attenuate inhibition of the cell on which the TIP is expressed, such as a T cell in which the TIP is expressed. For example, a TIP expressed on a T cell (e.g. first T-cell) can comprise an affinity modified IgSF domain that inhibits specific binding between a counter-structure on a second T-cell and an inhibitory counter-structure (i.e. inhibitory receptor) expressed on the first T-cell. In some cases, this embodiment can be used independently or in conjunction with embodiments wherein an affinity modified IgSF domain of the invention is expressed on a first T-cell and specifically binds at least one stimulatory counter-structure expressed on a second T-cell and increases immunological activity in the second T-cell. By this mechanism, an increased immunomodulatory response is generated in the second T-cell by specific binding of the TIP expressed on the first T-cell to a stimulatory counter-structure on the second cell; and the second T-cell is inhibited from attenuating the immunomodulatory activity of the first T-cell by specific binding of an affinity modified IgSF domain expressed on the first T-cell that inhibits specific binding by and between a counter-structure on the second T-cell and an inhibitory counter-structure expressed on the first T-cell. The T-cells used in this and the preceding embodiments are generally murine or human T-cells although other mammalian T-cells can be employed. Often, cytotoxic T-cells (CTL) are used.

[0191] As previously noted, in some embodiments a TIP of the present invention is expressed on a first T-cell and comprises an affinity modified IgSF domain that specifically binds to a stimulatory counter-structure (e.g. stimulatory receptor) on a second T-cell while also

inhibiting specific binding between a native counter-structure (e.g. inhibitory ligand) on the second T-cell to its inhibitory native counter-structure (e.g. inhibitory receptor) on the first T-cell. Inhibition of specific binding between the counter-structure on the second T-cell to the counter-structure on the first T-cell can be achieved by competitive binding of an affinity modified IgSF domain with at least one of the two native counter-structures such that their mutual binding is interfered with. Typically, the IgSF domain is affinity modified to have a higher binding affinity to its counter-structure than the native counter-structures have to each other. In some embodiments of this design, a TIP can comprise an affinity modified IgSF domain that binds to both the inhibitory and stimulatory counter-structures. Thus, in this embodiment the affinity-modified IgSF has dual binding capability. In some embodiments, a TIP comprises a first affinity-modified IgSF domain that binds a counter-structure on the first T-cell and a second affinity-modified IgSF domain that inhibits specific binding by and between the counter-structures on the first and second T-cells.

[0192] In yet another embodiment, the affinity modified IgSF domain that binds to the stimulatory counter-structure on the first T-cell is on a first TIP and the affinity modified IgSF domain that inhibits specific binding by and between the counter-structures on the first and second T-cells is on a second TIP. In this embodiment, the first and second TIP are different polypeptide chains. In some embodiments, the first affinity-modified IgSF domain and the second affinity-modified IgSF domain are the identical affinity-modified IgSF domain. For example, in a specific embodiment the ICOSL (inducible costimulator ligand) IgSF domain (e.g. affinity modified IgV domain) is affinity modified to specifically bind with increased affinity to both ICOS and CD28. In some embodiments, the affinity modified IgSF domain is an affinity modified ICOSL IgSF domain (e.g. affinity modified IgV domain) with increased affinity to both ICOS and CD28, or decreased affinity to one of or both of: ICOS and CD28.

[0193] In some embodiments, the transmembrane immunomodulatory proteins results in inhibition of specific binding by and between native counter-structures. In some embodiments, this can be achieved by an affinity-modified IgSF domain having greater affinity for one or both native counter-structures thereby competitively inhibiting the specific binding by and between these counter-structures.

[0194] In some embodiments, the TIP comprises an affinity modified IgSF domain that is an affinity modified CD155 IgSF domain with increased affinity to CD226 and attenuated affinity to TIGIT (T-cell immunoreceptor with Ig and ITIM domains).

[0195] In some embodiments, the TIP (e.g. expressed on a first T cell) comprises an affinity modified CD80 (B7-1) IgSF domain that is affinity modified to bind with increased affinity to the stimulatory counter-structure CD28 (e.g. on a second T-cell). Additionally, in this embodiment, the affinity modified CD80 (B7-1) domain can bind with increased affinity to PD-L1 (e.g. expressed on the second T-cell) and inhibit specific binding to its PD-1 counter-structure (e.g. expressed on the first T-cell). In yet a further addition either of the preceding embodiments, the affinity modified CD80 (B7-1) domain can be affinity modified such that it does not substantially specifically bind to CTLA-4 or binds with attenuated affinity and therefore is not significantly inhibited in its specific binding to the stimulatory counter-structure CD28 by CTLA-4.

[0196] In some embodiments, a transmembrane immunomodulatory protein (TIP) can be used as a decoy counter-structure to inhibit specific binding by and between native counter-structures, at least one of which comprises an IgSF family member. In some cases, specific binding of a TIP comprising an affinity modified IgSF domain with one of the native counter-structures inhibits mutual specific binding by and between the native counter-structures (e.g. native receptor and ligand pairs). Thus, in some embodiments, TIPs can attenuate specific binding by means of competitive or non-competitive binding. In some embodiments, the native counter-structure is a cell surface receptor, which can be a stimulatory receptor or an inhibitory receptor. Embodiments wherein specific binding of the affinity modified IgSF domain of a TIP increases or attenuates immunological activity of the T-cell are included within the scope of the invention.

[0197] In some embodiments, a native counter-structure is an inhibitory counter-structure that acts to attenuate immunological activity when specifically bound by its native counter-structure. For example, a native cell surface counter-structure expressed on an antigen presenting cell (APC) or a mammalian tumor cell can specifically bind a native inhibitory counter-structure on an NK cell or a lymphocyte such as a T-cell. Specific binding to the inhibitory counter-structure acts to attenuate immunomodulatory activity of the NK cell or lymphocyte on which the inhibitory counter-structure is expressed.

[0198] In some embodiments, an inhibitory counter-structure is an inhibitory receptor. In some embodiments, the inhibitory counter-structure is an ITIM (immunoreceptor tyrosine-based inhibition motif) containing inhibitory counter-structure. The ITIM motif is found in the endodomain of many inhibitory receptors of the immune system (Cell Signal, 16 (4): 435-456,

2004). In some embodiments, the affinity modified domain is an affinity modified form of a wild-type inhibitory receptor that results in greater affinity of the affinity modified domain of the TIP for its native binding partner than the wild-type inhibitory receptor for the native binding partner. Thus, in these embodiments a TIP can attenuate the inhibitory response of ITIM motif receptors by specific binding of the TIP affinity modified IgSF domain to its native IgSF domain counter-structure, such as specific binding of the TIP affinity modified IgSF domain to the ITIM containing inhibitory receptor. As an example, an ITIM containing counter-structure is PD-1. Typically, PD-1 is the inhibitory receptor that is specifically bound to the inhibitory ligand PD-L1. Upon specific binding of PD-L1 to PD-1, PD-1 is involved in inhibiting T-cell activation via signal transduction from the ITIM domain.

[0199] In some embodiments, the inhibitory receptor counter-structure is PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA. In some embodiments, the TIP contains an affinity-modified domain that is an affinity-modified IgSF domain of PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA that binds with greater affinity to the native inhibitory ligand of the inhibitory receptor than the wild-type inhibitory receptor (see Table 1 for ligand binding partners of exemplary inhibitory receptors). In some embodiments, a TIP can comprise an affinity modified PD-1 IgSF domain that binds with greater affinity to PD-L1 than wild-type PD-1. Specific binding can be achieved by competitive or non-competitive binding and are specific embodiments of the invention. Competitive binding by and between the affinity modified IgSF domain and the counter-structure (i.e. inhibitory receptor, e.g. PD-1) inhibits its binding to its native ligand counter-structure (e.g., PD-L1). In some embodiments, the TIP of this embodiment substantially lacks the signal transduction mechanism of the wild-type inhibitory receptor and therefore does not itself induce an inhibitory response.

IV. COMPOSITIONS, METHODS AND THERAPEUTIC APPLICATIONS

[0200] Provided herein are compositions and methods related to the provided transmembrane immunomodulatory proteins and engineered cells thereof for use in modulating immunological activity of a mammalian cell. The compositions can be used in associated methods to, for example, modulate immunological activity in an immunotherapy approach to the treatment of, for example, a mammalian cancer or, in other embodiments the treatment of autoimmune disorders. The methods employed generally comprise a method of contacting a TIP of the present invention with a mammalian cell under conditions that are permissive to

specific binding of the affinity modified IgSF domain and modulation of the immunological activity of the mammalian cell. The methods can be employed *ex vivo* or *in vivo*. In some embodiments, the method of modulating immunological activity is achieved by expression of a TIP of the present invention on a lymphocyte (e.g., a T-cell or TIL) or NK cell engineered to express the TIP. The cell expressing the TIP is contacted with a mammalian cell such as an APC, a second lymphocyte or tumor cell under conditions that are permissive of specific binding of the affinity modified IgSF domain to a counter-structure on the mammalian cell such that immunological activity can be modulated in the mammalian cell. In some embodiments, the method is conducted by adoptive cell transfer wherein cells expressing the TIP (e.g., a T-cell) are infused back into the patient.

[0201] Provided herein are methods of administering a therapeutic amount of a cell composition containing the provided transmembrane immunomodulatory proteins to a subject having a disease or disorder. The pharmaceutical compositions described herein can be used in a variety of therapeutic applications, such as the treatment of a disease. For example, in some embodiments the pharmaceutical composition is used to treat inflammatory or autoimmune disorders, cancer, organ transplantation, viral infections, and/or bacterial infections in a mammal. The pharmaceutical composition can modulate an immune response to treat the disease. For example, in some embodiments, the pharmaceutical composition stimulates the immune response, which can be useful, for example, in the treatment of cancer, viral infections, or bacterial infections. In some embodiments, the pharmaceutical composition suppresses an immune response, which can be useful in the treatment of inflammatory or autoimmune disorders, or organ transplantation.

[0202] The provided methods are believed to have utility in a variety of applications, including, but not limited to, e.g., in prophylactic or therapeutic methods for treating a variety of immune system diseases or conditions in a mammal in which modulation or regulation of the immune system and immune system responses is beneficial. For example, suppressing an immune response can be beneficial in prophylactic and/or therapeutic methods for inhibiting rejection of a tissue, cell, or organ transplant from a donor by a recipient. In a therapeutic context, the mammalian subject is typically one with an immune system disease or condition, and administration is conducted to prevent further progression of the disease or condition.

[0203] Cell compositions expressing transmembrane immunomodulatory proteins of the present invention and associated methods can be used in immunotherapy applications. In some embodiments, engineered cells for expression of a transmembrane immunomodulatory protein (TIP) are cells isolated from a mammal, such as a mouse or human. In some embodiments, the mammalian cell serving as a host cell for expression of a TIP is a lymphocyte such as a tumor infiltrating lymphocyte (TIL), a natural killer (NK) cell, or a T-cell such as a CD8+ cytotoxic T lymphocyte or a CD4+ helper T lymphocyte. In some embodiments, the cells are autologous cells. In aspects of the provided method, the engineered cells are contacted, generally under physiological conditions, with a mammalian cell in which modulation of immunological activity is desired. For example, the mammalian cell can be a murine or human cell such as an antigen presenting cell or tumor cell. In some embodiments, the engineered cells are autologous cells. In other embodiments, the cells are allogeneic. Cells can be contacted in vivo or ex vivo. In some embodiments, the engineered cells are administered to the subject, such as by infusion. Thus, composition and methods can be used in adoptive cell transfer immunotherapy.

[0204] In some embodiments, an effective amount of a pharmaceutical composition is administered to inhibit, halt, or reverse progression of cancers that are sensitive to modulation of immunological activity by transmembrane immunomodulatory proteins of the present invention. In some embodiments, the methods of the invention are used in the treatment of a mammalian patient of cancers such as lymphoma, lymphoid leukemia, myeloid leukemia, cervical cancer, neuroblastoma, or multiple myeloma. Other cancers which can be treated by the methods of the invention include, but are not limited to, melanoma, bladder cancer, hematological malignancies (leukemia, lymphoma, myeloma), liver cancer, brain cancer, renal cancer, breast cancer, pancreatic cancer (adenocarcinoma), colorectal cancer, lung cancer (small cell lung cancer and non-small-cell lung cancer), spleen cancer, cancer of the thymus or blood cells (i.e., leukemia), prostate cancer, testicular cancer, ovarian cancer, uterine cancer, gastric carcinoma, or Ewing's sarcoma.

[0205] Human cancer cells can be treated in vivo, or ex vivo. In ex vivo treatment of a human patient, tissue or fluids containing cancer cells are treated outside the body and then the tissue or fluids are reintroduced back into the patient. In some embodiments, the cancer is treated in a human patient in vivo by administration of the therapeutic composition into the patient. Thus, the present invention provides ex vivo and in vivo methods to inhibit, halt, or reverse progression of the tumor, or otherwise result in a statistically significant increase in

progression-free survival (i.e., the length of time during and after treatment in which a patient is living with cancer that does not get worse), or overall survival (also called “survival rate;” i.e., the percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for cancer) relative to treatment with a control.

[0206] In some embodiments, a pharmaceutical composition of the invention can also be used to inhibit growth of mammalian, particularly human, cancer cells as a monotherapy (i.e., as a single agent), in combination with at least one chemotherapeutic agent (i.e., a combination therapy), in combination with a cancer vaccine, in combination with an immune checkpoint inhibitor and/or in combination with radiation therapy. In some aspects of the present disclosure, the immune checkpoint inhibitor is nivolumab, tremelimumab, pembrolizumab, ipilimumab, or the like.

[0207] In some embodiments, the provided compositions can attenuate an immune response, such as, for example, where the transmembrane immunomodulatory protein comprises an affinity modified IgSF domain of an inhibitory ligand. In some embodiments, the compositions can be used to treat an autoimmune disease. In some embodiments, the administration of a therapeutic composition of the invention to a subject suffering from an immune system disease (e.g., autoimmune disease) can result in suppression or inhibition of such immune system attack or biological responses associated therewith. By suppressing this immune system attack on healthy body tissues, the resulting physical symptoms (e.g., pain, joint inflammation, joint swelling or tenderness) resulting from or associated with such attack on healthy tissues can be decreased or alleviated, and the biological and physical damage resulting from or associated with the immune system attack can be decreased, retarded, or stopped. In a prophylactic context, the subject may be one with, susceptible to, or believed to present an immune system disease, disorder or condition, and administration is typically conducted to prevent progression of the disease, disorder or condition, inhibit or alleviate symptoms, signs, or biological responses associated therewith, prevent bodily damage potentially resulting therefrom, and/or maintain or improve the subject's physical functioning.

[0208] In some embodiments, the pharmaceutical compositions comprising cells engineered with TIPs can be used to treat one or more other immune disease or disorder in the subject. The immune system disease or disorder of the patient may be or involve, e.g., but is not limited to, Addison's Disease, Allergy, Alopecia Areata, Alzheimer's, Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, Ankylosing Spondylitis, Antiphospholipid Syndrome

(Hughes Syndrome), arthritis, Asthma, Atherosclerosis, Atherosclerotic plaque, autoimmune disease (e.g., lupus, RA, MS, Graves' disease, etc.), Autoimmune Hemolytic Anemia, Autoimmune Hepatitis, Autoimmune inner ear disease, Autoimmune Lymphoproliferative syndrome, Autoimmune Myocarditis, Autoimmune Oophoritis, Autoimmune Orchitis, Azoospermia, Behcet's Disease, Berger's Disease, Bullous Pemphigoid, Cardiomyopathy, Cardiovascular disease, Celiac Sprue/Coeliac disease, Chronic Fatigue Immune Dysfunction Syndrome (CFIDS), Chronic idiopathic polyneuritis, Chronic Inflammatory Demyelinating, Polyradicalneuropathy (CIPD), Chronic relapsing polyneuropathy (Guillain-Barré syndrome), Churg-Strauss Syndrome (CSS), Cicatricial Pemphigoid, Cold Agglutinin Disease (CAD), COPD, CREST syndrome, Crohn's disease, Dermatitis, Herpetiformus, Dermatomyositis, diabetes, Discoid Lupus, Eczema, Epidermolysis bullosa acquisita, Essential Mixed Cryoglobulinemia, Evan's Syndrome, Exophthalmos, Fibromyalgia, Goodpasture's Syndrome, graft-related disease or disorder, Graves'Disease, GVHD, Hashimoto's Thyroiditis, Idiopathic Pulmonary Fibrosis, Idiopathic Thrombocytopenia Purpura (ITP), IgA Nephropathy, immunoproliferative disease or disorder (e.g., psoriasis), Inflammatory bowel disease (IBD), Insulin Dependent Diabetes Mellitus (IDDM), Interstitial lung disease, juvenile diabetes, Juvenile Arthritis, juvenile idiopathic arthritis (JIA), Kawasaki's Disease, Lambert-Eaton Myasthenic Syndrome, Lichen Planus, lupus, Lupus Nephritis, Lymphocytic Lymphoprophitis, Ménière's Disease, Miller Fish Syndrome/acute disseminated encephalomyeloradiculopathy, Mixed Connective Tissue Disease, Multiple Sclerosis (MS), muscular rheumatism, Myalgic encephalomyelitis (ME), Myasthenia Gravis, Ocular Inflammation, Pemphigus Foliaceus, Pemphigus Vulgaris, Pernicious Anaemia, Polyarteritis Nodosa, Polychondritis, Polyglandular Syndromes (Whitaker's syndrome), Polymyalgia Rheumatica, Polymyositis, Primary Agammaglobulinemia, Primary Biliary Cirrhosis/Autoimmune cholangiopathy, Psoriasis, Psoriatic arthritis, Raynaud's Phenomenon, Reiter's Syndrome/Reactive arthritis, Restenosis, Rheumatic Fever, rheumatic disease, Rheumatoid Arthritis, Sarcoidosis, Schmidt's syndrome, Scleroderma, Sjörger's Syndrome, Solid-organ transplant rejection (kidney, heart, liver, lung, etc.), Stiff-Man Syndrome, Systemic Lupus Erythematosus (SLE), systemic scleroderma, Takayasu Arteritis, Temporal Arteritis/Giant Cell Arteritis, Thyroiditis, Type 1 diabetes, Type 2 diabetes, Ulcerative colitis, Uveitis, Vasculitis, Vitiligo, Wegener's Granulomatosis, and preventing or suppressing an immune response associated with rejection of a donor tissue, cell, graft, or organ transplant by a recipient subject. Graft-related diseases or disorders include graft

versus host disease (GVDH), such as associated with bone marrow transplantation, and immune disorders resulting from or associated with rejection of organ, tissue, or cell graft transplantation (e.g., tissue or cell allografts or xenografts), including, e.g., grafts of skin, muscle, neurons, islets, organs, parenchymal cells of the liver, etc. With regard to a donor tissue, cell, graft or solid organ transplant in a recipient subject, it is believed that a therapeutic composition of the invention disclosed herein may be effective in preventing acute rejection of such transplant in the recipient and/or for long-term maintenance therapy to prevent rejection of such transplant in the recipient (e.g., inhibiting rejection of insulin-producing islet cell transplant from a donor in the subject recipient suffering from diabetes).

[0209] In some embodiments, a therapeutic amount of the pharmaceutical composition is administered. Typically, precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising engineered cells, e.g. T cells, as described herein may be administered at a dosage of 10^4 to 10^9 cells/kg body weight, such as 10^5 to 10^6 cells/kg body weight, including all integer values within those ranges. Engineered cell compositions, such as T cell compositions, may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al, New Eng. J. of Med. 319: 1676, 1988). The optimal dosage and treatment regime for a particular patient can readily be determined by one skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly.

[0210] The administration of the subject compositions may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In one embodiment, the therapeutic composition is administered to a patient by intradermal or subcutaneous injection. In another embodiment, the therapeutic compositions is administered by i.v. injection. In some cases, the cell compositions may be injected directly into a tumor, lymph node, or site of infection.

Pharmaceutical Formulation

[0211] Provided are pharmaceutical compositions containing the transmembrane immunomodulatory proteins, including engineered cells expressing such transmembrane immunomodulatory proteins. In some embodiments, the pharmaceutical compositions and formulations include one or more optional pharmaceutically acceptable carrier or excipient.

[0212] Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present invention are preferably formulated for intravenous administration.

[0213] Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages may be determined by clinical trials.

[0214] Such a formulation may, for example, be in a form suitable for intravenous infusion. A pharmaceutically acceptable carrier may be a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting cells of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or some combination thereof. Each component of the carrier must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation. It also must be suitable for contact with any tissue, organ, or portion of the body that it may encounter, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.

[0215] An effective amount of a pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding agent molecule is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician

may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. The pharmaceutical composition of the invention can be administered parentally, subcutaneously, or intravenously, or as described elsewhere herein. The pharmaceutical composition of the invention may be administered in a therapeutically effective amount one, two, three or four times per month, two times per week, biweekly (every two weeks), or bimonthly (every two months). Administration may last for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or longer (e.g., one, two, three, four or more years, including for the life of the subject).

[0216] For any composition, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, pigs, or monkeys. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. The exact dosage will be determined in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the cell composition or to maintain the desired effect. Factors that may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Appropriate dosages may be ascertained through use of appropriate dose-response data. A number of biomarkers or physiological markers for therapeutic effect can be monitored including T cell activation or proliferation, cytokine synthesis or production (e.g., production of TNF- α , IFN- γ , IL-2), induction of various activation markers (e.g., CD25, IL-2 receptor), inflammation, joint swelling or tenderness, serum level of C-reactive protein, anti-collagen antibody production, and/or T cell-dependent antibody response(s).

[0217] A variety of means are known for determining if administration of a therapeutic composition of the invention sufficiently modulates immunological activity by eliminating, sequestering, or inactivating immune cells mediating or capable of mediating an undesired immune response; inducing, generating, or turning on immune cells that mediate or are capable of mediating a protective immune response; changing the physical or functional properties of immune cells; or a combination of these effects. Examples of measurements of the modulation of immunological activity include, but are not limited to, examination of the presence or absence of immune cell populations (using flow cytometry, immunohistochemistry, histology, electron

microscopy, polymerase chain reaction (PCR)); measurement of the functional capacity of immune cells including ability or resistance to proliferate or divide in response to a signal (such as using T cell proliferation assays and pepsin analysis based on ³H-thymidine incorporation following stimulation with anti-CD3 antibody, anti-T cell receptor antibody, anti-CD28 antibody, calcium ionophores, PMA, antigen presenting cells loaded with a peptide or protein antigen; B cell proliferation assays); measurement of the ability to kill or lyse other cells (such as cytotoxic T cell assays); measurements of the cytokines, chemokines, cell surface molecules, antibodies and other products of the cells (e.g., by flow cytometry, enzyme-linked immunosorbent assays, Western blot analysis, protein microarray analysis, immunoprecipitation analysis); measurement of biochemical markers of activation of immune cells or signaling pathways within immune cells (e.g., Western blot and immunoprecipitation analysis of tyrosine, serine or threonine phosphorylation, polypeptide cleavage, and formation or dissociation of protein complexes; protein array analysis; DNA transcriptional, profiling using DNA arrays or subtractive hybridization); measurements of cell death by apoptosis, necrosis, or other mechanisms (e.g., annexin V staining, TUNEL assays, gel electrophoresis to measure DNA laddering, histology; fluorogenic caspase assays, Western blot analysis of caspase substrates); measurement of the genes, proteins, and other molecules produced by immune cells (e.g., Northern blot analysis, polymerase chain reaction, DNA microarrays, protein microarrays, 2-dimensional gel electrophoresis, Western blot analysis, enzyme linked immunosorbent assays, flow cytometry); and measurement of clinical symptoms or outcomes such as improvement of autoimmune, neurodegenerative, and other diseases involving self proteins or self polypeptides (clinical scores, requirements for use of additional therapies, functional status, imaging studies) for example, by measuring relapse rate or disease severity (using clinical scores known to the ordinarily skilled artisan) in the case of multiple sclerosis, measuring blood glucose in the case of type I diabetes, or joint inflammation in the case of rheumatoid arthritis.

V. EXEMPLARY EMBODIMENTS

[0218] Among the provided embodiments are:

1. A transmembrane immunomodulatory protein (TIP) comprising:
 - (i) an ectodomain comprising at least one non-immunoglobulin affinity-modified immunoglobulin superfamily (IgSF) domain comprising one or more amino acid substitution(s)

in a wild-type IgSF domain, wherein the at least one affinity-modified IgSF domain specifically binds at least one cell surface cognate binding partner of the wild-type IgSF domain; and

(ii) a transmembrane domain.

2. The transmembrane immunomodulatory protein of embodiment 1, wherein the at least one cell surface cognate binding partner is expressed on a mammalian cell.

3. The transmembrane immunomodulatory protein of embodiment 2, wherein the mammalian cell is an antigen presenting cell (APC), a tumor cell, or a lymphocyte, which optionally is a T-cell.

4. The transmembrane immunomodulatory protein of any of embodiments 1-3, wherein the mammalian cell is a mouse, rat, cynomolgus monkey, or human cell.

5. The transmembrane immunomodulatory protein of any of embodiments 1-4, wherein the at least one affinity modified IgSF domain has increased binding affinity to the at least one cell surface cognate binding partner compared with the reference wild-type IgSF domain.

6. The transmembrane immunomodulatory protein of any of embodiments 2-5, wherein specific binding of the transmembrane immunomodulatory protein comprising the at least one affinity-modified IgSF domain modulates immunological activity of the mammalian cell compared with the reference transmembrane domain comprising the wild-type IgSF domain.

7. The transmembrane immunomodulatory protein of any of embodiments 2-6, wherein specific binding of the transmembrane immunomodulatory protein comprising the at least one affinity-modified IgSF domain increases immunological activity of the mammalian cell compared with the reference transmembrane domain comprising the wild-type IgSF domain.

8. The transmembrane immunomodulatory protein of any of embodiments 2-6, wherein specific binding of the transmembrane immunomodulatory protein attenuates immunological activity of the mammalian cell compared with the reference transmembrane domain comprising the wild-type IgSF domain.

9. The transmembrane protein of any of embodiments 1-8, wherein the wild-type IgSF domain is from an IgSF family member of a family selected from Signal-Regulatory Protein (SIRP) Family, Triggering Receptor Expressed On Myeloid Cells Like (TREM) Family, Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM) Family, Sialic Acid Binding Ig-Like Lectin (SIGLEC) Family, Butyrophilin Family, B7 family, CD28 family, V-set and Immunoglobulin Domain Containing (VSIG) family, V-set transmembrane Domain

(VSTM) family, Major Histocompatibility Complex (MHC) family, Signaling lymphocytic activation molecule (SLAM) family, Leukocyte immunoglobulin-like receptor (LIR), Nectin (Nec) family, Nectin-like (NECL) family, Poliovirus receptor related (PVR) family, Natural cytotoxicity triggering receptor (NCR) family, T cell immunoglobulin and mucin (TIM) family or Killer-cell immunoglobulin-like receptors (KIR) family.

10. The transmembrane immunomodulatory protein of any of embodiments 1-9, wherein the wild-type IgSF domain is from an IgSF member selected from CD80, CD86, PD-L1, PD-L2, ICOS Ligand, B7-H3, B7-H4, CD28, CTLA4, PD-1, ICOS, BTLA, CD4, CD8-alpha, CD8-beta, LAG3, TIM-3, CEACAM1, TIGIT, PVR, PVRL2, CD226, CD2, CD160, CD200, CD200R or Nkp30.

11. The transmembrane immunomodulatory protein of any of embodiments 1-10, wherein the wild-type IgSF domain is a human IgSF member.

12. The transmembrane immunomodulatory protein of any of embodiments 1-11, wherein the at least one affinity modified IgSF domain has at least 90% sequence identity to a wild-type IgSF domain or a specific binding fragment thereof contained in the sequence of amino acids set forth in any of SEQ ID NOS: 1-54.

13. The transmembrane immunomodulatory protein of any of embodiments 1-12, wherein the transmembrane immunomodulatory protein has at least 90% sequence identity to the amino acid sequence selected from any of SEQ ID NOS: 393-419.

14. The transmembrane immunomodulatory protein of any of embodiments 1-13, wherein the at least one cell surface cognate binding partner is a stimulatory receptor expressed on a T-cell and the at least one affinity-modified IgSF domain has increased binding affinity to the stimulatory receptor compared to the affinity of the wild-type IgSF domain.

15. The transmembrane immunomodulatory protein of embodiment 14, wherein binding of the affinity-modified IgSF domain to the stimulatory receptor increases immunological activity of the T-cell.

16. The transmembrane immunomodulatory protein of embodiment 14 or embodiment 15, wherein the stimulatory receptor is CD28, ICOS or CD226.

17. The transmembrane immunomodulatory protein of any one of embodiments 14-16, wherein the at least one affinity-modified IgSF domain is an affinity modified B7-1 IgSF domain and the stimulatory receptor is CD28.

18. The transmembrane immunomodulatory protein of any one of embodiments 14-16, wherein the at least one affinity-modified IgSF domain is an affinity modified ICOSL IgSF domain and the stimulatory receptor is ICOS.

19. The transmembrane immunomodulatory protein of any one of embodiments 14-16, wherein the affinity-modified IgSF domain is an affinity modified ICOSL IgSF domain and the stimulatory receptor is CD28.

20. The transmembrane immunomodulatory protein of any one of embodiments 14-16, 18 and 19, wherein the at least one affinity-modified IgSF domain is an affinity-modified ICOSL IgSF domain that has increased binding affinity to at least one of: ICOS and CD28.

21. The transmembrane immunomodulatory protein of any one of embodiments 14-16- and 18-20, wherein the affinity modified IgSF domain is an affinity modified ICOSL IgV IgSF domain with increased binding affinity to both ICOS and CD28.

22. The transmembrane immunomodulatory protein of any one of embodiments 17-21, wherein the affinity-modified IgSF domain does not substantially specifically bind to CTLA-4 or exhibits decreased binding affinity to CTLA-4 compared to the wild-type IgSF domain.

23. The transmembrane immunomodulatory protein of any of embodiments 1-22, wherein the at least one affinity-modified IgSF domain specifically binds to no more than one cell surface cognate binding partner.

24. The transmembrane immunomodulatory protein of any of embodiments 1-23, wherein the transmembrane immunomodulatory protein specifically binds to no more than one cell surface cognate binding partner.

25. The transmembrane immunomodulatory protein of any of embodiments 1-22, wherein the at least one affinity-modified domain specifically binds to at least two cell surface cognate binding partners.

26. The transmembrane immunomodulatory protein of embodiment 25, wherein:
the first cell surface cognate binding partner is a stimulatory receptor expressed on a T cell; and

the second cell surface cognate binding partner is an inhibitory ligand of an inhibitory receptor, wherein the inhibitory receptor is expressed on a T-cell.

27. The transmembrane immunomodulatory protein of embodiment 26, wherein binding of the affinity-modified domain to the inhibitory ligand competitively inhibits binding of the inhibitory ligand to the inhibitory receptor.

28. The transmembrane immunomodulatory protein of embodiment 26 or embodiment 27, wherein:

the inhibitory receptor is PD-1, CTLA-4, LAG-3, TIGIT, CD96, CD112R, BTLA, CD160 or TIM-3; or

the ligand of the inhibitory receptor is PD-L1, PD-L2, B7-1, B7-2, HVEM, MHC class II, PVR, CEACAM-1 or GAL9.

29. The transmembrane immunomodulatory protein of any one of embodiments 26-28, wherein the affinity modified IgSF domain is an affinity modified B7-1 domain and the stimulatory receptor is CD28.

30. The transmembrane immunomodulatory protein of embodiment 29, wherein the inhibitory ligand is PD-L1 and the inhibitory receptor is PD-1.

31. The transmembrane immunomodulatory protein of embodiment 29 or embodiment 30, wherein the affinity-modified IgSF domain exhibits decreased binding affinity to CTLA-4 compared to the wild-type IgSF domain for CTLA-4.

32. The transmembrane immunomodulatory protein of any one of embodiments 29-31, wherein the affinity-modified IgSF domain does not substantially specifically bind to CTLA-4.

33. The transmembrane immunomodulatory protein of any of embodiments 1-13, wherein the affinity modified IgSF domain is an affinity modified CD155 IgSF domain or an affinity modified CD112 IgSF domain and the stimulatory receptor is CD226.

34. The transmembrane immunomodulatory protein of embodiment 33, wherein the affinity-modified IgSF domain exhibits decreased binding affinity to TIGIT (T-cell immunoreceptor with Ig and ITIM domains) compared to the affinity of the wild-type IgSF domain.

35. The transmembrane immunomodulatory protein of any of embodiments 1-13, wherein the at least one affinity-modified IgSF domain specifically binds to a cell surface cognate binding partner that is a tumor specific antigen.

36. The transmembrane immunomodulatory protein of embodiment 35, wherein the tumor specific antigen is B7-H6.

37. The transmembrane immunomodulatory protein of embodiment 35 or embodiment 36, wherein the affinity modified IgSF domain is an affinity modified Nkp30 IgSF domain.

38. The transmembrane immunomodulatory protein of any one of embodiments 1-37, wherein the at least one affinity-modified IgSF domain is a first affinity-modified IgSF domain and the ectodomain comprises a second affinity-modified IgSF domain.

39. The transmembrane immunomodulatory protein of embodiment 38, wherein the first and second affinity-modified IgSF domain are different.

40. The transmembrane immunomodulatory protein of embodiment 38 or embodiment 39, wherein the first affinity-modified IgSF domain and the second affinity-modified IgSF domain each comprise one or more amino acid different substitutions in the same wild-type IgSF domain.

41. The transmembrane immunomodulatory protein of embodiment 38 or embodiment 39, wherein the first affinity-modified IgSF domain and the second affinity-modified IgSF domain each comprise one or more amino acid substitutions in a different wild-type IgSF domain.

42. The transmembrane immunomodulatory protein of any of embodiments 1-41, wherein the transmembrane immunomodulatory protein further comprises an endodomain or cytoplasmic signaling domains.

43. The transmembrane immunomodulatory protein of embodiment 42, wherein the endodomain is the endodomain from the wild-type IgSF member comprising the wild-type IgSF domain or is a functionally active portion thereof.

44. The transmembrane immunomodulatory protein of embodiment 42, wherein the transmembrane immunomodulatory protein is a chimeric receptor, wherein the endodomain is not the endodomain from the wild-type IgSF member comprising the wild-type IgSF domain.

45. The transmembrane immunomodulatory protein of embodiment 42 or embodiment 44, wherein the endodomain comprises at least one ITAM (immunoreceptor tyrosine-based activation motif)-containing signaling domain.

46. The transmembrane immunomodulatory protein of any of embodiments 42, 44 and 45, wherein the endodomain comprises a CD3-zeta signaling domain.

47. The transmembrane immunomodulatory protein of embodiment 45 or embodiment 46, wherein the endodomain further comprises at least one of: a CD28 costimulatory domain, an ICOS signaling domain, an OX40 signaling domain, and a 41BB signaling domain.

48. The transmembrane immunomodulatory protein of any of embodiments 1-13, wherein the wild-type IgSF domain is from an IgSF member that is an inhibitory receptor comprising an ITIM signaling domain.

49. The transmembrane immunomodulatory protein of embodiment 48, wherein the inhibitory receptor is PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA and the at least one affinity-modified IgSF domain is an affinity-modified IgSF domain of PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA, respectively.

50. The transmembrane immunomodulatory protein of embodiment 48 or embodiment 49, wherein the inhibitory receptor is PD-1 and the at least one affinity-modified IgSF domain is an affinity-modified IgSF of PD-1.

51. The transmembrane immunomodulatory protein of any of embodiments 48-50, wherein the affinity-modified IgSF domain has increased binding affinity for a trans surface cognate binding partner compared to the wildtype IgSF domain, whereby the increased binding affinity competitively inhibits binding of the trans surface cognate binding partner to the inhibitory receptor.

52. The transmembrane immunomodulatory protein of any of embodiments 48-51, wherein the transmembrane immunomodulatory protein does not comprise an endodomain, ITIM or cytoplasmic signaling domains.

53. The transmembrane immunomodulatory protein of any of embodiments 1-52, wherein the affinity modified IgSF domain differs by no more than ten amino acid substitutions from the wildtype IgSF domain.

54. The transmembrane immunomodulatory protein of any of embodiments 1-53, wherein the affinity modified IgSF domain differs by no more than five amino acid substitutions from the wildtype IgSF domain.

55. The transmembrane immunomodulatory protein of any of embodiments 1-54, wherein the affinity-modified IgSF domain is or comprises an affinity modified IgV domain, affinity modified IgC1 domain or an affinity modified IgC2 domain or is a specific binding fragment thereof comprising the one or more amino acid substitutions.

56. The transmembrane immunomodulatory protein of any of embodiments 1-55, wherein the ectodomain further comprises one or more non-affinity modified IgSF domains.

57. The transmembrane immunomodulatory protein of embodiment 56, wherein the one or more non-affinity modified IgSF domains is from a wild-type IgSF member comprising the wild-type IgSF domain.

58. The transmembrane immunomodulatory protein of any of embodiments 1-57, wherein the transmembrane domain is the native transmembrane domain from the corresponding wild-type IgSF member.

59. The transmembrane immunomodulatory protein of any of embodiments 1-57, wherein the transmembrane domain is not the native transmembrane domain from the corresponding wild-type IgSF member.

60. The transmembrane immunomodulatory protein of embodiment 59, wherein the transmembrane protein is a transmembrane protein derived from CD8.

61. A recombinant nucleic acid encoding a transmembrane immunomodulatory proteins of any of embodiments 1-60.

62. A recombinant expression vector comprising the nucleic acid of embodiment 61.

63. A recombinant host cell comprising the expression vector of embodiment 62.

64. A recombinant host cell comprising the nucleic acid of embodiment 61.

65. The recombinant host cell of embodiment 63 or embodiment 64, wherein the host cell is a mammalian host cell.

66. The recombinant host cell of any of embodiments 63-65, wherein the mammalian host cell is a human host cell.

67. An engineered cell comprising the transmembrane immunomodulatory protein of any of embodiments 1-60.

68. The engineered cell of embodiment 67, wherein the cell is an immune cell.

69. The engineered cell of embodiment 67 or embodiment 68, wherein the cell is a lymphocyte.

70. The engineered cell of embodiment 69, wherein the lymphocyte is a T cell, a B cell or an NK cell.

71. The engineered cell of any of embodiments 67-70, wherein the cell is a T cell.

72. The engineered cell of embodiment 71, wherein the T cells is CD4+ or CD8+.

73. The engineered cell of embodiment 67 or embodiment 68, wherein the cell is an antigen presenting cell.

74. The engineered cell of any of embodiments 67-73, further comprising a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR).
75. A pharmaceutical composition comprising the cell of any of embodiments 67-74 and a pharmaceutically acceptable carrier.
76. The pharmaceutical composition of embodiment 75 that is sterile.
77. A method of modulating an immune response in a mammalian subject, comprising administering a cell of any of embodiments 67-74 or a pharmaceutical composition of embodiment 75 or embodiment 76 to the subject.
78. The method of embodiment 76 or embodiment 77, wherein modulating the immune response treats a disease or disorder in the subject.
79. The method of any of embodiments 77-78, wherein the modulated immune response is increased.
80. The method of embodiment 78 or embodiment 79, wherein the disease or disorder is a tumor.
81. The method of any of embodiments 78-80, wherein the disease or disorder is a cancer.
82. The method of any of embodiments 78-81, wherein the disease or disorder is melanoma, lung cancer, bladder cancer, or a hematological malignancy.
83. The method of any of embodiments 77-78, wherein the modulated immune response is decreased.
84. The method of embodiment 78 or embodiment 83, wherein the disease or disorder is an inflammatory disease or condition.
85. The method of any of embodiments 78, 83 and 84, wherein the disease or condition is Crohn's disease, ulcerative colitis, multiple sclerosis, asthma, rheumatoid arthritis, or psoriasis.
86. The method of any of embodiments 77-85, wherein the subject is human.
87. The method of any of embodiments 77-86, wherein the cell is autologous to the subject.
88. The method of any of embodiments 77-87, wherein the cell is allogenic to the subject.
89. A transmembrane immunomodulatory protein (TIP) comprising:

an ectodomain, wherein the ectodomain comprises at least one non-immunoglobulin affinity-modified immunoglobulin superfamily (IgSF) domain; and

a transmembrane domain, wherein: the TIP is expressed on a first T-cell; the affinity-modified IgSF domain specifically binds at least one counter-structure expressed on a mammalian cell; the mammalian cell is an antigen presenting cell (APC), a tumor cell, or a second T-cell; and specific binding of the affinity-modified IgSF domain to a counter-structure modulates immunological activity of the mammalian cell.

90. The transmembrane immunomodulatory protein (TIP) of embodiment 89, wherein:

the TIP comprises a first affinity-modified IgSF domain, wherein the counter-structure expressed on the mammalian cell is a stimulatory counter-structure expressed on the second T-cell; and

the first affinity-modified IgSF domain specifically binds to the stimulatory counter-structure and increases immunomodulatory activity of the second T-cell.

91. The transmembrane immunomodulatory protein of embodiment 90, further comprising a second affinity-modified IgSF domain expressed on the first T-cell that competitively inhibits specific binding of a counter-structure expressed on the second T-cell to its inhibitory counter-structure expressed on the first T-cell.

92. The transmembrane immunomodulatory protein of embodiment 91, wherein the first affinity modified IgSF domain is an affinity modified B7-1 domain and the stimulatory counter-structure is CD28.

93. The transmembrane immunomodulatory protein of embodiment 92, wherein the counter-structure expressed on the second T-cell is PD-L1 and the inhibitory counter-structure expressed on the first T-cell is PD-1.

94. The transmembrane immunomodulatory protein (TIP) according to embodiments 92 or 93, wherein the first affinity-modified IgSF domain does not substantially specifically bind to CTLA-4.

95. The transmembrane immunomodulatory protein of embodiment 90, wherein the first affinity-modified IgSF domain is an affinity modified ICOSL domain and the stimulatory counter-structure is ICOS.

96. The transmembrane immunomodulatory protein of embodiment 90, wherein the first affinity-modified IgSF domain is an affinity modified ICOSL domain and the stimulatory counter-structure is CD28.

97. The transmembrane immunomodulatory protein of embodiment 90, wherein the first affinity-modified IgSF domain has increased affinity to the stimulatory counter-structure.

98. The transmembrane immunomodulatory protein (TIP) of embodiment 91, wherein the TIP ectodomain comprises both the first affinity-modified IgSF domain and the second affinity-modified IgSF domain.

99. The transmembrane immunomodulatory protein of embodiment 98, wherein the first affinity-modified IgSF domain and the second affinity-modified IgSF domain are the identical affinity-modified IgSF domain.

100. The transmembrane immunomodulatory protein of embodiment 91, wherein at least one of the first and second T-cell is a native T-cell or an engineered T-cell.

101. The transmembrane immunomodulatory protein of embodiment 91, wherein the engineered T-cell is a chimeric antigen receptor (CAR) or a T-cell receptor (TCR) engineered T-cell.

102. The transmembrane immunomodulatory protein of embodiment 90, wherein the first affinity modified IgSF domain is an ICOSL (inducible costimulator ligand) IgV IgSF domain with increased affinity to at least one of: ICOS and CD28.

103. The transmembrane immunomodulatory protein of embodiment 90, wherein the first affinity modified IgSF domain is an affinity modified ICOSL IgV IgSF domain with increased affinity to both ICOS and CD28.

104. The transmembrane immunomodulatory protein of embodiment 91, wherein the first affinity modified IgSF domain is a CD155 IgSF domain with increased affinity to CD226 and attenuated affinity to TIGIT (T-cell immunoreceptor with Ig and ITIM domains).

105. The transmembrane immunomodulatory protein of embodiment 89, wherein the mammalian cell is an autologous cell.

106. The transmembrane immunomodulatory protein of embodiment 89, wherein the mammalian cell is an allogenic cell.

107. The transmembrane immunomodulatory protein of embodiment 89, wherein the mammalian cell is a mouse, rat, cynomolgus monkey, or human cell.

108. The transmembrane immunomodulatory protein of embodiment 89, further comprising an endodomain or cytoplasmic signaling domains.

109. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity-modified IgSF domain specifically binds to the counter-structure on the mammalian cell with increased affinity.

110. The transmembrane immunomodulatory protein of embodiment 109, wherein immunological activity of the mammalian cell is increased.

111. The transmembrane immunomodulatory protein of embodiment 89, wherein immunological activity of the mammalian cell is attenuated.

112. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity modified IgSF domain differs by no more than ten amino acid substitutions from the native IgSF domain.

113. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity modified IgSF domain differs by no more than five amino acid substitutions from the native IgSF domain.

114. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity modified IgSF domain specifically binds to no more than one counter-structure.

115. The transmembrane immunomodulatory protein (TIP) of embodiment 89, wherein the TIP specifically binds to no more than one cell surface counter-structure.

116. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity modified IgSF domain specifically binds to at least two cell surface counter-structures.

117. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity modified IgSF domain is an affinity modified IgV, IgC1, or IgC2 domain.

118. The transmembrane immunomodulatory protein of embodiment 89, wherein the affinity-modified IgSF domain has increased binding affinity for a first counter-structure expressed on a mammalian cell, whereby the increased binding affinity competitively inhibits binding of the first counter-structure to a second counter-structure.

119. The transmembrane immunomodulatory protein of embodiment 118, wherein the second counter-structure is a cell surface receptor.

120. The transmembrane immunomodulatory protein of embodiment 119, wherein the cell surface receptor is an inhibitory receptor.

121. The transmembrane immunomodulatory protein of embodiment 120, wherein the inhibitory receptor is PD-1 and the affinity-modified IgSF domain is a PD-1 IgSF domain.

122. The transmembrane immunomodulatory protein of embodiment 118, wherein the second counter-structure is PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA.

123. The transmembrane immunomodulatory protein (TIP) of embodiment 118, wherein the TIP increases immunological activity of the T-cell.

124. The transmembrane immunomodulatory protein (TIP) of embodiment 89, wherein the TIP is a chimeric antigen receptor (CAR), and wherein the affinity-modified IgSF domain specifically binds to a tumor specific IgSF counter-structure.

125. The transmembrane immunomodulatory protein of embodiment 124, wherein the CAR endodomain comprises a CD3-zeta signaling domain.

126. The transmembrane immunomodulatory protein of embodiment 124, wherein the CAR endodomain comprises at least one CD3 ITAM (immunoreceptor tyrosine-based activation motif).

127. The transmembrane immunomodulatory protein of embodiment 125, wherein the CAR endodomain further comprises at least one of: a CD28 costimulatory domain, an OX40 signaling domain, and a 41BB signaling domain.

128. The transmembrane immunomodulatory protein of embodiment 124, wherein the affinity modified IgSF domain specifically binds the tumor specific antigen B7-H6.

129. The transmembrane immunomodulatory protein according to embodiments 89, 90, or 91, wherein the transmembrane immunomodulatory protein has at least 90% sequence identity with an amino acid sequence selected from SEQ ID NOS: 1-26.

130. The transmembrane immunomodulatory protein according to embodiments 89, 90, or 91, wherein the transmembrane immunomodulatory protein has at least 95% sequence identity with an amino acid sequence selected from SEQ ID NOS: 1-26.

131. A recombinant nucleic acid encoding any one of the transmembrane immunomodulatory proteins of embodiments 89 to 130.

132. A recombinant expression vector comprising a nucleic acid according to embodiment 131.

133. A recombinant host cell comprising the expression vector of embodiment 132.

134. The recombinant host cell of embodiment 133, wherein the host cell is a mammalian host cell.

135. The recombinant host cell of embodiment 133 wherein the mammalian host cell is a human host cell.

136. A method of treating a mammalian patient in need of an enhanced or inhibited immunological response by administering a therapeutically effective amount of a transmembrane immunomodulatory protein of any one of embodiments 89 to 130.

137. The method of embodiment 136, wherein the enhanced immunological response treats melanoma, lung cancer, bladder cancer, or a hematological malignancy in the patient.

138. The method of embodiment 136, wherein the inhibited immunological response treats Crohn's disease, ulcerative colitis, multiple sclerosis, asthma, rheumatoid arthritis, or psoriasis in the patient.

VI. EXAMPLES

[0219] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

[0220] Examples 1-10 describe the design, creation, and screening of affinity modified CD80 (B7-1), CD86 (B7-2), ICOSL, and NKp30 immunomodulatory proteins, which are components of the immune synapse (IS) that have a demonstrated dual role in both immune activation and inhibition. These examples demonstrate that affinity modification of IgSF domains yields proteins that can act to both increase and decrease immunological activity. This work also describes the various combinations of those domains fused in pairs (i.e., stacked) to form a Type II immunomodulatory protein to achieve immunomodulatory activity. Example 11 further exemplifies such domains in a transmembrane immunomodulatory protein (TIP) format and the generation of engineered cells co-expressing the TIP with a chimeric antigen receptor (CAR).

EXAMPLE 1

Generation of Mutant DNA Constructs of IgSF Domains

[0221] Example 1 describes the generation of mutant DNA constructs of human CD80, CD86, ICOSL and NKp30 IgSF domains for translation and expression on the surface of yeast as yeast display libraries.

A. Degenerate Libraries

[0222] For libraries that target specific residues of target protein for complete or partial randomization with degenerate codons, the coding DNAs for the extracellular domains (ECD) of human CD80 (SEQ ID NO:28), ICOSL (SEQ ID NO:32), and NKp30 (SEQ ID NO:54) were ordered from Integrated DNA Technologies (Coralville, IA) as a set of overlapping oligonucleotides of up to 80 base pairs (bp) in length. To generate a library of diverse variants of each ECD, the oligonucleotides contained desired degenerate codons at desired amino acid positions. Degenerate codons were generated using an algorithm at the URL: rosettadesign.med.unc.edu/SwiftLib/.

[0223] In general, positions to mutate and degenerate codons were chosen from crystal structures (CD80, NKp30) or homology models (ICOSL) of the target-ligand pairs of interest were used to identify ligand contact residues as well as residues that are at the protein interaction interface. This analysis was performed using a structure viewer available at the URL: spdbv.vital-it.ch). For example, a crystal structure for CD80 bound to CTLA4 is publicly available at the URL: www.rcsb.org/pdb/explore/explore.do?structureId=1I8L and a targeted library was designed based on the CD80::CTLA4 interface for selection of improved binders to CTLA4. However, there are no CD80 structures available with ligands CD28 and PDL1, so the same library was also used to select for binders of CD28 (binds the same region on CD80 as CTLA4) and PDL1 (not known if PDL1 binds the same site as CTLA4). The next step in library design was the alignment of human, mouse, rat and monkey CD80, ICOSL or NKp30 sequences to identify conserved residues. Based on this analysis, conserved target residues were mutated with degenerate codons that only specified conservative amino acid changes plus the wild-type residue. Residues that were not conserved were mutated more aggressively, but also including the wild-type residue. Degenerate codons that also encoded the wild-type residue were deployed to avoid excessive mutagenesis of target protein. For the same reason, only up to 20 positions were targeted for mutagenesis at a time. These residues were a combination of contact residues and non-contact interface residues.

[0224] The oligonucleotides were dissolved in sterile water, mixed in equimolar ratios, heated to 95°C for five minutes and slowly cooled to room temperature for annealing. ECD-specific oligonucleotide primers that anneal to the start and end of the ECDs, respectively, were then used to generate PCR product. The ECD-specific oligonucleotides which overlap by 40-50bp with a modified version of pBYDS03 cloning vector (Life Technologies USA), beyond

and including the BamH1 and Kpn1 cloning sites, were then used to amplify 100ng of PCR product from the prior step to generate a total of 5 µg of DNA. Both PCR's were by polymerase chain reaction (PCR) using OneTaq 2x PCR master mix (New England Biolabs, USA). The second PCR products were purified using a PCR purification kit (Qiagen, Germany) and resuspended in sterile deionized water. To prepare for library insertion, a modified yeast display version of vector pBYDS03 was digested with BamH1 and Kpn1 restriction enzymes (New England Biolabs, USA) and the large vector fragment was gel-purified and dissolved in sterile, deionized water. Electroporation-ready DNA for the next step was generated by mixing 12 µg of library DNA with 4 µg of linearized vector in a total volume of 50 µl deionized and sterile water. An alternative way to generate targeted libraries was to carry out site-directed mutagenesis (Multisite kit, Agilent, USA) of target ECDs with oligonucleotides containing degenerate codons. This approach was used to generate sublibraries that only target specific stretches of the DNA for mutagenesis. In these cases, sublibraries were mixed before proceeding to the selection steps. In general, library sizes were in the range of 10E7 to 10E8 clones, except that sublibraries were only in the range of 10E4 to 10E5. Large libraries and sublibraries were generated for CD80, ICOSL, CD86 and NKp30. Sublibraries were generated for CD80, ICOSL and NKp30.

B. Random Libraries

[0225] Random libraries were also constructed to identify variants of the ECD of CD80 (SEQ ID NO:28), CD86 (SEQ ID NO: 29), ICOSL (SEQ ID NO:32) and NKp30 (SEQ ID NO:54). DNA encoding wild-type ECDs was cloned between the BamH1 and Kpn1 sites of modified yeast display vector pBYDS03 and then released using the same restriction enzymes. The released DNA was then mutagenized with the Genemorph II kit (Agilent, USA) so as to generate an average of three to five amino acid changes per library variant. Mutagenized DNA was then amplified by the two-step PCR and further processed as described above for targeted libraries.

EXAMPLE 2

Introduction of DNA Libraries into Yeast

[0226] Example 2 describes the introduction of CD80, CD86, ICOSL and NKp30 DNA libraries into yeast.

[0227] To introduce degenerate and random library DNA into yeast, electroporation-competent cells of yeast strain BJ5464 (ATCC.org; ATCC number 208288) were prepared and electroporated on a Gene Pulser II (Biorad, USA) with the electroporation-ready DNA from the step above essentially as described (Colby, D.W. et al. 2004 *Methods Enzymology* 388, 348-358). The only exception is that transformed cells were grown in non-inducing minimal selective SCD-Leu medium to accommodate the LEU2 selective marker carried by modified plasmid pBYDS03.

[0228] Library size was determined by plating dilutions of freshly recovered cells on SCD-Leu agar plates and then extrapolating library size from the number of single colonies from plating that generated at least 50 colonies per plate. The remainder of the electroporated culture was grown to saturation and cells from this culture were subcultured into the same medium once more to minimize the fraction of untransformed cells. To maintain library diversity, this subculturing step was carried out using an inoculum that contained at least 10x more cells than the calculated library size. Cells from the second saturated culture were resuspended in fresh medium containing sterile 25% (weight/volume) glycerol to a density of 10^{10} /ml and frozen and stored at -80°C (frozen library stock).

[0229] One liter of SCD-Leu media consists of 14.7 grams of sodium citrate, 4.29 grams of citric acid monohydrate, 20 grams of dextrose, 6.7 grams of Difco brand yeast nitrogen base, and 1.6 grams yeast synthetic drop-out media supplement without leucine. Media was filtered sterilized before use using a $0.2\ \mu\text{M}$ vacuum filter device.

[0230] Library size was determined by plating dilutions of freshly recovered cells on SCD-Leu agar plates and then extrapolating library size from the number of single colonies from a plating that generate at least 50 colonies per plate.

[0231] To segregate plasmid from cells that contain two or more different library clones, a number of cells corresponding to 10 times the library size, were taken from the overnight SCD-Leu culture and subcultured 1/100 into fresh SCD-Leu medium and grown overnight. Cells from this overnight culture were resuspended in sterile 25% (weight/volume) glycerol to a density of 10^{10} /ml and frozen and stored at -80°C (frozen library stock).

EXAMPLE 3

Yeast Selection

[0232] Example 3 describes the selection of yeast expressing affinity modified variants of CD80, CD86, ICOSL and NKp30.

[0233] A number of cells equal to at least 10 times the library size were thawed from individual library stocks, suspended to 0.1×10^6 cells/ml in non-inducing SCD-Leu medium, and grown overnight. The next day, a number of cells equal to 10 times the library size were centrifuged at 2000 RPM for two minutes and resuspended to 0.5×10^6 cells/ml in inducing SCDG-Leu media. One liter of the SCDG-Leu induction media consists of 5.4 grams Na_2HPO_4 , 8.56 grams of $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$, 20 grams galactose, 2.0 grams dextrose, 6.7 grams Difco yeast nitrogen base, and 1.6 grams of yeast synthetic drop out media supplement without leucine dissolved in water and sterilized through a $0.22 \mu\text{m}$ membrane filter device. The culture was grown for two days at 20°C to induce expression of library proteins on the yeast cell surface.

[0234] Cells were processed with magnetic beads to reduce non-binders and enrich for all CD80, CD86, ICOSL or NKp30 variants with the ability to bind their exogenous recombinant counter-structure proteins (cognate binding partners). For example, yeast displayed targeted or random CD80 libraries were selected against each of CD28, CTLA-4, PD-L1. ICOSL libraries were selected against ICOS and CD28 and NKp30 libraries were selected against B7-H6. This was then followed by two to three rounds of fluorescence activated cell sorting (FACS) using exogenous counter-structure protein staining to enrich the fraction of yeast cells that displays improved binders. Magnetic bead enrichment and selections by flow cytometry are essentially as described in Keith D. Miller,¹ Noah B. Pefaur,² and Cheryl L. Baird¹ Current Protocols in Cytometry 4.7.1-4.7.30, July 2008.

[0235] With CD80, CD86, ICOSL, and NKp30 libraries, target ligand proteins were sourced from R&D Systems (USA) as follows: human rCD28.Fc (i.e., recombinant CD28-Fc fusion protein), rPDL1.Fc, rCTLA4.Fc, rICOS.Fc, and rB7H6.Fc. Magnetic streptavidin beads were obtained from New England Biolabs, USA. For biotinylation of counter-structure protein, biotinylation kit cat# 21955, Life Technologies, USA, was used. For two-color, flow cytometric sorting, a Becton Dickinson FACS Aria II sorter was used. CD80, CD86, ICOSL, or NKp30 display levels were monitored with an anti-hemagglutinin tag antibody labeled with Alexafluor 488 (Life Technologies, USA). Ligand binding Fc fusion proteins rCD28.Fc, rCTLA4.Fc, rPDL1.Fc, rICOS.Fc, or rB7-H6.Fc were detected with PE conjugated human Ig specific goat

Fab (Jackson ImmunoResearch, USA). Doublet yeast were gated out using forward scatter (FSC) / side scatter (SSC) parameters, and sort gates were based upon higher ligand binding detected in FL2 that possessed more limited HA tag expression binding in FL1.

[0236] Yeast outputs from the flow cytometric sorts were assayed for higher specific binding affinity. Sort output yeast were expanded and re-induced to express the particular IgSF affinity modified domain variants they encode. This population then can be compared to the parental, wild-type yeast strain, or any other selected outputs, such as the bead output yeast population, by flow cytometry.

[0237] For ICOSL, the second sort outputs (F2) were compared to parental ICOSL yeast for binding of each rICOS.Fc, rCD28.Fc, and rCTLA4.Fc by double staining each population with anti-HA (hemagglutinin) tag expression and the anti-human Fc secondary to detect ligand binding.

[0238] In the case of ICOSL yeast variants selected for binding to ICOS, the F2 sort outputs gave Mean Fluorescence Intensity (MFI) values of 997, when stained with 5.6 nM rICOS.Fc, whereas the parental ICOSL strain MFI was measured at 397 when stained with the same concentration of rICOS.Fc. This represents a roughly three-fold improvement of the average binding in this F2 selected pool of clones, and it is predicted that individual clones from that pool will have much better improved MFI/affinity when individually tested.

[0239] In the case of ICOSL yeast variants selected for binding to CD28, the F2 sort outputs gave MFI values of 640 when stained with 100nM rCD28.Fc, whereas the parental ICOSL strain MFI was measured at 29 when stained with the same concentration of rCD28.Fc (22-fold improvement). In the case of ICOSL yeast variants selected for binding to CTLA4, the F2 sort outputs gave MFI values of 949 when stained with 100nM rCTLA4.Fc, whereas the parental ICOSL strain MFI was measured at 29 when stained with the same concentration of rCTLA4.Fc (32-fold improvement).

[0240] In the case of NKp30 yeast variants selected for binding to B7-H6, the F2 sort outputs gave MFI values of 533 when stained with 16.6nM rB7H6.Fc, whereas the parental NKp30 strain MFI was measured at 90 when stained with the same concentration of rB7H6.Fc (6-fold improvement).

[0241] Importantly, the MFIs of all F2 outputs described above when measured with the anti-HA tag antibody on FL1 did not increase and sometimes decreased compared to wild-type strains, indicating that increased binding was not a function of increased expression of the selected variants on the surface of yeast, and validated gating strategies of only selecting mid to low expressors with high ligand binding.

EXAMPLE 4

Reformatting Selection Outputs as Fc-Fusions and in Various Immunomodulatory Protein Types

[0242] Example 4 describes reformatting of selection outputs as immunomodulatory proteins containing an affinity modified (variant) extracellular domain (ECD) of CD80 or ICOSL fused to an Fc molecule (variant ECD-Fc fusion molecules).

[0243] Output cells from final flow cytometric CD80 and ICOSL sorts were grown to terminal density in SCD-Leu medium. Plasmid DNA from each output were isolated using a yeast plasmid DNA isolation kit (Zymoresearch, USA). For Fc fusions, PCR primers with added restriction sites suitable for cloning into the Fc fusion vector of choice were used to batch-amplify from the plasmid DNA preps the coding DNA for the mutant target's ECD. After restriction digestion, the PCR products were ligated into an appropriate Fc fusion vector followed by chemical transformation into strain XL1 Blue E. Coli (Agilent, USA) or NEB5alpha (New England Biolabs) as directed by supplier Exemplary of an Fc fusion vector is pFUSE-hIgG1-Fc2 (Invivogen, USA).

[0244] Dilutions of transformation reactions were plated on LB-agar containing 100 µg/ml carbenicillin (Teknova, USA) to generate single colonies. Up to 96 colonies from each transformation were then grown in 96 well plates to saturation overnight at 37°C in LB-broth (Teknova cat # L8112) and a small aliquot from each well was submitted for DNA sequencing of the ECD insert in order to identify the mutation(s) in all clones. Sample preparation for DNA sequencing was carried out using protocols provided by the service provider (Genewiz; South Plainfield, NJ). After removal of sample for DNA sequencing, glycerol was then added to the remaining cultures for a final glycerol content of 25% and plates were stored at -20°C for future use as master plates (see below). Alternatively, samples for DNA sequencing were generated by replica plating from grown liquid cultures to solid agar plates using a disposable 96 well

replicator (VWR, USA). These plates were incubated overnight to generate growth patches and the plates were submitted to Genewiz as specified by Genewiz.

[0245] After identification of clones of interest from analysis of Genewiz-generated DNA sequencing data, clones of interest were recovered from master plates and individually grown to density in 5 ml liquid LB-broth containing 100 µg/ml carbenicillin (Teknova, USA) and 2 ml of each culture were then used for preparation of approximately 10 µg of miniprep plasmid DNA of each clone using a standard kit such as the Pureyield kit (Promega). Identification of clones of interest generally involved the following steps. First, DNA sequence data files were downloaded from the Genewiz website. All sequences were then manually curated so that they start at the beginning of the ECD coding region. The curated sequences were then batch-translated using a suitable program available at the URL: www.ebi.ac.uk/Tools/st/emboss_transeq/. The translated sequences were then aligned using a suitable program available at the URL: multalin.toulouse.inra.fr/multalin/multalin.html.

[0246] Clones of interest were then identified using the following criteria: 1.) identical clone occurs at least two times in the alignment and 2.) a mutation occurs at least two times in the alignment and preferably in distinct clones. Clones that meet at least one of these criteria were clones that have been enriched by our sorting process due to improved binding.

[0247] The methods generated immunomodulatory proteins containing an ECD of CD80 or ICOSL with at least one affinity-modified domain in which the encoding DNA was generated to encode a protein designed as follows: signal peptide followed by variant (mutant) ECD followed by a linker of three alanines (AAA) followed by a human IgG1 Fc containing the mutation N297G (N82G with reference to wild-type human IgG1 Fc set forth in SEQ ID NO: 226). The human IgG1 Fc also contained the mutations R292C and V302C (corresponding to R77C and V87C with reference to wild-type human IgG1 Fc set forth in SEQ ID NO: 226). Since the construct does not include any antibody light chains that can form a covalent bond with a cysteine, the human IgG1 Fc also contained replacement of the cysteine residues to a serine residue at position 5 (C5S) compared to the wild-type or unmodified Fc set forth in SEQ ID NO: 226.

[0248] In addition, Example 8 below describes further immunomodulatory proteins that were generated as stack constructs containing at least two different affinity modified domains from identified variant CD80, CD86, ICOSL, and NKp30 molecules linked together and fused to an Fc.

EXAMPLE 5

Expression and Purification of Fc-Fusions

[0249] Example 5 describes the high throughput expression and purification of Fc-fusion proteins containing variant ECD CD80, CD86, ICOSL, and Nkp30.

[0250] Recombinant variant Fc fusion proteins were produced with Expi293 expression system (Invitrogen, USA). 4µg of each plasmid DNA from the previous step was added to 200µl Opti-MEM (Invitrogen, USA) at the same time as 10.8µl ExpiFectamine was separately added to another 200µl Opti-MEM. After 5 minutes, the 200µl of plasmid DNA was mixed with the 200µl of ExpiFectamine and was further incubated for an additional 20 minutes before adding this mixture to cells. Ten million Expi293 cells were dispensed into separate wells of a sterile 10ml, conical bottom, deep 24 well growth plate (Thomson Instrument Company, USA) in a volume 3.4ml Expi293 media (Invitrogen, USA). Plates were shaken for 5 days at 120 RPM in a mammalian cell culture incubator set to 95% humidity and 8% CO₂. Following a 5 day incubation, cells were pelleted and culture supernatants were removed.

[0251] Protein was purified from supernatants using a high throughput 96 well Protein A purification kit using the manufacturer's protocol (Catalog number 45202, Life Technologies, USA). Resulting elution fractions were buffer exchanged into PBS using Zeba 96 well spin desalting plate (Catalog number 89807, Life Technologies, USA) using the manufacturer's protocol. Purified protein was quantitated using 280nm absorbance measured by Nanodrop instrument (Thermo Fisher Scientific, USA), and protein purity was assessed by loading 5 µg of protein on NUPAGE pre-cast, polyacrylamide gels (Life Technologies, USA) under denaturing and reducing conditions and subsequent gel electrophoresis. Proteins were visualized in gel using standard Coomassie staining.

EXAMPLE 6

Assessment of Binding and Activity of Affinity-Matured IgSF Domain-Containing Molecules

A. Binding to Cell Surface-Expressed Counter Structures

[0252] This Example describes Fc-fusion binding studies to show specificity and affinity of CD80 and ICOSL domain variant immunomodulatory proteins for cognate binding partners.

[0253] To produce cells expressing cognate binding partners, full-length mammalian surface expression constructs for each of human CD28, CTLA4, PD-L1, ICOS and B7-H6 were designed in pcDNA3.1 expression vector (Life Technologies) and sourced from Genscript, USA. Binding studies were carried out using the Expi293F transient transfection system (Life Technologies, USA) described above. The number of cells needed for the experiment was determined, and the appropriate 30 ml scale of transfection was performed using the manufacturer's suggested protocol. For each CD28, CTLA-4, PD-L1, ICOS, B7-H6, or mock 30 ml transfection, 75 million Expi293F cells were incubated with 30 µg expression construct DNA and 1.5ml diluted ExpiFectamine 293 reagent for 48 hours, at which point cells were harvested for staining.

[0254] For staining by flow cytometry, 200,000 cells of appropriate transient transfection or negative control were plated in 96 well round bottom plates. Cells were spun down and resuspended in staining buffer (PBS (phosphate buffered saline), 1% BSA (bovine serum albumin), and 0.1% sodium azide) for 20 minutes to block non-specific binding. Afterwards, cells were centrifuged again and resuspended in staining buffer containing 100nM to 1nM variant immunomodulatory protein, depending on the experiment of each candidate CD80 variant Fc, ICOSL variant Fc, or stacked IgSF variant Fc fusion protein in 50 µl. Primary staining was performed on ice for 45 minutes, before washing cells in staining buffer twice. PE-conjugated anti-human Fc (Jackson ImmunoResearch, USA) was diluted 1:150 in 50 µl staining buffer and added to cells and incubated another 30 minutes on ice. Secondary antibody was washed out twice, cells were fixed in 4% formaldehyde/PBS, and samples were analyzed on FACScan flow cytometer (Becton Dickinson, USA).

[0255] Mean Fluorescence Intensity (MFI) was calculated for each transfectant and negative parental line with Cell Quest Pro software (Becton Dickinson, USA).

B. Bioactivity Characterization

[0256] This Example further describes Fc-fusion variant protein bioactivity characterization in human primary T cell in vitro assays.

1. Mixed Lymphocyte Reaction (MLR)

[0257] Soluble rICOSL.Fc or rCD80.Fc bioactivity was tested in a human Mixed Lymphocyte Reaction (MLR). Human primary dendritic cells (DC) were generated by culturing monocytes isolated from PBMC (BenTech Bio, USA) in vitro for 7 days with 500U/ml rIL-4

(R&D Systems, USA) and 250U/ml rGM-CSF (R&D Systems, USA) in Ex-Vivo 15 media (Lonza, Switzerland). 10,000 matured DC and 100,000 purified allogeneic CD4+ T cells (BenTech Bio, USA) were co-cultured with ICOSL variant fusion protein, CD80 variant Fc fusion protein, or controls in 96 well round bottom plates in 200µl final volume of Ex-Vivo 15 media. On day 5, IFN-gamma secretion in culture supernatants was analyzed using the Human IFN-gamma DuoSet ELISA kit (R&D Systems, USA). Optical density was measured by VMax ELISA Microplate Reader (Molecular Devices, USA) and quantitated against titrated rIFN-gamma standard included in the IFN-gamma Duo-set kit (R&D Systems, USA).

2. Anti-CD3 Coimmobilization Assay

[0258] Costimulatory bioactivity of ICOSL fusion variants and CD80 Fc fusion variants was determined in anti-CD3 coimmobilization assays. 1nM or 4nM mouse anti-human CD3 (OKT3, Biolegends, USA) was diluted in PBS with 1nM to 80nM rICOSL.Fc or rCD80.Fc variant proteins. This mixture was added to tissue culture treated flat bottom 96 well plates (Corning, USA) overnight to facilitate adherence of the stimulatory proteins to the wells of the plate. The next day, unbound protein was washed off the plates and 100,000 purified human pan T cells (BenTech Bio, US) or human T cell clone BC3 (Astarte Biologics, USA) were added to each well in a final volume of 200µl of Ex-Vivo 15 media (Lonza, Switzerland). Cells were cultured 3 days before harvesting culture supernatants and measuring human IFN-gamma levels with DuoSet ELISA kit (R&D Systems, USA) as mentioned above.

C. Results

[0259] Results for the binding and activity studies for exemplary tested variants are shown in Tables 8-10. In particular, Table 8 indicates exemplary IgSF domain amino acid substitutions (replacements) in the ECD of CD80 selected in the screen for affinity-maturation against the respective cognate structure CD28. Table 9 indicates exemplary IgSF domain amino acid substitutions (replacements) in the ECD of CD80 selected in the screen for affinity-maturation against the respective cognate structure PD-L1. Table 10 indicates exemplary IgSF domain amino acid substitutions (replacements) in the ECD of ICOSL selected in the screen for affinity-maturation against the respective cognate structures ICOS and CD28. For each Table, the exemplary amino acid substitutions are designated by amino acid position number corresponding to the respective reference unmodified ECD sequence as follows. For example, the reference unmodified ECD sequence in Tables 8 and 9 is the unmodified CD80 ECD

sequence set forth in SEQ ID NO:28 and the reference unmodified ECD sequence in Table 10 is the unmodified ICOSL ECD sequence (SEQ ID NO:32). The amino acid position is indicated in the middle, with the corresponding unmodified (e.g. wild-type) amino acid listed before the number and the identified variant amino acid substitution listed after the number. Column 2 sets forth the SEQ ID NO identifier for the variant ECD for each variant ECD-Fc fusion molecule.

[0260] Also shown is the binding activity as measured by the Mean Fluorescence Intensity (MFI) value for binding of each variant Fc-fusion molecule to cells engineered to express the cognate counter structure ligand and the ratio of the MFI compared to the binding of the corresponding unmodified ECD-Fc fusion molecule not containing the amino acid substitution(s) to the same cell-expressed counter structure ligand. The functional activity of the variant Fc-fusion molecules to modulate the activity of T cells also is shown based on the calculated levels of IFN-gamma in culture supernatants (pg/ml) generated either i) with the indicated variant ECD-Fc fusion molecule coimmobilized with anti-CD3 or ii) with the indicated variant ECD-Fc fusion molecule in an MLR assay. The Tables also depict the ratio of IFN-gamma produced by each variant ECD-Fc compared to the corresponding unmodified ECD-Fc in both functional assays.

[0261] As shown, the selections resulted in the identification of a number of CD80 or ICOSL IgSF domain variants that were affinity-modified to exhibit increased binding for at least one, and in some cases more than one, cognate counter structure ligand. In addition, the results showed that affinity modification of the variant molecules also exhibited improved activities to both increase and decrease immunological activity depending on the format of the molecule. For example, coimmobilization of the ligand likely provides a multivalent interaction with the cell to cluster or increase the avidity to favor agonist activity and increase T cell activation compared to the unmodified (e.g. wildtype) ECD-Fc molecule not containing the amino acid replacement(s). However, when the molecule is provided as a bivalent Fc molecule in solution, the same IgSF domain variants exhibited an antagonist activity to decrease T cell activation compared to the unmodified (e.g. wildtype) ECD-Fv molecule not containing the amino acid replacement(s).

Table 8: CD80 variants selected against CD28. Molecule sequences, binding data, and costimulatory bioactivity data.

CD80 mutation(s)	SEQ ID NO (ECD)	Binding			Coimmobilization with anti-CD3	MLR
		CD28 MFI (parental ratio)	CTLA-4 MFI (parental ratio)	PD-L1 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
L70Q/A91G	55	125 (1.31)	283 (1.36)	6 (0.08)	93 (1.12)	716 (0.83)
L70Q/A91G/T130A	56	96 (1.01)	234 (1.13)	7 (0.10)	99 (1.19)	752 (0.87)
L70Q/A91G/I118A/ T120S/T130A	57	123 (1.29)	226 (1.09)	7 (0.10)	86 (1.03)	741 (0.86)
V4M/L70Q/A91G/ T120S/T130A	58	89 (0.94)	263 (1.26)	6 (0.09)	139 (1.67)	991 (1.14)
L70Q/A91G/T120S/ T130A	59	106 (1.12)	263 (1.26)	6 (0.09)	104 (1.25)	741 (0.86)
V20L/L70Q/A91S/ T120S/T130A	60	105 (1.11)	200 (0.96)	9 (0.13)	195 (2.34)	710 (0.82)
S44P/L70Q/A91G/ T130A	61	88 (0.92)	134 (0.64)	5 (0.07)	142 (1.71)	854 (0.99)
L70Q/A91G/E117G/ T120S/T130A	62	120 (1.27)	193 (0.93)	6 (0.08)	98 (1.05)	736 (0.85)
A91G/T120S/ T130A	63	84 (0.89)	231 (1.11)	44 (0.62)	276 (3.33)	714 (0.82)
L70R/A91G/T120S/ T130A	64	125 (1.32)	227 (1.09)	6 (0.09)	105 (1.26)	702 (0.81)
L70Q/E81A/A91G/ T120S/I127T/ T130A	65	140 (1.48)	185 (0.89)	18 (0.25)	98 (1.18)	772 (0.89)
L70Q/Y87N/A91G/ T130A	66	108 (1.13)	181 (0.87)	6 (0.08)	136 (1.63)	769 (0.89)
T28S/L70Q/A91G/ E95K/T120S/T130A	67	32 (0.34)	65 (0.31)	6 (0.08)	120 (1.44)	834 (0.96)
N63S/L70Q/A91G/ T120S/T130A	68	124 (1.30)	165 (0.79)	6 (0.08)	116 (1.39)	705 (0.81)
K36E/I67T/L70Q/ A91G/T120S/ T130A/N152T	69	8 (0.09)	21 (0.10)	5 (0.08)	53 (0.63)	852 (0.98)
E52G/L70Q/A91G/ T120S/T130A	70	113 (1.19)	245 (1.18)	6 (0.08)	94 (1.13)	874 (1.01)
K37E/F59S/L70Q/ A91G/T120S/ T130A	71	20 (0.21)	74 (0.36)	6 (0.08)	109 (1.31)	863 (1.00)
A91G/S103P	72	39	56	9	124	670

Table 8: CD80 variants selected against CD28. Molecule sequences, binding data, and costimulatory bioactivity data.

CD80 mutation(s)	SEQ ID NO (ECD)	Binding			Coimmobilization with anti-CD3	MLR
		CD28 MFI (parental ratio)	CTLA-4 MFI (parental ratio)	PD-L1 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
		(0.41)	(0.27)	(0.13)	(1.49)	(0.77)
K89E/T130A	73	90 (0.95)	148 (0.71)	75 (1.07)	204 (2.45)	761 (0.88)
A91G	74	96 (1.01)	200 (0.96)	85 (1.21)	220 (2.65)	877 (1.01)
D60V/A91G/T120S/ T130A	75	111 (1.17)	222 (1.07)	12 (0.18)	120 (1.44)	744 (0.86)
K54M/A91G/T120S	76	68 (0.71)	131 (0.63)	5 (0.08)	152 (1.83)	685 (0.79)
M38T/L70Q/E77G/ A91G/T120S/ T130A/N152T	77	61 (0.64)	102 (0.49)	5 (0.07)	119 (1.43)	796 (0.92)
R29H/E52G/L70R/ E88G/A91G/T130A	78	100 (1.05)	119 (0.57)	5 (0.08)	200 (2.41)	740 (0.85)
Y31H/T41G/L70Q/ A91G/T120S/ T130A	79	85 (0.89)	85 (0.41)	6 (0.08)	288 (3.47)	782 (0.90)
V68A/I10A	80	103 (1.08)	233 (1.12)	48 (0.68)	163 (1.96)	861 (0.99)
S66H/D90G/T110A/ F116L	81	33 (0.35)	121 (0.58)	11 (0.15)	129 (1.55)	758 (0.88)
R29H/E52G/T120S/ T130A	82	66 (0.69)	141 (0.68)	11 (0.15)	124 (1.49)	800 (0.92)
A91G/L102S	83	6 (0.06)	6 (0.03)	5 (0.08)	75 (0.90)	698 (0.81)
I67T/L70Q/A91G/ T120S	84	98 (1.03)	160 (0.77)	5 (0.08)	1751 (21.1)	794 (0.92)
L70Q/A91G/T110A/ T120S/T130A	85	8 (0.09)	14 (0.07)	5 (0.07)	77 (0.93)	656 (0.76)
M38V/T41D/M43I/ W50G/D76G/V83A/ K89E/T120S/T130A	86	5 (0.06)	8 (0.04)	8 (0.11)	82 (0.99)	671 (0.78)
V22A/L70Q/S121P	87	5 (0.06)	7 (0.04)	5 (0.07)	105 (1.27)	976 (1.13)
A12V/S15F/Y31H/ T41G/T130A/P137L/ N152T	88	6 (0.06)	6 (0.03)	5 (0.08)	104 (1.25)	711 (0.82)
I67F/L70R/E88G/ A91G/T120S/T130A	89	5 (0.05)	6 (0.03)	6 (0.08)	62 (0.74)	1003 (1.16)
E24G/L25P/L70Q/ T120S	90	26 (0.27)	38 (0.18)	8 (0.11)	101 (1.21)	969 (1.12)
A91G/F92L/F108L/	91	50	128	16	59	665

Table 8: CD80 variants selected against CD28. Molecule sequences, binding data, and costimulatory bioactivity data.

CD80 mutation(s)	SEQ ID NO (ECD)	Binding			Coimmobilization with anti-CD3	MLR
		CD28 MFI (parental ratio)	CTLA-4 MFI (parental ratio)	PD-L1 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
T120S		(0.53)	(0.61)	(0.11)	(0.71)	(0.77)
WT CD80	28	95 (1.00)	208 (1.00)	70 (1.00)	83 (1.00)	866 (1.00)

Table 9: CD80 variants selected against PD-L1. Molecule sequences, binding data, and costimulatory bioactivity data.

CD80 mutation(s)	SEQ ID NO (ECD)	Binding			Coimmobilization with anti-CD3	MLR
		CD28 MFI (parental ratio)	CTLA-4 MFI (parental ratio)	PD-L1 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
R29D/Y31L/Q33H/ K36G/M38I/ T41A/ M43R/M47T/E81V/ L85R/K89N/A91T/ F92P/K93V/ R94L/ I118T/N149S	92	1071 (0.08)	1089 (0.02)	37245 (2.09)	387 (0.76)	5028 (0.26)
R29D/Y31L/Q33H/ K36G/M38I/T41A/ M43R/M47T/E81V/ L85R/K89N/A91T/ F92P/K93V/R94L/ N144S/N149S	93	1065 (0.08)	956 (0.02)	30713 (1.72)	400 (0.79)	7943 (0.41)
R29D/Y31L/Q33H/ K36G/M38I/T41A/ M42T/M43R/M47T/ E81V/L85R/K89N/ A91T/F92P/K93V/ R94L/L148S/N149S	94	926 (0.07)	954 (0.02)	47072 (2.64)	464 (0.91)	17387 (0.91)
E24G/R29D/Y31L/ Q33H/K36G/M38I/ T41A/M43R/M47T/ F59L/E81V/L85R/ K89N/A91T/F92P/ K93V/R94L/H96R	95	1074 (0.08)	1022 (0.02)	1121 (0.06)	406 (0.80)	13146 (0.69)

Table 9: CD80 variants selected against PD-L1. Molecule sequences, binding data, and costimulatory bioactivity data.

CD80 mutation(s)	SEQ ID NO (ECD)	Binding			Coimmobilization with anti-CD3	MLR
		CD28 MFI (parental ratio)	CTLA-4 MFI (parental ratio)	PD-L1 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
R29D/Y31L/Q33H/ K36G/M38I/T41A/ M43R/M47T/E81V/ L85R/K89N/A91T/ F92P/K93V/R94L/ N149S	96	1018 (0.08)	974 (0.02)	25434 (1.43)	405 (0.80)	24029 (1.25)
R29V/M43Q/E81R/ L85I/K89R/D90L/ A91E/F92N/K93Q/ R94G	97	1029 (0.08)	996 (0.02)	1575 (0.09)	342 (0.67)	11695 (0.61)
T41I/A91G	98	17890 (1.35)	50624 (1.01)	12562 (0.70)	433 (0.85)	26052 (1.36)
K89R/D90K/A91G/ F92Y/K93R/N122S/ N178S	99	41687 (3.15)	49429 (0.99)	20140 (1.13)	773 (1.52)	6345 (0.33)
K89R/D90K/A91G/ F92Y/K93R	100	51663 (3.91)	72214 (1.44)	26405 (1.48)	1125 (2.21)	9356 (0.49)
K36G/K37Q/M38I/ F59L/E81V/L85R/ K89N/A91T/F92P/ K93V/R94L/E99G/ T130A/N149S	101	1298 (0.10)	1271 (0.03)	3126 (0.18)	507 (1.00)	3095 (0.16)
AE88D/K89R/D90K/ A91G/F92Y/K93R	102	31535 (2.38)	50868 (1.02)	29077 (1.63)	944 (1.85)	5922 (0.31)
K36G/K37Q/M38I/ L40M	103	1170 (0.09)	1405 (0.03)	959 (0.05)	427 (0.84)	811 (0.04)
K36G	104	29766 (2.25)	58889 (1.18)	20143 (1.13)	699 (1.37)	30558 (1.59)
WTCD80	28	13224 (1.00)	50101 (1.00)	17846 (1.00)	509 (1.00)	19211 (1.00)

Table 10: ICOSL variants selected against CD28 or ICOS. Molecule sequences, binding data, and costimulatory bioactivity data.

ICOSL mutation(s)	SEQ ID NO (ECD)	Binding		Coimmobilization with anti-CD3	MLR
		ICOS OD (parental ratio)	CD28 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
N52S	109	1.33 (1.55)	162 (9.00)	1334 (1.93)	300 (0.44)
N52H	110	1.30 (1.51)	368 (20.44)	1268 (1.83)	39 (0.06)
N52D	111	1.59 (1.85)	130 (7.22)	1943 (2.80)	190 (0.28)
N52Y/N57Y/ F138L/L203P	112	1.02 (1.19)	398 (22.11)	510* (1.47*)	18 (0.03)
N52H/N57Y/ Q100P	113	1.57 (1.83)	447 (24.83)	2199 (3.18)	25 (0.04)
N52S/Y146C/ Y152C	114	1.26 (1.47)	39 (2.17)	1647 (2.38)	152 (0.22)
N52H/C198R	115	1.16 (1.35)	363 (20.17)	744* (2.15*)	ND (ND)
N52H/C140D/ T225A	116	ND (ND)	154 (8.56)	522* (1.51*)	ND (ND)
N52H/C198R/ T225A	117	1.41 (1.64)	344 (19.11)	778* (2.25*)	0 (0)
N52H/K92R	118	1.48 (1.72)	347 (19.28)	288* (0.83*)	89 (0.13)
N52H/S99G	119	0.09 (0.10)	29 (1.61)	184* (0.53*)	421 (0.61)
N52Y	120	0.08 (0.09)	18 (1.00)	184* (0.53*)	568 (0.83)
N57Y	121	1.40 (1.63)	101 (5.61)	580* (1.68*)	176 (0.26)
N57Y/Q100P	122	0.62 (0.72)	285 (15.83)	301* (0.87*)	177 (0.26)
N52S/S130G/ Y152C	123	0.16 (0.19)	24 (1.33)	266* (0.77*)	1617 (2.35)
N52S/Y152C	124	0.18 (0.21)	29 (1.61)	238* (0.69*)	363 (0.53)
N52S/C198R	125	1.80 (2.09)	82 (4.56)	1427 (2.06)	201 (0.29)
N52Y/N57Y/ Y152C	126	0.08 (0.09)	56 (3.11)	377* (1.09*)	439 (0.64)
N52Y/N57Y/ H129P/C198R	127	ND (ND)	449 (24.94)	1192 (1.72)	ND (ND)
N52H/L161P/ C198R	128	0.18 (0.21)	343 (19.05)	643* (1.86*)	447 (0.65)
N52S/T113E	129	1.51 (1.76)	54 (3.00)	451* (1.30*)	345 (0.50)
S54A	130	1.62 (1.88)	48 (2.67)	386* (1.12*)	771 (1.12)
N52D/S54P	131	1.50 (1.74)	38 (2.11)	476* (1.38*)	227 (0.33)
N52K/L208P	132	1.91	291	1509	137

Table 10: ICOSL variants selected against CD28 or ICOS. Molecule sequences, binding data, and costimulatory bioactivity data.

ICOSL mutation(s)	SEQ ID NO (ECD)	Binding		Coimmobilization with anti-CD3	MLR
		ICOS OD (parental ratio)	CD28 MFI (parental ratio)	IFN-gamma pg/ml (parental ratio)	IFN-gamma levels pg/ml (parental ratio)
		(2.22)	(16.17)	(2.18)	(0.20)
N52S/Y152H	133	0.85 (0.99)	68 (3.78)	2158 (3.12)	221 (0.32)
N52D/V151A	134	0.90 (1.05)	19 (1.06)	341* (0.99*)	450 (0.66)
N52H/I143T	135	1.83 (2.13)	350 (19.44)	2216 (3.20)	112 (0.16)
N52S/L80P	136	0.09 (0.10)	22 (1.22)	192* (0.55*)	340 (0.49)
F120S/Y152H/ N201S	137	0.63 (0.73)	16 (0.89)	351* (1.01*)	712 (1.04)
N52S/R75Q/L203P	138	1.71 (1.99)	12 (0.67)	1996 (2.88)	136 (0.20)
N52S/D158G	139	1.33 (1.55)	39 (2.17)	325* (0.94*)	277 (0.40)
N52D/Q133H	140	1.53 (1.78)	104 (5.78)	365* (1.05*)	178 (0.26)
WT ICOSL	32	0.86 (1.00)	18 (1.00)	692 / 346* (1.00)	687 (1.00)

*: Parental ratio calculated using 346 pg/ml IFN-gamma for WT ICOSL

EXAMPLE 7

Ligand Binding Competition Assay

[0262] As shown in Example 6, several CD80 variant molecules exhibited improved binding to one or both of CD28 and PD-L1. To further assess the binding activity of CD80 to ligands CD28 and PD-L1, this Example describes a ligand competition assay assessing the non-competitive nature of exemplary CD80 variants to bind both CD28 and PD-L1.

[0263] An ELISA based binding assay was set up incorporating plate-bound CD80 variant A91G ECD-Fc to assess the ability of CD80 to simultaneously bind CD28 and PD-L1.

Maxisorp 96 well ELISA plates (Nunc, USA) were coated overnight with 100nM human recombinant CD80 variant A91G ECD-Fc fusion protein in PBS. The following day unbound protein was washed out, and the plate was blocked with 1% bovine serum albumin (Millipore, USA)/PBS for 1 hour at room temperature. This blocking reagent was washed out three times

with PBS/ 0.05% Tween, which included a two minute incubation on a platform shaker for each wash.

[0264] In one arm of the competition assay, CD80 was incubated with CD28, and then CD28-bound CD80 was then assessed for competitive binding in the presence of either the other known CD80 ligand counter structures PD-L1 or CTLA-4 or negative control ligand PD-L2. Specifically, biotinylated recombinant human CD28 Fc fusion protein (rCD28.Fc; R&D Systems) was titrated into the wells starting at 10nM, diluting out for eight points with 1:2 dilutions in 25 μ l volume. Immediately after adding the biotinylated rCD28.Fc, unlabeled competitive binders, recombinant human PD-L1 monomeric his- tagged protein, recombinant human CTLA-4 monomeric his-tagged protein, or a negative control human recombinant PD-L2 Fc fusion protein (R&D Systems) were added to wells at 2000/1000/500nM respectively in 25 μ l volume for a final volume of 50 μ l. These proteins were incubated together for one hour before repeating the three wash steps as described above.

[0265] After washing, 2.5ng per well of HRP-conjugated streptavidin (Jackson ImmunoResearch, USA) was diluted in 1%BSA/PBS and added to wells to detect bound biotinylated rCD28.Fc. After one hour incubation, wells were washed again three times as described above. To detect signal, 50 μ l of TMB substrate (Pierce, USA) was added to wells following wash and incubated for 7 minutes, before adding 50ul 2M sulfuric acid stop solution. Optical density was determined on an Emax Plus microplate reader (Molecular Devices, USA). Optical density values were graphed in Prism (Graphpad, USA).

[0266] The results are set forth in FIG. 1A. The results showed decreased binding of biotinylated rCD28.Fc to the CD80 variant A91G ECD-Fc fusion protein with titration of the rCD28.Fc. When rCD28.Fc binding was performed in the presence of non-competitive control protein, rPDL2, there was no decrease in CD28 binding for CD80 (solid triangle). In contrast, a competitive control protein, rCTLA-4, when incubated with the CD28.Fc, did result in decreased CD28 binding for CD80 as expected (x line). When recombinant PD-L1 was incubated with CD28.Fc, no decrease in CD28 binding to CD80 was observed, which demonstrated that the epitopes of CD28 and PD-L1 for CD80 are non-competitive. Binding of the recombinant PD-L1 protein used in the CD28 competition assay to CD80 was confirmed by incubating the biotinylated PD-L1 in the presence of non-biotinylated rCD28.Fc (square).

[0267] The reverse competition also was set up in which CD80 was incubated with PD-L1, and then PD-L1-bound CD80 was then assessed for competitive binding in the presence of either the other known CD80 ligand counter structures CD28 or CTLA-4 or negative control ligand PD-L2. Specifically, the assay was performed by titrating biotinylated recombinant human PD-L1-his monomeric protein into wells containing the recombinant CD80 variant. Because binding is weaker with this ligand, titrations started at 5000nM with similar 1:2 dilutions over eight points in 25 μ L. When the rPD-L1-his was used to detect binding, the competitive ligands human rCD28.Fc, human rCTLA-4.Fc, or human rPD-L2.Fc control were added at 2.5nM final concentration in 25 μ l for a total volume of 50 μ l. The subsequent washes, detection, and OD measurements were the same as described above.

[0268] The results are set forth in FIG. 1B. Titrated PD-L1-his binding alone confirmed that PD-L1 bound to the CD80 variant A91G ECD-Fc fusion molecule immobilized on the plate (square). When PD-L1-his binding was performed in the presence of non-competitive control protein, rPDL2, there was no decrease in PD-L1 binding for CD80 (triangle). The CD28-competitive control protein, rCTLA-4, when incubated with the PD-L1-his, did not result in decreased PD-L1 binding for CD80 (x line), even though CTLA-4 is competitive for CD28. This result further demonstrated that lack of competition between CD28 and PD-L1 for CD80 binding. Finally, when PD-L1-his was incubated with CD28.Fc, no decrease in PD-L1 binding to CD80 was observed, which demonstrated that the epitopes of CD28 and PD-L1 for CD80 are non-competitive.

[0269] Thus, the results showed that CTLA-4, but not PD-L1 or the negative control PD-L2, competed for binding of CD28 to CD80 (FIG. 1A) and that CD28, CTLA-4, and PD-L2 did not compete for binding of PD-L1 to CD80 (FIG. 1B). Thus, these results demonstrated that CD28 and PD-L1 are non-competitive binders of CD80, and that this non-competitive binding can be demonstrated independently of which ligand is being detected in the ELISA.

EXAMPLE 8

Generation and Assessment of Stacked Molecules Containing Different Affinity-Modified Domains

[0270] Selected variant molecules described above that were affinity-modified for one or more counter structure ligand were used to generate “stack” molecule (i.e., Type II immunomodulatory protein) containing two or more affinity-modified IgSF domains. Stack

constructs were obtained as geneblocks (Integrated DNA Technologies, Coralville, IA) that encode the stack in a format that enables its fusion to Fc by standard Gibson assembly using a Gibson assembly kit (New England Biolabs).

[0271] The encoding nucleic acid molecule of all stacks was generated to encode a protein designed as follows: Signal peptide, followed by the first variant IgV of interest, followed by a 15 amino acid linker which is composed of three GGGGS(G4S) motifs (SEQ ID NO:228), followed by the second IgV of interest, followed by two GGGGS linkers (SEQ ID NO: 229) followed by three alanines (AAA), followed by a human IgG1 Fc as described above. To maximize the chance for correct folding of the IgV domains in each stack, the first IgV was preceded by all residues that normally occur in the wild-type protein between this IgV and the signal peptide (leading sequence). Similarly, the first IgV was followed by all residues that normally connect it in the wild-type protein to either the next Ig domain (typically an IgC domain) or if such a second IgV domain is absent, the residues that connect it to the transmembrane domain (trailing sequence). The same design principle was applied to the second IgV domain except that when both IgV domains were derived from same parental protein (e.g. a CD80 IgV stacked with another CD80 IgV), the linker between both was not duplicated.

[0272] Table 11 sets forth the design for exemplary stacked constructs. The exemplary stack molecules shown in Table 11 contain the IgV domains as indicated and additionally leading or trailing sequences as described above. In the Table, the following components are present in order: signal peptide (SP; SEQ ID NO:225), IgV domain 1 (IgV1), trailing sequence 1 (TS1), linker 1 (LR1; SEQ ID NO:228), IgV domain 2(IgV2), trailing sequence 2 (TS2), linker 2 (LR2; SEQ ID NO:230) and Fc domain (SEQ ID NO:226 containing C5S/N82G amino acid substitution). In some cases, a leading sequence 1(LS1) is present between the signal peptide and IgV1 and in some cases a leading sequence 2 (LS2) is present between the linker and IgV2.

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
NKp30 WT	+	-	SEQ ID NO: 214	SEQ ID NO: 235	+	-	SEQ ID NO: 196	SEQ ID NO: 233	+	+
ICOSL WT										
NKp30 L30V/A60V/S64P/ S86G	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	-	SEQ ID NO: 212	SEQ ID NO: 233	+	+
ICOSL N52S/N57Y/H94D /L96F/L98F/Q100										

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
R										
NKp30 L30V/A60V/S64P/ S86G)	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	+
ICOSL N52D										
NKp30 L30V/A60V/S64P/ S86G ICOSL N52H/N57Y/Q100 P	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	+
ICOSL WT Nkp30 WT	+	-	SEQ ID NO: 196	SEQ ID NO: 233	+	-	SEQ ID NO: 214	SEQ ID NO: 235	+	+
ICOSL N52D NKp30 L30V/A60V/S64P/ S86G	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	+
ICOSL N52H/N57Y/Q100 P NKp30 L30V/A60V/S64P/ S86G	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	+
Domain 1: NKp30 WT Domain 2: CD80 WT	+	-	SEQ ID NO: 214	SEQ ID NO: 235	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	+
Domain 1: NKp30 WT Domain 2: CD86 WT	+	-	SEQ ID NO: 214	SEQ ID NO: 235	+	SEQ ID NO: 236	SEQ ID NO: 220	SEQ ID NO: 237	+	+
Domain 1: NKp30 L30V/A60V/S64P/ S86G Domain 2: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	+
Domain 1: NKp30 L30V/A60V/S64P/ S86G Domain 2: CD80 I67T/L70Q/A91G/ T120S	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
Domain 1: NKp30 L30V/A60V/S64P/ S86G Domain 2: CD86 Q35H/H90L/Q102 H	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	+
Domain 1: CD80 WT Domain 2: Nkp30 WT	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	-	SEQ ID NO: 214	SEQ ID NO: 235	+	+
Domain 1: CD86 WT Domain 2: Nkp30 WT	+	SEQ ID NO: 236	SEQ ID NO: 220	SEQ ID NO: 237	+	-	SEQ ID NO: 214	SEQ ID NO: 235	+	+
Domain 1: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S Domain 2: NKp30 L30V/A60V/S64P/ S86G	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	+
Domain 1: CD80 I67T/L70Q/A91G/ T120S Domain 2: NKp30 L30V/A60V/S64P/ S86G	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	+
Domain 1: CD86 Q35H/H90L/Q102 H Domain 2: NKp30 L30V/A60V/S64P/ S86G	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	-	SEQ ID NO: 215	SEQ ID NO: 235	+	+
Domain 1: CD80 WT Domain 2: ICOSL WT	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	-	SEQ ID NO: 196	SEQ ID NO: 233	+	+
Domain 1: CD80 WT Domain 2: CD86 WT	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	SEQ ID NO: 236	SEQ ID NO: 220	SEQ ID NO: 237	+	+
Domain 1: CD80 WT	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
Domain 2: CD80 WT										
Domain 1: CD80 E88D/K89R/D90K /A91G/F92Y/K93R										
Domain 2: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	+
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T										
Domain 2: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	+
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T										
Domain 2: CD80 I67T/L70Q/A91G/ T120S	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	+
Domain 1: CD80 E88D/K89R/D90K /A91G/F92Y/K93R										
Domain 2: CD86 Q35H/H90L/Q102 H	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	+
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T										
Domain 2: CD86 Q35H/H90L/Q102 H	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	+
Domain 1: CD80 E88D/K89R/D90K /A91G/F92Y/K93R										
Domain 2: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	+
Domain 1: CD80 A12T/H18L/N43V/	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
F59L/E77K/P109S/ I118T Domain 2: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S										
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T Domain 2: ICOSL N52D	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	+
Domain 1: CD80 E88D/K89R/D90K /A91G/F92Y/K93R Domain 2: ICOSL N52H/N57Y/Q100 P	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	+
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T Domain 2: ICOSL N52H/N57Y/Q100 P	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	+
Domain 1: ICOSL WT Domain 2: CD80 WT	+	-	SEQ ID NO: 196	SEQ ID NO: 233	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	+
Domain 1: CD86 WT Domain 2: CD80 WT	+	SEQ ID NO: 236	SEQ ID NO: 220	SEQ ID NO: 237	+	-	SEQ ID NO: 152	SEQ ID NO: 231	+	+
Domain 1: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T										
Domain 1: CD80 I67T/L70Q/A91G/ T120S Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: CD80 I67T/L70Q/A91G/ T120S Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+
Domain 1: CD86 Q35H/H90L/Q102 H Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: CD86 Q35H/H90L/Q102 H Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52D	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R										
Domain 1: ICOSL N52D										
Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52H/N57Y/Q100 P										
Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52H/N57Y/Q100 P										
Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+
Domain 1: CD80 V68M/L70P/L72P/ K86E										
Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	-	SEQ ID NO: 195	SEQ ID NO: 231	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: CD80 R29V/Y31F/K36G/ M38L/N43Q/E81R /V83I/L85I/K89R/ D90L/A91E/F92N/ K93Q/R94G										
Domain 2: CD80 E88D/K89R/D90K /A91G/F92Y/K93R	+	-	SEQ ID NO: 194	SEQ ID NO: 231	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	+
Domain 1: CD80 V68M/L70P/L72P/ K86E										
Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T	+	-	SEQ ID NO: 195	SEQ ID NO: 231	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+
Domain 1: CD80 R29V/Y31F/K36G/										
	+	-	SEQ ID NO: 194	SEQ ID NO: 231	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
M38L/N43Q/E81R/ /V83I/L85I/K89R/ D90L/A91E/F92N/ K93Q/R94G Domain 2: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T										
Domain 1: CD80 E88D/K89R/D90K /A91G/F92Y/K93R Domain 2: CD80 V68M/L70P/L72P/ K86E	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	-	SEQ ID NO: 195	SEQ ID NO: 231	+	+
Domain 1: CD80 E88D/K89R/D90K /A91G/F92Y/K93R Domain 2: CD80 R29V/Y31F/K36G/ M38L/N43Q/E81R /V83I/L85I/K89R/ D90L/A91E/F92N/ K93Q/R94G	+	-	SEQ ID NO: 189	SEQ ID NO: 231	+	-	SEQ ID NO: 194	SEQ ID NO: 231	+	+
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T Domain 2: CD80 V68M/L70P/L72P/ K86E	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 195	SEQ ID NO: 231	+	+
Domain 1: CD80 A12T/H18L/N43V/ F59L/E77K/P109S/ I118T Domain 2: CD80 R29V/Y31F/K36G/ M38L/N43Q/E81R /V83I/ L85I/K89R/D90L/ A91E/F92N/K93Q/ R94G	+	-	SEQ ID NO: 193	SEQ ID NO: 231	+	-	SEQ ID NO: 194	SEQ ID NO: 231	+	+
Domain 1: CD86 WT Domain 2: ICOSL WT	+	SEQ ID NO: 236	SEQ ID NO: 220	SEQ ID NO: 237	+	-	SEQ ID NO: 196	SEQ ID NO: 233	+	+
Domain 1: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
/D90N/A91G/P109S Domain 2: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S										
Domain 1: CD80 I67T/L70Q/A91G/ T120S Domain 2: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	+
Domain 1: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109S Domain 2: ICOSL N52D	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	+
Domain 1: CD80 I67T/L70Q/A91G/ T120S Domain 2: ICOSL N52D	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	+
Domain 1: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109S Domain 2: ICOSL N52H/N57Y/Q100 P	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	+
Domain 1: CD80 I67T/L70Q/A91G/ T120S Domain 2: ICOSL N52H/N57Y/Q100 P	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	+
Domain 1: CD86 Q35H/H90L/Q102 H Domain 2: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
F120S										
Domain 1: CD86 Q35H/H90L/Q102 H Domain 2: ICOSL N52D	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	+
Domain 1: CD86 Q35H/H90L/Q102 H Domain 2: ICOSL N52H/N57Y/Q100 P	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	+
Domain 1: ICOSL WT Domain 2: CD86 WT	+	-	SEQ ID NO: 196	SEQ ID NO: 233	+	SEQ ID NO: 236	SEQ ID NO: 220	SEQ ID NO: 237	+	+
Domain 1: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S Domain 2: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S Domain 2: CD80 I67T/L70Q/A91G/ T120S	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52D Domain 2: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	-	SEQ ID NO: 192	SEQ ID NO: 231	+	+
Domain 1: ICOSL N52D Domain 2: CD80 I67T/L70Q/A91G/ T120S	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	-	SEQ ID NO: 175	SEQ ID NO: 231	+	+
Domain 1: ICOSL	+	-	SEQ ID	SEQ ID	+	-	SEQ ID	SEQ ID	+	+

Table 11: Amino acid sequence (SEQ ID NO) of components of exemplary stacked constructs										
	SP	First domain			LR1	Second domain			LR2	Fc
		LS1	IgV1	TS1		LS2	IgV2	TS2		
N52H/N57Y/Q100 P Domain 2: CD80 R29H/Y31H/T41G /Y87N/E88G/K89E /D90N/A91G/P109 S			NO: 201	NO: 233			NO: 192	NO: 231		
Domain 1: ICOSL N52S/N57Y/H94D /L96F/L98F/Q100 R/G103E/ F120S Domain 2: CD86 Q35H/H90L/Q102 H	+	-	SEQ ID NO: 213	SEQ ID NO: 233	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	+
Domain 1: ICOSL N52D Domain 2: CD86 Q35H/H90L/Q102 H	+	-	SEQ ID NO: 199	SEQ ID NO: 233	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	+
Domain 1: ICOSL N52H/N57Y/Q100 P Domain 2: CD86 Q35H/H90L/Q102 H	+	-	SEQ ID NO: 201	SEQ ID NO: 233	+	SEQ ID NO: 236	SEQ ID NO: 221	SEQ ID NO: 237	+	+

[0273] High throughput expression and purification of the variant IgV-stacked-Fc fusion molecules containing various combinations of variant IgV domains from CD80, CD86, ICOSL or Nkp30 containing at least one affinity-modified IgV domain were generated as described in Example 5. Binding of the variant IgV-stacked-Fc fusion molecules to respective counter structures and functional activity by anti-CD3 coimmobilization assay also were assessed as described in Example 6. For example, costimulatory bioactivity of the stacked IgSF Fc fusion proteins was determined in a similar immobilized anti-CD3 assay as above. In this case, 4nM of anti-CD3 (OKT3, Biolegend, USA) was coimmobilized with 4nM to 120nM of human rB7-H6.Fc (R&D Systems, USA) or human rPD-L1.Fc (R&D Systems, USA) overnight on tissue-culture treated 96 well plates (Corning, USA). The following day unbound protein was washed off with PBS and 100,000 purified pan T cells were added to each well in 100ul Ex-Vivo 15 media (Lonza, Switzerland). The stacked IgSF domains were subsequently added at concentrations ranging from 8nM to 40nM in a volume of 100ul for 200ul volume total. Cells

were cultured 3 days before harvesting culture supernatants and measuring human IFN-gamma levels with DuoSet ELISA kit (R&D Systems, USA) as mentioned above.

[0274] The results are set forth in Tables 12-16. Specifically, Table 12 sets forth binding and functional activity results for variant IgV-stacked-Fc fusion molecules containing an Nkp30 IgV domain and an ICOSL IgV domain. Table 13 sets forth binding and functional activity results for variant IgV-stacked-Fv fusion molecules containing an Nkp30 IgV domain and a CD80 or CD86 IgV domain. Table 14 sets forth binding and functional activity results for variant IgV-stacked-Fc fusion molecules containing a variant CD80 IgV domain and a CD80, CD86 or ICOSL IgV domain. Table 15 sets forth binding and functional activity results for variant IgV-stacked-Fc fusion molecules containing two variant CD80 IgV domains. Table 16 sets forth results for variant IgV-stacked Fc fusion molecules containing a variant CD80 or CD86 IgV domain and a variant ICOSL IgV domain.

[0275] For each of Tables 12-16, Column 1 indicates the structural organization and orientation of the stacked, affinity modified or wild-type (WT) domains beginning with the amino terminal (N terminal) domain, followed by the middle WT or affinity modified domain located before the C terminal human IgG1 Fc domains. Column 2 sets forth the SEQ ID NO identifier for the sequence of each IgV domain contained in a respective “stack” molecule. Column 3 shows the binding partners which the indicated affinity modified stacked domains from column 1 were selected against.

[0276] Also shown is the binding activity as measured by the Mean Fluorescence Intensity (MFI) value for binding of each stack molecule to cells engineered to express various counter structure ligands and the ratio of the MFI compared to the binding of the corresponding stack molecule containing unmodified IgV domains not containing the amino acid substitution(s) to the same cell-expressed counter structure ligand. The functional activity of the variant stack molecules to modulate the activity of T cells also is shown based on the calculated levels of IFN-gamma in culture supernatants (pg/ml) generated with the indicated variant stack molecule in solution and the appropriate ligand coimmobilized with anti-CD3 as described in Example 6. The Tables also depict the ratio of IFN-gamma produced by each variant stack molecule compared to the corresponding unmodified stack molecule in the coimmobilization assay.

[0277] As shown, the results showed that it was possible to generate stack molecules containing at least one variant IgSF domains that exhibited affinity-modified activity of increased binding for at least one cognate counter structure ligand compared to a corresponding

stack molecule containing the respective unmodified (e.g. wild-type) IgV domain. In some cases, the stack molecule, either from one or a combination of both variant IgSF domains in the molecule, exhibited increased binding for more than one cognate counter structure ligand. The results also showed that the order of the IgV domains in the stacked molecules could, in some cases, alter the degree of improved binding activity. In some cases, functional T cell activity also was altered when assessed in the targeted coimmobilization assay.

TABLE 12: Stacked variant IgV Fc fusion proteins containing an NKp30 IgV domain and an ICOSL IgV domain						
Domain Structure N terminal to C terminal: domain 1/domain 2/Fc	SEQ ID NO (IgV)	Counter structure selected against	Binding Activity			Anti-CD3 coimmobilization assay pg/ml IFN-gamma (WT parental IFN-gamma ratio)
			B7H6 MFI (WT parental MFI ratio)	ICOS MFI (WT parental MFI ratio)	CD28 MFI (WT parental MFI ratio)	
Domain 1: NKp30 WT Domain 2: ICOSL WT	214 196	-	64538 (1.00)	26235 (1.00)	6337 (1.00)	235 (1.00)
Domain 1: NKp30 (L30V A60V S64P S86G) Domain 2: ICOSL (N52S N57Y H94D L96F L98F Q100R)	215 212	B7-H6 ICOS-CD28	59684 (0.92)	12762 (0.49)	9775 (1.54)	214 (0.91)
Domain 1: NKp30 (L30V A60V S64P S86G) Domain 2: ICOSL (N52D)	215 199	B7-H6 ICOS-CD28	65470 (1.01)	30272 (1.15)	9505 (1.50)	219 (0.93)
Domain 1: NKp30 (L30V A60V S64P S86G)/ Domain 2: ICOSL (N52H N57Y Q100P)	215 201	B7-H6 ICOS-CD28	38153 (0.59)	27903 (1.06)	11300 (1.78)	189 (0.80)
Domain 1: ICOSL WT Domain 2: Nkp30 WT	196 214	-	117853 (1.0)	70320 (1.0)	7916 (1.0)	231 (1.0)
Domain 1: ICOSL (N52D) Domain 2: NKp30 (L30V A60V S64P S86G)	199 215	ICOS-CD28 B7-H6	100396 (0.85)	83912 (1.19)	20778 (2.62)	228 (0.98)
Domain 1: ICOSL (N52H N57Y Q100P) Domain 2: NKp30 (L30V A60V S64P S86G)	201 215	ICOS-CD28 B7-H6	82792 (0.70)	68874 (0.98)	72269 (9.12)	561 (2.43)

TABLE 13: Stacked variant IgV Fc fusion proteins containing an NKp30 IgV domain and a CD80 or CD86 IgV domain

Domain Structure N terminal to C terminal: domain 1/domain 2/Fc	SEQ ID NO (IgV)	Counter structure selected against	Binding Activity		Anti-CD3 coimmobilization assay pg/ml IFN- gamma (WT parental IFN- gamma ratio)
			B7H6 MFI (WT parental MFI ratio)	CD28 MFI (WT parental MFI ratio)	
Domain 1: NKp30 WT	214	-	88823	7022	68
Domain 2: CD80 WT	152		(1.00)	(1.00)	(1.00)
Domain 1: NKp30 WT	214	-	14052	1690	92
Domain 2: CD86 WT	220		(1.00)	(1.00)	(1.00)
Domain 1: NKp30 (L30V A60V S64P S86G)	215	B7-H6	53279 (0.60)	9027 (1.29)	94 (1.38)
Domain 2: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28			
Domain 1: NKp30 (L30V A60V S64P S86G)	215	B7-H6	41370 (0.47)	11240 (1.60)	60 (0.88)
Domain 2: CD80 I67T/L70Q/A91G/T120S	175	CD28			
Domain 1: NKp30 (L30V A60V S64P S86G)/	215	B7-H6	68480 (4.87)	9115 (5.39)	110 (1.19)
Domain 2: CD86 Q35H/H90L/Q102H	221	CD28			
Domain 1: CD80 WT	152	-	110461	13654	288
Domain 2: Nkp30 WT	214		(1.00)	(1.00)	(1.00)
Domain 1: CD86 WT	220	CD28	128899	26467	213
Domain 2: Nkp30 WT	214	B7-H6	(1.00)	(1.00)	(1.00)
Domain 1: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	55727 (0.50)	4342 (0.32)	100 (0.35)
Domain 2: NKp30 (L30V A60V S64P S86G)	215	B7-H6			
Domain 1: CD80 I67T/L70Q/A91G/T120S	175	CD28	40412	7094	84
			(0.37)	(0.52)	(0.29)

Domain 2: NKp30 (L30V A60V S64P S86G)	215	B7-H6			
Domain 1: CD86 Q35H/H90L/Q102H	221	CD28	220836 (1.71)	11590 (0.44)	113 (0.53)
Domain 2: NKp30 (L30V A60V S64P S86G)	215	B7-H6			

TABLE 14: Stacked variant IgV Fc fusion proteins containing a CD80 IgV domain and a CD80, CD86, or ICOSL IgV domain

Domain Structure N terminal to C terminal: domain 1/domain 2/Fc	SEQ ID NO (IgV)	Counter structure selected against	Binding Activity			Anti-CD3 coimmobilization assay pg/ml IFN- gamma (WT parental IFN- gamma ratio)
			CD28 MFI (WT parental MFI ratio)	PD-L1 MFI (WT parental MFI ratio)	ICOS MFI (WT parental MFI ratio)	
Domain 1: CD80 WT	152		1230 (1.00)	2657 (1.00)	11122 (1.00)	69 (1.00)
Domain 2: ICOSL WT	196					
Domain 1: CD80 WT	152		60278 (1.00)	2085 (1.00)		59 (1.00)
Domain 2: CD86 WT	220					
Domain 1: CD80 WT	152		1634 (1.00)	6297 (1.00)		98 (1.00)
Domain 2: CD80 WT	152					
Domain 1: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1				
Domain 2: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	4308 (2.64)	4234 (0.67)		214 (2.18)
Domain 1: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1				
Domain 2: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	7613 (4.66)	2030 (0.32)		137 (1.40)
Domain 1: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1				
Domain 2: CD80 I67T/L70Q/A91G/T120S	175	CD28	3851 (2.36)	3657 (0.58)		81 (0.83)
Domain 1: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1				
Domain 2: CD86 Q35H/H90L/Q102H	221	CD28	4117 (0.07)	2914 (1.40)		96 (1.63)
Domain 1: CD80	193	PD-L1	2868	3611		94

A12T/H18L/N43V/F59L/E7 7K/P109S/I118T			(0.05)	(1.73)		(1.60)
Domain 2: CD86 Q35H/H90L/Q102H	221	CD28				
Domain 1: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1				
Domain 2: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28	3383 (2.75)	4515 (1.70)	5158 (0.46)	90 (1.30)
Domain 1: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1				
Domain 2: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28	2230 (1.81)	2148 (0.81)	3860 (0.35)	112 (1.62)
Domain 1: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1 ICOS/CD 28				
Domain 2: ICOSL N52D	199		5665 (4.61)	6446 (2.43)	15730 (1.41)	126 (1.83)
Domain 1: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1				
Domain 2: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28	6260 (5.09)	4543 (1.71)	11995 (1.08)	269 (3.90)
Domain 1: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1				
Domain 2: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28	3359 (2.73)	3874 (1.46)	8541 (0.77)	97 (1.41)
Domain 1: ICOSL WT	196		3000 (1.00)	2966 (1.00)	14366 (1.00)	101 (1.00)
Domain 2: CD80 WT	152					
Domain 1: CD86 WT	220		4946 (1.00)	1517 (1.00)		125 (1.00)
Domain 2: CD80 WT	152					
Domain 1: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28				
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1	2832 (1.73)	3672 (0.58)		114 (1.16)
Domain 1: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	4542 (2.78)	2878 (0.45)		142 (1.45)

Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1				
Domain 1: CD80 I67T/L70Q/A91G/T120S	175	CD28				
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1	938 (0.57)	995 (0.16)		102 (1.04)
Domain 1: CD80 I67T/L70Q/A91G/T120S	175	CD28				
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	4153 (2.54)	2827 (0.45)		108 (1.10)
Domain 1: CD86 Q35H/H90L/Q102H	221	CD28				
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1	14608 (2.95)	2535 (1.67)		257 (2.06)
Domain 1: CD86 Q35H/H90L/Q102H	221	CD28				
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	2088 (0.42)	2110 (1.39)		101 (0.81)
Domain 1: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28				
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1	3634 (1.21)	4893 (1.65)	6403 (0.45)	123 (1.22)
Domain 1: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28				
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	1095 (0.37)	5929 (2.0)	7923 (0.55)	127 (1.26)
Domain 1: ICOSL N52D	199	ICOSL/C D28				
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1	2023 (0.67)	5093 (1.72)	16987 (1.18)	125 (1.24)
Domain 1: ICOSL N52D	199	ICOS/CD 28				
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	3441 (1.15)	3414 (1.15)	20889 (1.45)	165 (1.63)
Domain 1: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28	7835 (2.61)	6634 (2.24)	20779 (1.45)	95 (0.94)

Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1				
Domain 1: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28				
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	8472 (2.82)	3789 (1.28)	13974 (0.97)	106 (1.05)

TABLE 15: Stacked variant IgV Fc fusion proteins containing two CD80 IgV domains

Domain Structure N terminal to C terminal: domain 1/domain 2/Fc	SEQ ID NO (IgV)	Counter structure selected against	Binding Activity		Functional Activity MLR IFN-gamma pg/ml
			PD-L1 MFI (WT parental MFI ratio)	CTLA-4 MFI (WT parental MFI ratio)	
Domain 1: CD80 WT	152		6297 (1.00)	4698 (1.00)	35166 (1.00)
Domain 2: CD80 WT	152				
Domain 1: CD80 V68M/L70P/L72P/K86E	195	CTLA-4			
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1	2464 (0.39)	4955 (1.05)	5705 (0.16)
Domain 1: CD80 R29V/Y31F/K36G/M38L/N 43Q/E81R/V83I/L85I/K89R/ D90L/A91E/F92N/K93Q/R9 4G	194	CTLA-4	1928 (0.31)	1992 (0.42)	1560 (0.04)
Domain 2: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1			
Domain 1: CD80 V68M/L70P/L72P/K86E	195	CTLA-4			
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	1215 (0.19)	1382 (0.29)	2171 (0.06)
Domain 1: CD80 R29V/Y31F/K36G/M38L/N 43Q/E81R/V83I/L85I/K89R/ D90L/A91E/F92N/K93Q/R9 4G	194	CTLA-4			
Domain 2: CD80 A12T/H18L/N43V/F59L/E7 7K/P109S/I118T	193	PD-L1	1592 (0.25)	1962 (0.42)	1512 (0.04)
Domain 1: CD80 E88D/K89R/D90K/A91G/F9 2Y/K93R	189	PD-L1			
Domain 2: CD80 V68M/L70P/L72P/K86E	195	CTLA-4	1747 (0.28)	2057 (0.44)	9739 (0.28)

Domain 1: CD80 E88D/K89R/D90K/A91G/F92Y/K93R	189	PD-L1			
Domain 2: CD80 R29V/Y31F/K36G/M38L/N43Q/E81R/V83I/L85I/K89R/D90L/A91E/F92N/K93Q/R94G	194	CTLA-4	1752 (0.28)	1772 (0.38)	5412 (0.15)
Domain 1: CD80 A12T/H18L/N43V/F59L/E77K/P109S/I118T	193	PD-L1			
Domain 2: CD80 V68M/L70P/L72P/K86E	195	CTLA-4	1636 (0.26)	1887 (0.40)	7608 (0.22)
Domain 1: CD80 A12T/H18L/N43V/F59L/E77K/P109S/I118T	193	PD-L1			
Domain 2: CD80 R29V/Y31F/K36G/M38L/N43Q/E81R/V83I/L85I/K89R/D90L/A91E/F92N/K93Q/R94G	194	CTLA-4	2037 (0.32)	4822 (1.03)	11158 (0.32)

TABLE 16: Stacked variant IgV Fc fusion proteins containing a CD80 or CD86 IgV domain and an ICOSL IgV domain

Domain Structure N terminal to C terminal: domain 1/domain 2/Fc	SEQ ID NO (IgV)	Counter structure selected against	Binding Activity		Functional Activity MLR IFN-gamma pg/ml
			PD-L1 MFI (WT parental MFI ratio)	CTLA-4 MFI (WT parental MFI ratio)	
Domain 1: CD80 WT	152		1230 (1.00)	11122 (1.00)	1756 (1.00)
Domain 2: ICOSL WT	196				
Domain 1: CD86 WT	220		29343 (1.00)	55193 (1.00)	6305 (1.00)
Domain 2: ICOSL WT	196				
Domain 1: CD80 R29H/Y31H/T41G/Y87N/E88G/K89E/D90N/A91G/P109S	192	CD28			
Domain 2: ICOSL N52S/N57Y/H94D/L96F/L98F/Q100R/G103E/F120S	213	ICOS/CD28	2280 (1.85)	3181 (0.29)	2281 (1.30)
Domain 1: CD80 I67T/L70Q/A91G/T120S	175	CD28			
Domain 2: ICOSL N52S/N57Y/H94D/L96F/L98F/Q100R/G103E/F120S	213	ICOS/CD28	2309 (1.88)	26982 (2.43)	1561 (0.89)
Domain 1: CD80	192	CD28	4285	22744	1612

R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S			(3.48)	(2.04)	(0.92)
Domain 2: ICOSL N52D	199	ICOS/CD 28			
Domain 1: CD80 I67T/L70Q/A91G/T120S	175	CD28			
Domain 2: ICOSL N52D	199	ICOS/CD 28	3024 (2.46)	16916 (1.52)	3857 (2.20)
Domain 1: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28			
Domain 2: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28	6503 (5.29)	7240 (0.65)	6886 (3.92)
Domain 1: CD80 I67T/L70Q/A91G/T120S	175	CD28			
Domain 2: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28	3110 (2.53)	4848 (0.44)	3393 (1.93)
Domain 1: CD86 Q35H/H90L/Q102H	221	CD28			
Domain 2: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28	11662 (0.40)	21165 (0.38)	880 (0.14)
Domain 1: CD86 Q35H/H90L/Q102H	221	CD28			
Domain 2: ICOSL N52D	199	ICOS/CD 28	24230 (0.83)	73287 (1.33)	1110 (0.18)
Domain 1: CD86 Q35H/H90L/Q102H	221	CD28 ICOS/CD 28			
Domain 2: ICOSL N52H/N57Y/Q100P	201		1962 (0.07)	1630 (0.03)	587 (0.09)
Domain 1: ICOSL WT	196		3000 (1.00)	14366 (1.00)	4113 (1.00)
Domain 2: CD80 WT	152				
Domain 1: ICOSL WT	196		18005 (1.00)	53602 (1.00)	18393 (1.00)
Domain 2: CD86 WT	220				
Domain 1: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOSL/C D28			
Domain 2: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	10426 (3.48)	51286 (3.57)	18680 (4.54)
Domain 1: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28	17751 (5.92)	29790 (2.07)	10637 (2.59)

F120S					
Domain 2: CD80 I67T/L70Q/A91G/T120S	175	CD28			
Domain 1: ICOSL N52D	199	ICOS/CD 28			
Domain 2: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	2788 (0.93)	25870 (1.80)	6205 (1.51)
Domain 1: ICOSL N52D	199	ICOS/CD 28			
Domain 2: CD80 I67T/L70Q/A91G/T120S	175	CD28	2522 (0.84)	13569 (0.94)	5447 (1.32)
Domain 1: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28			
Domain 2: CD80 R29H/Y31H/T41G/Y87N/E8 8G/K89E/D90N/A91G/P109 S	192	CD28	9701 (3.23)	9187 (0.64)	5690 (1.38)
Domain 1: ICOSL N52S/N57Y/H94D/L96F/L9 8F/Q100R/G103E/ F120S	213	ICOS/CD 28			
Domain 2: CD86 Q35H/H90L/Q102H	221	CD28	27050 (1.50)	21257 (0.40)	8131 (0.44)
Domain 1: ICOSL N52D	199	ICOS/CD 28			
Domain 2: CD86 Q35H/H90L/Q102H	221	CD28	34803 (1.93)	80210 (1.50)	6747 (0.37)
Domain 1: ICOSL N52H/N57Y/Q100P	201	ICOS/CD 28			
Domain 2: CD86 Q35H/H90L/Q102H	221	CD28	5948 (0.33)	4268 (0.08)	26219 (1.43)

Example 9: Generation, Selection and Screening of Affinity-modified IgSF Domain

Variants of CD155

[0278] Affinity-modified IgSF domain variants of CD155 were generated substantially as described in Examples 1-6 above with some slight modifications. For example, for the generation of CD155 variants, only the IgV domain, and not the other two domains of the ECD, was included in the generated proteins.

[0279] To generate a library targeting specific residues of CD155 by complete or partial randomization with degenerate codons, the coding DNA for the immunoglobulin-like V-type (IgV) domain of human CD155 (SEQ ID NO:241) was ordered from Integrated DNA Technologies (Coralville, IA) as a set of overlapping oligonucleotides of up to 80 base pairs (bp) in length. In general, to generate a library of diverse variants of the IgV domain, the oligonucleotides contained desired degenerate codons at desired amino acid positions.

Degenerate codons were generated using an algorithm at the URL:

rosettadesign.med.unc.edu/SwiftLib/. In general, positions to mutate and degenerate codons were chosen from crystal structure information (PDB: 3UDW) or homology models built from this structure containing the target-ligand pairs of interest to identify ligand contact residues as well as residues that are at the protein interaction interface. For example, a crystal structure of CD155 bound to TIGIT is publicly available at the URL:

www.rcsb.org/pdb/explore/explore.do?structureId=3UDW for Protein Data Base code 3UDW.

This analysis was performed using a structure viewer available at the URL: spdbv.vital-it.ch.

[0280] The oligonucleotides were used for PCR amplification to generate library DNA inserts for insertion into the modified yeast display version of vector pBYDS03 substantially as described in Example 1. Alternatively, Ultramers (Integrated DNA Technologies) of up to 200 bp in length were used in conjunction with megaprimer PCR (URL:

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC146891/pdf/253371.pdf>) to generate larger stretches of degenerate codons that could not be as easily incorporated using multiple small overlapping primers. Following the generation of full length product using megaprimer PCR, the mutant IgV domain library was PCR amplified again using DNA primers containing 40 bp overlap region with the modified pBYDS03 cloning variant for homologous recombination into yeast. The library of DNA inserts were prepared for library insertion substantially as described in Example 1 and electroporation-ready DNA was prepared.

[0281] As alternative approaches, either sublibraries generated by site-directed mutagenesis to target specific residues of the IgV domain of CD155 or random libraries of the IgV domain of CD155 were generated to further identify variants of the IgV domain of CD155 substantially as described in Example 1.

[0282] The degenerate or random library DNA was inserted into yeast substantially as described in Example 2. Yeast expressing affinity modified variants of CD155 were selected using the method substantially described in Example 3. For the selection, the following target

ligand proteins were employed: human rTIGIT.Fc (i.e., recombinant TIGIT-Fc fusion protein) and rCD226.Fc. Magnetic Protein A beads were obtained from New England Biolabs, USA. For two-color, flow cytometric sorting, a Bio-Rad S3e sorter was used. CD155 display levels were monitored with an anti-hemagglutinin antibody labeled with Alexafluor 488 (Life Technologies, USA). Ligand binding of Fc fusion proteins, rTIGIT.Fc or rCD226.Fc, were detected with PE conjugated human Ig specific goat Fab (Jackson ImmunoResearch, USA). Doublet yeast were gated out using forward scatter (FSC) / side scatter (SSC) parameters, and sort gates were based upon higher ligand binding detected in FL2 that possessed more limited tag expression binding in FL1.

[0283] Second sort outputs (F2) were obtained substantially as described in Example 3 by expanding and re-inducing expression of sort outputs that had been assayed for higher specific binding affinity and were used to assess binding compared to the parental, wild-type yeast strain. For CD155, the second FACS outputs (F2) were compared to parental CD155 yeast for binding rTIGIT.Fc or rCD226.Fc by double staining each population with anti-HA (hemagglutinin) tag expression and the anti-human Fc secondary to detect ligand binding.

[0284] Selected outputs were reformatted as immunomodulatory proteins containing an affinity modified (variant) immunoglobulin-like V-type (IgV) domain of CD155 fused to an Fc molecule (variant IgV domain -Fc fusion molecules) substantially as described in Example 4, except including only the IgV domain and not the full ECD domain. In some alternative methods for the CD155 outputs, DNA from the outputs were PCR amplified with primers containing 40 bp overlap regions on either end with an Fc fusion vector to carry out in vitro recombination using Gibson Assembly Mastermix (New England Biolabs), which was subsequently used in heat shock transformation into E. Coli strain NEB5alpha. Exemplary of an Fc fusion vector is pFUSE-hIgG1-Fc2 (Invivogen, USA).

[0285] After transformation, samples were prepared for DNA sequencing substantially as described in Example 4. The sequences were then manually curated as described in Example 4, except that they were manually curated so that they start at the beginning of the IgV coding region. The curated sequences were batch-translated and aligned as described in Example 4. Clones of interest were identified using the criteria as described in Example 4. Table 17 sets forth the identified variant CD155 affinity-modified molecules, including the amino acid substitutions contained in each variant.

[0286] The methods generated immunomodulatory proteins containing an affinity-modified IgV domain of CD155 in which the encoding DNA was generated to encode a protein as follows: signal peptide followed by variant (mutant) IgV domain followed by a linker of three alanines (AAA) followed by a human IgG1 Fc containing the mutation N297G (N82G with reference to wild-type human IgG1 Fc set forth in SEQ ID NO: 226). The human IgG1 Fc also contained the mutations R292C and V302C (corresponding to R77C and V87C with reference to wild-type human IgG1 Fc set forth in SEQ ID NO: 226). Since the construct does not include any antibody light chains that can form a covalent bond with a cysteine, the human IgG1 Fc also contained replacement of the cysteine residues to a serine residue at position 5 (C5S) compared to the wild-type or unmodified Fc set forth in SEQ ID NO: 226.

[0287] Recombinant variant CD155 Fc fusion proteins were expressed and purified substantially as described in Example 5. Binding and activity of the affinity-modified variant CD155 Fc fusion proteins was assessed substantially as described in Example 6, except that cells expressing full length human CD226 and TIGIT cognate binding partners were generated. Cells were stained by flow cytometry with CD155 Fc variant and mean fluorescence intensity (MFI) was determined as described in Example 5. For bioactivity characterization, recombinant CD155 Fc variants were assessed in an anti-CD3 coimmobilization assay substantially as described in Example 5.

[0288] The results for the binding and activity studies are set forth in Table 17. The Table indicates exemplary IgSF domain amino acid substitutions (replacements) in the IgV domain of CD155 selected in the screen for affinity-maturation against the respective cognate structures TIGIT and CD226. The exemplary amino acid substitutions are designated by amino acid position number corresponding to position of the unmodified sequence set forth in SEQ ID NO: 241 (IgV). The amino acid position is indicated in the middle, with the corresponding unmodified (e.g. wild-type) amino acid listed before the number and the identified variant amino acid substitution listed after the number. Column 2 sets forth the SEQ ID NO identifier for the variant for each variant ECD-Fc fusion molecule.

[0289] Also shown is the binding activity as measured by the Mean Fluorescence Intensity (MFI) value for binding of each variant Fc-fusion molecule to cells engineered to express the cognate counter structure ligand as the ratio of the MFI compared to the binding of the corresponding unmodified ECD-Fc fusion molecule not containing the amino acid substitution(s) to the same cell-expressed counter structure ligand. The functional activity of the

variant Fc-fusion molecules to modulate the activity of T cells also is shown based on the calculated levels of IFN-gamma in culture supernatants (pg/ml) generated with the indicated variant Fc fusion molecule coimmobilized with anti-CD3 as a ratio of IFN-gamma produced by each variant CD155 IgV-Fc compared to the corresponding unmodified CD155 IgV-Fc in both functional assays.

TABLE 17: CD155 variants selected against cognate binding partners. Molecule sequences, binding data, and costimulatory bioactivity data.

CD155 mutations	SEQ ID NO (IgV)	CD226 tfxn MFI (CD226 MFI parental ratio)	TIGIT tfxn MFI (TIGIT MFI parental ratio)	CD96 MFI (CD96 MFI parental ratio)	Mock Expi293 MFI (Mock MFI parental ratio)	Anti-CD3 IFN-gamma (pg/ml) (Anti-CD3 IFN-gamma parental ratio)
P18S, P64S, F91S	264	497825 (133.7)	247219 (91.1)	140065 (45.4)	3528 (1.2)	270.1 (0.7)
P18S, F91S, L104P	265	26210 (7.0)	75176 (27.7)	10867 (3.5)	2130 (0.7)	364.2 (0.9)
L44P	266	581289 (156.1)	261931 (96.5)	152252 (49.4)	3414 (1.2)	277.6 (0.7)
A56V	267	455297 (122.3)	280265 (103.2)	161162 (52.2)	2601 (0.9)	548.2 (1.4)
P18L, L79V, F91S	268	5135 (1.4)	4073 (1.5)	3279 (1.1)	2719 (0.9)	1241.5 (3.2)
P18S, F91S	269	408623 (109.8)	284190 (104.7)	147463 (47.8)	3348 (1.1)	760.6 (2.0)
P18T, F91S	270	401283 (107.8)	223985 (82.5)	157644 (51.1)	3065 (1.1)	814.7 (2.1)
P18T, S42P, F91S	271	554105 (148.8)	223887 (82.5)	135395 (43.9)	3796 (1.3)	539.7 (1.4)
G7E, P18T, Y30C, F91S	272	12903 (3.5)	12984 (4.8)	7906 (2.6)	2671 (0.9)	275.9 (0.7)
P18T, F91S, G111D	273	438327 (117.7)	287315 (105.8)	167583 (54.3)	4012 (1.4)	307.2 (0.8)
P18S, F91P	274	4154 (1.1)	3220 (1.2)	2678 (0.9)	2816 (1.0)	365.7 (0.9)
P18T, F91S, F108L	275	394546 (106.0)	298680 (110.0)	193122 (62.6)	2926 (1.0)	775.4 (2.0)
P18T, T45A, F91S	277	435847 (117.1)	222044 (81.8)	191026 (61.9)	2948 (1.0)	1546.8 (4.0)
P18T, F91S, R94H	278	3589 (1.0)	2942 (1.1)	2509 (0.8)	2390 (0.8)	1273.2 (3.3)
P18S, Y30C, F91S	279	382352 (102.7)	276358 (101.8)	56934 (18.5)	3540 (1.2)	426.5 (1.1)
A81V, L83P	280	4169 (1.1)	2912 (1.1)	2616 (0.8)	2993 (1.0)	339.7 (0.9)
L88P	281	65120 (17.5)	74845 (27.6)	35280 (11.4)	2140 (0.7)	969.2 (2.5)
Wild type	241	3723	2715	3085	2913	389.6

TABLE 17: CD155 variants selected against cognate binding partners. Molecule sequences, binding data, and costimulatory bioactivity data.

CD155 mutations	SEQ ID NO (IgV)	CD226 tfxn MFI (CD226 MFI parental ratio)	TIGIT tfxn MFI (TIGIT MFI parental ratio)	CD96 MFI (CD96 MFI parental ratio)	Mock Expi293 MFI (Mock MFI parental ratio)	Anti-CD3 IFN-gamma (pg/ml) (Anti-CD3 IFN-gamma parental ratio)
		(1.0)	(1.0)	(1.0)	(1.0)	(1.0)
R94H	282	18905 (5.1)	104013 (38.3)	11727 (3.8)	1663 (0.6)	372.6 (1.0)
A13E, P18S, A56V, F91S	283	357808 (96.1)	179060 (66.0)	118570 (38.4)	2844 (1.0)	349.2 (0.9)
P18T, F91S, V115A	284	38487 (10.3)	46313 (17.1)	22718 (7.4)	2070 (0.7)	1574.5 (4.0)
P18T, Q60K	285	238266 (64.0)	173730 (64.0)	154448 (50.1)	4778 (1.6)	427.2 (1.1)

Example 10: Generation, Selection and Screening of Affinity-modified IgSF Domain Variants of CD112

[0290] Affinity-modified IgSF domain variants of CD112 were generated substantially as described in Examples 1-6 above with some slight modifications. For example, for the generation of CD112 variants, only the IgV domain, and not the other two domains of the ECD, was included in the generated proteins.

[0291] To generate a library targeting specific residues of CD155 by complete or partial randomization with degenerate codons, the coding DNA for the immunoglobulin-like V-type (IgV) domain of human CD112 (SEQ ID NO:286) was ordered from Integrated DNA Technologies (Coralville, IA) as a set of overlapping oligonucleotides of up to 80 base pairs (bp) in length. In general, to generate a library of diverse variants of the IgV domain, the oligonucleotides contained desired degenerate codons at desired amino acid positions. Degenerate codons were generated using an algorithm at the URL: rosettadesign.med.unc.edu/SwiftLib/. In general, positions to mutate and degenerate codons were chosen from crystal structure information (PDB: 3UDW) or homology models built from this structure containing the target-ligand pairs of interest to identify ligand contact residues as well as residues that are at the protein interaction interface.

[0292] The oligonucleotides were used for PCR amplification to generate library DNA inserts for insertion into the modified yeast display version of vector pBYDS03 substantially as described in Example 1. Alternatively, Ultramers (Integrated DNA Technologies) of up to 200

bp in length were used in conjunction with megaprimer PCR (URL: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC146891/pdf/253371.pdf>) to generate larger stretches of degenerate codons that could not be as easily incorporated using multiple small overlapping primers. Following the generation of full length product using megaprimer PCR, the mutant IgV domain library was PCR amplified again using DNA primers containing 40 bp overlap region with the modified pBYDS03 cloning variant for homologous recombination into yeast. The library of DNA inserts were prepared for library insertion substantially as described in Example 1 and electroporation-ready DNA was prepared.

[0293] As alternative approaches, either sublibraries generated by site-directed mutagenesis to target specific residues of the IgV domain of CD112 or random libraries of the IgV domain of CD112 were generated to further identify variants of the IgV domain of CD112 substantially as described in Example 1.

[0294] The degenerate or random library DNA was inserted into yeast substantially as described in Example 2. Yeast expressing affinity modified variants of CD112 were selected using the method substantially described in Example 3. For the selection, the following target ligand proteins were employed: human rTIGIT.Fc (i.e., recombinant TIGIT-Fc fusion protein), rCD226.Fc and rCD112R.Fc. Magnetic Protein A beads were obtained from New England Biolabs, USA. For two-color, flow cytometric sorting, a Bio-Rad S3e sorter was used. CD112 display levels were monitored with an anti-hemagglutinin antibody labeled with Alexafluor 488 (Life Technologies, USA). Ligand binding of Fc fusion proteins, rTIGIT.Fc, rCD226.Fc, or rCD112R.Fc, were detected with PE conjugated human Ig specific goat Fab (Jackson ImmunoResearch, USA). Doublet yeast were gated out using forward scatter (FSC) / side scatter (SSC) parameters, and sort gates were based upon higher ligand binding detected in FL2 that possessed more limited tag expression binding in FL1.

[0295] Second sort outputs (F2) were obtained substantially as described in Example 3 by expanding and re-inducing expression of sort outputs that had been assayed for higher specific binding affinity and were used to assess binding compared to the parental, wild-type yeast strain. For CD112, the second FACS outputs (F2) were compared to parental CD112 yeast for binding of each rTIGIT.Fc, rCD226.Fc, and rCD112R by double staining each population with anti-HA (hemagglutinin) tag expression and the anti-human Fc secondary to detect ligand binding.

[0296] Selected outputs were reformatted as immunomodulatory proteins containing an affinity modified (variant) immunoglobulin-like V-type (IgV) domain of CD112 fused to an Fc molecule (variant IgV domain -Fc fusion molecules) substantially as described in Example 4, except including only the IgV domain and not the full ECD domain. In some alternative methods for the CD112 outputs, DNA from the outputs were PCR amplified with primers containing 40 bp overlap regions on either end with an Fc fusion vector to carry out in vitro recombination using Gibson Assembly Mastermix (New England Biolabs), which was subsequently used in heat shock transformation into E. Coli strain NEB5alpha. Exemplary of an Fc fusion vector is pFUSE-hIgG1-Fc2 (Invivogen, USA).

[0297] After transformation, samples were prepared for DNA sequencing substantially as described in Example 4. The sequences were then manually curated as described in Example 4, except that they were manually curated so that they start at the beginning of the IgV coding region. The curated sequences were batch-translated and aligned as described in Example 4. Clones of interest were identified using the criteria as described in Example 4. Table 18 sets forth the identified variant CD112 affinity-modified molecules, including the amino acid substitutions contained in each variant.

[0298] The methods generated immunomodulatory proteins containing an affinity-modified IgV domain of CD112 in which the encoding DNA was generated to encode a protein as follows: signal peptide followed by variant (mutant) IgV domain followed by a linker of three alanines (AAA) followed by a human IgG1 Fc containing the mutation N297G (N82G with reference to wild-type human IgG1 Fc set forth in SEQ ID NO: 226). The human IgG1 Fc also contained the mutations R292C and V302C (corresponding to R77C and V87C with reference to wild-type human IgG1 Fc set forth in SEQ ID NO: 226). Since the construct does not include any antibody light chains that can form a covalent bond with a cysteine, the human IgG1 Fc also contained replacement of the cysteine residues to a serine residue at position 5 (C5S) compared to the wild-type or unmodified Fc set forth in SEQ ID NO: 226.

[0299] Recombinant variant CD112 Fc fusion proteins were expressed and purified substantially as described in Example 5. Binding and activity of the affinity-modified variant CD112 Fc fusion proteins was assessed substantially as described in Example 6, except that cells expressing full length human CD226, TIGIT and CD112R cognate binding partners were generated. Cells were stained by flow cytometry with CD112 Fc variant and mean fluorescence intensity (MFI) was determined as described in Example 5. For bioactivity characterization,

recombinant CD112 Fc variants were assessed in an anti-CD3 coimmobilization assay substantially as described in Example 5.

[0300] The results for the binding and activity studies are set forth in Table 18. The Table indicates exemplary IgSF domain amino acid substitutions (replacements) in the IgV domain of CD112 selected in the screen for affinity-maturation against the respective cognate structures TIGIT, CD226 and CD112R. The exemplary amino acid substitutions are designated by amino acid position number corresponding to position of the unmodified sequence set forth in SEQ ID NO: 286. The amino acid position is indicated in the middle, with the corresponding unmodified (e.g. wild-type) amino acid listed before the number and the identified variant amino acid substitution listed after the number. Column 2 sets forth the SEQ ID NO identifier for the variant ECD for each variant ECD-Fc fusion molecule.

[0301] Also shown is the binding activity as measured by the Mean Fluorescence Intensity (MFI) value for binding of each variant Fc-fusion molecule to cells engineered to express the cognate counter structure ligand as the ratio of the MFI compared to the binding of the corresponding unmodified ECD-Fc fusion molecule not containing the amino acid substitution(s) to the same cell-expressed counter structure ligand. The functional activity of the variant Fc-fusion molecules to modulate the activity of T cells also is shown based on the calculated levels of IFN-gamma in culture supernatants (pg/ml) generated with the indicated variant Fc fusion molecule coimmobilized with anti-CD3 as a ratio of IFN-gamma produced by each variant CD112 IgV-Fc compared to the corresponding unmodified CD112 IgV-Fc in both functional assays.

TABLE 18: CD112 variants selected against cognate binding partners. Molecule sequences, binding data, and costimulatory bioactivity data.						
CD112 mutations	SEQ ID NO (IgV)	TIGIT tfxn MFI (TIGIT MFI parental ratio)	CD112R tfxn MFI (CD112R MFI parental ratio)	CD226 MFI (CD226 MFI parental ratio)	Mock Expi293 MFI (Mock MFI parental ratio)	Anti-CD3 IFN-gamma (pg/ml) (Anti-CD3 IFN-gamma parental ratio)
WT CD112	286	210829 (1.00)	1452 (1.00)	265392 (1.00)	1112 (1.00)	676.6 (1.00)
Y33H, A112V, G117D	334	12948 (0.06)	1552 (1.07)	1368 (0.01)	1241 (1.12)	164.8 (0.24)
V19A, Y33H, S64G, S80G, G98S, N106Y, A112V	335	48356 (0.23)	1709 (1.18)	2831 (0.01)	1098 (0.99)	
L32P, A112V	336	191432 (0.91)	1557 (1.07)	11095 (0.04)	1259 (1.13)	390.4 (0.58)
A95V, A112I	337	238418	1706	51944	1215	282.5

TABLE 18: CD112 variants selected against cognate binding partners. Molecule sequences, binding data, and costimulatory bioactivity data.

CD112 mutations	SEQ ID NO (IgV)	TIGIT tfxn MFI (TIGIT MFI parental ratio)	CD112R tfxn MFI (CD112R MFI parental ratio)	CD226 MFI (CD226 MFI parental ratio)	Mock Expi293 MFI (Mock MFI parental ratio)	Anti-CD3 IFN-gamma (pg/ml) (Anti-CD3 IFN-gamma parental ratio)
		(1.13)	(1.17)	(0.20)	(1.09)	(0.42)
P28S, A112V	338	251116 (1.19)	1985 (1.37)	153382 (0.58)	1189 (1.07)	503.4 (0.74)
P27A, T38N, V101A, A112V	339	255803 (1.21)	2138 (1.47)	222822 (0.84)	1399 (1.26)	240.7 (0.36)
S118F	340	11356 (0.05)	5857 (4.03)	6938 (0.03)	1270 (1.14)	271.7 (0.40)
R12W, H48Y, F54S, S118F	341	10940 (0.05)	3474 (2.39)	5161 (0.02)	1069 (0.96)	
R12W, Q79R, S118F	342	2339 (0.01)	7370 (5.08)	1880 (0.01)	1338 (1.20)	447.4 (0.66)
T113S, S118Y	343	6212 (0.03)	6823 (4.70)	1554 (0.01)	1214 (1.09)	225.1 (0.33)
S118Y	344	2921 (0.01)	6535 (4.50)	2003 (0.01)	1463 (1.32)	190.4 (0.28)
N106I, S118Y	345	2750 (0.01)	7729 (5.32)	1815 (0.01)	1222 (1.10)	265.8 (0.39)
N106I, S118F	346	1841 (0.01)	9944 (6.85)	1529 (0.01)	1308 (1.18)	437.9 (0.65)
A95T, L96P, S118Y	347	2352 (0.01)	4493 (3.09)	1412 (0.01)	1329 (1.19)	292.4 (0.43)
Y33H, P67S, N106Y, A112V	348	225015 (1.07)	3259 (2.24)	204434 (0.77)	1296 (1.17)	618.8 (0.91)
N106Y, A112V	349	6036 (0.03)	1974 (1.36)	15334 (0.06)	1108 (1.00)	409.9 (0.61)
T18S, Y33H, A112V	350	252647 (1.20)	1347 (0.93)	183181 (0.69)	1412 (1.27)	601.8 (0.89)
P9S, Y33H, N47S, A112V	351	240467 (1.14)	1418 (0.98)	203608 (0.77)	1361 (1.22)	449.1 (0.66)
P42S, P67H, A112V	352	204484 (0.97)	1610 (1.11)	188647 (0.71)	1174 (1.06)	530.6 (0.78)
P27L, L32P, P42S, A112V	353	219883 (1.04)	1963 (1.35)	84319 (0.32)	1900 (1.71)	251.6 (0.37)
G98D, A112V	354	4879 (0.02)	2369 (1.63)	6100 (0.02)	1729 (1.55)	387.0 (0.57)
Y33H, S35P, N106Y, A112V	355	250724 (1.19)	1715 (1.18)	94373 (0.36)	1495 (1.34)	516.2 (0.76)
L32P, P42S, T100A, A112V	356	242675 (1.15)	1742 (1.20)	202567 (0.76)	1748 (1.57)	435.3 (0.64)
P27S, P45S, N106I, A112V	357	223557 (1.06)	1799 (1.24)	84836 (0.32)	1574 (1.42)	277.5 (0.41)
Y33H, N47K, A112V	358	251339 (1.19)	1525 (1.05)	199601 (0.75)	1325 (1.19)	483.2 (0.71)
Y33H, N106Y, A112V	359	297169 (1.41)	1782 (1.23)	258315 (0.97)	1440 (1.30)	485.4 (0.72)
K78R, D84G, A112V, F114S	360	236662 (1.12)	1638 (1.13)	24850 (0.09)	1345 (1.21)	142.5 (0.21)
Y33H, N47K, F54L, A112V	361	14483	1617	2371	1353	352.8

TABLE 18: CD112 variants selected against cognate binding partners. Molecule sequences, binding data, and costimulatory bioactivity data.

CD112 mutations	SEQ ID NO (IgV)	TIGIT tfxn MFI (TIGIT MFI parental ratio)	CD112R tfxn MFI (CD112R MFI parental ratio)	CD226 MFI (CD226 MFI parental ratio)	Mock Expi293 MFI (Mock MFI parental ratio)	Anti-CD3 IFN-gamma (pg/ml) (Anti-CD3 IFN-gamma parental ratio)
		(0.07)	(1.11)	(0.01)	(1.22)	(0.52)
Y33H, A112V	362	98954 (0.47)	1216 (0.84)	1726 (0.01)	1298 (1.17)	
A95V, A112V	363	168521 (0.80)	2021 (1.39)	200789 (0.76)	1459 (1.31)	412.9 (0.61)
R12W, A112V	364	135635 (0.64)	1582 (1.09)	23378 (0.09)	1412 (1.27)	165.8 (0.24)
A112V	370	213576 (1.01)	1986 (1.37)	151900 (0.57)	1409 (1.27)	211.4 (0.31)
Y33H, A112V	362	250667 (1.19)	1628 (1.12)	230578 (0.87)	1216 (1.09)	612.7 (0.91)
R12W, P27S, A112V	365	3653 (0.02)	1308 (0.90)	9105 (0.03)	1051 (0.94)	
Y33H, V51M, A112V	366	218698 (1.04)	1384 (0.95)	195450 (0.74)	1170 (1.05)	709.4 (1.05)
Y33H, A112V, S118T	367	219384 (1.04)	1566 (1.08)	192645 (0.73)	1313 (1.18)	396.3 (0.59)
Y33H, V101A, A112V, P115S	368	5605 (0.03)	1582 (1.09)	5079 (0.02)	1197 (1.08)	
H24R, T38N, D43G, A112V	369	227095 (1.08)	1537 (1.06)	229311 (0.86)	1336 (1.20)	858.6 (1.27)
A112V	370	4056 (0.02)	1356 (0.93)	10365 (0.04)	986 (0.89)	
P27A, A112V	371	193537 (0.92)	1531 (1.05)	230708 (0.87)	3084 (2.77)	355.1 (0.52)
A112V, S118T	372	233173 (1.11)	1659 (1.14)	121817 (0.46)	845 (0.76)	533.3 (0.79)
R12W, A112V, M122I	373	235935 (1.12)	1463 (1.01)	217748 (0.82)	1350 (1.21)	528.0 (0.78)
Q83K, N106Y, A112V	374	205948 (0.98)	2042 (1.41)	234958 (0.89)	1551 (1.39)	481.4 (0.71)
R12W, P27S, A112V, S118T	375	11985 (0.06)	2667 (1.84)	12756 (0.05)	1257 (1.13)	334.4 (0.49)
P28S, Y33H, A112V	376	4711 (0.02)	1412 (0.97)	3968 (0.01)	955 (0.86)	
P27S, Q90R, A112V	377	3295 (0.02)	1338 (0.92)	6755 (0.03)	1048 (0.94)	
L15V, P27A, A112V, S118T	378	209888 (1.00)	1489 (1.03)	84224 (0.32)	1251 (1.13)	512.3 (0.76)

Example 11: Generation and Assessment of Engineered Cells Expressing a Transmembrane Immunomodulatory Protein

[0302] Engineered T cells were generated in which a transmembrane immunomodulatory protein (TIP) containing an extracellular domain (ECD) containing either a variant CD80 or ICOSL affinity-modified IgSF domain as described above was co-expressed with a chimeric antigen receptor (CAR). The TIP also contained a transmembrane domain and a cytoplasmic domain of the corresponding wild-type CD80 or ICOSL transmembrane protein sequence. The immunomodulatory activity of the engineered cells was compared to cells that only expressed the CAR or cells that co-expressed the corresponding wild-type CD80 or ICOSL transmembrane protein with the CAR.

[0303] The exemplary CD80-TIP was a variant CD80 having an affinity-modified IgSF domain containing amino acid mutations in the IgV and IgC domains corresponding to I67T/L70Q/A91G/T120S with reference to positions in the CD80 extracellular domain set forth in SEQ ID NO:28 and a transmembrane and cytoplasmic domain corresponding to residues 243-288 of SEQ ID NO:1. The amino acid sequence of the exemplary CD80-TIP is set forth in SEQ ID NO:381 and is encoded by the sequence of nucleotides set forth in SEQ ID NO:382. The corresponding wild-type CD80 transmembrane protein had the sequence of amino acids set forth as amino acid residues 35-288 of SEQ ID NO:1 and encoded by the sequence of amino acids set forth in SEQ ID NO: 391.

[0304] The exemplary ICOSL-TIP was a variant ICOSL having an affinity-modified IgSF domain containing amino acid mutations in the IgV domain corresponding to N52H/I143T with reference to positions in the ICOSL extracellular domain set forth in SEQ ID NO:32 and a transmembrane and cytoplasmic domain corresponding to residues 257-302 of SEQ ID NO:5. The amino acid sequence of the exemplary ICOSL-TIP is set forth in SEQ ID NO:383 and is encoded by the sequence of nucleotides set forth in SEQ ID NO:384. The corresponding wild-type ICOSL transmembrane protein had the sequence of amino acids set forth as amino acid residues 19-302 of SEQ ID NO:5 and encoded by the sequence of amino acids set forth in SEQ ID NO: 392.

[0305] The TIP containing the affinity-modified domain or the wild-type transmembrane protein containing a corresponding non-affinity modified IgSF domain were co-expressed in T cells with a 1st generation chimeric antigen receptor (CAR) containing a CD3zeta intracellular signaling domain. The 1st generation CAR included an ScFv specific for CD19 (SEQ ID

NO:385), a hinge and transmembrane domain derived from CD8 (SEQ ID NO:386) and an intracellular signaling domain derived from CD3zeta (set forth in SEQ ID NO:387). The nucleotide sequence encoding the CD19 scFv – CD3zeta CAR is set forth in SEQ ID NO:388.

[0306] Nucleic acid molecules encoding the CAR alone or also encoding one of the exemplary TIPs or wild-type transmembrane proteins separated from the CAR by a self-cleaving T2A sequence (SEQ ID NO:390 and encoded by the sequence of nucleotides set forth in SEQ ID NO:389) were generated. Exemplary constructs contained nucleic acid sequences set forth in Table 19. As a control, a nucleic acid construct encoding a 2nd generation CAR additionally containing a CD28 costimulatory domain also was generated (CD19 scFv – CD28 – CD3zeta).

Table 19: Nucleic Acid Constructs			
	CAR (SEQ ID NO)	T2A Linker (SEQ ID NO)	TIP (SEQ ID NO)
CD19 scFv – CD3zeta	+ (386)	-	-
CD19 scFv – CD3zeta – T2A – B7-1	+ (386)	+ (389)	Wildtype CD80 (391)
CD19 scFv – CD3zeta – T2A – B7-1_TIP	+ (386)	+ (389)	CD80 TIP (382)
CD19 scFv – CD3zeta – T2A – ICOSL	+ (386)	+ (389)	Wildtype ICOSL (392)
CD19 scFv – CD3zeta – T2A – ICOSL_TIP	+ (386)	+ (389)	ICOSL TIP (384)

[0307] The nucleic acid molecules were individually cloned into a lentiviral vector, which was used to transduce T cells isolated from human PBMC samples obtained from three different healthy donors. Lentivirus particles containing the nucleic acid sequences were produced after co-transfection of HEK293 cells with the vectors and lentivirus packaging constructs. The lentivirus particles were collected from the culture medium by ultracentrifugation and titered by qRT-PCR. Human peripheral blood mononuclear cells (PBMC) were isolated from three normal blood donors using density sedimentation. The PBMC were cultured overnight with anti-CD3 and anti-CD28 antibodies and IL-2, then transduced with the lentivirus preparations at a multiplicity of infection of 5:1. The lentiviral vectors encoding the control 2nd generation CAR was only used to transduce cells from one donor.

[0308] After two weeks (14 days) of culture, the cells were analyzed for cytotoxicity following co-culture with target antigen-expressing cells using the Acea Real-Time Cell Analyzer (RTCA), which measures the impedance variations in the culture media of a 96-well microelectronic plate (E-plate), and shows the changes in cell number and morphology in a real-time plot. CD19-expressing HeLa target cells (HeLa-CD19) were seeded into a 96-well E-plate and the impedance of each monolayer was monitored for 24 hours using the RTCA system. The engineered T cells were added to the wells at an effector:target ratio of 10:1 and the wells were monitored for another 48 hours. The results were displayed and recorded as Cell Index (CI) value derived from the change in measured electrical impedance and were then ratio transformed by dividing the CI readouts of all wells at all time points over the CI value of individual wells at a same time (base-time) to obtain a normalized cell index value representing the percentage of the value at the base-time (see Zhang et al. "Introduction to the Data Analysis of the Roche xCELLigence® System with RTCA Package." *Bioconductor*. May, 3, 2016, bioconductor.org/packages/devel/bioc/vignettes/RTCA/inst/doc/aboutRTCA.pdf. Accessed September 9, 2016). In this assay, a decrease in the impedance of a monolayer reflects killing of the target cells by the transduced cells.

[0309] The results showed that decreased impedance was observed in cells expressing the 1st generation CAR compared to non-transduced T cells, although the degree of decreased impedance for cells expressing the 1st generation CAR was less than cells expressing the 2nd generation CAR. The decreased impedance in cells expressing the 1st generation CAR continued generally for up to the first 8 hours of the assay, while only the 2nd generation CAR-expressing cells continued to decrease the impedance thereafter.

[0310] As shown in FIG. 2, in one donor, each of the cells co-expressing the TIP or corresponding wild-type transmembrane protein with the 1st generation CAR exhibited a greater decrease in impedance, indicating greater cytotoxic activity, compared to cells only expressing the 1st generation CAR. Further, the results showed that the cytotoxic activity was greater in CAR-expressing cells that co-expressed the CD80-TIP or ICOSL-TIP relative to CAR-expressing cells that co-expressed the corresponding wild-type CD80 or ICOSL transmembrane proteins containing a non-affinity modified IgSF domain. The observed results of these TIP-engineered cells showed that cytotoxic activity in cells co-expressing the CD80-TIP or ICOSL-TIP with the CAR exhibit increased activity to modulate the cytotoxic immune response of antigen-specific T cells, such as the CAR-expressing T cells.

[0311] In the other two donors, the cells expressing the CD80-TIP did not result in a greater decreased impedance compared to cells expressing the corresponding wild-type CD80 transmembrane protein. In one donor, there were not enough cells to transduce with the wild-type transmembrane protein construct, although in this donor the ICOS-L TIP gave the best cytotoxicity compared to the other constructs tested. In the other donor, the cells expressing the ICOS-L-TIP did not result in a greater decreased impedance compared to cells expressing the corresponding wild-type ICOS-L transmembrane protein. In the tested cells, all cells co-expressing either a CD80-TIP, ICOSL-TIP or corresponding wild type transmembrane protein with the CAR exhibited greater cytotoxic activity than cells only expressing the 1st generation CAR. The differences in the results observed among donors may be related to the differences in the T cells among the donors, differences in expression levels of the various engineered proteins on the surface of the cells, the particular conditions used in this exemplary assay for assessing killing in cells (e.g. assessing Day 14 transduced cells, assessing a single effector:target cell ratio) or other factors.

[0312] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED:

1. A transmembrane immunomodulatory protein (TIP) comprising:
 - (i) an ectodomain comprising at least one non-immunoglobulin affinity-modified immunoglobulin superfamily (IgSF) domain comprising one or more amino acid substitution(s) in a wild-type IgSF domain, wherein the at least one affinity-modified IgSF domain specifically binds at least one cell surface cognate binding partner of the wild-type IgSF domain; and
 - (ii) a transmembrane domain.
2. The transmembrane immunomodulatory protein of claim 1, wherein the at least one cell surface cognate binding partner is expressed on a mammalian cell.
3. The transmembrane immunomodulatory protein of claim 2, wherein the mammalian cell is an antigen presenting cell (APC), a tumor cell, or a lymphocyte, which optionally is a T-cell.
4. The transmembrane immunomodulatory protein of any of claims 1-3, wherein the mammalian cell is a mouse, rat, cynomolgus monkey, or human cell.
5. The transmembrane immunomodulatory protein of any of claims 1-4, wherein the at least one affinity modified IgSF domain has increased binding affinity to the at least one cell surface cognate binding partner compared with the reference wild-type IgSF domain.
6. The transmembrane immunomodulatory protein of any of claims 2-5, wherein specific binding of the transmembrane immunomodulatory protein comprising the at least one affinity-modified IgSF domain modulates immunological activity of the mammalian cell compared with the reference transmembrane domain comprising the wild-type IgSF domain.
7. The transmembrane immunomodulatory protein of any of claims 2-6, wherein specific binding of the transmembrane immunomodulatory protein comprising the at least one

affinity-modified IgSF domain increases immunological activity of the mammalian cell compared with the reference transmembrane domain comprising the wild-type IgSF domain.

8. The transmembrane immunomodulatory protein of any of claims 2-6, wherein specific binding of the transmembrane immunomodulatory protein attenuates immunological activity of the mammalian cell compared with the reference transmembrane domain comprising the wild-type IgSF domain.

9. The transmembrane protein of any of claims 1-8, wherein the wild-type IgSF domain is from an IgSF family member of a family selected from Signal-Regulatory Protein (SIRP) Family, Triggering Receptor Expressed On Myeloid Cells Like (TREM) Family, Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM) Family, Sialic Acid Binding Ig-Like Lectin (SIGLEC) Family, Butyrophilin Family, B7 family, CD28 family, V-set and Immunoglobulin Domain Containing (VSIG) family, V-set transmembrane Domain (VSTM) family, Major Histocompatibility Complex (MHC) family, Signaling lymphocytic activation molecule (SLAM) family, Leukocyte immunoglobulin-like receptor (LIR), Nectin (Nec) family, Nectin-like (NECL) family, Poliovirus receptor related (PVR) family, Natural cytotoxicity triggering receptor (NCR) family, T cell immunoglobulin and mucin (TIM) family or Killer-cell immunoglobulin-like receptors (KIR) family.

10. The transmembrane immunomodulatory protein of any of claims 1-9, wherein the wild-type IgSF domain is from an IgSF member selected from CD80, CD86, PD-L1, PD-L2, ICOS Ligand, B7-H3, B7-H4, CD28, CTLA4, PD-1, ICOS, BTLA, CD4, CD8-alpha, CD8-beta, LAG3, TIM-3, CEACAM1, TIGIT, PVR, PVRL2, CD226, CD2, CD160, CD200, CD200R or Nkp30.

11. The transmembrane immunomodulatory protein of any of claims 1-10, wherein the wild-type IgSF domain is a human IgSF member.

12. The transmembrane immunomodulatory protein of any of claims 1-11, wherein the at least one affinity modified IgSF domain has at least 90% sequence identity to a wild-type

IgSF domain or a specific binding fragment thereof contained in the sequence of amino acids set forth in any of SEQ ID NOS: 1-27.

13. The transmembrane immunomodulatory protein of any of claims 1-12, wherein the transmembrane immunomodulatory protein has at least 90% sequence identity to the amino acid sequence selected from any of SEQ ID NOS: 393-419.

14. The transmembrane immunomodulatory protein of any of claims 1-13, wherein the at least one cell surface cognate binding partner is a stimulatory receptor expressed on a T-cell and the at least one affinity-modified IgSF domain has increased binding affinity to the stimulatory receptor compared to the affinity of the wild-type IgSF domain.

15. The transmembrane immunomodulatory protein of claim 14, wherein binding of the affinity-modified IgSF domain to the stimulatory receptor increases immunological activity of the T-cell.

16. The transmembrane immunomodulatory protein of claim 14 or claim 15, wherein the stimulatory receptor is CD28, ICOS or CD226.

17. The transmembrane immunomodulatory protein of any one of claims 14-16, wherein the at least one affinity-modified IgSF domain is an affinity modified B7-1 IgSF domain and the stimulatory receptor is CD28.

18. The transmembrane immunomodulatory protein of any one of claims 14-16, wherein the at least one affinity-modified IgSF domain is an affinity modified ICOSL IgSF domain and the stimulatory receptor is ICOS.

19. The transmembrane immunomodulatory protein of any one of claims 14-16, wherein the affinity-modified IgSF domain is an affinity modified ICOSL IgSF domain and the stimulatory receptor is CD28.

20. The transmembrane immunomodulatory protein of any one of claims 14-16, 18 and 19, wherein the at least one affinity-modified IgSF domain is an affinity-modified ICOSL IgSF domain that has increased binding affinity to at least one of: ICOS and CD28.

21. The transmembrane immunomodulatory protein of any one of claims 14-16- and 18-20, wherein the affinity modified IgSF domain is an affinity modified ICOSL IgV IgSF domain with increased binding affinity to both ICOS and CD28.

22. The transmembrane immunomodulatory protein of any one of claims 17-21, wherein the affinity-modified IgSF domain does not substantially specifically bind to CTLA-4 or exhibits decreased binding affinity to CTLA-4 compared to the wild-type IgSF domain.

23. The transmembrane immunomodulatory protein of any of claims 1-22, wherein the at least one affinity-modified IgSF domain specifically binds to no more than one cell surface cognate binding partner.

24. The transmembrane immunomodulatory protein of any of claims 1-23, wherein the transmembrane immunomodulatory protein specifically binds to no more than one cell surface cognate binding partner.

25. The transmembrane immunomodulatory protein of any of claims 1-22, wherein the at least one affinity-modified domain specifically binds to at least two cell surface cognate binding partners.

26. The transmembrane immunomodulatory protein of claim 25, wherein:
the first cell surface cognate binding partner is a stimulatory receptor expressed on a T cell; and

the second cell surface cognate binding partner is an inhibitory ligand of an inhibitory receptor, wherein the inhibitory receptor is expressed on a T-cell.

27. The transmembrane immunomodulatory protein of claim 26, wherein binding of the affinity-modified domain to the inhibitory ligand competitively inhibits binding of the inhibitory ligand to the inhibitory receptor.

28. The transmembrane immunomodulatory protein of claim 26 or claim 27, wherein:

the inhibitory receptor is PD-1, CTLA-4, LAG-3, TIGIT, CD96, CD112R, BTLA, CD160 or TIM-3; or

the ligand of the inhibitory receptor is PD-L1, PD-L2, B7-1, B7-2, HVEM, MHC class II, PVR, CEACAM-1 or GAL9.

29. The transmembrane immunomodulatory protein of any one of claims 26-28, wherein the affinity modified IgSF domain is an affinity modified B7-1 domain and the stimulatory receptor is CD28.

30. The transmembrane immunomodulatory protein of claim 29, wherein the inhibitory ligand is PD-L1 and the inhibitory receptor is PD-1.

31. The transmembrane immunomodulatory protein of claim 29 or claim 30, wherein the affinity-modified IgSF domain exhibits decreased binding affinity to CTLA-4 compared to the wild-type IgSF domain for CTLA-4.

32. The transmembrane immunomodulatory protein of any one of claims 29-31, wherein the affinity-modified IgSF domain does not substantially specifically bind to CTLA-4.

33. The transmembrane immunomodulatory protein of any of claims 1-13, wherein the affinity modified IgSF domain is an affinity modified CD155 IgSF domain or an affinity modified CD112 IgSF domain and the stimulatory receptor is CD226.

34. The transmembrane immunomodulatory protein of claim 33, wherein the affinity-modified IgSF domain exhibits decreased binding affinity to TIGIT (T-cell immunoreceptor with Ig and ITIM domains) compared to the affinity of the wild-type IgSF domain.

35. The transmembrane immunomodulatory protein of any of claims 1-13, wherein the at least one affinity-modified IgSF domain specifically binds to a cell surface cognate binding partner that is a tumor specific antigen.

36. The transmembrane immunomodulatory protein of claim 35, wherein the tumor specific antigen is B7-H6.

37. The transmembrane immunomodulatory protein of claim 35 or claim 36, wherein the affinity-modified IgSF domain is an affinity modified Nkp30 IgSF domain.

38. The transmembrane immunomodulatory protein of any one of claims 1-37, wherein the at least one affinity-modified IgSF domain is a first affinity-modified IgSF domain and the ectodomain comprises a second affinity-modified IgSF domain.

39. The transmembrane immunomodulatory protein of claim 38, wherein the first and second affinity-modified IgSF domain are different.

40. The transmembrane immunomodulatory protein of claim 38 or claim 39, wherein the first affinity-modified IgSF domain and the second affinity-modified IgSF domain each comprise one or more amino acid different substitutions in the same wild-type IgSF domain.

41. The transmembrane immunomodulatory protein of claim 38 or claim 39, wherein the first affinity-modified IgSF domain and the second affinity-modified IgSF domain each comprise one or more amino acid substitutions in a different wild-type IgSF domain.

42. The transmembrane immunomodulatory protein of any of claims 1-41, wherein the transmembrane immunomodulatory protein further comprises an endodomain or cytoplasmic signaling domains.

43. The transmembrane immunomodulatory protein of claim 42, wherein the endodomain is the endodomain from the wild-type IgSF member comprising the wild-type IgSF domain or is a functionally active portion thereof.

44. The transmembrane immunomodulatory protein of claim 42, wherein the transmembrane immunomodulatory protein is a chimeric receptor, wherein the endodomain is not the endodomain from the wild-type IgSF member comprising the wild-type IgSF domain.

45. The transmembrane immunomodulatory protein of claim 42 or claim 44, wherein the endodomain comprises at least one ITAM (immunoreceptor tyrosine-based activation motif)-containing signaling domain.

46. The transmembrane immunomodulatory protein of any of claims 42, 44 and 45, wherein the endodomain comprises a CD3-zeta signaling domain.

47. The transmembrane immunomodulatory protein of claim 45 or claim 46, wherein the endodomain further comprises at least one of: a CD28 costimulatory domain, an ICOS signaling domain, an OX40 signaling domain, and a 41BB signaling domain.

48. The transmembrane immunomodulatory protein of any of claims 1-13, wherein the wild-type IgSF domain is from an IgSF member that is an inhibitory receptor comprising an ITIM signaling domain.

49. The transmembrane immunomodulatory protein of claim 48, wherein the inhibitory receptor is PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA and the at least one affinity-modified IgSF domain is an affinity-modified IgSF domain of PD-1, CTLA-4, LAG3, TIGIT, TIM-3, or BTLA, respectively.

50. The transmembrane immunomodulatory protein of claim 48 or claim 49, wherein the inhibitory receptor is PD-1 and the at least one affinity-modified IgSF domain is an affinity-modified IgSF of PD-1.

51. The transmembrane immunomodulatory protein of any of claims 48-50, wherein the affinity-modified IgSF domain has increased binding affinity for a trans surface cognate binding partner compared to the wildtype IgSF domain, whereby the increased binding affinity competitively inhibits binding of the trans surface cognate binding partner to the inhibitory receptor.

52. The transmembrane immunomodulatory protein of any of claims 48-51, wherein the transmembrane immunomodulatory protein does not comprise an endodomain, ITIM or cytoplasmic signaling domains.

53. The transmembrane immunomodulatory protein of any of claims 1-52, wherein the affinity modified IgSF domain differs by no more than ten amino acid substitutions from the wildtype IgSF domain.

54. The transmembrane immunomodulatory protein of any of claims 1-53, wherein the affinity modified IgSF domain differs by no more than five amino acid substitutions from the wildtype IgSF domain.

55. The transmembrane immunomodulatory protein of any of claims 1-54, wherein the affinity-modified IgSF domain is or comprises an affinity modified IgV domain, affinity modified IgC1 domain or an affinity modified IgC2 domain or is a specific binding fragment thereof comprising the one or more amino acid substitutions.

56. The transmembrane immunomodulatory protein of any of claims 1-55, wherein the ectodomain further comprises one or more non-affinity modified IgSF domains.

57. The transmembrane immunomodulatory protein of claim 56, wherein the one or more non-affinity modified IgSF domains is from a wild-type IgSF member comprising the wild-type IgSF domain.

58. The transmembrane immunomodulatory protein of any of claims 1-57, wherein the transmembrane domain is the native transmembrane domain from the corresponding wild-type IgSF member.

59. The transmembrane immunomodulatory protein of any of claims 1-57, wherein the transmembrane domain is not the native transmembrane domain from the corresponding wild-type IgSF member.

60. The transmembrane immunomodulatory protein of claim 59, wherein the transmembrane protein is a transmembrane protein derived from CD8.

61. A recombinant nucleic acid encoding a transmembrane immunomodulatory proteins of any of claims 1-60.

62. A recombinant expression vector comprising the nucleic acid of claim 61.

63. A recombinant host cell comprising the expression vector of claim 62.

64. A recombinant host cell comprising the nucleic acid of claim 61.

65. The recombinant host cell of claim 63 or claim 64, wherein the host cell is a mammalian host cell.

66. The recombinant host cell of any of claims 63-65, wherein the mammalian host cell is a human host cell.

67. An engineered cell comprising the transmembrane immunomodulatory protein of any of claims 1-60.

68. The engineered cell of claim 67, wherein the cell is an immune cell.

69. The engineered cell of claim 67 or claim 68, wherein the cell is a lymphocyte.

70. The engineered cell of claim 69, wherein the lymphocyte is a T cell, a B cell or an NK cell.
71. The engineered cell of any of claims 67-70, wherein the cell is a T cell.
72. The engineered cell of claim 71, wherein the T cells is CD4+ or CD8+.
73. The engineered cell of claim 67 or claim 68, wherein the cell is an antigen presenting cell.
74. The engineered cell of any of claims 67-73, further comprising a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR).
75. A pharmaceutical composition comprising the cell of any of claims 67-74 and a pharmaceutically acceptable carrier.
76. The pharmaceutical composition of claim 75 that is sterile.
77. A method of modulating an immune response in a mammalian subject, comprising administering a cell of any of claims 67-74 or a pharmaceutical composition of claim 75 or claim 76 to the subject.
78. The method of claim 76 or claim 77, wherein modulating the immune response treats a disease or disorder in the subject.
79. The method of any of claims 77-78, wherein the modulated immune response is increased.
80. The method of claim 78 or claim 79, wherein the disease or disorder is a tumor.
81. The method of any of claims 78-80, wherein the disease or disorder is a cancer.

82. The method of any of claims 78-81, wherein the disease or disorder is melanoma, lung cancer, bladder cancer, or a hematological malignancy.
83. The method of any of claims 77-78, wherein the modulated immune response is decreased.
84. The method of claim 78 or claim 83, wherein the disease or disorder is an inflammatory disease or condition.
85. The method of any of claims 78, 83 and 84, wherein the disease or condition is Crohn's disease, ulcerative colitis, multiple sclerosis, asthma, rheumatoid arthritis, or psoriasis.
86. The method of any of claims 77-85, wherein the subject is human.
87. The method of any of claims 77-86, wherein the cell is autologous to the subject.
88. The method of any of claims 77-87, wherein the cell is allogenic to the subject.

FIG. 1A





FIG. 1B




FIG. 2

761612000240SeqList
SEQUENCE LISTING

<110> Alpine Immune Sciences, Inc.
SWANSON, Ryan
KORNACKER, Michael

<120> TUNABLE VARIANT IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND ENGINEERED
CELL THERAPY

<130> 761612000240

<140> Not Yet Assigned

<141> Concurrently Herewith

<150> 62/218,531
<151> 2015-09-14

<150> 62/367,822
<151> 2016-07-28

<150> 62/367,819
<151> 2016-07-28

<150> 62/323,608
<151> 2016-04-15

<150> 62/323,595
<151> 2016-04-15

<160> 419

<170> PatentIn version 3.5

<210> 1
<211> 288
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> CD80(B7-1)

<400> 1
Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro Ser Lys Cys Pro Tyr
1 5 10 15
Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly Leu Ser His Phe Cys
20 25 30
Ser Gly Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu
35 40 45
Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile
50 55 60
Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp
65 70 75 80
Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr
85 90 95
Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly
100 105 110
Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg
115 120 125
Glu His Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr
130 135 140
Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile
145 150 155 160
Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu
165 170 175
Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp
180 185 190
Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met

761612000240SeqList

Thr	Thr	195	Asn	His	Ser	Phe	Met	200	Cys	Leu	Ile	Lys	Tyr	205	Gly	His	Leu	Arg
	210						215						220					
Val	Asn	Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro			
225					230					235					240			
Asp	Asn	Leu	Leu	Pro	Ser	Trp	Ala	Ile	Thr	Leu	Ile	Ser	Val	Asn	Gly			
				245					250					255				
Ile	Phe	Val	Ile	Cys	Cys	Leu	Thr	Tyr	Cys	Phe	Ala	Pro	Arg	Cys	Arg			
			260					265					270					
Glu	Arg	Arg	Arg	Asn	Glu	Arg	Leu	Arg	Arg	Glu	Ser	Val	Arg	Pro	Val			
		275					280					285						

<210> 2
 <211> 329
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD86(B7-2)

<400> 2

Met	Asp	Pro	Gln	Cys	Thr	Met	Gly	Leu	Ser	Asn	Ile	Leu	Phe	Val	Met			
1				5					10					15				
Ala	Phe	Leu	Leu	Ser	Gly	Ala	Ala	Pro	Leu	Lys	Ile	Gln	Ala	Tyr	Phe			
			20					25					30					
Asn	Glu	Thr	Ala	Asp	Leu	Pro	Cys	Gln	Phe	Ala	Asn	Ser	Gln	Asn	Gln			
		35					40					45						
Ser	Leu	Ser	Glu	Leu	Val	Val	Phe	Trp	Gln	Asp	Gln	Glu	Asn	Leu	Val			
	50					55					60							
Leu	Asn	Glu	Val	Tyr	Leu	Gly	Lys	Glu	Lys	Phe	Asp	Ser	Val	His	Ser			
65					70					75					80			
Lys	Tyr	Met	Gly	Arg	Thr	Ser	Phe	Asp	Ser	Asp	Ser	Trp	Thr	Leu	Arg			
				85				90						95				
Leu	His	Asn	Leu	Gln	Ile	Lys	Asp	Lys	Gly	Leu	Tyr	Gln	Cys	Ile	Ile			
			100					105					110					
His	His	Lys	Lys	Pro	Thr	Gly	Met	Ile	Arg	Ile	His	Gln	Met	Asn	Ser			
		115					120					125						
Glu	Leu	Ser	Val	Leu	Ala	Asn	Phe	Ser	Gln	Pro	Glu	Ile	Val	Pro	Ile			
	130				135					140								
Ser	Asn	Ile	Thr	Glu	Asn	Val	Tyr	Ile	Asn	Leu	Thr	Cys	Ser	Ser	Ile			
					150				155						160			
His	Gly	Tyr	Pro	Glu	Pro	Lys	Lys	Met	Ser	Val	Leu	Leu	Arg	Thr	Lys			
				165				170						175				
Asn	Ser	Thr	Ile	Glu	Tyr	Asp	Gly	Val	Met	Gln	Lys	Ser	Gln	Asp	Asn			
			180				185						190					
Val	Thr	Glu	Leu	Tyr	Asp	Val	Ser	Ile	Ser	Leu	Ser	Val	Ser	Phe	Pro			
		195				200						205						
Asp	Val	Thr	Ser	Asn	Met	Thr	Ile	Phe	Cys	Ile	Leu	Glu	Thr	Asp	Lys			
	210					215					220							
Thr	Arg	Leu	Leu	Ser	Ser	Pro	Phe	Ser	Ile	Glu	Leu	Glu	Asp	Pro	Gln			
225					230					235					240			
Pro	Pro	Pro	Asp	His	Ile	Pro	Trp	Ile	Thr	Ala	Val	Leu	Pro	Thr	Val			
				245					250					255				
Ile	Ile	Cys	Val	Met	Val	Phe	Cys	Leu	Ile	Leu	Trp	Lys	Trp	Lys	Lys			
			260					265					270					
Lys	Lys	Arg	Pro	Arg	Asn	Ser	Tyr	Lys	Cys	Gly	Thr	Asn	Thr	Met	Glu			
		275					280					285						
Arg	Glu	Glu	Ser	Glu	Gln	Thr	Lys	Lys	Arg	Glu	Lys	Ile	His	Ile	Pro			
	290					295					300							
Glu	Arg	Ser	Asp	Glu	Ala	Gln	Arg	Val	Phe	Lys	Ser	Ser	Lys	Thr	Ser			
305					310					315					320			
Ser	Cys	Asp	Lys	Ser	Asp	Thr	Cys	Phe										
				325														

<210> 3

761612000240SeqList

<211> 290
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD274 (PD-L1, B7-H1)

<400> 3
 Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu
 1 5 10 15
 Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
 20 25 30
 Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu
 35 40 45
 Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
 50 55 60
 Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser
 65 70 75 80
 Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn
 85 90 95
 Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
 100 105 110
 Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val
 115 120 125
 Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val
 130 135 140
 Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr
 145 150 155 160
 Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser
 165 170 175
 Gly Lys Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn
 180 185 190
 Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr
 195 200 205
 Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu
 210 215 220
 Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His
 225 230 235 240
 Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr
 245 250 255
 Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys
 260 265 270
 Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu
 275 280 285
 Glu Thr
 290

<210> 4
 <211> 273
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PDCD1LG2(PD-L2, CD273)

<400> 4
 Met Ile Phe Leu Leu Leu Met Leu Ser Leu Glu Leu Gln Leu His Gln
 1 5 10 15
 Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile
 20 25 30
 Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser
 35 40 45
 His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn
 50 55 60
 Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu

761612000240SeqList

```

65      70      75      80
Pro Leu Gly Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp
85      90      95
Glu Gly Gln Tyr Gln Cys Ile Ile Ile Tyr Gly Val Ala Trp Asp Tyr
100     105     110
Lys Tyr Leu Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr
115     120     125
His Ile Leu Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln
130     135     140
Ala Thr Gly Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val
145     150     155     160
Pro Ala Asn Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val
165     170     175
Thr Ser Val Leu Arg Leu Lys Pro Pro Gly Arg Asn Phe Ser Cys
180     185     190
Val Phe Trp Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp
195     200     205
Leu Gln Ser Gln Met Glu Pro Arg Thr His Pro Thr Trp Leu Leu His
210     215     220
Ile Phe Ile Pro Phe Cys Ile Ile Ala Phe Ile Phe Ile Ala Thr Val
225     230     235     240
Ile Ala Leu Arg Lys Gln Leu Cys Gln Lys Leu Tyr Ser Ser Lys Asp
245     250     255
Thr Thr Lys Arg Pro Val Thr Thr Thr Lys Arg Glu Val Asn Ser Ala
260     265     270
Ile

```

<210> 5
 <211> 302
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> ICOSLG(B7RP1, CD275, ICOSL, B7-H2)

```

<400> 5
Met Arg Leu Gly Ser Pro Gly Leu Leu Phe Leu Leu Phe Ser Ser Leu
1      5      10      15
Arg Ala Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp
20     25     30
Val Glu Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn
35     40     45
Asp Val Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr
50     55     60
Tyr His Ile Pro Gln Asn Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr
65     70     75     80
Arg Asn Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe
85     90     95
Ser Leu Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His
100    105    110
Cys Leu Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val
115    120    125
Glu Val Thr Leu His Val Ala Asn Phe Ser Val Pro Val Val Ser
130    135    140
Ala Pro His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser
145    150    155     160
Ile Asn Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp
165    170    175
Asn Ser Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn
180    185    190
Met Arg Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr
195    200    205
Pro Ser Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln
210    215    220
Asn Leu Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp
225    230    235     240

```

761612000240SeqList

Lys	Ile	Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr
				245					250					255	
Trp	Ser	Ile	Leu	Ala	Val	Leu	Cys	Leu	Val	Val	Val	Ala	Val	Ala	
			260					265					270		
Ile	Gly	Trp	Val	Cys	Arg	Asp	Arg	Cys	Leu	Gln	His	Ser	Tyr	Ala	Gly
		275					280					285			
Ala	Trp	Ala	Val	Ser	Pro	Glu	Thr	Glu	Leu	Thr	Gly	His	Val		
	290					295					300				

<210> 6
 <211> 534
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD276(B7-H3)

<400> 6

Met	Leu	Arg	Arg	Arg	Gly	Ser	Pro	Gly	Met	Gly	Val	His	Val	Gly	Ala
1				5				10						15	
Ala	Leu	Gly	Ala	Leu	Trp	Phe	Cys	Leu	Thr	Gly	Ala	Leu	Glu	Val	Gln
			20					25					30		
Val	Pro	Glu	Asp	Pro	Val	Val	Ala	Leu	Val	Gly	Thr	Asp	Ala	Thr	Leu
		35					40					45			
Cys	Cys	Ser	Phe	Ser	Pro	Glu	Pro	Gly	Phe	Ser	Leu	Ala	Gln	Leu	Asn
	50					55					60				
Leu	Ile	Trp	Gln	Leu	Thr	Asp	Thr	Lys	Gln	Leu	Val	His	Ser	Phe	Ala
65					70				75						80
Glu	Gly	Gln	Asp	Gln	Gly	Ser	Ala	Tyr	Ala	Asn	Arg	Thr	Ala	Leu	Phe
				85					90					95	
Pro	Asp	Leu	Leu	Ala	Gln	Gly	Asn	Ala	Ser	Leu	Arg	Leu	Gln	Arg	Val
			100					105					110		
Arg	Val	Ala	Asp	Glu	Gly	Ser	Phe	Thr	Cys	Phe	Val	Ser	Ile	Arg	Asp
		115					120					125			
Phe	Gly	Ser	Ala	Ala	Val	Ser	Leu	Gln	Val	Ala	Ala	Pro	Tyr	Ser	Lys
	130					135					140				
Pro	Ser	Met	Thr	Leu	Glu	Pro	Asn	Lys	Asp	Leu	Arg	Pro	Gly	Asp	Thr
145					150				155						160
Val	Thr	Ile	Thr	Cys	Ser	Ser	Tyr	Gln	Gly	Tyr	Pro	Glu	Ala	Glu	Val
				165					170					175	
Phe	Trp	Gln	Asp	Gly	Gln	Gly	Val	Pro	Leu	Thr	Gly	Asn	Val	Thr	Thr
			180					185					190		
Ser	Gln	Met	Ala	Asn	Glu	Gln	Gly	Leu	Phe	Asp	Val	His	Ser	Ile	Leu
		195					200					205			
Arg	Val	Val	Leu	Gly	Ala	Asn	Gly	Thr	Tyr	Ser	Cys	Leu	Val	Arg	Asn
	210					215					220				
Pro	Val	Leu	Gln	Gln	Asp	Ala	His	Ser	Ser	Val	Thr	Ile	Thr	Pro	Gln
225					230					235					240
Arg	Ser	Pro	Thr	Gly	Ala	Val	Glu	Val	Gln	Val	Pro	Glu	Asp	Pro	Val
				245					250					255	
Val	Ala	Leu	Val	Gly	Thr	Asp	Ala	Thr	Leu	Arg	Cys	Ser	Phe	Ser	Pro
			260					265					270		
Glu	Pro	Gly	Phe	Ser	Leu	Ala	Gln	Leu	Asn	Leu	Ile	Trp	Gln	Leu	Thr
		275					280					285			
Asp	Thr	Lys	Gln	Leu	Val	His	Ser	Phe	Thr	Glu	Gly	Arg	Asp	Gln	Gly
	290					295					300				
Ser	Ala	Tyr	Ala	Asn	Arg	Thr	Ala	Leu	Phe	Pro	Asp	Leu	Leu	Ala	Gln
305					310					315					320
Gly	Asn	Ala	Ser	Leu	Arg	Leu	Gln	Arg	Val	Arg	Val	Ala	Asp	Glu	Gly
				325					330					335	
Ser	Phe	Thr	Cys	Phe	Val	Ser	Ile	Arg	Asp	Phe	Gly	Ser	Ala	Ala	Val
			340					345					350		
Ser	Leu	Gln	Val	Ala	Ala	Pro	Tyr	Ser	Lys	Pro	Ser	Met	Thr	Leu	Glu
		355					360					365			
Pro	Asn	Lys	Asp	Leu	Arg	Pro	Gly	Asp	Thr	Val	Thr	Ile	Thr	Cys	Ser
	370					375					380				

761612000240SeqList

Ser	Tyr	Arg	Gly	Tyr	Pro	Glu	Ala	Glu	Val	Phe	Trp	Gln	Asp	Gly	Gln
385					390					395					400
Gly	Val	Pro	Leu	Thr	Gly	Asn	Val	Thr	Thr	Ser	Gln	Met	Ala	Asn	Glu
				405					410					415	
Gln	Gly	Leu	Phe	Asp	Val	His	Ser	Val	Leu	Arg	Val	Val	Leu	Gly	Ala
			420					425					430		
Asn	Gly	Thr	Tyr	Ser	Cys	Leu	Val	Arg	Asn	Pro	Val	Leu	Gln	Gln	Asp
		435					440					445			
Ala	His	Gly	Ser	Val	Thr	Ile	Thr	Gly	Gln	Pro	Met	Thr	Phe	Pro	Pro
	450					455					460				
Glu	Ala	Leu	Trp	Val	Thr	Val	Gly	Leu	Ser	Val	Cys	Leu	Ile	Ala	Leu
465					470					475					480
Leu	Val	Ala	Leu	Ala	Phe	Val	Cys	Trp	Arg	Lys	Ile	Lys	Gln	Ser	Cys
				485					490						
Glu	Glu	Glu	Asn	Ala	Gly	Ala	Glu	Asp	Gln	Asp	Gly	Glu	Gly	Glu	Gly
			500					505					510		
Ser	Lys	Thr	Ala	Leu	Gln	Pro	Leu	Lys	His	Ser	Asp	Ser	Lys	Glu	Asp
		515					520					525			
Asp	Gly	Gln	Glu	Ile	Ala										
	530														

<210> 7
 <211> 282
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> VTCN1(B7-H4)

<400> 7

Met	Ala	Ser	Leu	Gly	Gln	Ile	Leu	Phe	Trp	Ser	Ile	Ile	Ser	Ile	Ile
1				5				10					15		
Ile	Ile	Leu	Ala	Gly	Ala	Ile	Ala	Leu	Ile	Ile	Gly	Phe	Gly	Ile	Ser
			20					25					30		
Gly	Arg	His	Ser	Ile	Thr	Val	Thr	Val	Ala	Ser	Ala	Gly	Asn	Ile	
		35					40				45				
Gly	Glu	Asp	Gly	Ile	Leu	Ser	Cys	Thr	Phe	Glu	Pro	Asp	Ile	Lys	Leu
	50					55				60					
Ser	Asp	Ile	Val	Ile	Gln	Trp	Leu	Lys	Glu	Gly	Val	Leu	Gly	Leu	Val
65					70				75						80
His	Glu	Phe	Lys	Glu	Gly	Lys	Asp	Glu	Leu	Ser	Glu	Gln	Asp	Glu	Met
			85					90					95		
Phe	Arg	Gly	Arg	Thr	Ala	Val	Phe	Ala	Asp	Gln	Val	Ile	Val	Gly	Asn
			100					105					110		
Ala	Ser	Leu	Arg	Leu	Lys	Asn	Val	Gln	Leu	Thr	Asp	Ala	Gly	Thr	Tyr
		115					120					125			
Lys	Cys	Tyr	Ile	Ile	Thr	Ser	Lys	Gly	Lys	Gly	Asn	Ala	Asn	Leu	Glu
	130					135					140				
Tyr	Lys	Thr	Gly	Ala	Phe	Ser	Met	Pro	Glu	Val	Asn	Val	Asp	Tyr	Asn
145					150				155						160
Ala	Ser	Ser	Glu	Thr	Leu	Arg	Cys	Glu	Ala	Pro	Arg	Trp	Phe	Pro	Gln
			165					170						175	
Pro	Thr	Val	Val	Trp	Ala	Ser	Gln	Val	Asp	Gln	Gly	Ala	Asn	Phe	Ser
			180					185					190		
Glu	Val	Ser	Asn	Thr	Ser	Phe	Glu	Leu	Asn	Ser	Glu	Asn	Val	Thr	Met
		195					200					205			
Lys	Val	Val	Ser	Val	Leu	Tyr	Asn	Val	Thr	Ile	Asn	Asn	Thr	Tyr	Ser
	210					215					220				
Cys	Met	Ile	Glu	Asn	Asp	Ile	Ala	Lys	Ala	Thr	Gly	Asp	Ile	Lys	Val
225					230				235						240
Thr	Glu	Ser	Glu	Ile	Lys	Arg	Arg	Ser	His	Leu	Gln	Leu	Leu	Asn	Ser
			245						250					255	
Lys	Ala	Ser	Leu	Cys	Val	Ser	Ser	Phe	Phe	Ala	Ile	Ser	Trp	Ala	Leu
			260					265					270		
Leu	Pro	Leu	Ser	Pro	Tyr	Leu	Met	Leu	Lys						
		275					280								

761612000240SeqList

<210> 8
 <211> 220
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD28

<400> 8
 Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val
 1 5 10 15
 Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr
 20 25 30
 Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser
 35 40 45
 Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu
 50 55 60
 Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser
 65 70 75 80
 Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr
 85 90 95
 Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys
 100 105 110
 Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser
 115 120 125
 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
 130 135 140
 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
 145 150 155 160
 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
 165 170 175
 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
 180 185 190
 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
 195 200 205
 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
 210 215 220

<210> 9
 <211> 223
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CTLA4

<400> 9
 Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala
 1 5 10 15
 Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
 20 25 30
 Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
 35 40 45
 Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
 50 55 60
 Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
 65 70 75 80
 Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr
 85 90 95
 Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
 100 105 110
 Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
 115 120 125

761612000240SeqList

Cys	Lys	Val	Glu	Leu	Met	Tyr	Pro	Pro	Pro	Tyr	Tyr	Leu	Gly	Ile	Gly
130						135					140				
Asn	Gly	Thr	Gln	Ile	Tyr	Val	Ile	Asp	Pro	Glu	Pro	Cys	Pro	Asp	Ser
145					150					155					160
Asp	Phe	Leu	Leu	Trp	Ile	Leu	Ala	Ala	Val	Ser	Ser	Gly	Leu	Phe	Phe
				165					170					175	
Tyr	Ser	Phe	Leu	Leu	Thr	Ala	Val	Ser	Leu	Ser	Lys	Met	Leu	Lys	Lys
			180					185					190		
Arg	Ser	Pro	Leu	Thr	Thr	Gly	Val	Tyr	Val	Lys	Met	Pro	Pro	Thr	Glu
		195					200					205			
Pro	Glu	Cys	Glu	Lys	Gln	Phe	Gln	Pro	Tyr	Phe	Ile	Pro	Ile	Asn	
	210					215					220				

<210> 10
 <211> 288
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PDCD1(PD-1)

<400> 10

Met	Gln	Ile	Pro	Gln	Ala	Pro	Trp	Pro	Val	Val	Trp	Ala	Val	Leu	Gln
1				5					10					15	
Leu	Gly	Trp	Arg	Pro	Gly	Trp	Phe	Leu	Asp	Ser	Pro	Asp	Arg	Pro	Trp
			20					25					30		
Asn	Pro	Pro	Thr	Phe	Ser	Pro	Ala	Leu	Leu	Val	Val	Thr	Glu	Gly	Asp
		35					40					45			
Asn	Ala	Thr	Phe	Thr	Cys	Ser	Phe	Ser	Asn	Thr	Ser	Glu	Ser	Phe	Val
	50					55					60				
Leu	Asn	Trp	Tyr	Arg	Met	Ser	Pro	Ser	Asn	Gln	Thr	Asp	Lys	Leu	Ala
65				70						75				80	
Ala	Phe	Pro	Glu	Asp	Arg	Ser	Gln	Pro	Gly	Gln	Asp	Cys	Arg	Phe	Arg
			85						90					95	
Val	Thr	Gln	Leu	Pro	Asn	Gly	Arg	Asp	Phe	His	Met	Ser	Val	Val	Arg
			100					105					110		
Ala	Arg	Arg	Asn	Asp	Ser	Gly	Thr	Tyr	Leu	Cys	Gly	Ala	Ile	Ser	Leu
		115					120					125			
Ala	Pro	Lys	Ala	Gln	Ile	Lys	Glu	Ser	Leu	Arg	Ala	Glu	Leu	Arg	Val
	130					135					140				
Thr	Glu	Arg	Arg	Ala	Glu	Val	Pro	Thr	Ala	His	Pro	Ser	Pro	Ser	Pro
145					150					155					160
Arg	Pro	Ala	Gly	Gln	Phe	Gln	Thr	Leu	Val	Val	Gly	Val	Val	Gly	Gly
			165						170					175	
Leu	Leu	Gly	Ser	Leu	Val	Leu	Leu	Val	Trp	Val	Leu	Ala	Val	Ile	Cys
			180					185					190		
Ser	Arg	Ala	Ala	Arg	Gly	Thr	Ile	Gly	Ala	Arg	Arg	Thr	Gly	Gln	Pro
		195					200					205			
Leu	Lys	Glu	Asp	Pro	Ser	Ala	Val	Pro	Val	Phe	Ser	Val	Asp	Tyr	Gly
	210					215					220				
Glu	Leu	Asp	Phe	Gln	Trp	Arg	Glu	Lys	Thr	Pro	Glu	Pro	Pro	Val	Pro
225					230					235					240
Cys	Val	Pro	Glu	Gln	Thr	Glu	Tyr	Ala	Thr	Ile	Val	Phe	Pro	Ser	Gly
				245					250					255	
Met	Gly	Thr	Ser	Ser	Pro	Ala	Arg	Arg	Gly	Ser	Ala	Asp	Gly	Pro	Arg
			260					265					270		
Ser	Ala	Gln	Pro	Leu	Arg	Pro	Glu	Asp	Gly	His	Cys	Ser	Trp	Pro	Leu
		275					280					285			

<210> 11
 <211> 199
 <212> PRT
 <213> Homo sapiens

<220>

761612000240SeqList

<221> MISC_FEATURE

<223> ICOS

<400> 11

```

Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
1      5      10      15
Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
20      25      30
Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
35      40      45
Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
50      55      60
Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
65      70      75      80
Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
85      90      95
Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
100     105
Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Tyr Leu
115     120     125
His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
130     135     140
Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
145     150     155     160
Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Val His Asp Pro
165     170     175
Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser
180     185     190
Arg Leu Thr Asp Val Thr Leu
195

```

<210> 12

<211> 289

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> BTLA(CD272)

<400> 12

```

Met Lys Thr Leu Pro Ala Met Leu Gly Thr Gly Lys Leu Phe Trp Val
1      5      10      15
Phe Phe Leu Ile Pro Tyr Leu Asp Ile Trp Asn Ile His Gly Lys Glu
20      25      30
Ser Cys Asp Val Gln Leu Tyr Ile Lys Arg Gln Ser Glu His Ser Ile
35      40      45
Leu Ala Gly Asp Pro Phe Glu Leu Glu Cys Pro Val Lys Tyr Cys Ala
50      55      60
Asn Arg Pro His Val Thr Trp Cys Lys Leu Asn Gly Thr Thr Cys Val
65      70      75      80
Lys Leu Glu Asp Arg Gln Thr Ser Trp Lys Glu Glu Lys Asn Ile Ser
85      90      95
Phe Phe Ile Leu His Phe Glu Pro Val Leu Pro Asn Asp Asn Gly Ser
100     105     110
Tyr Arg Cys Ser Ala Asn Phe Gln Ser Asn Leu Ile Glu Ser His Ser
115     120     125
Thr Thr Leu Tyr Val Thr Asp Val Lys Ser Ala Ser Glu Arg Pro Ser
130     135     140
Lys Asp Glu Met Ala Ser Arg Pro Trp Leu Leu Tyr Arg Leu Leu Pro
145     150     155     160
Leu Gly Gly Leu Pro Leu Leu Ile Thr Thr Cys Phe Cys Leu Phe Cys
165     170     175
Cys Leu Arg Arg His Gln Gly Lys Gln Asn Glu Leu Ser Asp Thr Ala
180     185     190
Gly Arg Glu Ile Asn Leu Val Asp Ala His Leu Lys Ser Glu Gln Thr
195     200     205

```

761612000240SeqList

Glu	Ala	Ser	Thr	Arg	Gln	Asn	Ser	Gln	Val	Leu	Leu	Ser	Glu	Thr	Gly
210	210					215					220				
Ile	Tyr	Asp	Asn	Asp	Pro	Asp	Leu	Cys	Phe	Arg	Met	Gln	Glu	Gly	Ser
225					230					235					240
Glu	Val	Tyr	Ser	Asn	Pro	Cys	Leu	Glu	Glu	Asn	Lys	Pro	Gly	Ile	Val
				245					250					255	
Tyr	Ala	Ser	Leu	Asn	His	Ser	Val	Ile	Gly	Pro	Asn	Ser	Arg	Leu	Ala
			260					265					270		
Arg	Asn	Val	Lys	Glu	Ala	Pro	Thr	Glu	Tyr	Ala	Ser	Ile	Cys	Val	Arg
		275					280					285			
Ser															

<210> 13
 <211> 458
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD4

<400> 13

Met	Asn	Arg	Gly	Val	Pro	Phe	Arg	His	Leu	Leu	Val	Leu	Gln	Leu
1				5					10				15	
Ala	Leu	Leu	Pro	Ala	Ala	Thr	Gln	Gly	Lys	Lys	Val	Val	Leu	Gly
			20					25				30		Lys
Lys	Gly	Asp	Thr	Val	Glu	Leu	Thr	Cys	Thr	Ala	Ser	Gln	Lys	Lys
		35					40					45		Ser
Ile	Gln	Phe	His	Trp	Lys	Asn	Ser	Asn	Gln	Ile	Lys	Ile	Leu	Gly
	50					55				60				Asn
Gln	Gly	Ser	Phe	Leu	Thr	Lys	Gly	Pro	Ser	Lys	Leu	Asn	Asp	Arg
65					70					75				80
Asp	Ser	Arg	Arg	Ser	Leu	Trp	Asp	Gln	Gly	Asn	Phe	Pro	Leu	Ile
				85					90				95	Ile
Lys	Asn	Leu	Lys	Ile	Glu	Asp	Ser	Asp	Thr	Tyr	Ile	Cys	Glu	Val
			100					105					110	Glu
Asp	Gln	Lys	Glu	Glu	Val	Gln	Leu	Leu	Val	Phe	Gly	Leu	Thr	Ala
		115					120					125		Asn
Ser	Asp	Thr	His	Leu	Leu	Gln	Gly	Gln	Ser	Leu	Thr	Leu	Thr	Leu
	130					135					140			Glu
Ser	Pro	Pro	Gly	Ser	Ser	Pro	Ser	Val	Gln	Cys	Arg	Ser	Pro	Arg
145					150					155				Gly
Lys	Asn	Ile	Gln	Gly	Gly	Lys	Thr	Leu	Ser	Val	Ser	Gln	Leu	Glu
			165						170				175	Leu
Gln	Asp	Ser	Gly	Thr	Trp	Thr	Cys	Thr	Val	Leu	Gln	Asn	Gln	Lys
			180					185					190	Lys
Val	Glu	Phe	Lys	Ile	Asp	Ile	Val	Val	Leu	Ala	Phe	Gln	Lys	Ala
		195					200					205		Ser
Ser	Ile	Val	Tyr	Lys	Lys	Glu	Gly	Glu	Gln	Val	Glu	Phe	Ser	Phe
	210					215					220			Pro
Leu	Ala	Phe	Thr	Val	Glu	Lys	Leu	Thr	Gly	Ser	Gly	Glu	Leu	Trp
225					230					235				Trp
Gln	Ala	Glu	Arg	Ala	Ser	Ser	Ser	Lys	Ser	Trp	Ile	Thr	Phe	Asp
				245					250					Leu
Lys	Asn	Lys	Glu	Val	Ser	Val	Lys	Arg	Val	Thr	Gln	Asp	Pro	Lys
			260					265					270	
Gln	Met	Gly	Lys	Lys	Leu	Pro	Leu	His	Leu	Thr	Leu	Pro	Gln	Ala
		275					280					285		Leu
Pro	Gln	Tyr	Ala	Gly	Ser	Gly	Asn	Leu	Thr	Leu	Ala	Leu	Glu	Ala
	290					295					300			Lys
Thr	Gly	Lys	Leu	His	Gln	Glu	Val	Asn	Leu	Val	Val	Met	Arg	Ala
305					310					315				Thr
Gln	Leu	Gln	Lys	Asn	Leu	Thr	Cys	Glu	Val	Trp	Gly	Pro	Thr	Ser
				325					330					Pro
Lys	Leu	Met	Leu	Ser	Leu	Lys	Leu	Glu	Asn	Lys	Glu	Ala	Lys	Val
			340					345					350	Ser

761612000240SeqList

Lys	Arg	Glu	Lys	Ala	Val	Trp	Val	Leu	Asn	Pro	Glu	Ala	Gly	Met	Trp
		355					360					365			
Gln	Cys	Leu	Leu	Ser	Asp	Ser	Gly	Gln	Val	Leu	Leu	Glu	Ser	Asn	Ile
	370					375					380				
Lys	Val	Leu	Pro	Thr	Trp	Ser	Thr	Pro	Val	Gln	Pro	Met	Ala	Leu	Ile
385					390					395					400
Val	Leu	Gly	Gly	Val	Ala	Gly	Leu	Leu	Leu	Phe	Ile	Gly	Leu	Gly	Ile
				405					410					415	
Phe	Phe	Cys	Val	Arg	Cys	Arg	His	Arg	Arg	Gln	Ala	Glu	Arg	Met	
			420					425				430			
Ser	Gln	Ile	Lys	Arg	Leu	Leu	Ser	Glu	Lys	Lys	Thr	Cys	Gln	Cys	Pro
		435					440					445			
His	Arg	Phe	Gln	Lys	Thr	Cys	Ser	Pro	Ile						
	450					455									

<210> 14
 <211> 235
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD8A(CD8-alpha)

<400> 14

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15		
His	Ala	Ala	Arg	Pro	Ser	Gln	Phe	Arg	Val	Ser	Pro	Leu	Asp	Arg	Thr
			20					25					30		
Trp	Asn	Leu	Gly	Glu	Thr	Val	Glu	Leu	Lys	Cys	Gln	Val	Leu	Leu	Ser
		35					40					45			
Asn	Pro	Thr	Ser	Gly	Cys	Ser	Trp	Leu	Phe	Gln	Pro	Arg	Gly	Ala	Ala
	50					55				60					
Ala	Ser	Pro	Thr	Phe	Leu	Leu	Tyr	Leu	Ser	Gln	Asn	Lys	Pro	Lys	Ala
65				70					75					80	
Ala	Glu	Gly	Leu	Asp	Thr	Gln	Arg	Phe	Ser	Gly	Lys	Arg	Leu	Gly	Asp
				85					90					95	
Thr	Phe	Val	Leu	Thr	Leu	Ser	Asp	Phe	Arg	Arg	Glu	Asn	Glu	Gly	Tyr
			100					105					110		
Tyr	Phe	Cys	Ser	Ala	Leu	Ser	Asn	Ser	Ile	Met	Tyr	Phe	Ser	His	Phe
		115					120					125			
Val	Pro	Val	Phe	Leu	Pro	Ala	Lys	Pro	Thr	Thr	Thr	Pro	Ala	Pro	Arg
	130					135					140				
Pro	Pro	Thr	Pro	Ala	Pro	Thr	Ile	Ala	Ser	Gln	Pro	Leu	Ser	Leu	Arg
145				150						155				160	
Pro	Glu	Ala	Cys	Arg	Pro	Ala	Ala	Gly	Gly	Ala	Val	His	Thr	Arg	Gly
				165				170						175	
Leu	Asp	Phe	Ala	Cys	Asp	Ile	Tyr	Ile	Trp	Ala	Pro	Leu	Ala	Gly	Thr
			180					185					190		
Cys	Gly	Val	Leu	Leu	Leu	Ser	Leu	Val	Ile	Thr	Leu	Tyr	Cys	Asn	His
		195					200					205			
Arg	Asn	Arg	Arg	Arg	Val	Cys	Lys	Cys	Pro	Arg	Pro	Val	Val	Lys	Ser
	210					215					220				
Gly	Asp	Lys	Pro	Ser	Leu	Ser	Ala	Arg	Tyr	Val					
225					230					235					

<210> 15
 <211> 210
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD8B(CD8-beta)

<400> 15

761612000240SeqList

Met	Arg	Pro	Arg	Leu	Trp	Leu	Leu	Leu	Ala	Ala	Gln	Leu	Thr	Val	Leu
1				5					10					15	
His	Gly	Asn	Ser	Val	Leu	Gln	Gln	Thr	Pro	Ala	Tyr	Ile	Lys	Val	Gln
			20					25					30		
Thr	Asn	Lys	Met	Val	Met	Leu	Ser	Cys	Glu	Ala	Lys	Ile	Ser	Leu	Ser
		35					40					45			
Asn	Met	Arg	Ile	Tyr	Trp	Leu	Arg	Gln	Arg	Gln	Ala	Pro	Ser	Ser	Asp
						55					60				
Ser	His	His	Glu	Phe	Leu	Ala	Leu	Trp	Asp	Ser	Ala	Lys	Gly	Thr	Ile
65					70					75					80
His	Gly	Glu	Glu	Val	Glu	Gln	Glu	Lys	Ile	Ala	Val	Phe	Arg	Asp	Ala
				85					90					95	
Ser	Arg	Phe	Ile	Leu	Asn	Leu	Thr	Ser	Val	Lys	Pro	Glu	Asp	Ser	Gly
			100					105					110		
Ile	Tyr	Phe	Cys	Met	Ile	Val	Gly	Ser	Pro	Glu	Leu	Thr	Phe	Gly	Lys
		115					120					125			
Gly	Thr	Gln	Leu	Ser	Val	Val	Asp	Phe	Leu	Pro	Thr	Thr	Ala	Gln	Pro
	130					135					140				
Thr	Lys	Lys	Ser	Thr	Leu	Lys	Lys	Arg	Val	Cys	Arg	Leu	Pro	Arg	Pro
145					150					155					160
Glu	Thr	Gln	Lys	Gly	Pro	Leu	Cys	Ser	Pro	Ile	Thr	Leu	Gly	Leu	Leu
				165					170					175	
Val	Ala	Gly	Val	Leu	Val	Leu	Leu	Val	Ser	Leu	Gly	Val	Ala	Ile	His
			180					185					190		
Leu	Cys	Cys	Arg	Arg	Arg	Arg	Ala	Arg	Leu	Arg	Phe	Met	Lys	Gln	Phe
		195					200					205			
Tyr	Lys														
	210														

<210> 16
 <211> 525
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> LAG3

<400> 16

Met	Trp	Glu	Ala	Gln	Phe	Leu	Gly	Leu	Leu	Phe	Leu	Gln	Pro	Leu	Trp
1				5					10					15	
Val	Ala	Pro	Val	Lys	Pro	Leu	Gln	Pro	Gly	Ala	Glu	Val	Pro	Val	Val
			20					25					30		
Trp	Ala	Gln	Glu	Gly	Ala	Pro	Ala	Gln	Leu	Pro	Cys	Ser	Pro	Thr	Ile
		35					40					45			
Pro	Leu	Gln	Asp	Leu	Ser	Leu	Leu	Arg	Arg	Ala	Gly	Val	Thr	Trp	Gln
						55					60				
His	Gln	Pro	Asp	Ser	Gly	Pro	Pro	Ala	Ala	Ala	Pro	Gly	His	Pro	Leu
65					70					75					80
Ala	Pro	Gly	Pro	His	Pro	Ala	Ala	Pro	Ser	Ser	Trp	Gly	Pro	Arg	Pro
				85					90					95	
Arg	Arg	Tyr	Thr	Val	Leu	Ser	Val	Gly	Pro	Gly	Gly	Leu	Arg	Ser	Gly
			100					105					110		
Arg	Leu	Pro	Leu	Gln	Pro	Arg	Val	Gln	Leu	Asp	Glu	Arg	Gly	Arg	Gln
		115					120					125			
Arg	Gly	Asp	Phe	Ser	Leu	Trp	Leu	Arg	Pro	Ala	Arg	Arg	Ala	Asp	Ala
	130					135					140				
Gly	Glu	Tyr	Arg	Ala	Ala	Val	His	Leu	Arg	Asp	Arg	Ala	Leu	Ser	Cys
145					150					155					160
Arg	Leu	Arg	Leu	Arg	Leu	Gly	Gln	Ala	Ser	Met	Thr	Ala	Ser	Pro	Pro
				165					170					175	
Gly	Ser	Leu	Arg	Ala	Ser	Asp	Trp	Val	Ile	Leu	Asn	Cys	Ser	Phe	Ser
			180					185						190	
Arg	Pro	Asp	Arg	Pro	Ala	Ser	Val	His	Trp	Phe	Arg	Asn	Arg	Gly	Gln
		195					200					205			
Gly	Arg	Val	Pro	Val	Arg	Glu	Ser	Pro	His	His	His	Leu	Ala	Glu	Ser
	210					215					220				

761612000240SeqList

Phe	Leu	Phe	Leu	Pro	Gln	Val	Ser	Pro	Met	Asp	Ser	Gly	Pro	Trp	Gly
225					230					235					240
Cys	Ile	Leu	Thr	Tyr	Arg	Asp	Gly	Phe	Asn	Val	Ser	Ile	Met	Tyr	Asn
				245					250					255	
Leu	Thr	Val	Leu	Gly	Leu	Glu	Pro	Pro	Thr	Pro	Leu	Thr	Val	Tyr	Ala
			260					265					270		
Gly	Ala	Gly	Ser	Arg	Val	Gly	Leu	Pro	Cys	Arg	Leu	Pro	Ala	Gly	Val
		275					280					285			
Gly	Thr	Arg	Ser	Phe	Leu	Thr	Ala	Lys	Trp	Thr	Pro	Pro	Gly	Gly	Gly
	290					295					300				
Pro	Asp	Leu	Leu	Val	Thr	Gly	Asp	Asn	Gly	Asp	Phe	Thr	Leu	Arg	Leu
305					310					315					320
Glu	Asp	Val	Ser	Gln	Ala	Gln	Ala	Gly	Thr	Tyr	Thr	Cys	His	Ile	His
				325					330					335	
Leu	Gln	Glu	Gln	Gln	Leu	Asn	Ala	Thr	Val	Thr	Leu	Ala	Ile	Ile	Thr
			340					345					350		
Val	Thr	Pro	Lys	Ser	Phe	Gly	Ser	Pro	Gly	Ser	Leu	Gly	Lys	Leu	Leu
		355					360					365			
Cys	Glu	Val	Thr	Pro	Val	Ser	Gly	Gln	Glu	Arg	Phe	Val	Trp	Ser	Ser
	370					375					380				
Leu	Asp	Thr	Pro	Ser	Gln	Arg	Ser	Phe	Ser	Gly	Pro	Trp	Leu	Glu	Ala
385					390					395					400
Gln	Glu	Ala	Gln	Leu	Leu	Ser	Gln	Pro	Trp	Gln	Cys	Gln	Leu	Tyr	Gln
			405						410					415	
Gly	Glu	Arg	Leu	Leu	Gly	Ala	Ala	Val	Tyr	Phe	Thr	Glu	Leu	Ser	Ser
			420					425					430		
Pro	Gly	Ala	Gln	Arg	Ser	Gly	Arg	Ala	Pro	Gly	Ala	Leu	Pro	Ala	Gly
		435					440					445			
His	Leu	Leu	Leu	Phe	Leu	Ile	Leu	Gly	Val	Leu	Ser	Leu	Leu	Leu	Leu
	450					455					460				
Val	Thr	Gly	Ala	Phe	Gly	Phe	His	Leu	Trp	Arg	Arg	Gln	Trp	Arg	Pro
465					470					475					480
Arg	Arg	Phe	Ser	Ala	Leu	Glu	Gln	Gly	Ile	His	Pro	Pro	Gln	Ala	Gln
				485					490					495	
Ser	Lys	Ile	Glu	Glu	Leu	Glu	Gln	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro
			500					505					510		
Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Gln	Leu			
		515					520					525			

<210> 17
 <211> 301
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> HAVCR2(TIM-3)

<400> 17

Met	Phe	Ser	His	Leu	Pro	Phe	Asp	Cys	Val	Leu	Leu	Leu	Leu	Leu	Leu
1				5					10					15	
Leu	Leu	Thr	Arg	Ser	Ser	Glu	Val	Glu	Tyr	Arg	Ala	Glu	Val	Gly	Gln
			20					25					30		
Asn	Ala	Tyr	Leu	Pro	Cys	Phe	Tyr	Thr	Pro	Ala	Ala	Pro	Gly	Asn	Leu
		35					40					45			
Val	Pro	Val	Cys	Trp	Gly	Lys	Gly	Ala	Cys	Pro	Val	Phe	Glu	Cys	Gly
	50					55					60				
Asn	Val	Val	Leu	Arg	Thr	Asp	Glu	Arg	Asp	Val	Asn	Tyr	Trp	Thr	Ser
65					70					75					80
Arg	Tyr	Trp	Leu	Asn	Gly	Asp	Phe	Arg	Lys	Gly	Asp	Val	Ser	Leu	Thr
			85						90					95	
Ile	Glu	Asn	Val	Thr	Leu	Ala	Asp	Ser	Gly	Ile	Tyr	Cys	Cys	Arg	Ile
			100					105					110		
Gln	Ile	Pro	Gly	Ile	Met	Asn	Asp	Glu	Lys	Phe	Asn	Leu	Lys	Leu	Val
		115					120					125			
Ile	Lys	Pro	Ala	Lys	Val	Thr	Pro	Ala	Pro	Thr	Arg	Gln	Arg	Asp	Phe
	130					135					140				

761612000240SeqList

Thr	Ala	Ala	Phe	Pro	Arg	Met	Leu	Thr	Thr	Arg	Gly	His	Gly	Pro	Ala
145					150					155					160
Glu	Thr	Gln	Thr	Leu	Gly	Ser	Leu	Pro	Asp	Ile	Asn	Leu	Thr	Gln	Ile
				165					170					175	
Ser	Thr	Leu	Ala	Asn	Glu	Leu	Arg	Asp	Ser	Arg	Leu	Ala	Asn	Asp	Leu
			180					185					190		
Arg	Asp	Ser	Gly	Ala	Thr	Ile	Arg	Ile	Gly	Ile	Tyr	Ile	Gly	Ala	Gly
		195					200					205			
Ile	Cys	Ala	Gly	Leu	Ala	Leu	Ala	Leu	Ile	Phe	Gly	Ala	Leu	Ile	Phe
	210					215					220				
Lys	Trp	Tyr	Ser	His	Ser	Lys	Glu	Lys	Ile	Gln	Asn	Leu	Ser	Leu	Ile
225					230					235					240
Ser	Leu	Ala	Asn	Leu	Pro	Pro	Ser	Gly	Leu	Ala	Asn	Ala	Val	Ala	Glu
				245					250					255	
Gly	Ile	Arg	Ser	Glu	Glu	Asn	Ile	Tyr	Thr	Ile	Glu	Glu	Asn	Val	Tyr
			260					265					270		
Glu	Val	Glu	Glu	Pro	Asn	Glu	Tyr	Tyr	Cys	Tyr	Val	Ser	Ser	Arg	Gln
		275					280					285			
Gln	Pro	Ser	Gln	Pro	Leu	Gly	Cys	Arg	Phe	Ala	Met	Pro			
	290					295					300				

<210> 18
 <211> 526
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CEACAM1

<400> 18

Met	Gly	His	Leu	Ser	Ala	Pro	Leu	His	Arg	Val	Arg	Val	Pro	Trp	Gln
1				5					10					15	
Gly	Leu	Leu	Leu	Thr	Ala	Ser	Leu	Leu	Thr	Phe	Trp	Asn	Pro	Pro	Thr
			20					25					30		
Thr	Ala	Gln	Leu	Thr	Thr	Glu	Ser	Met	Pro	Phe	Asn	Val	Ala	Glu	Gly
		35					40					45			
Lys	Glu	Val	Leu	Leu	Leu	Val	His	Asn	Leu	Pro	Gln	Gln	Leu	Phe	Gly
	50					55					60				
Tyr	Ser	Trp	Tyr	Lys	Gly	Glu	Arg	Val	Asp	Gly	Asn	Arg	Gln	Ile	Val
65				70					75					80	
Gly	Tyr	Ala	Ile	Gly	Thr	Gln	Gln	Ala	Thr	Pro	Gly	Pro	Ala	Asn	Ser
			85						90				95		
Gly	Arg	Glu	Thr	Ile	Tyr	Pro	Asn	Ala	Ser	Leu	Leu	Ile	Gln	Asn	Val
			100					105					110		
Thr	Gln	Asn	Asp	Thr	Gly	Phe	Tyr	Thr	Leu	Gln	Val	Ile	Lys	Ser	Asp
		115					120					125			
Leu	Val	Asn	Glu	Glu	Ala	Thr	Gly	Gln	Phe	His	Val	Tyr	Pro	Glu	Leu
	130					135					140				
Pro	Lys	Pro	Ser	Ile	Ser	Ser	Asn	Asn	Ser	Asn	Pro	Val	Glu	Asp	Lys
145					150					155					160
Asp	Ala	Val	Ala	Phe	Thr	Cys	Glu	Pro	Glu	Thr	Gln	Asp	Thr	Thr	Tyr
				165					170					175	
Leu	Trp	Trp	Ile	Asn	Asn	Gln	Ser	Leu	Pro	Val	Ser	Pro	Arg	Leu	Gln
			180					185					190		
Leu	Ser	Asn	Gly	Asn	Arg	Thr	Leu	Thr	Leu	Leu	Ser	Val	Thr	Arg	Asn
		195					200					205			
Asp	Thr	Gly	Pro	Tyr	Glu	Cys	Glu	Ile	Gln	Asn	Pro	Val	Ser	Ala	Asn
	210					215					220				
Arg	Ser	Asp	Pro	Val	Thr	Leu	Asn	Val	Thr	Tyr	Gly	Pro	Asp	Thr	Pro
225					230					235					240
Thr	Ile	Ser	Pro	Ser	Asp	Thr	Tyr	Tyr	Arg	Pro	Gly	Ala	Asn	Leu	Ser
				245					250					255	
Leu	Ser	Cys	Tyr	Ala	Ala	Ser	Asn	Pro	Pro	Ala	Gln	Tyr	Ser	Trp	Leu
			260					265					270		
Ile	Asn	Gly	Thr	Phe	Gln	Gln	Ser	Thr	Gln	Glu	Leu	Phe	Ile	Pro	Asn
		275					280					285			

761612000240SeqList

Ile	Thr	Val	Asn	Asn	Ser	Gly	Ser	Tyr	Thr	Cys	His	Ala	Asn	Asn	Ser
	290					295					300				
Val	Thr	Gly	Cys	Asn	Arg	Thr	Thr	Val	Lys	Thr	Ile	Ile	Val	Thr	Glu
305					310					315					320
Leu	Ser	Pro	Val	Val	Ala	Lys	Pro	Gln	Ile	Lys	Ala	Ser	Lys	Thr	Thr
				325					330					335	
Val	Thr	Gly	Asp	Lys	Asp	Ser	Val	Asn	Leu	Thr	Cys	Ser	Thr	Asn	Asp
			340					345					350		
Thr	Gly	Ile	Ser	Ile	Arg	Trp	Phe	Phe	Lys	Asn	Gln	Ser	Leu	Pro	Ser
	355						360					365			
Ser	Glu	Arg	Met	Lys	Leu	Ser	Gln	Gly	Asn	Thr	Thr	Leu	Ser	Ile	Asn
	370					375					380				
Pro	Val	Lys	Arg	Glu	Asp	Ala	Gly	Thr	Tyr	Trp	Cys	Glu	Val	Phe	Asn
385					390					395					400
Pro	Ile	Ser	Lys	Asn	Gln	Ser	Asp	Pro	Ile	Met	Leu	Asn	Val	Asn	Tyr
				405					410					415	
Asn	Ala	Leu	Pro	Gln	Glu	Asn	Gly	Leu	Ser	Pro	Gly	Ala	Ile	Ala	Gly
			420					425					430		
Ile	Val	Ile	Gly	Val	Val	Ala	Leu	Val	Ala	Leu	Ile	Ala	Val	Ala	Leu
	435						440					445			
Ala	Cys	Phe	Leu	His	Phe	Gly	Lys	Thr	Gly	Arg	Ala	Ser	Asp	Gln	Arg
	450					455					460				
Asp	Leu	Thr	Glu	His	Lys	Pro	Ser	Val	Ser	Asn	His	Thr	Gln	Asp	His
465					470					475					480
Ser	Asn	Asp	Pro	Pro	Asn	Lys	Met	Asn	Glu	Val	Thr	Tyr	Ser	Thr	Leu
				485					490					495	
Asn	Phe	Glu	Ala	Gln	Gln	Pro	Thr	Gln	Pro	Thr	Ser	Ala	Ser	Pro	Ser
			500					505					510		
Leu	Thr	Ala	Thr	Glu	Ile	Ile	Tyr	Ser	Glu	Val	Lys	Lys	Gln		
	515						520					525			

<210> 19
 <211> 244
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> TIGIT

<400> 19

Met	Arg	Trp	Cys	Leu	Leu	Ile	Trp	Ala	Gln	Gly	Leu	Arg	Gln	Ala
1				5				10					15	
Pro	Leu	Ala	Ser	Gly	Met	Met	Thr	Gly	Thr	Ile	Glu	Thr	Thr	Gly
			20					25				30		Asn
Ile	Ser	Ala	Glu	Lys	Gly	Gly	Ser	Ile	Ile	Leu	Gln	Cys	His	Leu
	35					40					45			Ser
Ser	Thr	Ala	Gln	Val	Thr	Gln	Val	Asn	Trp	Glu	Gln	Gln	Asp	Gln
	50				55					60				
Leu	Leu	Ala	Ile	Cys	Asn	Ala	Asp	Leu	Gly	Trp	His	Ile	Ser	Pro
65				70					75					80
Phe	Lys	Asp	Arg	Val	Ala	Pro	Gly	Pro	Gly	Leu	Gly	Leu	Thr	Leu
			85					90					95	Gln
Ser	Leu	Thr	Val	Asn	Asp	Thr	Gly	Glu	Tyr	Phe	Cys	Ile	Tyr	His
			100					105				110		Thr
Tyr	Pro	Asp	Gly	Thr	Tyr	Thr	Gly	Arg	Ile	Phe	Leu	Glu	Val	Leu
	115						120					125		Glu
Ser	Ser	Val	Ala	Glu	His	Gly	Ala	Arg	Phe	Gln	Ile	Pro	Leu	Leu
	130					135					140			Gly
Ala	Met	Ala	Ala	Thr	Leu	Val	Val	Ile	Cys	Thr	Ala	Val	Ile	Val
145					150				155					160
Val	Ala	Leu	Thr	Arg	Lys	Lys	Lys	Ala	Leu	Arg	Ile	His	Ser	Val
			165					170						175
Gly	Asp	Leu	Arg	Arg	Lys	Ser	Ala	Gly	Gln	Glu	Glu	Trp	Ser	Pro
			180					185				190		Ser
Ala	Pro	Ser	Pro	Pro	Gly	Ser	Cys	Val	Gln	Ala	Glu	Ala	Ala	Pro
	195						200					205		Ala

761612000240SeqList

Gly	Leu	Cys	Gly	Glu	Gln	Arg	Gly	Glu	Asp	Cys	Ala	Glu	Leu	His	Asp
210	210					215					220				
Tyr	Phe	Asn	Val	Leu	Ser	Tyr	Arg	Ser	Leu	Gly	Asn	Cys	Ser	Phe	Phe
225					230					235					240
Thr	Glu	Thr	Gly												

<210> 20
 <211> 417
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PVR(CD155)

<400> 20

Met	Ala	Arg	Ala	Met	Ala	Ala	Ala	Trp	Pro	Leu	Leu	Leu	Val	Ala	Leu
1				5				10					15		
Leu	Val	Leu	Ser	Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln
			20					25				30			
Ala	Pro	Thr	Gln	Val	Pro	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro
		35					40				45				
Cys	Tyr	Leu	Gln	Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu
	50					55					60				
Thr	Trp	Ala	Arg	His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln
65					70					75				80	
Thr	Gln	Gly	Pro	Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala
				85					90					95	
Ala	Arg	Leu	Gly	Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly
			100					105					110		
Leu	Arg	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe
		115					120					125			
Pro	Gln	Gly	Ser	Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys
	130					135					140				
Pro	Gln	Asn	Thr	Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro
145					150					155				160	
Val	Pro	Met	Ala	Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln
			165						170					175	
Ile	Thr	Trp	His	Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val
			180					185					190		
Pro	Gly	Phe	Leu	Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu
		195					200					205			
Val	Pro	Ser	Ser	Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu
	210					215					220				
His	Glu	Ser	Phe	Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val
225					230					235				240	
Tyr	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr
				245					250					255	
Leu	Gly	Gln	Asn	Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro
			260					265					270		
Glu	Pro	Thr	Gly	Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro
		275					280				285				
Phe	Ala	Val	Ala	Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys
	290					295					300				
Pro	Ile	Asn	Thr	Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala
305					310					315				320	
Arg	Gln	Ala	Glu	Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu
			325						330					335	
His	Ser	Gly	Ile	Ser	Arg	Asn	Ala	Ile	Ile	Phe	Leu	Val	Leu	Gly	Ile
			340					345					350		
Leu	Val	Phe	Leu	Ile	Leu	Leu	Gly	Ile	Gly	Ile	Tyr	Phe	Tyr	Trp	Ser
		355					360					365			
Lys	Cys	Ser	Arg	Glu	Val	Leu	Trp	His	Cys	His	Leu	Cys	Pro	Ser	Ser
	370					375					380				
Thr	Glu	His	Ala	Ser	Ala	Ser	Ala	Asn	Gly	His	Val	Ser	Tyr	Ser	Ala
385					390					395					400

761612000240SeqList
Val Ser Arg Glu Asn Ser Ser Ser Gln Asp Pro Gln Thr Glu Gly Thr
405 410 415
Arg

<210> 21
<211> 538
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> PVRL2(CD112)

<400> 21
Met Ala Arg Ala Ala Ala Leu Leu Pro Ser Arg Ser Pro Pro Thr Pro
1 5 10 15
Leu Leu Trp Pro Leu Leu Leu Leu Leu Leu Glu Thr Gly Ala Gln
20 25 30
Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly Gly
35 40 45
Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu Tyr
50 55 60
Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His Gln
65 70 75 80
Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser Pro
85 90 95
Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser Thr
100 105 110
Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu His
115 120 125
Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala Thr
130 135 140
Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile Ala
145 150 155 160
Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln Asp
165 170 175
Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro Ala
180 185 190
Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr Gln
195 200 205
Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Cys Lys Val
210 215 220 225 230 235 240
Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys Val
225 230 235 240
Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu Ser
245 250 255
Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn Trp
260 265 270
Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser Asn
275 280 285
Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe Pro
290 295 300
Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val Asp
305 310 315 320
Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val Gly
325 330 335
Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn Thr
340 345 350
Ala Gly Ala Gly Ala Thr Gly Gly Ile Ile Gly Gly Ile Ala Ala
355 360 365
Ile Ile Ala Thr Ala Val Ala Ala Thr Gly Ile Leu Ile Cys Arg Gln
370 375 380
Gln Arg Lys Glu Gln Thr Leu Gln Gly Ala Glu Glu Asp Glu Asp Leu
385 390 395 400
Glu Gly Pro Pro Ser Tyr Lys Pro Pro Thr Pro Lys Ala Lys Leu Glu
405 410 415

761612000240SeqList

Ala	Gln	Glu	Met	Pro	Ser	Gln	Leu	Phe	Thr	Leu	Gly	Ala	Ser	Glu	His
			420					425					430		
Ser	Pro	Leu	Lys	Thr	Pro	Tyr	Phe	Asp	Ala	Gly	Ala	Ser	Cys	Thr	Glu
		435					440					445			
Gln	Glu	Met	Pro	Arg	Tyr	His	Glu	Leu	Pro	Thr	Leu	Glu	Glu	Arg	Ser
		450				455					460				
Gly	Pro	Leu	His	Pro	Gly	Ala	Thr	Ser	Leu	Gly	Ser	Pro	Ile	Pro	Val
465					470					475					480
Pro	Pro	Gly	Pro	Pro	Ala	Val	Glu	Asp	Val	Ser	Leu	Asp	Leu	Glu	Asp
				485					490					495	
Glu	Glu	Gly	Glu	Glu	Glu	Glu	Glu	Tyr	Leu	Asp	Lys	Ile	Asn	Pro	Ile
			500					505					510		
Tyr	Asp	Ala	Leu	Ser	Tyr	Ser	Ser	Pro	Ser	Asp	Ser	Tyr	Gln	Gly	Lys
		515					520					525			
Gly	Phe	Val	Met	Ser	Arg	Ala	Met	Tyr	Val						
	530					535									

<210> 22
 <211> 336
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD226

<400> 22

Met	Asp	Tyr	Pro	Thr	Leu	Leu	Leu	Ala	Leu	Leu	His	Val	Tyr	Arg	Ala
1				5					10					15	
Leu	Cys	Glu	Glu	Val	Leu	Trp	His	Thr	Ser	Val	Pro	Phe	Ala	Glu	Asn
			20					25					30		
Met	Ser	Leu	Glu	Cys	Val	Tyr	Pro	Ser	Met	Gly	Ile	Leu	Thr	Gln	Val
		35					40					45			
Glu	Trp	Phe	Lys	Ile	Gly	Thr	Gln	Gln	Asp	Ser	Ile	Ala	Ile	Phe	Ser
	50				55					60					
Pro	Thr	His	Gly	Met	Val	Ile	Arg	Lys	Pro	Tyr	Ala	Glu	Arg	Val	Tyr
65					70					75					80
Phe	Leu	Asn	Ser	Thr	Met	Ala	Ser	Asn	Asn	Met	Thr	Leu	Phe	Phe	Arg
				85					90					95	
Asn	Ala	Ser	Glu	Asp	Asp	Val	Gly	Tyr	Tyr	Ser	Cys	Ser	Leu	Tyr	Thr
			100					105					110		
Tyr	Pro	Gln	Gly	Thr	Trp	Gln	Lys	Val	Ile	Gln	Val	Val	Gln	Ser	Asp
		115					120					125			
Ser	Phe	Glu	Ala	Ala	Val	Pro	Ser	Asn	Ser	His	Ile	Val	Ser	Glu	Pro
	130					135					140				
Gly	Lys	Asn	Val	Thr	Leu	Thr	Cys	Gln	Pro	Gln	Met	Thr	Trp	Pro	Val
145					150					155					160
Gln	Ala	Val	Arg	Trp	Glu	Lys	Ile	Gln	Pro	Arg	Gln	Ile	Asp	Leu	Leu
			165						170					175	
Thr	Tyr	Cys	Asn	Leu	Val	His	Gly	Arg	Asn	Phe	Thr	Ser	Lys	Phe	Pro
			180					185					190		
Arg	Gln	Ile	Val	Ser	Asn	Cys	Ser	His	Gly	Arg	Trp	Ser	Val	Ile	Val
		195					200					205			
Ile	Pro	Asp	Val	Thr	Val	Ser	Asp	Ser	Gly	Leu	Tyr	Arg	Cys	Tyr	Leu
	210					215					220				
Gln	Ala	Ser	Ala	Gly	Glu	Asn	Glu	Thr	Phe	Val	Met	Arg	Leu	Thr	Val
225					230					235					240
Ala	Glu	Gly	Lys	Thr	Asp	Asn	Gln	Tyr	Thr	Leu	Phe	Val	Ala	Gly	Gly
			245						250					255	
Thr	Val	Leu	Leu	Leu	Leu	Phe	Val	Ile	Ser	Ile	Thr	Thr	Ile	Ile	Val
			260					265					270		
Ile	Phe	Leu	Asn	Arg	Arg	Arg	Arg	Arg	Glu	Arg	Arg	Asp	Leu	Phe	Thr
		275					280					285			
Glu	Ser	Trp	Asp	Thr	Gln	Lys	Ala	Pro	Asn	Asn	Tyr	Arg	Ser	Pro	Ile
	290					295					300				
Ser	Thr	Ser	Gln	Pro	Thr	Asn	Gln	Ser	Met	Asp	Asp	Thr	Arg	Glu	Asp
305					310					315					320

761612000240SeqList

Ile Tyr Val Asn Tyr Pro Thr Phe Ser Arg Arg Pro Lys Thr Arg Val
 325 330 335

<210> 23
 <211> 351
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD2

<400> 23
 Met Ser Phe Pro Cys Lys Phe Val Ala Ser Phe Leu Leu Ile Phe Asn
 1 5 10 15
 Val Ser Ser Lys Gly Ala Val Ser Lys Glu Ile Thr Asn Ala Leu Glu
 20 25 30
 Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp Ile Pro Ser Phe
 35 40 45
 Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu Lys Thr Ser Asp
 50 55 60
 Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu Thr Phe Lys Glu
 65 70 75 80
 Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu Lys Ile Lys His
 85 90 95
 Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser Ile Tyr Asp Thr
 100 105 110
 Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu Lys Ile Gln Glu
 115 120 125
 Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile Asn Thr Thr Leu
 130 135 140
 Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu Asn Leu Tyr Gln
 145 150 155 160
 Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile Thr His Lys Trp
 165 170 175
 Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala Gly Asn Lys Val
 180 185 190
 Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro Glu Lys Gly Leu
 195 200 205
 Asp Ile Tyr Leu Ile Ile Gly Ile Cys Gly Gly Gly Ser Leu Leu Met
 210 215 220
 Val Phe Val Ala Leu Leu Val Phe Tyr Ile Thr Lys Arg Lys Lys Gln
 225 230 235 240
 Arg Ser Arg Arg Asn Asp Glu Glu Leu Glu Thr Arg Ala His Arg Val
 245 250 255
 Ala Thr Glu Glu Arg Gly Arg Lys Pro His Gln Ile Pro Ala Ser Thr
 260 265 270
 Pro Gln Asn Pro Ala Thr Ser Gln His Pro Pro Pro Pro Gly His
 275 280 285
 Arg Ser Gln Ala Pro Ser His Arg Pro Pro Pro Pro Gly His Arg Val
 290 295 300
 Gln His Gln Pro Gln Lys Arg Pro Pro Ala Pro Ser Gly Thr Gln Val
 305 310 315 320
 His Gln Gln Lys Gly Pro Pro Leu Pro Arg Pro Arg Val Gln Pro Lys
 325 330 335
 Pro Pro His Gly Ala Ala Glu Asn Ser Leu Ser Pro Ser Ser Asn
 340 345 350

<210> 24
 <211> 180
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD160

761612000240SeqList

```

<400> 24
Met Leu Leu Glu Pro Gly Arg Gly Cys Cys Ala Leu Ala Ile Leu Leu
1      5      10
Ala Ile Val Asp Ile Gln Ser Gly Gly Cys Ile Asn Ile Thr Ser Ser
20
Ala Ser Gln Glu Gly Thr Arg Leu Asn Leu Ile Cys Thr Val Trp His
35
Lys Lys Glu Glu Ala Glu Gly Phe Val Val Phe Leu Cys Lys Asp Arg
50
Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu Lys Gln Leu Arg Leu Lys
65
Arg Asp Pro Gly Ile Asp Gly Val Gly Glu Ile Ser Ser Gln Leu Met
80
Phe Thr Ile Ser Gln Val Thr Pro Leu His Ser Gly Thr Tyr Gln Cys
100
Cys Ala Arg Ser Gln Lys Ser Gly Ile Arg Leu Gln Gly His Phe Phe
115
Ser Ile Leu Phe Thr Glu Thr Gly Asn Tyr Thr Val Thr Gly Leu Lys
130
Gln Arg Gln His Leu Glu Phe Ser His Asn Glu Gly Thr Leu Ser Ser
145
Gly Phe Leu Gln Glu Lys Val Trp Val Met Leu Val Thr Ser Leu Val
160
Ala Leu Gln Ala
180

```

```

<210> 25
<211> 278
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> MISC_FEATURE
<223> CD200

```

```

<400> 25
Met Glu Arg Leu Val Ile Arg Met Pro Phe Ser His Leu Ser Thr Tyr
1      5      10
Ser Leu Val Trp Val Met Ala Ala Val Val Leu Cys Thr Ala Gln Val
20
Gln Val Val Thr Gln Asp Glu Arg Glu Gln Leu Tyr Thr Pro Ala Ser
35
Leu Lys Cys Ser Leu Gln Asn Ala Gln Glu Ala Leu Ile Val Thr Trp
50
Gln Lys Lys Lys Ala Val Ser Pro Glu Asn Met Val Thr Phe Ser Glu
65
Asn His Gly Val Val Ile Gln Pro Ala Tyr Lys Asp Lys Ile Asn Ile
80
Thr Gln Leu Gly Leu Gln Asn Ser Thr Ile Thr Phe Trp Asn Ile Thr
100
Leu Glu Asp Glu Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe Gly Phe
115
Gly Lys Ile Ser Gly Thr Ala Cys Leu Thr Val Tyr Val Gln Pro Ile
130
Val Ser Leu His Tyr Lys Phe Ser Glu Asp His Leu Asn Ile Thr Cys
145
Ser Ala Thr Ala Arg Pro Ala Pro Met Val Phe Trp Lys Val Pro Arg
160
Ser Gly Ile Glu Asn Ser Thr Val Thr Leu Ser His Pro Asn Gly Thr
180
Thr Ser Val Thr Ser Ile Leu His Ile Lys Asp Pro Lys Asn Gln Val
195
Gly Lys Glu Val Ile Cys Gln Val Leu His Leu Gly Thr Val Thr Asp
210
Phe Lys Gln Thr Val Asn Lys Gly Tyr Trp Phe Ser Val Pro Leu Leu
225
230
235
240

```

761612000240SeqList
 Leu Ser Ile Val Ser Leu Val Ile Leu Leu Val Leu Ile Ser Ile Leu
 245 250
 Leu Tyr Trp Lys Arg His Arg Asn Gln Asp Arg Gly Glu Leu Ser Gln
 260 265 270
 Gly Val Gln Lys Met Thr
 275

<210> 26
 <211> 325
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD200R1(CD200R)

<400> 26
 Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Leu Ile Leu
 1 5 10 15
 Thr Ile Phe Leu Val Ala Ala Ser Ser Ser Leu Cys Met Asp Glu Lys
 20 25 30
 Gln Ile Thr Gln Asn Tyr Ser Lys Val Leu Ala Glu Val Asn Thr Ser
 35 40 45
 Trp Pro Val Lys Met Ala Thr Asn Ala Val Leu Cys Cys Pro Pro Ile
 50 55 60
 Ala Leu Arg Asn Leu Ile Ile Ile Thr Trp Glu Ile Ile Leu Arg Gly
 65 70 75 80
 Gln Pro Ser Cys Thr Lys Ala Tyr Arg Lys Glu Thr Asn Glu Thr Lys
 85 90 95
 Glu Thr Asn Cys Thr Asp Glu Arg Ile Thr Trp Val Ser Arg Pro Asp
 100 105 110
 Gln Asn Ser Asp Leu Gln Ile Arg Pro Val Ala Ile Thr His Asp Gly
 115 120 125
 Tyr Tyr Arg Cys Ile Met Val Thr Pro Asp Gly Asn Phe His Arg Gly
 130 135 140
 Tyr His Leu Gln Val Leu Val Thr Pro Glu Val Thr Leu Phe Gln Asn
 145 150 155 160
 Arg Asn Arg Thr Ala Val Cys Lys Ala Val Ala Gly Lys Pro Ala Ala
 165 170 175
 Gln Ile Ser Trp Ile Pro Glu Gly Asp Cys Ala Thr Lys Gln Glu Tyr
 180 185 190
 Trp Ser Asn Gly Thr Val Thr Val Lys Ser Thr Cys His Trp Glu Val
 195 200 205
 His Asn Val Ser Thr Val Thr Cys His Val Ser His Leu Thr Gly Asn
 210 215 220
 Lys Ser Leu Tyr Ile Glu Leu Leu Pro Val Pro Gly Ala Lys Lys Ser
 225 230 235 240
 Ala Lys Leu Tyr Ile Pro Tyr Ile Ile Leu Thr Ile Ile Ile Leu Thr
 245 250 255
 Ile Val Gly Phe Ile Trp Leu Leu Lys Val Asn Gly Cys Arg Lys Tyr
 260 265 270
 Lys Leu Asn Lys Thr Glu Ser Thr Pro Val Val Glu Glu Asp Glu Met
 275 280 285
 Gln Pro Tyr Ala Ser Tyr Thr Glu Lys Asn Asn Pro Leu Tyr Asp Thr
 290 295 300
 Thr Asn Lys Val Lys Ala Ser Glu Ala Leu Gln Ser Glu Val Asp Thr
 305 310 315 320
 Asp Leu His Thr Leu
 325

<210> 27
 <211> 201
 <212> PRT
 <213> Homo sapiens

<220>

761612000240SeqList

<221> MISC_FEATURE
 <223> NC R3 (NKp30)

<400> 27
 Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
 1 5 10 15
 Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Gly Gly
 20 25 30
 Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu
 35 40 45
 Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys
 50 55 60
 Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu
 65 70 75 80
 Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg
 85 90 95
 Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val
 100 105 110
 Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu
 115 120 125
 Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala
 130 135 140
 Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val
 145 150 155 160
 Tyr Tyr Gln Gly Lys Cys Leu Thr Trp Lys Gly Pro Arg Arg Gln Leu
 165 170 175
 Pro Ala Val Val Pro Ala Pro Leu Pro Pro Pro Cys Gly Ser Ser Ala
 180 185 190
 His Leu Leu Pro Pro Val Pro Gly Gly
 195 200

<210> 28
 <211> 208
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD80(B7-1) ECD

<400> 28
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

761612000240SeqList

<210> 29
 <211> 224
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD86(B7-2) ECD

<400> 29
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro
 1 5 10 15
 Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val
 20 25 30
 Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly
 35 40 45
 Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser
 50 55 60
 Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys
 65 70 75 80
 Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly
 85 90 95
 Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn
 100 105 110
 Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val
 115 120 125
 Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys
 130 135 140
 Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp
 145 150 155 160
 Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val
 165 170 175
 Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr
 180 185 190
 Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro
 195 200 205
 Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro
 210 215 220

<210> 30
 <211> 220
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD274 (PD-L1, B7-H1) ECD

<400> 30
 Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser
 1 5 10 15
 Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu Asp Leu
 20 25 30
 Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile Ile Gln
 35 40 45
 Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser Tyr Arg
 50 55 60
 Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn Ala Ala
 65 70 75 80
 Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr Arg Cys
 85 90 95
 Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys Val
 100 105 110
 Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro
 115 120 125

761612000240SeqList

Val	Thr	Ser	Glu	His	Glu	Leu	Thr	Cys	Gln	Ala	Glu	Gly	Tyr	Pro	Lys
130						135					140				
Ala	Glu	Val	Ile	Trp	Thr	Ser	Ser	Asp	His	Gln	Val	Leu	Ser	Gly	Lys
145					150					155					160
Thr	Thr	Thr	Thr	Asn	Ser	Lys	Arg	Glu	Glu	Lys	Leu	Phe	Asn	Val	Thr
				165						170				175	
Ser	Thr	Leu	Arg	Ile	Asn	Thr	Thr	Thr	Asn	Glu	Ile	Phe	Tyr	Cys	Thr
			180					185					190		
Phe	Arg	Arg	Leu	Asp	Pro	Glu	Glu	Asn	His	Thr	Ala	Glu	Leu	Val	Ile
		195					200					205			
Pro	Glu	Leu	Pro	Leu	Ala	His	Pro	Pro	Asn	Glu	Arg				
	210					215					220				

<210> 31
 <211> 201
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PDCD1LG2(PD-L2, CD273) ECD

<400> 31

Leu	Phe	Thr	Val	Thr	Val	Pro	Lys	Glu	Leu	Tyr	Ile	Ile	Glu	His	Gly
1				5					10					15	
Ser	Asn	Val	Thr	Leu	Glu	Cys	Asn	Phe	Asp	Thr	Gly	Ser	His	Val	Asn
		20					25						30		
Leu	Gly	Ala	Ile	Thr	Ala	Ser	Leu	Gln	Lys	Val	Glu	Asn	Asp	Thr	Ser
		35					40					45			
Pro	His	Arg	Glu	Arg	Ala	Thr	Leu	Leu	Glu	Glu	Gln	Leu	Pro	Leu	Gly
	50					55					60				
Lys	Ala	Ser	Phe	His	Ile	Pro	Gln	Val	Gln	Val	Arg	Asp	Glu	Gly	Gln
65				70					75					80	
Tyr	Gln	Cys	Ile	Ile	Ile	Tyr	Gly	Val	Ala	Trp	Asp	Tyr	Lys	Tyr	Leu
			85					90						95	
Thr	Leu	Lys	Val	Lys	Ala	Ser	Tyr	Arg	Lys	Ile	Asn	Thr	His	Ile	Leu
			100					105					110		
Lys	Val	Pro	Glu	Thr	Asp	Glu	Val	Glu	Leu	Thr	Cys	Gln	Ala	Thr	Gly
	115						120					125			
Tyr	Pro	Leu	Ala	Glu	Val	Ser	Trp	Pro	Asn	Val	Ser	Val	Pro	Ala	Asn
	130					135					140				
Thr	Ser	His	Ser	Arg	Thr	Pro	Glu	Gly	Leu	Tyr	Gln	Val	Thr	Ser	Val
145					150				155						160
Leu	Arg	Leu	Lys	Pro	Pro	Pro	Gly	Arg	Asn	Phe	Ser	Cys	Val	Phe	Trp
			165						170					175	
Asn	Thr	His	Val	Arg	Glu	Leu	Thr	Leu	Ala	Ser	Ile	Asp	Leu	Gln	Ser
		180						185					190		
Gln	Met	Glu	Pro	Arg	Thr	His	Pro	Thr							
	195						200								

<210> 32
 <211> 238
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> ICOSLG(B7RP1, CD275, ICOSL, B7-H2) ECD

<400> 32

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
		20					25						30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			

761612000240SeqList

Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
50	55	60													
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65	70	75													80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Asn	Leu	
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 33
 <211> 438
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD276(B7-H3) ECD

<400> 33

Leu	Glu	Val	Gln	Val	Pro	Glu	Asp	Pro	Val	Val	Ala	Leu	Val	Gly	Thr
1				5					10					15	
Asp	Ala	Thr	Leu	Cys	Cys	Ser	Phe	Ser	Pro	Glu	Pro	Gly	Phe	Ser	Leu
			20					25					30		
Ala	Gln	Leu	Asn	Leu	Ile	Trp	Gln	Leu	Thr	Asp	Thr	Lys	Gln	Leu	Val
		35					40					45			
His	Ser	Phe	Ala	Glu	Gly	Gln	Asp	Gln	Gly	Ser	Ala	Tyr	Ala	Asn	Arg
	50					55					60				
Thr	Ala	Leu	Phe	Pro	Asp	Leu	Leu	Ala	Gln	Gly	Asn	Ala	Ser	Leu	Arg
65					70					75					80
Leu	Gln	Arg	Val	Arg	Val	Ala	Asp	Glu	Gly	Ser	Phe	Thr	Cys	Phe	Val
				85					90					95	
Ser	Ile	Arg	Asp	Phe	Gly	Ser	Ala	Ala	Val	Ser	Leu	Gln	Val	Ala	Ala
			100					105					110		
Pro	Tyr	Ser	Lys	Pro	Ser	Met	Thr	Leu	Glu	Pro	Asn	Lys	Asp	Leu	Arg
		115					120					125			
Pro	Gly	Asp	Thr	Val	Thr	Ile	Thr	Cys	Ser	Ser	Tyr	Gln	Gly	Tyr	Pro
	130					135					140				
Glu	Ala	Glu	Val	Phe	Trp	Gln	Asp	Gly	Gln	Gly	Val	Pro	Leu	Thr	Gly
145					150					155					160
Asn	Val	Thr	Thr	Ser	Gln	Met	Ala	Asn	Glu	Gln	Gly	Leu	Phe	Asp	Val
				165					170					175	
His	Ser	Ile	Leu	Arg	Val	Val	Leu	Gly	Ala	Asn	Gly	Thr	Tyr	Ser	Cys
		180						185					190		
Leu	Val	Arg	Asn	Pro	Val	Leu	Gln	Asp	Ala	His	Ser	Ser	Val	Thr	
		195					200				205				
Ile	Thr	Pro	Gln	Arg	Ser	Pro	Thr	Gly	Ala	Val	Glu	Val	Gln	Val	Pro
	210					215					220				
Glu	Asp	Pro	Val	Val	Ala	Leu	Val	Gly	Thr	Asp	Ala	Thr	Leu	Arg	Cys
225					230					235					240
Ser	Phe	Ser	Pro	Glu	Pro	Gly	Phe	Ser	Leu	Ala	Gln	Leu	Asn	Leu	Ile
				245					250					255	

761612000240SeqList

Trp	Gln	Leu	Thr	Asp	Thr	Lys	Gln	Leu	Val	His	Ser	Phe	Thr	Glu	Gly
			260					265					270		
Arg	Asp	Gln	Gly	Ser	Ala	Tyr	Ala	Asn	Arg	Thr	Ala	Leu	Phe	Pro	Asp
		275					280					285			
Leu	Leu	Ala	Gln	Gly	Asn	Ala	Ser	Leu	Arg	Leu	Gln	Arg	Val	Arg	Val
	290					295					300				
Ala	Asp	Glu	Gly	Ser	Phe	Thr	Cys	Phe	Val	Ser	Ile	Arg	Asp	Phe	Gly
305					310					315					320
Ser	Ala	Ala	Val	Ser	Leu	Gln	Val	Ala	Ala	Pro	Tyr	Ser	Lys	Pro	Ser
				325				330						335	
Met	Thr	Leu	Glu	Pro	Asn	Lys	Asp	Leu	Arg	Pro	Gly	Asp	Thr	Val	Thr
			340					345					350		
Ile	Thr	Cys	Ser	Ser	Tyr	Arg	Gly	Tyr	Pro	Glu	Ala	Glu	Val	Phe	Trp
		355					360					365			
Gln	Asp	Gly	Gln	Gly	Val	Pro	Leu	Thr	Gly	Asn	Val	Thr	Thr	Ser	Gln
	370					375					380				
Met	Ala	Asn	Glu	Gln	Gly	Leu	Phe	Asp	Val	His	Ser	Val	Leu	Arg	Val
385					390					395					400
Val	Leu	Gly	Ala	Asn	Gly	Thr	Tyr	Ser	Cys	Leu	Val	Arg	Asn	Pro	Val
				405					410					415	
Leu	Gln	Gln	Asp	Ala	His	Gly	Ser	Val	Thr	Ile	Thr	Gly	Gln	Pro	Met
			420					425					430		
Thr	Phe	Pro	Pro	Glu	Ala										
			435												

<210> 34
 <211> 235
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> VTCN1(B7-H4) ECD

<400> 34

Leu	Ile	Ile	Gly	Phe	Gly	Ile	Ser	Gly	Arg	His	Ser	Ile	Thr	Val	Thr
1				5					10					15	
Thr	Val	Ala	Ser	Ala	Gly	Asn	Ile	Gly	Glu	Asp	Gly	Ile	Leu	Ser	Cys
			20					25					30		
Thr	Phe	Glu	Pro	Asp	Ile	Lys	Leu	Ser	Asp	Ile	Val	Ile	Gln	Trp	Leu
		35					40					45			
Lys	Glu	Gly	Val	Leu	Gly	Leu	Val	His	Glu	Phe	Lys	Glu	Gly	Lys	Asp
	50					55					60				
Glu	Leu	Ser	Glu	Gln	Asp	Glu	Met	Phe	Arg	Gly	Arg	Thr	Ala	Val	Phe
65					70				75					80	
Ala	Asp	Gln	Val	Ile	Val	Gly	Asn	Ala	Ser	Leu	Arg	Leu	Lys	Asn	Val
				85					90					95	
Gln	Leu	Thr	Asp	Ala	Gly	Thr	Tyr	Lys	Cys	Tyr	Ile	Ile	Thr	Ser	Lys
			100					105					110		
Gly	Lys	Gly	Asn	Ala	Asn	Leu	Glu	Tyr	Lys	Thr	Gly	Ala	Phe	Ser	Met
		115					120					125			
Pro	Glu	Val	Asn	Val	Asp	Tyr	Asn	Ala	Ser	Ser	Glu	Thr	Leu	Arg	Cys
	130					135					140				
Glu	Ala	Pro	Arg	Trp	Phe	Pro	Gln	Pro	Thr	Val	Val	Trp	Ala	Ser	Gln
145					150					155					160
Val	Asp	Gln	Gly	Ala	Asn	Phe	Ser	Glu	Val	Ser	Asn	Thr	Ser	Phe	Glu
				165					170					175	
Leu	Asn	Ser	Glu	Asn	Val	Thr	Met	Lys	Val	Val	Ser	Val	Leu	Tyr	Asn
			180					185					190		
Val	Thr	Ile	Asn	Asn	Thr	Tyr	Ser	Cys	Met	Ile	Glu	Asn	Asp	Ile	Ala
		195					200					205			
Lys	Ala	Thr	Gly	Asp	Ile	Lys	Val	Thr	Glu	Ser	Glu	Ile	Lys	Arg	Arg
	210					215					220				
Ser	His	Leu	Gln	Leu	Leu	Asn	Ser	Lys	Ala	Ser					
225					230					235					

761612000240SeqList

<210> 35
 <211> 134
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD28 ECD

<400> 35
 Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr Asp Asn
 1 5 10 15
 Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser Arg Glu
 20 25 30
 Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu Val Cys
 35 40 45
 Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser Lys Thr
 50 55 60
 Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr Phe Tyr
 65 70 75 80
 Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys Lys Ile
 85 90 95
 Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly
 100 105 110
 Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
 115 120 125
 Pro Gly Pro Ser Lys Pro
 130

<210> 36
 <211> 126
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CTLA4 ECD

<400> 36
 Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg
 1 5 10 15
 Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr
 20 25 30
 Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu
 35 40 45
 Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp
 50 55 60
 Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr
 65 70 75 80
 Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val
 85 90 95
 Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr
 100 105 110
 Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp
 115 120 125

<210> 37
 <211> 150
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PDCD1(PD-1) ECD

<400> 37

761612000240SeqList

Pro	Gly	Trp	Phe	Leu	Asp	Ser	Pro	Asp	Arg	Pro	Trp	Asn	Pro	Pro	Thr
1				5				10					15		
Phe	Ser	Pro	Ala	Leu	Leu	Val	Val	Thr	Glu	Gly	Asp	Asn	Ala	Thr	Phe
			20					25				30			
Thr	Cys	Ser	Phe	Ser	Asn	Thr	Ser	Glu	Ser	Phe	Val	Leu	Asn	Trp	Tyr
		35					40					45			
Arg	Met	Ser	Pro	Ser	Asn	Gln	Thr	Asp	Lys	Leu	Ala	Phe	Pro	Glu	
	50					55					60				
Asp	Arg	Ser	Gln	Pro	Gly	Gln	Asp	Cys	Arg	Phe	Arg	Val	Thr	Gln	Leu
65					70					75					80
Pro	Asn	Gly	Arg	Asp	Phe	His	Met	Ser	Val	Val	Arg	Ala	Arg	Arg	Asn
				85					90					95	
Asp	Ser	Gly	Thr	Tyr	Leu	Cys	Gly	Ala	Ile	Ser	Leu	Ala	Pro	Lys	Ala
			100					105					110		
Gln	Ile	Lys	Glu	Ser	Leu	Arg	Ala	Glu	Leu	Arg	Val	Thr	Glu	Arg	Arg
		115					120					125			
Ala	Glu	Val	Pro	Thr	Ala	His	Pro	Ser	Pro	Ser	Pro	Arg	Pro	Ala	Gly
	130					135					140				
Gln	Phe	Gln	Thr	Leu	Val										
145					150										

<210> 38
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> ICOS ECD

<400> 38

Glu	Ile	Asn	Gly	Ser	Ala	Asn	Tyr	Glu	Met	Phe	Ile	Phe	His	Asn	Gly
1				5				10						15	
Gly	Val	Gln	Ile	Leu	Cys	Lys	Tyr	Pro	Asp	Ile	Val	Gln	Gln	Phe	Lys
			20					25				30			
Met	Gln	Leu	Leu	Lys	Gly	Gly	Gln	Ile	Leu	Cys	Asp	Leu	Thr	Lys	Thr
		35					40					45			
Lys	Gly	Ser	Gly	Asn	Thr	Val	Ser	Ile	Lys	Ser	Leu	Lys	Phe	Cys	His
	50					55					60				
Ser	Gln	Leu	Ser	Asn	Asn	Ser	Val	Ser	Phe	Phe	Leu	Tyr	Asn	Leu	Asp
65				70						75					80
His	Ser	His	Ala	Asn	Tyr	Tyr	Phe	Cys	Asn	Leu	Ser	Ile	Phe	Asp	Pro
			85					90					95		
Pro	Pro	Phe	Lys	Val	Thr	Leu	Thr	Gly	Gly	Tyr	Leu	His	Ile	Tyr	Glu
			100					105					110		
Ser	Gln	Leu	Cys	Cys	Gln	Leu	Lys								
		115					120								

<210> 39
 <211> 127
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> BTLA(CD272) ECD

<400> 39

Lys	Glu	Ser	Cys	Asp	Val	Gln	Leu	Tyr	Ile	Lys	Arg	Gln	Ser	Glu	His
1				5					10					15	
Ser	Ile	Leu	Ala	Gly	Asp	Pro	Phe	Glu	Leu	Glu	Cys	Pro	Val	Lys	Tyr
			20					25				30			
Cys	Ala	Asn	Arg	Pro	His	Val	Thr	Trp	Cys	Lys	Leu	Asn	Gly	Thr	Thr
		35					40					45			
Cys	Val	Lys	Leu	Glu	Asp	Arg	Gln	Thr	Ser	Trp	Lys	Glu	Glu	Lys	Asn
	50					55					60				

761612000240SeqList

Ile	Ser	Phe	Phe	Ile	Leu	His	Phe	Glu	Pro	Val	Leu	Pro	Asn	Asp	Asn
65					70					75					80
Gly	Ser	Tyr	Arg	Cys	Ser	Ala	Asn	Phe	Gln	Ser	Asn	Leu	Ile	Glu	Ser
				85					90					95	
His	Ser	Thr	Thr	Leu	Tyr	Val	Thr	Asp	Val	Lys	Ser	Ala	Ser	Glu	Arg
			100					105					110		
Pro	Ser	Lys	Asp	Glu	Met	Ala	Ser	Arg	Pro	Trp	Leu	Leu	Tyr	Arg	
		115					120					125			

<210> 40
 <211> 371
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD4 ECD

<400> 40

Lys	Lys	Val	Val	Leu	Gly	Lys	Lys	Gly	Asp	Thr	Val	Glu	Leu	Thr	Cys
1				5					10					15	
Thr	Ala	Ser	Gln	Lys	Lys	Ser	Ile	Gln	Phe	His	Trp	Lys	Asn	Ser	Asn
			20					25					30		
Gln	Ile	Lys	Ile	Leu	Gly	Asn	Gln	Gly	Ser	Phe	Leu	Thr	Lys	Gly	Pro
		35				40						45			
Ser	Lys	Leu	Asn	Asp	Arg	Ala	Asp	Ser	Arg	Arg	Ser	Leu	Trp	Asp	Gln
	50					55					60				
Gly	Asn	Phe	Pro	Leu	Ile	Ile	Lys	Asn	Leu	Lys	Ile	Glu	Asp	Ser	Asp
65				70					75					80	
Thr	Tyr	Ile	Cys	Glu	Val	Glu	Asp	Gln	Lys	Glu	Glu	Val	Gln	Leu	Leu
				85				90						95	
Val	Phe	Gly	Leu	Thr	Ala	Asn	Ser	Asp	Thr	His	Leu	Leu	Gln	Gly	Gln
			100					105					110		
Ser	Leu	Thr	Leu	Thr	Leu	Glu	Ser	Pro	Pro	Gly	Ser	Ser	Pro	Ser	Val
		115					120					125			
Gln	Cys	Arg	Ser	Pro	Arg	Gly	Lys	Asn	Ile	Gln	Gly	Gly	Lys	Thr	Leu
	130					135					140				
Ser	Val	Ser	Gln	Leu	Glu	Leu	Gln	Asp	Ser	Gly	Thr	Trp	Thr	Cys	Thr
145				150						155				160	
Val	Leu	Gln	Asn	Gln	Lys	Lys	Val	Glu	Phe	Lys	Ile	Asp	Ile	Val	Val
				165					170					175	
Leu	Ala	Phe	Gln	Lys	Ala	Ser	Ser	Ile	Val	Tyr	Lys	Lys	Glu	Gly	Glu
			180					185					190		
Gln	Val	Glu	Phe	Ser	Phe	Pro	Leu	Ala	Phe	Thr	Val	Glu	Lys	Leu	Thr
		195					200					205			
Gly	Ser	Gly	Glu	Leu	Trp	Trp	Gln	Ala	Glu	Arg	Ala	Ser	Ser	Ser	Lys
	210					215					220				
Ser	Trp	Ile	Thr	Phe	Asp	Leu	Lys	Asn	Lys	Glu	Val	Ser	Val	Lys	Arg
225				230						235				240	
Val	Thr	Gln	Asp	Pro	Lys	Leu	Gln	Met	Gly	Lys	Lys	Leu	Pro	Leu	His
				245					250					255	
Leu	Thr	Leu	Pro	Gln	Ala	Leu	Pro	Gln	Tyr	Ala	Gly	Ser	Gly	Asn	Leu
			260					265					270		
Thr	Leu	Ala	Leu	Glu	Ala	Lys	Thr	Gly	Lys	Leu	His	Gln	Glu	Val	Asn
		275					280					285			
Leu	Val	Val	Met	Arg	Ala	Thr	Gln	Leu	Gln	Lys	Asn	Leu	Thr	Cys	Glu
		290				295					300				
Val	Trp	Gly	Pro	Thr	Ser	Pro	Lys	Leu	Met	Leu	Ser	Leu	Lys	Leu	Glu
305					310					315				320	
Asn	Lys	Glu	Ala	Lys	Val	Ser	Lys	Arg	Glu	Lys	Ala	Val	Trp	Val	Leu
				325					330					335	
Asn	Pro	Glu	Ala	Gly	Met	Trp	Gln	Cys	Leu	Leu	Ser	Asp	Ser	Gly	Gln
			340					345					350		
Val	Leu	Leu	Glu	Ser	Asn	Ile	Lys	Val	Leu	Pro	Thr	Trp	Ser	Thr	Pro
		355					360					365			
Val	Gln	Pro													
		370													

761612000240SeqList

<210> 41
 <211> 161
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD8A(CD8-alpha) ECD

<400> 41
 Ser Gln Phe Arg Val Ser Pro Leu Asp Arg Thr Trp Asn Leu Gly Glu
 1 5 10 15
 Thr Val Glu Leu Lys Cys Gln Val Leu Leu Ser Asn Pro Thr Ser Gly
 20 25 30
 Cys Ser Trp Leu Phe Gln Pro Arg Gly Ala Ala Ala Ser Pro Thr Phe
 35 40 45
 Leu Leu Tyr Leu Ser Gln Asn Lys Pro Lys Ala Ala Glu Gly Leu Asp
 50 55 60
 Thr Gln Arg Phe Ser Gly Lys Arg Leu Gly Asp Thr Phe Val Leu Thr
 65 70 75 80
 Leu Ser Asp Phe Arg Arg Glu Asn Glu Gly Tyr Tyr Phe Cys Ser Ala
 85 90 95
 Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu
 100 105 110
 Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala
 115 120 125
 Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg
 130 135 140
 Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys
 145 150 155 160
 Asp

<210> 42
 <211> 149
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD8B(CD8-beta) ECD

<400> 42
 Leu Gln Gln Thr Pro Ala Tyr Ile Lys Val Gln Thr Asn Lys Met Val
 1 5 10 15
 Met Leu Ser Cys Glu Ala Lys Ile Ser Leu Ser Asn Met Arg Ile Tyr
 20 25 30
 Trp Leu Arg Gln Arg Gln Ala Pro Ser Ser Asp Ser His His Glu Phe
 35 40 45
 Leu Ala Leu Trp Asp Ser Ala Lys Gly Thr Ile His Gly Glu Glu Val
 50 55 60
 Glu Gln Glu Lys Ile Ala Val Phe Arg Asp Ala Ser Arg Phe Ile Leu
 65 70 75 80
 Asn Leu Thr Ser Val Lys Pro Glu Asp Ser Gly Ile Tyr Phe Cys Met
 85 90 95
 Ile Val Gly Ser Pro Glu Leu Thr Phe Gly Lys Gly Thr Gln Leu Ser
 100 105 110
 Val Val Asp Phe Leu Pro Thr Thr Ala Gln Pro Thr Lys Lys Ser Thr
 115 120 125
 Leu Lys Lys Arg Val Cys Arg Leu Pro Arg Pro Glu Thr Gln Lys Gly
 130 135 140
 Pro Leu Cys Ser Pro
 145

761612000240SeqList

<210> 43
 <211> 422
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> LAG3 ECD

<400> 43
 Val Pro Val Val Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys
 1 5 10 15
 Ser Pro Thr Ile Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly
 20 25 30
 Val Thr Trp Gln His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro
 35 40 45
 Gly His Pro Leu Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp
 50 55 60
 Gly Pro Arg Pro Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly
 65 70 75 80
 Leu Arg Ser Gly Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu
 85 90 95
 Arg Gly Arg Gln Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg
 100 105 110
 Arg Ala Asp Ala Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg
 115 120 125
 Ala Leu Ser Cys Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr
 130 135 140
 Ala Ser Pro Pro Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn
 145 150 155 160
 Cys Ser Phe Ser Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg
 165 170 175
 Asn Arg Gly Gln Gly Arg Val Pro Val Arg Glu Ser Pro His His His
 180 185 190
 Leu Ala Glu Ser Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser
 195 200 205
 Gly Pro Trp Gly Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser
 210 215 220
 Ile Met Tyr Asn Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Pro Leu
 225 230 235 240
 Thr Val Tyr Ala Gly Ala Gly Ser Arg Val Gly Leu Pro Cys Arg Leu
 245 250 255
 Pro Ala Gly Val Gly Thr Arg Ser Phe Leu Thr Ala Lys Trp Thr Pro
 260 265 270
 Pro Gly Gly Gly Pro Asp Leu Leu Val Thr Gly Asp Asn Gly Asp Phe
 275 280 285
 Thr Leu Arg Leu Glu Asp Val Ser Gln Ala Gln Ala Gly Thr Tyr Thr
 290 295 300
 Cys His Ile His Leu Gln Glu Gln Gln Leu Asn Ala Thr Val Thr Leu
 305 310 315 320
 Ala Ile Ile Thr Val Thr Pro Lys Ser Phe Gly Ser Pro Gly Ser Leu
 325 330 335
 Gly Lys Leu Leu Cys Glu Val Thr Pro Val Ser Gly Gln Glu Arg Phe
 340 345 350
 Val Trp Ser Ser Leu Asp Thr Pro Ser Gln Arg Ser Phe Ser Gly Pro
 355 360 365
 Trp Leu Glu Ala Gln Glu Ala Gln Leu Leu Ser Gln Pro Trp Gln Cys
 370 375 380
 Gln Leu Tyr Gln Gly Glu Arg Leu Leu Gly Ala Ala Val Tyr Phe Thr
 385 390 395 400
 Glu Leu Ser Ser Pro Gly Ala Gln Arg Ser Gly Arg Ala Pro Gly Ala
 405 410 415
 Leu Pro Ala Gly His Leu
 420

<210> 44
 <211> 181

761612000240SeqList

<212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> HAVCR2(TIM-3) ECD

<400> 44
 Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr Leu Pro
 1 5 10 15
 Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp
 20 25 30
 Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val Leu Arg
 35 40 45
 Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp Leu Asn
 50 55 60
 Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn Val Thr
 65 70 75 80
 Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro Gly Ile
 85 90 95
 Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys Pro Ala Lys
 100 105 110
 Val Thr Pro Ala Pro Thr Arg Gln Arg Asp Phe Thr Ala Ala Phe Pro
 115 120 125
 Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala Glu Thr Gln Thr Leu
 130 135 140
 Gly Ser Leu Pro Asp Ile Asn Leu Thr Gln Ile Ser Thr Leu Ala Asn
 145 150 155 160
 Glu Leu Arg Asp Ser Arg Leu Ala Asn Asp Leu Arg Asp Ser Gly Ala
 165 170 175
 Thr Ile Arg Ile Gly
 180

<210> 45
 <211> 394
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CEACAM1 ECD

<400> 45
 Gln Leu Thr Thr Glu Ser Met Pro Phe Asn Val Ala Glu Gly Lys Glu
 1 5 10 15
 Val Leu Leu Leu Val His Asn Leu Pro Gln Gln Leu Phe Gly Tyr Ser
 20 25 30
 Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Val Gly Tyr
 35 40 45
 Ala Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Asn Ser Gly Arg
 50 55 60
 Glu Thr Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Val Thr Gln
 65 70 75 80
 Asn Asp Thr Gly Phe Tyr Thr Leu Gln Val Ile Lys Ser Asp Leu Val
 85 90 95
 Asn Glu Glu Ala Thr Gly Gln Phe His Val Tyr Pro Glu Leu Pro Lys
 100 105 110
 Pro Ser Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp Lys Asp Ala
 115 120 125
 Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Thr Tyr Leu Trp
 130 135 140
 Trp Ile Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln Leu Ser
 145 150 155 160
 Asn Gly Asn Arg Thr Leu Thr Leu Leu Ser Val Thr Arg Asn Asp Thr
 165 170 175
 Gly Pro Tyr Glu Cys Glu Ile Gln Asn Pro Val Ser Ala Asn Arg Ser
 180 185 190

761612000240SeqList

Asp	Pro	Val	Thr	Leu	Asn	Val	Thr	Tyr	Gly	Pro	Asp	Thr	Pro	Thr	Ile
		195					200					205			
Ser	Pro	Ser	Asp	Thr	Tyr	Tyr	Arg	Pro	Gly	Ala	Asn	Leu	Ser	Leu	Ser
	210					215					220				
Cys	Tyr	Ala	Ala	Ser	Asn	Pro	Pro	Ala	Gln	Tyr	Ser	Trp	Leu	Ile	Asn
225					230					235					240
Gly	Thr	Phe	Gln	Gln	Ser	Thr	Gln	Glu	Leu	Phe	Ile	Pro	Asn	Ile	Thr
			245						250					255	
Val	Asn	Asn	Ser	Gly	Ser	Tyr	Thr	Cys	His	Ala	Asn	Asn	Ser	Val	Thr
			260					265					270		
Gly	Cys	Asn	Arg	Thr	Thr	Val	Lys	Thr	Ile	Ile	Val	Thr	Glu	Leu	Ser
		275					280					285			
Pro	Val	Val	Ala	Lys	Pro	Gln	Ile	Lys	Ala	Ser	Lys	Thr	Thr	Val	Thr
	290					295					300				
Gly	Asp	Lys	Asp	Ser	Val	Asn	Leu	Thr	Cys	Ser	Thr	Asn	Asp	Thr	Gly
305					310					315					320
Ile	Ser	Ile	Arg	Trp	Phe	Phe	Lys	Asn	Gln	Ser	Leu	Pro	Ser	Ser	Glu
			325						330					335	
Arg	Met	Lys	Leu	Ser	Gln	Gly	Asn	Thr	Thr	Leu	Ser	Ile	Asn	Pro	Val
			340					345					350		
Lys	Arg	Glu	Asp	Ala	Gly	Thr	Tyr	Trp	Cys	Glu	Val	Phe	Asn	Pro	Ile
		355					360					365			
Ser	Lys	Asn	Gln	Ser	Asp	Pro	Ile	Met	Leu	Asn	Val	Asn	Tyr	Asn	Ala
	370					375					380				
Leu	Pro	Gln	Glu	Asn	Gly	Leu	Ser	Pro	Gly						
385					390										

<210> 46
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> TIGIT ECD

<400> 46

Met	Met	Thr	Gly	Thr	Ile	Glu	Thr	Thr	Gly	Asn	Ile	Ser	Ala	Glu	Lys
1				5					10					15	
Gly	Gly	Ser	Ile	Ile	Leu	Gln	Cys	His	Leu	Ser	Ser	Thr	Thr	Ala	Gln
			20					25					30		
Val	Thr	Gln	Val	Asn	Trp	Glu	Gln	Asp	Gln	Leu	Leu	Ala	Ile	Cys	
		35				40				45					
Asn	Ala	Asp	Leu	Gly	Trp	His	Ile	Ser	Pro	Ser	Phe	Lys	Asp	Arg	Val
	50				55					60					
Ala	Pro	Gly	Pro	Gly	Leu	Gly	Leu	Thr	Leu	Gln	Ser	Leu	Thr	Val	Asn
65					70				75					80	
Asp	Thr	Gly	Glu	Tyr	Phe	Cys	Ile	Tyr	His	Thr	Tyr	Pro	Asp	Gly	Thr
			85					90					95		
Tyr	Thr	Gly	Arg	Ile	Phe	Leu	Glu	Val	Leu	Glu	Ser	Ser	Val	Ala	Glu
			100					105					110		
His	Gly	Ala	Arg	Phe	Gln	Ile	Pro								
		115					120								

<210> 47
 <211> 323
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PVR(CD155) ECD

<400> 47

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5					10					15	

761612000240SeqList

Val	Pro	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20					25					30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70					75				80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 48
 <211> 329
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> PVRL2(CD112) ECD

<400> 48

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40				45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50				55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			

761612000240SeqList

Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
130	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 49
 <211> 236
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD226 ECD

<400> 49

Glu	Glu	Val	Leu	Trp	His	Thr	Ser	Val	Pro	Phe	Ala	Glu	Asn	Met	Ser
1				5					10					15	
Leu	Glu	Cys	Val	Tyr	Pro	Ser	Met	Gly	Ile	Leu	Thr	Gln	Val	Glu	Trp
			20					25					30		
Phe	Lys	Ile	Gly	Thr	Gln	Gln	Asp	Ser	Ile	Ala	Ile	Phe	Ser	Pro	Thr
		35					40					45			
His	Gly	Met	Val	Ile	Arg	Lys	Pro	Tyr	Ala	Glu	Arg	Val	Tyr	Phe	Leu
	50					55					60				
Asn	Ser	Thr	Met	Ala	Ser	Asn	Asn	Met	Thr	Leu	Phe	Phe	Arg	Asn	Ala
65				70						75				80	
Ser	Glu	Asp	Asp	Val	Gly	Tyr	Tyr	Ser	Cys	Ser	Leu	Tyr	Thr	Tyr	Pro
			85					90						95	
Gln	Gly	Thr	Trp	Gln	Lys	Val	Ile	Gln	Val	Val	Gln	Ser	Asp	Ser	Phe
			100					105					110		
Glu	Ala	Ala	Val	Pro	Ser	Asn	Ser	His	Ile	Val	Ser	Glu	Pro	Gly	Lys
		115					120					125			
Asn	Val	Thr	Leu	Thr	Cys	Gln	Pro	Gln	Met	Thr	Trp	Pro	Val	Gln	Ala
	130					135					140				
Val	Arg	Trp	Glu	Lys	Ile	Gln	Pro	Arg	Gln	Ile	Asp	Leu	Leu	Thr	Tyr
145					150					155					160
Cys	Asn	Leu	Val	His	Gly	Arg	Asn	Phe	Thr	Ser	Lys	Phe	Pro	Arg	Gln
				165					170					175	
Ile	Val	Ser	Asn	Cys	Ser	His	Gly	Arg	Trp	Ser	Val	Ile	Val	Ile	Pro
			180					185					190		
Asp	Val	Thr	Val	Ser	Asp	Ser	Gly	Leu	Tyr	Arg	Cys	Tyr	Leu	Gln	Ala
		195					200					205			
Ser	Ala	Gly	Glu	Asn	Glu	Thr	Phe	Val	Met	Arg	Leu	Thr	Val	Ala	Glu
	210					215					220				
Gly	Lys	Thr	Asp	Asn	Gln	Tyr	Thr	Leu	Phe	Val	Ala				
225					230					235					

761612000240SeqList

<210> 50
 <211> 185
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD2 ECD

<400> 50
 Lys Glu Ile Thr Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp
 1 5 10 15
 Ile Asn Leu Asp Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp
 20 25 30
 Ile Lys Trp Glu Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg
 35 40 45
 Lys Glu Lys Glu Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys
 50 55 60
 Asn Gly Thr Leu Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile
 65 70 75 80
 Tyr Lys Val Ser Ile Tyr Asp Thr Lys Gly Lys Asn Val Leu Glu Lys
 85 90 95
 Ile Phe Asp Leu Lys Ile Gln Glu Arg Val Ser Lys Pro Lys Ile Ser
 100 105 110
 Trp Thr Cys Ile Asn Thr Thr Leu Thr Cys Glu Val Met Asn Gly Thr
 115 120 125
 Asp Pro Glu Leu Asn Leu Tyr Gln Asp Gly Lys His Leu Lys Leu Ser
 130 135 140
 Gln Arg Val Ile Thr His Lys Trp Thr Thr Ser Leu Ser Ala Lys Phe
 145 150 155 160
 Lys Cys Thr Ala Gly Asn Lys Val Ser Lys Glu Ser Ser Val Glu Pro
 165 170 175
 Val Ser Cys Pro Glu Lys Gly Leu Asp
 180 185

<210> 51
 <211> 133
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD160 ECD

<400> 51
 Ile Asn Ile Thr Ser Ser Ala Ser Gln Glu Gly Thr Arg Leu Asn Leu
 1 5 10 15
 Ile Cys Thr Val Trp His Lys Lys Glu Glu Ala Glu Gly Phe Val Val
 20 25 30
 Phe Leu Cys Lys Asp Arg Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu
 35 40 45
 Lys Gln Leu Arg Leu Lys Arg Asp Pro Gly Ile Asp Gly Val Gly Glu
 50 55 60
 Ile Ser Ser Gln Leu Met Phe Thr Ile Ser Gln Val Thr Pro Leu His
 65 70 75 80
 Ser Gly Thr Tyr Gln Cys Cys Ala Arg Ser Gln Lys Ser Gly Ile Arg
 85 90 95
 Leu Gln Gly His Phe Phe Ser Ile Leu Phe Thr Glu Thr Gly Asn Tyr
 100 105 110
 Thr Val Thr Gly Leu Lys Gln Arg Gln His Leu Glu Phe Ser His Asn
 115 120 125
 Glu Gly Thr Leu Ser
 130

761612000240SeqList

<210> 52
 <211> 202
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD200 ECD

<400> 52
 Gln Val Gln Val Val Thr Gln Asp Glu Arg Glu Gln Leu Tyr Thr Pro
 1 5 10 15
 Ala Ser Leu Lys Cys Ser Leu Gln Asn Ala Gln Glu Ala Leu Ile Val
 20 25 30
 Thr Trp Gln Lys Lys Lys Ala Val Ser Pro Glu Asn Met Val Thr Phe
 35 40 45
 Ser Glu Asn His Gly Val Val Ile Gln Pro Ala Tyr Lys Asp Lys Ile
 50 55 60
 Asn Ile Thr Gln Leu Gly Leu Gln Asn Ser Thr Ile Thr Phe Trp Asn
 65 70 75 80
 Ile Thr Leu Glu Asp Glu Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe
 85 90 95
 Gly Phe Gly Lys Ile Ser Gly Thr Ala Cys Leu Thr Val Tyr Val Gln
 100 105 110
 Pro Ile Val Ser Leu His Tyr Lys Phe Ser Glu Asp His Leu Asn Ile
 115 120 125
 Thr Cys Ser Ala Thr Ala Arg Pro Ala Pro Met Val Phe Trp Lys Val
 130 135 140
 Pro Arg Ser Gly Ile Glu Asn Ser Thr Val Thr Leu Ser His Pro Asn
 145 150 155 160
 Gly Thr Thr Ser Val Thr Ser Ile Leu His Ile Lys Asp Pro Lys Asn
 165 170 175
 Gln Val Gly Lys Glu Val Ile Cys Gln Val Leu His Leu Gly Thr Val
 180 185 190
 Thr Asp Phe Lys Gln Thr Val Asn Lys Gly
 195 200

<210> 53
 <211> 215
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD200R1(CD200R) ECD

<400> 53
 Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val Leu Ala Glu
 1 5 10 15
 Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala Val Leu Cys
 20 25 30
 Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr Trp Glu Ile
 35 40 45
 Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Arg Lys Glu Thr
 50 55 60
 Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile Thr Trp Val
 65 70 75 80
 Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Pro Val Ala Ile
 85 90 95
 Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro Asp Gly Asn
 100 105 110
 Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro Glu Val Thr
 115 120 125
 Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala Val Ala Gly
 130 135 140
 Lys Pro Ala Ala Gln Ile Ser Trp Ile Pro Glu Gly Asp Cys Ala Thr
 145 150 155 160

761612000240SeqList

Lys	Gln	Glu	Tyr	Trp	Ser	Asn	Gly	Thr	Val	Thr	Val	Lys	Ser	Thr	Cys
				165					170					175	
His	Trp	Glu	Val	His	Asn	Val	Ser	Thr	Val	Thr	Cys	His	Val	Ser	His
			180					185					190		
Leu	Thr	Gly	Asn	Lys	Ser	Leu	Tyr	Ile	Glu	Leu	Leu	Pro	Val	Pro	Gly
		195					200					205			
Ala	Lys	Lys	Ser	Ala	Lys	Leu									
	210					215									

<210> 54
 <211> 117
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> NC R3 (NKp30) ECD

<400> 54

Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser
1				5					10					15	
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu	Ala	Ile
			20				25						30		
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val
		35					40					45			
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Ser
	50					55					60				
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65				70						75				80	
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu	Lys	Glu
			100					105					110		
His	Pro	Gln	Leu	Gly											
		115													

<210> 55
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v1 ECD

<400> 55

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55				60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
			85						90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150						155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr

761612000240SeqList

Asn	His	Ser	Phe	165	Cys	Leu	Ile	Lys	170	Gly	His	Leu	Arg	175	Val	Asn
			180	Met					185	Tyr				190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn	
		195					200					205				

<210> 56
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v2 ECD

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
		20						25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
			85						90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150						155				160	
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
			165					170					175		
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 57
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v3 ECD

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
		20						25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
			85						90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ala	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys

761612000240SeqList

Ser	Ala	115	Ser	Gly	Gly	Phe	Pro	120	Glu	Pro	His	Leu	Ser	125	Trp	Leu	Glu	Asn
	130						135							140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu			
145					150					155					160			
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr			
				165					170						175			
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn			
			180					185						190				
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn			
		195					200					205						

<210> 58
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v4 ECD

<400> 58

Val	Ile	His	Met	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70				75						80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
			85					90						95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100				105						110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys	
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150						155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165				170						175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 59
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v5 ECD

<400> 59

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr

761612000240SeqList

```

65      70      75      80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
      100      105      110
Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
      115      120      125
Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
      130      135      140
Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
      145      150      155      160
Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
      165      170      175
Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
      180      185      190
Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
      195      200      205

```

<210> 60
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v6 ECD

```

<400> 60
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10      15
Gly His Asn Leu Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ser Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
      100      105      110
Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
      115      120      125
Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
      130      135      140
Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
      145      150      155      160
Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
      165      170      175
Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
      180      185      190
Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
      195      200      205

```

<210> 61
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v7 ECD

```

<400> 61
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10      15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp

```


761612000240SeqList

<223> CD80 v9 ECD

<400> 63

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 64

<211> 208

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v10 ECD

<400> 64

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Arg	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

761612000240SeqList

<210> 65
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v11 ECD

<400> 65
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Ala Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Thr Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 66
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v12 ECD

<400> 66
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Asn Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175

761612000240SeqList

Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 67
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v13 ECD

<400> 67

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Ser	Arg	Ile	Tyr	Trp
		20						25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Lys	His
			85					90						95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100				105						110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115				120						125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150						155				160	
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
			165					170						175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 68
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v14 ECD

<400> 68

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
		20						25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Ser	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
			85					90						95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100				105						110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115				120						125			

761612000240SeqList

Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 69
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v15 ECD

<400> 69

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
		20					25					30			
Gln	Lys	Glu	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn	
		35				40					45				
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Thr	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70				75						80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
			85					90					95		
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100				105					110			
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115				120					125				
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Thr	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165				170						175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 70
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v16 ECD

<400> 70

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
		20					25					30			
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35				40					45				
Ile	Trp	Pro	Gly	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70				75						80	

761612000240SeqList

Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 71
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v17 ECD

<400> 71

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Glu	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Ser	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75				80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 72
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v18 ECD

<400> 72

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		

761612000240SeqList

Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Pro	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 73
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v19 ECD

<400> 73

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Glu	Asp	Ala	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 74
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v20 ECD

761612000240SeqList

<400> 74

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
		130				135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 75

<211> 208

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v21 ECD

<400> 75

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Val	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Ala	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
		130				135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 76

761612000240SeqList

<211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v22 ECD

<400> 76
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Met Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 77
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v23 ECD

<400> 77
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Thr Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Gly Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Thr Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

761612000240SeqList

Gln Thr Phe 180 Asn Trp Asn Thr Thr 185 Lys Gln Glu His Phe 190 Pro Asp Asn
 195 200 205

<210> 78
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v24 ECD

<400> 78
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr His Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Gly Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Arg Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Gly Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 79
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v25 ECD

<400> 79
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile His Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Gly Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn

	130					135					140					
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu	
145					150					155					160	
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr	
				165					170					175		
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn	
			180					185					190			
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn	
		195					200					205				

<220>
<223> CD80 v26 ECD

<400>	80														
Val 1	Ile	His	Val	Thr 5	Lys	Glu	Val	Lys	Glu 10	Val	Ala	Thr	Leu	Ser 15	Cys
Gly	His	Asn	Val 20	Ser	Val	Glu	Glu	Leu 25	Ala	Gln	Thr	Arg	Ile 30	Tyr	Trp
Gln	Lys	Glu 35	Lys	Lys	Met	Val	Leu 40	Thr	Met	Met	Ser	Gly 45	Asp	Met	Asn
Ile	Trp 50	Pro	Glu	Tyr	Lys	Asn 55	Arg	Thr	Ile	Phe	Asp 60	Ile	Thr	Asn	Asn
Leu 65	Ser	Ile	Ala	Ile	Leu 70	Ala	Leu	Arg	Pro	Ser 75	Asp	Glu	Gly	Thr	Tyr 80
Glu	Cys	Val	Val	Leu 85	Lys	Tyr	Glu	Lys	Asp 90	Ala	Phe	Lys	Arg	Glu 95	His
Leu	Ala	Glu	Val 100	Thr	Leu	Ser	Val	Lys 105	Ala	Asp	Phe	Pro	Ala 110	Pro	Ser
Ile	Ser	Asp 115	Phe	Glu	Ile	Pro	Thr 120	Ser	Asn	Ile	Arg	Arg 125	Ile	Ile	Cys
Ser	Thr 130	Ser	Gly	Gly	Phe	Pro 135	Glu	Pro	His	Leu	Ser 140	Trp	Leu	Glu	Asn
Gly 145	Glu	Glu	Leu	Asn	Ala 150	Ile	Asn	Thr	Thr	Val 155	Ser	Gln	Asp	Pro	Glu 160
Thr	Glu	Leu	Tyr	Ala 165	Val	Ser	Ser	Lys	Leu	Asp 170	Phe	Asn	Met	Thr	Thr
Asn	His	Ser	Phe 180	Met	Cys	Leu	Ile	Lys 185	Tyr	Gly	His	Leu	Arg 190	Val	Asn
Gln	Thr	Phe 195	Asn	Trp	Asn	Thr	Thr 200	Lys	Gln	Glu	His	Phe 205	Pro	Asp	Asn

<220>
<223> CD80 v27 ECD

<400> 81																
Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys	
1				5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp	
			20					25					30			
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn	
		35					40					45				
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn	
	50					55					60					
Leu	His	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr	
65					70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Gly	Ala	Phe	Lys	Arg	Glu	His	

761612000240SeqList

```

      85      90      95
Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Ala Pro Ser
      100      105      110
Ile Ser Asp Leu Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
      115      120      125
Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
      130      135      140
Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
145      150      155      160
Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
      165      170      175
Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
      180      185      190
Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
      195      200      205

```

<210> 82
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v28 ECD

```

<400> 82
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10      15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr His Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Gly Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
      100      105      110
Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
      115      120      125
Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
      130      135      140
Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
145      150      155      160
Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
      165      170      175
Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
      180      185      190
Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
      195      200      205

```

<210> 83
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v29 ECD

```

<400> 83
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10      15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn

```

761612000240SeqList

Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
50						55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Ser	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150						155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 84
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v30 ECD

<400> 84

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50				55						60				
Leu	Ser	Thr	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70						75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150						155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 85
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v31 ECD

761612000240SeqList

<400> 85
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Ala Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 86
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v32 ECD

<400> 86
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Val Val Leu Asp Met Ile Ser Gly Asp Met Asn
 35 40 45
 Ile Gly Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Gly Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Ala Val Leu Lys Tyr Glu Glu Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 87
 <211> 208

761612000240SeqList

<212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v33 ECD

<400> 87
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Ala Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Thr Pro Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 88
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v34 ECD

<400> 88
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Val Thr Leu Phe Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile His Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Gly Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Leu His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Thr Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190

761612000240SeqList

Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 89
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v35 ECD

<400> 89
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Phe Val Ile Arg Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Gly Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205

<210> 90
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v36 ECD

<400> 90
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Gly Pro Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140

761612000240SeqList

Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 91
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v37 ECD

<400> 91

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55				60					
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70				75						80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Leu	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Leu	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Ser	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 92
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v38 ECD

<400> 92

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Asp	Ile	Leu	Trp
			20					25					30		
His	Lys	Glu	Gly	Lys	Ile	Val	Leu	Ala	Met	Arg	Ser	Gly	Asp	Thr	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55				60					
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70				75						80
Val	Cys	Val	Val	Arg	Lys	Tyr	Glu	Asn	Asp	Thr	Pro	Val	Leu	Glu	His
				85					90					95	

761612000240SeqList

Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Thr	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
		130				135					140				
Gly	Glu	Glu	Leu	Ser	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 93
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v39 ECD

<400> 93

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Asp	Ile	Leu	Trp
			20					25					30		
His	Lys	Glu	Gly	Lys	Ile	Val	Leu	Ala	Met	Arg	Ser	Gly	Asp	Thr	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Val	Cys	Val	Val	Arg	Lys	Tyr	Glu	Asn	Asp	Thr	Pro	Val	Leu	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Ser
		130				135					140				
Gly	Glu	Glu	Leu	Ser	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 94
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v40 ECD

<400> 94

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Asp	Ile	Leu	Trp
			20					25					30		
His	Lys	Glu	Gly	Lys	Ile	Val	Leu	Ala	Thr	Arg	Ser	Gly	Asp	Thr	Asn
		35					40					45			

761612000240SeqList

Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
50						55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Val	Cys	Val	Val	Arg	Lys	Tyr	Glu	Asn	Asp	Thr	Pro	Val	Leu	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Ser	Ser	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 95
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v41 ECD

<400> 95

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Gly	Leu	Ala	Gln	Thr	Asp	Ile	Leu	Trp
			20					25				30			
His	Lys	Glu	Gly	Lys	Ile	Val	Leu	Ala	Met	Arg	Ser	Gly	Asp	Thr	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Leu	Asp	Ile	Thr	Asn	Asn
	50				55						60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Val	Cys	Val	Val	Arg	Lys	Tyr	Glu	Asn	Asp	Thr	Pro	Val	Leu	Glu	Arg
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Ser	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Ser	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 96
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v42 ECD

<400> 96

761612000240SeqList

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Asp	Ile	Leu	Trp
			20					25					30		
His	Lys	Glu	Gly	Lys	Ile	Val	Leu	Ala	Met	Arg	Ser	Gly	Asp	Thr	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Val	Cys	Val	Val	Arg	Lys	Tyr	Glu	Asn	Asp	Thr	Pro	Val	Leu	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Ser	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 97
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v43 ECD

<400> 97

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Val	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Gln	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Arg	Cys	Val	Val	Ile	Lys	Tyr	Glu	Arg	Leu	Glu	Asn	Gln	Gly	Glu	His
				85					90				95		
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 98
 <211> 208
 <212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v44 ECD

<400> 98

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Ile	Met	Met	Ser	Gly	Asp	Met	Asn
			35				40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
		130				135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 99

<211> 208

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v45 ECD

<400> 99

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
			35				40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Arg	Lys	Gly	Tyr	Arg	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Ser	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
		130				135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155					160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
				165					170					175	
Ser	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn

195

<210> 100
<211> 208
<212> PRT
<213> Artificial Sequence

<220>
<223> CD80 v46 ECD

<400> 100
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1 5 10 15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
20 25 30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
35 40 45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
50 55 60
Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65 70 75 80
Glu Cys Val Val Leu Lys Tyr Glu Arg Lys Gly Tyr Arg Arg Glu His
85 90 95
Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
100 105 110
Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
115 120 125
Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
130 135 140
Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
145 150 155 160
Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
165 170 175
Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
180 185 190
Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
195 200 205

<210> 101
<211> 208
<212> PRT
<213> Artificial Sequence

<220>
<223> CD80 v47 ECD

<400> 101
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1 5 10 15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
20 25 30
Gln Lys Glu Gly Gln Ile Val Leu Thr Met Met Ser Gly Asp Met Asn
35 40 45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Leu Asp Ile Thr Asn Asn
50 55 60
Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65 70 75 80
Val Cys Val Val Arg Lys Tyr Glu Asn Asp Thr Pro Val Leu Glu His
85 90 95
Leu Ala Gly Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
100 105 110
Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile Ile Cys
115 120 125
Ser Ala Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
130 135 140
Gly Glu Glu Leu Ser Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu

761612000240SeqList

145	Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr	160
					165					170						175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn		
			180					185					190				
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn		
		195					200					205					

<210> 102
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v48 ECD

<400>	102																
Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys		
1				5					10					15			
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp		
			20					25					30				
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn		
		35				40						45					
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn		
	50				55					60							
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr		
65				70					75						80		
Glu	Cys	Val	Val	Leu	Lys	Tyr	Asp	Arg	Lys	Gly	Tyr	Arg	Arg	Glu	His		
			85					90					95				
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser		
			100					105					110				
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys		
		115					120					125					
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn		
	130					135					140						
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu		
145				150					155						160		
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr		
				165				170						175			
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn		
			180					185					190				
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn		
		195					200					205					

<210> 103
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v49 ECD

<400>	103																
Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys		
1				5					10					15			
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp		
			20					25					30				
Gln	Lys	Glu	Gly	Gln	Ile	Val	Met	Thr	Met	Met	Ser	Gly	Asp	Met	Asn		
		35				40						45					
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn		
	50				55					60							
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr		
65				70					75						80		
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Ala	Phe	Lys	Arg	Glu	His		
			85					90					95				
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser		

761612000240SeqList

Ile	Ser	Asp	100	Phe	Glu	Ile	Pro	Thr	105	Ser	Asn	Ile	Arg	Arg	110	Ile	Ile	Cys
Ser	Thr	Ser	115	Gly	Gly	Phe	Pro	Glu	120	Pro	His	Leu	Ser	Trp	125	Leu	Glu	Asn
Gly	130	Glu	Glu	Leu	Asn	Ala	135	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu	140
145	Thr	Glu	Leu	Tyr	Ala	150	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr	155
Asn	His	Ser	165	Phe	Met	Cys	Leu	Ile	Lys	170	Tyr	Gly	His	Leu	Arg	Val	Asn	175
Gln	Thr	Phe	180	Asn	Trp	Asn	Thr	Thr	185	Lys	Gln	Glu	His	Phe	190	Pro	Asp	Asn
		195						200						205				

<210> 104
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v50 ECD

<400> 104

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10				15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
		20						25				30			
Gln	Lys	Glu	Gly	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
	35						40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55				60					
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65				70					75					80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Ala	Phe	Lys	Arg	Glu	His
			85						90				95		
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100					105					110		
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115					120					125			
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
	130					135					140				
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145				150					155						160
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
			165					170					175		
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180					185					190		
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
		195					200					205			

<210> 105
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v51 ECD

<400> 105

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10				15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	His	Ile	His	Trp
		20						25				30			
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Gly	Met	Met	Ser	Gly	Asp	Met	Asn
	35						40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn

761612000240SeqList

50	Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65	Glu	Cys	Val	Val	Leu	Lys	Asn	Gly	Glu	Asn	Gly	Phe	Lys	Arg	Glu	His
				85	Leu	Ser	Val	Lys	Ala	Asp	Phe	Ser	Thr	Pro	Ser	
			100					105						110		
	Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
			115					120						125		
	Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
			130					135					140			
	Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
	145					150					155					160
	Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
					165					170					175	
	Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
				180					185					190		
	Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
			195					200					205			

<210> 106
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v52 ECD

<400> 106	Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Thr	Thr	Leu	Ser	Cys
1	Gly	Leu	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30			
	Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Val	Ser	Gly	Asp	Met	Asn
			35					40					45			
	Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Leu	Asp	Ile	Thr	Asn	Asn
			50				55					60				
	Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Lys	Gly	Thr	Tyr
	65					70					75					80
	Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Ala	Phe	Lys	Arg	Glu	His
				85						90					95	
	Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Ser	Thr	Pro	Ser
				100					105					110		
	Ile	Ser	Asp	Phe	Glu	Thr	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
			115					120						125		
	Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
			130				135					140				
	Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
	145					150					155					160
	Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
					165					170					175	
	Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
				180					185					190		
	Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn
			195					200					205			

<210> 107
 <211> 208
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v53 ECD

<400> 107
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys

761612000240SeqList

1				5					10				15				
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Val	Ile	Phe	Trp		
			20					25					30				
Gln	Lys	Glu	Gly	Lys	Leu	Val	Leu	Thr	Met	Gln	Ser	Gly	Asp	Met	Asn		
		35					40					45					
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn		
	50					55					60						
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr		
65					70					75					80		
Arg	Cys	Ile	Val	Ile	Lys	Tyr	Glu	Arg	Leu	Glu	Asn	Gln	Gly	Glu	His		
			85						90					95			
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser		
			100					105					110				
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys		
		115					120					125					
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn		
	130					135					140						
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu		
145					150					155					160		
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr		
				165					170					175			
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn		
			180					185					190				
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn		
		195					200					205					

<210> 108

<211> 208

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v54 ECD

<400> 108

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys		
1				5					10				15				
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp		
			20					25					30				
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn		
		35					40					45					
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn		
	50					55					60						
Leu	Ser	Ile	Met	Ile	Pro	Ala	Pro	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr		
65					70					75					80		
Glu	Cys	Val	Val	Leu	Glu	Tyr	Glu	Lys	Asp	Ala	Phe	Lys	Arg	Glu	His		
			85						90					95			
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser		
			100					105					110				
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys		
		115					120					125					
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn		
	130					135					140						
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu		
145					150					155					160		
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr		
				165					170					175			
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn		
			180					185					190				
Gln	Thr	Phe	Asn	Trp	Asn	Thr	Thr	Lys	Gln	Glu	His	Phe	Pro	Asp	Asn		
		195					200					205					

<210> 109

<211> 238

<212> PRT

<213> Artificial Sequence

761612000240SeqList

<220>

<223> ICOSL v1 ECD

<400> 109

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
100     105     110
Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
115
His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
130     135     140
Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
145     150     155
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
165     170     175
Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
180     185     190
Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
195     200     205
Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
210     215     220
Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
225     230     235

```

<210> 110

<211> 238

<212> PRT

<213> Artificial Sequence

<220>

<223> ICOSL v2 ECD

<400> 110

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
100     105     110
Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
115
His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
130     135     140
Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
145     150     155
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
165     170     175

```

761612000240SeqList

Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 111
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v3 ECD

<400> 111

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
		20						25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Asp	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85					90						95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165					170						175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 112
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v4 ECD

<400> 112

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
		20						25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Tyr	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				

761612000240SeqList

Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70				75						80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Leu	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Pro	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 113
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v5 ECD

<400> 113

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	His	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55				60					
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70				75						80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Pro	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 114
 <211> 238
 <212> PRT

<213> Artificial Sequence

<220>

<223> ICOSL v6 ECD

<400> 114

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
100     105     110
Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
115     120     125
His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
130     135     140
Gly Cys Pro Arg Pro Asn Val Cys Trp Ile Asn Lys Thr Asp Asn Ser
145     150     155     160
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
165     170     175
Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
180     185     190
Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
195     200     205
Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
210     215     220
Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
225     230     235

```

<210> 115

<211> 238

<212> PRT

<213> Artificial Sequence

<220>

<223> ICOSL v7 ECD

<400> 115

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
100     105     110
Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
115     120     125
His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
130     135     140
Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
145     150     155     160
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg

```

Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
Val	Asn	Ile	Gly	Cys	Arg	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		

<400> 1	116															
Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val	
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His	
Ile	Pro	Gln	His	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn	
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu	
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val	
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro	
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Asp	Thr	Ser	Ile	Asn	
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser	
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser	
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu	
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile	
Ala	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr			

<400>	117															
Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu	
1				5					10					15		
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val	
			20					25					30			
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His	
		35					40					45				
Ile	Pro	Gln	His	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn	

761612000240SeqList

50	Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65	Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85							90					95	
	Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100						105					110		
	Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
			115					120					125			
	His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
			130				135					140				
	Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145						150					155					160
	Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165						170					175	
	Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180						185					190		
	Val	Asn	Ile	Gly	Cys	Arg	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
			195					200					205			
	Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
			210				215					220				
225	Ala	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
						230					235					

<210> 118
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v10 ECD

<400> 118

1	Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
				5						10					15	
	Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20						25					30		
	Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
			35					40					45			
	Ile	Pro	Gln	His	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
			50				55					60				
	Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65						70					75					80
	Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Arg	Phe	His	Cys	Leu
				85						90					95	
	Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100						105					110		
	Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
			115					120					125			
	His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
			130				135					140				
	Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145						150					155					160
	Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165						170					175	
	Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180						185					190		
	Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
			195					200					205			
	Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
			210				215					220				
225	Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
						230					235					

<210> 119
 <211> 238

761612000240SeqList

<212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v11 ECD

<400> 119
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Gly Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
 145 150 155 160
 Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
 165 170 175
 Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
 180 185 190
 Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
 195 200 205
 Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
 210 215 220
 Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
 225 230 235

<210> 120
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v12 ECD

<400> 120
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Tyr Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
 145 150 155 160

761612000240SeqList

Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 121
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v13 ECD

<400> 121

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70				75					80	
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155				160	
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 122
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v14 ECD

<400> 122

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			

761612000240SeqList

Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
50	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Pro	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Asn	Leu	
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 123
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v15 ECD

<400> 123

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Ser	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Gly	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Cys	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Asn	Leu	
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 124

761612000240SeqList

<211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v16 ECD

<400> 124
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Cys Trp Ile Asn Lys Thr Asp Asn Ser
 145 150 155 160
 Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
 165 170 175
 Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
 180 185 190
 Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
 195 200 205
 Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
 210 215 220
 Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
 225 230 235

<210> 125
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v17 ECD

<400> 125
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser

761612000240SeqList

```

145      150      155      160
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
      165      170
Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
      180      185      190
Val Asn Ile Gly Cys Arg Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
      195      200      205
Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
      210      215      220
Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
225      230      235

```

<210> 126
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v18 ECD

```

<400> 126
Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
      20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
      35      40      45
Ile Pro Gln Tyr Ser Ser Leu Glu Tyr Val Asp Ser Arg Tyr Arg Asn
      50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
      85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
      100      105      110
Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
      115      120      125
His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
      130      135      140
Gly Tyr Pro Arg Pro Asn Val Cys Trp Ile Asn Lys Thr Asp Asn Ser
145      150      155      160
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
      165      170      175
Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
      180      185      190
Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
      195      200      205
Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
      210      215      220
Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
225      230      235

```

<210> 127
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v19 ECD

```

<400> 127
Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
      20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His

```

761612000240SeqList

Ile	Pro	35	Gln	Tyr	Ser	Ser	Leu	40	Glu	Tyr	Val	Asp	Ser	45	Arg	Tyr	Arg	Asn
Arg	Ala	50	Leu	Met	Ser	Pro	Ala	55	Gly	Met	Leu	Arg	Gly	60	Asp	Phe	Ser	Leu
65	Arg	Leu	Phe	Asn	Val	70	Thr	Pro	Gln	Asp	Glu	75	Gln	Lys	Phe	His	Cys	Leu
				85							90					95		
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val			
			100						105					110				
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro			
		115					120						125					
Pro	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn			
	130					135					140							
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser			
145					150					155					160			
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg			
				165					170					175				
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser			
			180						185				190					
Val	Asn	Ile	Gly	Cys	Arg	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu			
		195					200					205						
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile			
	210					215					220							
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr					
225					230					235								

<210> 128
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v20 ECD

<400> 128

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
		20					25						30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	His	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65				70					75					80	
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90				95		
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150				155						160
Pro	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Arg	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

761612000240SeqList

<210> 129
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v21 ECD

<400> 129
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Glu Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
 145 150 155 160
 Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
 165 170 175
 Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
 180 185 190
 Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
 195 200 205
 Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
 210 215 220
 Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
 225 230 235

<210> 130
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v22 ECD

<400> 130
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Asn Ser Ala Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140

761612000240SeqList

Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 131
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v23 ECD

<400> 131

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Asp	Ser	Pro	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50				55					60					
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65				70					75						80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85					90					95		
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
	115						120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130				135						140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 132
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v24 ECD

<400> 132

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		

761612000240SeqList

Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40				45				
Ile	Pro	Gln	Lys	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Pro
	195						200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 133
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v25 ECD

<400> 133

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
		20						25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40				45				
Ile	Pro	Gln	Ser	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85						90					95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	His	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
	195						200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

761612000240SeqList

<210> 134
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v26 ECD

<400> 134
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Asp Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Ala Tyr Trp Ile Asn Lys Thr Asp Asn Ser
 145 150 155 160
 Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
 165 170 175
 Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
 180 185 190
 Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
 195 200 205
 Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
 210 215 220
 Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
 225 230 235

<210> 135
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v27 ECD

<400> 135
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Thr Asn

	130					135					140				
Gly 145	Tyr	Pro	Arg	Pro	Asn 150	Val	Tyr	Trp	Ile	Asn 155	Lys	Thr	Asp	Asn	Ser 160
Leu	Leu	Asp	Gln	Ala 165	Leu	Gln	Asn	Asp	Thr 170	Val	Phe	Leu	Asn	Met 175	Arg
Gly	Leu	Tyr	Asp 180	Val	Val	Ser	Val	Leu 185	Arg	Ile	Ala	Arg	Thr 190	Pro	Ser
Val	Asn	Ile 195	Gly	Cys	Cys	Ile	Glu 200	Asn	Val	Leu	Leu	Gln 205	Asn	Leu	
Thr	Val 210	Gly	Ser	Gln	Thr	Gly 215	Asn	Asp	Ile	Gly	Glu 220	Arg	Asp	Lys	Ile
Thr 225	Glu	Asn	Pro	Val	Ser 230	Thr	Gly	Glu	Lys	Asn 235	Ala	Ala	Thr		

<220>
<223> ICOSL v28 ECD

<210>	137
<211>	238
<212>	PRT
<213>	Artificial Sequence

<400> 137
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val

761612000240SeqList

<210> 139
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v31 ECD

<400> 139
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Gly Asn Ser
 145 150 155 160
 Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
 165 170 175
 Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
 180 185 190
 Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln Asn Leu
 195 200 205
 Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
 210 215 220
 Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
 225 230 235

<210> 140
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v32 ECD

<400> 140
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Asp Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125

761612000240SeqList

His	Ser	Pro	Ser	His	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 141
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v33 ECD

<400> 141

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Ser	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	Asp	Cys	Phe
			85					90						95	
Val	Phe	Ser	Arg	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100				105						110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 142
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v34 ECD

<400> 142

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	

761612000240SeqList

Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Ser	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	Asp	Cys	Phe
			85						90					95	
Val	Phe	Ser	Arg	Ser	Leu	Glu	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Ser	Val	Pro	Val	Val	Ser	Ala	Pro	
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
			165						170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr		
225					230					235					

<210> 143
 <211> 117
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> NKp30 v1 ECD

<400> 143

Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser
1				5					10					15	
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Val	Ala	Ile
			20					25					30		
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val
		35					40					45			
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Val	Pro	Leu	Ala	Pro
	50					55				60					
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65					70					75					80
Arg	Gly	His	Asp	Ala	Gly	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu	Lys	Glu
			100					105					110		
His	Pro	Gln	Leu	Gly											
		115													

<210> 144
 <211> 117
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> NKp30 v2 ECD

<400> 144

Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser
1				5					10					15	

761612000240SeqList

Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Val	Ala	Ile
			20					25					30		
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val
		35					40					45			
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Ser
	50					55					60				
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65					70					75				80	
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu	Lys	Glu
			100					105					110		
His	Pro	Gln	Leu	Gly											
			115												

<210> 145
 <211> 117
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> NKp30 v3 ECD

<400> 145

Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser
1				5					10					15	
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu	Ala	Ile
			20					25					30		
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val
		35					40					45			
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Val	Pro	Leu	Ala	Ser
	50					55					60				
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65					70					75				80	
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu	Lys	Glu
			100					105					110		
His	Pro	Gln	Leu	Gly											
			115												

<210> 146
 <211> 117
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> NKp30 v4 ECD

<400> 146

Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser
1				5					10					15	
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu	Ala	Ile
			20					25					30		
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val
		35					40					45			
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Pro
	50					55					60				
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65					70					75				80	
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu	Lys	Glu
			100					105					110		
His	Pro	Gln	Leu	Gly											
			115												

761612000240SeqList

<210> 147
 <211> 117
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> NKp30 v5 ECD

<400> 147
 Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
 1 5 10 15
 Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
 20 25 30
 Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
 35 40 45
 Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
 50 55 60
 Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
 65 70 75 80
 Arg Gly His Asp Ala Gly Ile Tyr Val Cys Arg Val Glu Val Leu Gly
 85 90 95
 Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu
 100 105 110
 His Pro Gln Leu Gly
 115

<210> 148
 <211> 224
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD86 v1 ECD

<400> 148
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro
 1 5 10 15
 Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val
 20 25 30
 Phe Trp His Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly
 35 40 45
 Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser
 50 55 60
 Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys
 65 70 75 80
 Asp Lys Gly Leu Tyr Gln Cys Ile Ile Leu His Lys Lys Pro Thr Gly
 85 90 95
 Met Ile Arg Ile His His Met Asn Ser Glu Leu Ser Val Leu Ala Asn
 100 105 110
 Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val
 115 120 125
 Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys
 130 135 140
 Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp
 145 150 155 160
 Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val
 165 170 175
 Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr
 180 185 190
 Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro
 195 200 205
 Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro
 210 215 220

761612000240SeqList

<210> 149
 <211> 224
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD86 v2 ECD

<400> 149
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro
 1 5 10 15
 Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val
 20 25 30
 Phe Trp His Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly
 35 40 45
 Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser
 50 55 60
 Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys
 65 70 75 80
 Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly
 85 90 95
 Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn
 100 105 110
 Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val
 115 120 125
 Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys
 130 135 140
 Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp
 145 150 155 160
 Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val
 165 170 175
 Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr
 180 185 190
 Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro
 195 200 205
 Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Asp His Ile Pro
 210 215 220

<210> 150
 <211> 224
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD86 v3 ECD

<400> 150
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro
 1 5 10 15
 Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val
 20 25 30
 Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly
 35 40 45
 Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser
 50 55 60
 Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys
 65 70 75 80
 Asp Lys Gly Leu Tyr Gln Cys Ile Ile Leu His Lys Lys Pro Thr Gly
 85 90 95
 Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn
 100 105 110
 Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val
 115 120 125
 Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys
 130 135 140
 Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp

761612000240SeqList

145 150 155 160
 Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val
 165 170 175
 Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr
 180 185 190
 Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro
 195 200 205
 Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro
 210 215 220

<210> 151
 <211> 224
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD86 v4 ECD

<400> 151
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro
 1 5 10 15
 Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val
 20 25 30
 Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly
 35 40 45
 Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser
 50 55 60
 Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys
 65 70 75 80
 Asp Lys Gly Leu Tyr Gln Cys Ile Ile His Lys Lys Pro Thr Gly
 85 90 95
 Met Ile Arg Ile His His Met Asn Ser Glu Leu Ser Val Leu Ala Asn
 100 105 110
 Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val
 115 120 125
 Tyr Ile Asn Leu Thr Cys Ser Ile His Gly Tyr Pro Glu Pro Lys
 130 135 140
 Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp
 145 150 155 160
 Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val
 165 170 175
 Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr
 180 185 190
 Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro
 195 200 205
 Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro
 210 215 220

<210> 152
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 WT IgV

<400> 152
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr

65 70 75 80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
Leu Ala Glu Val Thr 90 95

100

<220>
<223> CD80 v1 IgV

<210>	154
<211>	101
<212>	PRT
<213>	Artificial Sequence

[illegible]

<220>
<223> CD80 v6 IgV

<400> 155
Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1 5 10 15

761612000240SeqList

Gly	His	Asn	Leu	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Ser	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 156
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v7 IgV

<400> 156

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Pro	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 157
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v9 IgV

<400> 157

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1			5					10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 158
 <211> 101
 <212> PRT
 <213> Artificial Sequence

761612000240SeqList

<220>

<223> CD80 v10 IgV

<400> 158

```

Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Arg Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr
      100

```

<210> 159

<211> 101

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v11 IgV

<400> 159

```

Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Ala Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr
      100

```

<210> 160

<211> 101

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v12 IgV

<400> 160

```

Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Asn Glu Lys Asp Gly Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr

```

100

<210> 161
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v13 IgV

<400> 161
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Ser Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Lys His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 162
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v14 IgV

<400> 162
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Ser Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 163
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v15 IgV

<400> 163
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Glu Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45

761612000240SeqList

Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
50						55				60					
Leu	Ser	Thr	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 164
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v16 IgV

<400> 164

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Gly	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
50					55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 165
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v17 IgV

<400> 165

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Glu	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Ser	Asp	Ile	Thr	Asn	Asn
50					55					60					
Leu	Ser	Ile	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 166
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v19 IgV

761612000240SeqList

<400> 166
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Glu Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 167
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v21 IgV

<400> 167
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Val Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 168
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v22 IgV

<400> 168
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Met Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 169

761612000240SeqList

<211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v23 IgV

<400> 169
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Thr Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Gly Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 170
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v24 IgV

<400> 170
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr His Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Gly Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Arg Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Gly Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 171
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v25 IgV

<400> 171
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile His Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Gly Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80

761612000240SeqList

Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 172
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v26 IgV

<400> 172
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Ala Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 173
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v27 IgV

<400> 173
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu His Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Gly Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 174
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v28 IgV

<400> 174
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr His Ile Tyr Trp

761612000240SeqList

			20					25				30			
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Gly	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Ala	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 175
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v30 IgV

<400> 175

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
	35						40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Thr	Val	Ile	Gln	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 176
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v32 IgV

<400> 176

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Val	Val	Leu	Asp	Met	Ile	Ser	Gly	Asp	Met	Asn
	35						40					45			
Ile	Gly	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Gly	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Ala	Val	Leu	Lys	Tyr	Glu	Glu	Asp	Ala	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 177
 <211> 101
 <212> PRT
 <213> Artificial Sequence

761612000240SeqList

<220>

<223> CD80 v33 IgV

<400> 177

```

Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10      15
Gly His Asn Val Ser Ala Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr
      100

```

<210> 178

<211> 101

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v34 IgV

<400> 178

```

Val Ile His Val Thr Lys Glu Val Lys Glu Val Val Thr Leu Phe Cys
1      5      10      15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile His Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Gly Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr
      100

```

<210> 179

<211> 101

<212> PRT

<213> Artificial Sequence

<220>

<223> CD80 v35 IgV

<400> 179

```

Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
1      5      10      15
Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
      20      25      30
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
      35      40      45
Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
      50      55      60
Leu Ser Phe Val Ile Arg Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
65      70      75      80
Glu Cys Val Val Leu Lys Tyr Gly Lys Asp Gly Phe Lys Arg Glu His
      85      90      95
Leu Ala Glu Val Thr
      100

```

761612000240SeqList

<210> 180
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v36 IgV

<400> 180
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Gly Pro Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 181
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v37 IgV

<400> 181
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Leu Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 182
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v38 IgV

<400> 182
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Asp Ile Leu Trp
 20 25 30
 His Lys Glu Gly Lys Ile Val Leu Ala Met Arg Ser Gly Asp Thr Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn

761612000240SeqList

50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Val Cys Val Val Arg Lys Tyr Glu Asn Asp Thr Pro Val Leu Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 183
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v40 IgV

<400> 183
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Asp Ile Leu Trp
 20 25 30
 His Lys Glu Gly Lys Ile Val Leu Ala Thr Arg Ser Gly Asp Thr Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Val Cys Val Val Arg Lys Tyr Glu Asn Asp Thr Pro Val Leu Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 184
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v41 IgV

<400> 184
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Gly Leu Ala Gln Thr Asp Ile Leu Trp
 20 25 30
 His Lys Glu Gly Lys Ile Val Leu Ala Met Arg Ser Gly Asp Thr Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Leu Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Val Cys Val Val Arg Lys Tyr Glu Asn Asp Thr Pro Val Leu Glu Arg
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 185
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v43 IgV

<400> 185

761612000240SeqList

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Val	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Gln	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Arg	Cys	Val	Val	Ile	Lys	Tyr	Glu	Arg	Leu	Glu	Asn	Gln	Gly	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 186
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v44 IgV

<400> 186

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Ile	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Gly	Phe	Lys	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 187
 <211> 101
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD80 v45 IgV

<400> 187

Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5					10					15	
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
		35					40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
	50					55					60				
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70					75					80
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Arg	Lys	Gly	Tyr	Arg	Arg	Glu	His
				85					90					95	
Leu	Ala	Glu	Val	Thr											
			100												

<210> 188

761612000240SeqList

<211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v47 IgV

<400> 188
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Gly Gln Ile Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Leu Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Val Cys Val Val Arg Lys Tyr Glu Asn Asp Thr Pro Val Leu Glu His
 85 90 95
 Leu Ala Gly Val Thr
 100

<210> 189
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v48 IgV

<400> 189
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Asp Arg Lys Gly Tyr Arg Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 190
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v49 IgV

<400> 190
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Gly Gln Ile Val Met Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80

761612000240SeqList

Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 191
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v50 IgV

<400> 191
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Gly Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 192
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v51 IgV

<400> 192
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr His Ile His Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Gly Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Asn Gly Glu Asn Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr
 100

<210> 193
 <211> 101
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 v52 IgV

<400> 193
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Thr Thr Leu Ser Cys
 1 5 10 15
 Gly Leu Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 Page 107

761612000240SeqList

<220>

<223> ICOSL WT IgV

<400> 196

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln Asn Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
100     105     110

```

<210> 197

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> ICOSL v1 IgV

<400> 197

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
100     105     110

```

<210> 198

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> ICOSL v2 IgV

<400> 198

```

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35      40      45
Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
100     105     110

```

761612000240SeqList

<210> 199
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v3 IgV

<400> 199
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Asp Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 200
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v4 IgV

<400> 200
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Tyr Ser Ser Leu Glu Tyr Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 201
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v5 IgV

<400> 201
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln His Ser Ser Leu Glu Tyr Val Asp Ser Arg Tyr Arg Asn

761612000240SeqList

50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Pro Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 202
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v10 IgV

<400> 202
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Arg Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 203
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v11 IgV

<400> 203
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Gly Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 204
 <211> 111
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> ICOSL v12 IgV

761612000240SeqList

```

<400> 204
Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
      20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
      35      40      45
Ile Pro Gln Tyr Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
      50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
      85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
      100      105      110

```

```

<210> 205
<211> 111
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> ICOSL v13 IgV

```

```

<400> 205
Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
      20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
      35      40      45
Ile Pro Gln Asn Ser Ser Leu Glu Tyr Val Asp Ser Arg Tyr Arg Asn
      50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
      85      90      95
Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
      100      105      110

```

```

<210> 206
<211> 111
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> ICOSL v14 IgV

```

```

<400> 206
Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1      5      10      15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
      20      25      30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
      35      40      45
Ile Pro Gln Asn Ser Ser Leu Glu Tyr Val Asp Ser Arg Tyr Arg Asn
      50      55      60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65      70      75      80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
      85      90      95
Val Leu Ser Pro Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
      100      105      110

```

```

<210> 207

```

761612000240SeqList

<211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v22 IgV

<400> 207
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Asn Ser Ala Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 208
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v23 IgV

<400> 208
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Asp Ser Pro Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 209
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v24 IgV

<400> 209
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Lys Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80

761612000240SeqList

Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 210
 <211> 111
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> ICOSL v28 IgV

<400> 210
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Pro
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 211
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v30 IgV

<400> 211
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Gln Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 212
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v33 IgV

<400> 212
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15

761612000240SeqList

Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Ser	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	Asp	Cys	Phe
			85						90					95	
Val	Phe	Ser	Arg	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	
			100					105					110		

<210> 213
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v34 IgV

<400> 213

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Ser	Ser	Ser	Leu	Glu	Tyr	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55					60				
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70					75					80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	Asp	Cys	Phe
			85						90					95	
Val	Phe	Ser	Arg	Ser	Leu	Glu	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	
			100					105					110		

<210> 214
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> NKp30 WT IgC-like

<400> 214

Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser
1				5					10					15	
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu	Ala	Ile
			20					25					30		
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val
		35					40					45			
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Ser
	50					55					60				
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65					70					75					80
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val				
			100					105							

<210> 215
 <211> 108
 <212> PRT
 <213> Homo sapiens

761612000240SeqList

<220>
 <221> MISC_FEATURE
 <223> NKp30 v1 IgC-like

<400> 215
 Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
 1 5 10 15
 Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Val Ala Ile
 20 25 30
 Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
 35 40 45
 Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Val Pro Leu Ala Pro
 50 55 60
 Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
 65 70 75 80
 Arg Gly His Asp Ala Gly Ile Tyr Val Cys Arg Val Glu Val Leu Gly
 85 90 95
 Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val
 100 105

<210> 216
 <211> 108
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> NKp30 v2 IgC-like

<400> 216
 Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
 1 5 10 15
 Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Val Ala Ile
 20 25 30
 Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
 35 40 45
 Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
 50 55 60
 Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
 65 70 75 80
 Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
 85 90 95
 Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val
 100 105

<210> 217
 <211> 108
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> NKp30 v3 IgC-like

<400> 217
 Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
 1 5 10 15
 Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
 20 25 30
 Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
 35 40 45
 Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Val Pro Leu Ala Ser
 50 55 60
 Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
 65 70 75 80

761612000240SeqList

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
85 90 95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val
100 105

<210>	218
<211>	108
<212>	PRT
<213>	Artificial Sequence

<220>
<223> NKp30 v4 IgC-like

<400>	218															
Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser	
1				5					10					15		
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu	Ala	Ile	
			20					25					30			
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val	
		35					40					45				
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Pro	
	50					55					60					
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val	
65					70					75					80	
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly	
			85						90					95		
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val					
			100					105								

```
<210> 219
<211> 108
<212> PRT
<213> Artificial Sequence
```

<220>
<223> NKp30 v5 IgC-like

<400>	219															
Leu	Trp	Val	Ser	Gln	Pro	Pro	Glu	Ile	Arg	Thr	Leu	Glu	Gly	Ser	Ser	
1				5					10					15		
Ala	Phe	Leu	Pro	Cys	Ser	Phe	Asn	Ala	Ser	Gln	Gly	Arg	Leu	Ala	Ile	
			20					25					30			
Gly	Ser	Val	Thr	Trp	Phe	Arg	Asp	Glu	Val	Val	Pro	Gly	Lys	Glu	Val	
		35					40					45				
Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Ser	
	50					55					60					
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val	
65					70					75					80	
Arg	Gly	His	Asp	Ala	Gly	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly	
			85						90					95		
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val					
			100					105								

<210>	220
<211>	99
<212>	PRT
<213>	Artificial Sequence

<220>
<223> CD86 WT IgV

<400> 220
Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln
1 5 10 15
Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val
Page 117

761612000240SeqList

Leu	Asn	Glu	20	Val	Tyr	Leu	Gly	Lys	25	Glu	Lys	Phe	Asp	Ser	30	Val	His	Ser
		35						40						45				
Lys	Tyr	Met	Gly	Arg	Thr	Ser	Phe	Asp	Ser	Asp	Ser	Trp	Thr	Leu	Arg			
	50					55				60								
Leu	His	Asn	Leu	Gln	Ile	Lys	Asp	Lys	Gly	Leu	Tyr	Gln	Cys	Ile	Ile			
65				70					75					80				
His	His	Lys	Lys	Pro	Thr	Gly	Met	Ile	Arg	Ile	His	Gln	Met	Asn	Ser			
			85					90						95				
Glu	Leu	Ser																

<210> 221
 <211> 99
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD86 v1 IgV

<400> 221

Asn	Glu	Thr	Ala	Asp	Leu	Pro	Cys	Gln	Phe	Ala	Asn	Ser	Gln	Asn	Gln			
1			5						10					15				
Ser	Leu	Ser	Glu	Leu	Val	Val	Phe	Trp	His	Asp	Gln	Glu	Asn	Leu	Val			
			20					25					30					
Leu	Asn	Glu	Val	Tyr	Leu	Gly	Lys	Glu	Lys	Phe	Asp	Ser	Val	His	Ser			
	35					40						45						
Lys	Tyr	Met	Gly	Arg	Thr	Ser	Phe	Asp	Ser	Asp	Ser	Trp	Thr	Leu	Arg			
	50					55				60								
Leu	His	Asn	Leu	Gln	Ile	Lys	Asp	Lys	Gly	Leu	Tyr	Gln	Cys	Ile	Ile			
65				70					75					80				
Leu	His	Lys	Lys	Pro	Thr	Gly	Met	Ile	Arg	Ile	His	His	Met	Asn	Ser			
			85					90						95				
Glu	Leu	Ser																

<210> 222
 <211> 99
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD86 v2 IgV

<400> 222

Asn	Glu	Thr	Ala	Asp	Leu	Pro	Cys	Gln	Phe	Ala	Asn	Ser	Gln	Asn	Gln			
1			5						10					15				
Ser	Leu	Ser	Glu	Leu	Val	Val	Phe	Trp	His	Asp	Gln	Glu	Asn	Leu	Val			
			20					25					30					
Leu	Asn	Glu	Val	Tyr	Leu	Gly	Lys	Glu	Lys	Phe	Asp	Ser	Val	His	Ser			
	35					40						45						
Lys	Tyr	Met	Gly	Arg	Thr	Ser	Phe	Asp	Ser	Asp	Ser	Trp	Thr	Leu	Arg			
	50					55				60								
Leu	His	Asn	Leu	Gln	Ile	Lys	Asp	Lys	Gly	Leu	Tyr	Gln	Cys	Ile	Ile			
65				70					75					80				
His	His	Lys	Lys	Pro	Thr	Gly	Met	Ile	Arg	Ile	His	Gln	Met	Asn	Ser			
			85					90						95				
Glu	Leu	Ser																

<210> 223
 <211> 99
 <212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> CD86 v3 IgV

<400> 223

```

Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln
1      5      10      15
Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val
      20      25      30
Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His Ser
      35      40      45
Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg
      50      55      60
Leu His Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile
65      70      75      80
Leu His Lys Lys Pro Thr Gly Met Ile Arg Ile His Gln Met Asn Ser
      85      90      95
Glu Leu Ser

```

<210> 224

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> CD86 v4 IgV

<400> 224

```

Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln
1      5      10      15
Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val
      20      25      30
Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His Ser
      35      40      45
Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg
      50      55      60
Leu His Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile
65      70      75      80
His His Lys Lys Pro Thr Gly Met Ile Arg Ile His His Met Asn Ser
      85      90      95
Glu Leu Ser

```

<210> 225

<211> 19

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> VH signal peptide

<400> 225

```

Met Gly Ser Thr Ala Ile Leu Ala Leu Leu Leu Ala Val Leu Gln Gly
1      5      10      15
Val Ser Ala

```

<210> 226

<211> 232

<212> PRT

761612000240SeqList

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> IgG1 Fc

<400> 226

```

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1      5      10      15
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20      25      30
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
35      40      45
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50      55      60
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65      70      75      80
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
85      90      95
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
100     105     110
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
115     120     125
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
130     135     140
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145     150     155     160
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
165     170     175
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
180     185     190
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
195     200     205
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
210     215     220
Ser Leu Ser Leu Ser Pro Gly Lys
225     230

```

<210> 227

<211> 235

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> IgG2 Fc

<400> 227

```

Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro
1      5      10      15
Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro
20      25      30
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
35      40      45
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn
50      55      60
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
65      70      75      80
Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val
85      90      95
Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
100     105     110
Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys
115     120     125
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
130     135     140
Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe

```

761612000240SeqList

145	Tyr	Pro	Ser	Asp	Ile	150	Ala	Val	Glu	Trp	Glu	155	Ser	Asn	Gly	Gln	Pro	160	Glu	
					165	Thr	Thr	Pro	Pro	Met	170	Leu	Asp	Ser	Asp	Gly	175	Ser	Phe	
			180	Ser	Lys	Leu	Thr	Val	185	Asp	Lys	Ser	Arg	Trp	190	Gln	Gln	Gly		
		195	Asn	Val	Phe	Ser	Cys	Ser	Val	200	Met	His	Glu	Ala	Leu	205	His	Asn	His	Tyr
	210	Thr	Gln	Lys	Ser	Leu	Ser	Leu	215	Ser	Pro	Gly	Lys	220						
225						230							235							

<210> 228
 <211> 15
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> IgV-IgV linker

<400> 228
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

<210> 229
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgV-Fc linker 1

<400> 229
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10

<210> 230
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgV-Fc linker 2

<400> 230
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ala Ala
 1 5 10

<210> 231
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 WT linker 1

<400> 231
 Lys Ala Asp Phe Pro Thr Pro Ser Ile Ser Asp Phe Glu Ile Pro
 1 5 10 15

<210> 232
 <211> 10

<212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80 WT linker 2

<400> 232
 Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 1 5 10

<210> 233
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL WT linker 1

<400> 233
 Val Thr Leu His Val Ala Ala Asn Phe Ser Val
 1 5 10

<210> 234
 <211> 29
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL WT linker 2

<400> 234
 Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile Thr
 1 5 10 15
 Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
 20 25

<210> 235
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> NKp30 WT linker 1

<400> 235
 Val Glu Lys Glu His Pro Gln Leu Gly
 1 5

<210> 236
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD86 WT linker 1

<400> 236
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe
 1 5

<210> 237
 <211> 18
 <212> PRT

<213> Artificial Sequence

<220>

<223> CD86 WT linker 2

<400> 237

Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile
1 5 10 15
Thr Glu

<210> 238

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> CD86 WT linker 3

<400> 238

Arg Leu Leu Ser Ser Pro Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro
1 5 10 15
Pro Pro Asp His Ile Pro
20

<210> 239

<211> 238

<212> PRT

<213> Artificial Sequence

<220>

<223> ICOSL v35 ECD

<400> 239

Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
1 5 10 15
Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
20 25 30
Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
35 40 45
Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
50 55 60
Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
65 70 75 80
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
85 90 95
Val Leu Ser Gln Ser Leu Glu Phe Gln Glu Val Leu Ser Val Glu Val
100 105 110
Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
115 120 125
His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Ile Asn
130 135 140
Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
145 150 155 160
Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
165 170 175
Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
180 185 190
Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Asn Leu
195 200 205
Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
210 215 220
Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
225 230 235

761612000240SeqList

<210> 240
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL v35 IgV

<400> 240
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln Ser Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Glu Phe Gln Glu Val Leu Ser Val Glu
 100 105 110

<210> 241
 <211> 116
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD155 IgV

<400> 241
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Pro Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 242
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v1 ECD

<400> 242
 Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
 1 5 10 15
 Val Ser Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
 20 25 30
 Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
 35 40 45

761612000240SeqList

His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Ser
50						55				60					
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70					75					80
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
			165						170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 243
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v2 ECD

<400> 243

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5				10						15	
Val	Ser	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20					25					30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
			35				40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55				60					
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70					75				80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Pro	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu

761612000240SeqList

```

      165      170      175
Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
      180      185      190
Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
      195      200      205
Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
      210      215      220
Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
225      230      235
Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
      245      250      255
Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
      260      265      270
Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
      275      280      285
Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
      290      295      300
Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
305      310      315      320
Ser Arg Asn

```

<210> 244
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v3 ECD

```

<400> 244
Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
1      5      10      15
Val Pro Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
      20      25      30
Val Pro Asn Met Glu Val Thr His Val Ser Gln Pro Thr Trp Ala Arg
      35      40      45
His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
      50      55      60
Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
65      70      75      80
Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu
      85      90      95
Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
      100      105      110
Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
      115      120      125
Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
      130      135      140
Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
145      150      155      160
Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
      165      170      175
Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
      180      185      190
Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
      195      200      205
Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
      210      215      220
Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
225      230      235
Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
      245      250      255
Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
      260      265      270
Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
      275      280      285

```

761612000240SeqList

Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
290						295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 245
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v4 ECD

<400> 245

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5				10						15	
Val	Pro	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20				25						30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Val	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70				75						80
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120						125		
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 246
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v5 ECD

761612000240SeqList

```

<400> 246
Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
1      5      10      15
Val Leu Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
      20      25      30
Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
      35      40      45
His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
      50      55      60
Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Val Gly
65      70      75      80
Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu
      85      90      95
Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
      100      105      110
Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
      115      120      125
Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
      130      135      140
Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
145      150      155      160
Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
      165      170      175
Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
      180      185      190
Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
      195      200      205
Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
      210      215      220
Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
225      230      235      240
Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
      245      250      255
Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
      260      265      270
Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
      275      280      285
Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
      290      295      300
Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
305      310      315      320
Ser Arg Asn

```

```

<210> 247
<211> 323
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD155 v6 ECD

```

```

<400> 247
Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
1      5      10      15
Val Ser Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
      20      25      30
Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
      35      40      45
His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
      50      55      60
Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
65      70      75      80
Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu
      85      90      95
Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser

```

761612000240SeqList

Arg	Ser	Val	100	Asp	Ile	Trp	Leu	Arg	105	Val	Leu	Ala	Lys	Pro	110	Gln	Asn	Thr
Ala	Glu	Val	115	Gln	Lys	Val	Gln	Leu	120	Thr	Gly	Glu	Pro	125	Val	Pro	Met	Ala
Arg	Cys	Val	130	Ser	Thr	Gly	135	Gly	Arg	Pro	Pro	Ala	Gln	140	Ile	Thr	Trp	His
145	Ser	Asp	Leu	Gly	150	Gly	Met	Pro	Asn	Thr	Ser	155	Gln	Val	Pro	Gly	Phe	160
165	Ser	Gly	Thr	Val	165	Thr	Val	Thr	Ser	Leu	Trp	170	Ile	Leu	Val	Pro	Ser	175
180	Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	185	Cys	Lys	Val	Glu	His	190	Glu	Ser	Phe
195	Glu	Lys	Pro	Gln	Leu	Leu	Thr	200	Val	Asn	Leu	Thr	Val	205	Tyr	Tyr	Pro	Pro
210	Glu	Val	Ser	Ile	Ser	Gly	215	Tyr	Asp	Asn	Asn	Trp	Tyr	220	Leu	Gly	Gln	Asn
225	Glu	Ala	Thr	Leu	Thr	230	Cys	Asp	Ala	Arg	Ser	235	Asn	Pro	Glu	Pro	Thr	240
245	Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	250	Ala	Val	Ala	255
260	Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	265	Ile	Asn	Thr	270
275	Thr	Leu	Ile	Cys	Asn	Val	Thr	280	Asn	Ala	Leu	Gly	Ala	285	Arg	Gln	Ala	Glu
290	Leu	Thr	Val	Gln	Val	Lys	295	Glu	Gly	Pro	Pro	Ser	300	Glu	His	Ser	Gly	Ile
305	Ser	Arg	Asn			310						315						320

<210> 248
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v7 ECD

<400> 248

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1	Val	Thr	Gly	5	Leu	Gly	Asp	Ser	10	Thr	Leu	Pro	Cys	15	Leu
20	Val	Pro	Asn	20	Met	Glu	Val	Thr	25	His	Val	Ser	Gln	30	Leu
35	His	Gly	Glu	35	Ser	Gly	Ser	Met	40	Ala	Val	Phe	His	45	Thr
50	Ser	Gly	Glu	50	Ser	Gly	Ser	Met	55	Ala	Val	Phe	His	60	Gln
65	Ser	Tyr	Ser	65	Glu	Ser	Lys	Arg	70	Leu	Glu	Phe	Val	75	Ala
80	Ala	Glu	Leu	80	Arg	Asn	Ala	Ser	85	Leu	Arg	Met	Ser	90	Gly
95	Asp	Glu	Gly	95	Asn	Tyr	Thr	Cys	100	Leu	Phe	Val	Thr	105	Phe
110	Arg	Ser	Val	110	Asp	Ile	Trp	Leu	115	Arg	Val	Leu	Ala	120	Lys
125	Ala	Glu	Val	125	Gln	Lys	Val	Gln	130	Leu	Thr	Gly	Glu	135	Pro
140	Arg	Cys	Val	140	Ser	Thr	Gly	Gly	145	Arg	Pro	Pro	Ala	150	Gln
155	Ser	Asp	Leu	155	Gly	Gly	Met	Pro	160	Asn	Thr	Ser	Gln	165	Val
170	Ser	Gly	Thr	170	Val	Thr	Val	Thr	175	Ser	Leu	Trp	Ile	180	Leu
185	Gln	Val	Asp	185	Gly	Lys	Asn	Val	190	Thr	Cys	Lys	Val	195	Glu
200	Glu	Lys	Pro	200	Gln	Leu	Leu	Thr	205	Val	Asn	Leu	Thr	210	Val
215				215					220						

761612000240SeqList

Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 249
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v8 ECD

<400> 249

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5				10						15	
Val	Thr	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20				25						30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Pro	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70				75					80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
		130				135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150				155					160	
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

761612000240SeqList

<210> 250
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v9 ECD

<400> 250
 Trp Pro Pro Pro Gly Thr Glu Asp Val Val Val Gln Ala Pro Thr Gln
 1 5 10 15
 Val Thr Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Cys Leu Gln
 20 25 30
 Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
 35 40 45
 His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
 50 55 60
 Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
 65 70 75 80
 Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu
 85 90 95
 Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
 100 105 110
 Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
 115 120 125
 Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
 130 135 140
 Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
 145 150 155 160
 Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
 165 170 175
 Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
 180 185 190
 Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
 195 200 205
 Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
 210 215 220
 Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
 225 230 235 240
 Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
 245 250 255
 Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
 260 265 270
 Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
 275 280 285
 Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
 290 295 300
 Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
 305 310 315 320
 Ser Arg Asn

<210> 251
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v10 ECD

<400> 251
 Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
 1 5 10 15
 Val Thr Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
 20 25 30
 Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg

761612000240SeqList

His	Gly	35	Glu	Ser	Gly	Ser	Met	40	Ala	Val	Phe	His	Gln	45	Thr	Gln	Gly	Pro
50							55					60						
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly			
65					70					75				80				
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu			
				85					90					95				
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Asp	Ser			
			100					105					110					
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr			
		115					120					125						
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala			
130						135					140							
Arg	Cys	Val	Ser	Thr	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His				
145					150				155					160				
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu			
				165					170					175				
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser			
			180					185					190					
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe			
		195					200					205						
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro			
		210				215					220							
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn			
225					230				235					240				
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly			
				245					250					255				
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala			
			260					265					270					
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr			
		275					280					285						
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu			
	290					295					300							
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile			
305					310					315				320				
Ser	Arg	Asn																

<210> 252
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v11 ECD

<400> 252

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5				10						15	
Val	Ser	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20				25					30			
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55				60					
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70				75					80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Pro	Gly	Leu	Arg	Val	Glu
				85					90				95		
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160

761612000240SeqList

Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 253
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v12 ECD

<400> 253

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5					10					15	
Val	Thr	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20					25					30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70					75				80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Leu	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr

761612000240SeqList

Thr	Leu	275	Ile	Cys	Asn	Val	Thr	280	Asn	Ala	Leu	Gly	Ala	285	Arg	Gln	Ala	Glu
	290						295						300					
Leu	Thr	Val	Gln	Val	Lys	310	Glu	Gly	Pro	Pro	Ser	315	Glu	His	Ser	Gly	Ile	
305																	320	
Ser	Arg	Asn																

<210> 254
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v13 ECD

<400> 254

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln			
1				5					10					15				
Val	Ser	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln			
			20					25					30					
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg			
			35				40					45						
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro			
	50					55					60							
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly			
65					70				75					80				
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu			
				85					90					95				
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser			
			100					105					110					
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr			
		115					120					125						
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala			
	130					135					140							
Arg	Cys	Val	Ser	Thr	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His				
145					150				155					160				
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu			
			165					170						175				
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser			
			180					185					190					
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe			
		195					200					205						
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro			
	210					215					220							
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn			
225					230				235					240				
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly			
			245						250					255				
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala			
			260					265					270					
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr			
	275						280					285						
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu			
	290					295					300							
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile			
305					310					315					320			
Ser	Arg	Asn																

<210> 255
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>

761612000240SeqList

<223> CD155 v14 ECD

<400> 255

```

Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
1      5      10      15
Val Thr Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
      20      25      30
Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Ala Trp Ala Arg
      35      40      45
His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
      50      55      60
Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
65      70      75      80
Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu
      85      90      95
Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
      100     105     110
Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
      115     120     125
Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
      130     135     140
Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
145     150     155     160
Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
      165     170     175
Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
      180     185     190
Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
      195     200     205
Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
      210     215     220
Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
225     230     235     240
Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
      245     250     255
Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
      260     265     270
Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
      275     280     285
Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
      290     295     300
Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
305     310     315     320
Ser Arg Asn

```

<210> 256

<211> 323

<212> PRT

<213> Artificial Sequence

<220>

<223> CD155 v15 ECD

<400> 256

```

Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
1      5      10      15
Val Thr Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
      20      25      30
Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
      35      40      45
His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
      50      55      60
Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
65      70      75      80
Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Ser Gly Leu His Val Glu
      85      90      95

```

761612000240SeqList

Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
		130				135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
			165						170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
		210				215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
		290				295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn													

<210> 257
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v16 ECD

<400> 257

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5				10						15	
Val	Ser	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Cys	Leu	Gln
			20				25						30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
		50				55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70					75					80
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
		130				135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
			165						170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro

761612000240SeqList

210	Glu	Val	Ser	Ile	Ser	Gly	215	Tyr	Asp	Asn	Asn	Trp	220	Tyr	Leu	Gly	Gln	Asn
225	Glu	Ala	Thr	Leu	Thr	Cys	230	Asp	Ala	Arg	Ser	235	Asn	Pro	Glu	Pro	Thr	Gly
				245	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala		
			260					265						270				
	Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr		
		275						280					285					
	Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu		
		290					295					300						
	Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile		
305						310					315					320		
	Ser	Arg	Asn															

<210> 258
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v17 ECD

<400> 258

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5				10						15	
Val	Pro	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20				25						30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50				55					60					
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70				75					80	
Val	Glu	Pro	Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly	Leu	Arg	Val	Glu
				85				90					95		
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155				160	
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165				170					175		
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260				265						270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
		290				295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
	Ser	Arg	Asn												

761612000240SeqList

<210> 259
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v18 ECD

<400> 259
 Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
 1 5 10 15
 Val Pro Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
 20 25 30
 Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
 35 40 45
 His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
 50 55 60
 Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
 65 70 75 80
 Ala Glu Leu Arg Asn Ala Ser Pro Arg Met Phe Gly Leu Arg Val Glu
 85 90 95
 Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
 100 105 110
 Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
 115 120 125
 Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
 130 135 140
 Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
 145 150 155 160
 Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
 165 170 175
 Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
 180 185 190
 Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
 195 200 205
 Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
 210 215 220
 Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
 225 230 235 240
 Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
 245 250 255
 Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
 260 265 270
 Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
 275 280 285
 Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
 290 295 300
 Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
 305 310 315 320
 Ser Arg Asn

<210> 260
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v19 ECD

<400> 260
 Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
 1 5 10 15
 Val Pro Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
 20 25 30

761612000240SeqList

Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
	65				70					75				80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly	Leu	His	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
	145				150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
	225				230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			
Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
	290					295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
	305				310					315					320
Ser	Arg	Asn													

<210> 261
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v20 ECD

<400> 261

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Glu	Pro	Thr	Gln
1				5					10					15	
Val	Ser	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20					25					30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Val	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
	65				70					75				80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His

761612000240SeqList

```

145      150      155      160
Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
      165      170      175
Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
      180      185      190
Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
      195      200      205
Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
      210      215      220
Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
225      230      235      240
Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
      245      250      255
Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
      260      265      270
Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
      275      280      285
Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
290      295      300
Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
305      310      315      320
Ser Arg Asn

```

```

<210> 262
<211> 323
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD155 v21 ECD

```

```

<400> 262
Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
1      5      10      15
Val Thr Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
      20      25      30
Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
      35      40      45
His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro
      50      55      60
Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
65      70      75      80
Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu
      85      90      95
Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
      100      105      110
Arg Ser Ala Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
      115      120      125
Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
      130      135      140
Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
145      150      155      160
Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
      165      170      175
Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
      180      185      190
Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
      195      200      205
Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
      210      215      220
Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
225      230      235      240
Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
      245      250      255
Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
260      265      270

```

761612000240SeqList
 Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
 275 280 285
 Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
 290 295 300
 Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
 305 310 315 320
 Ser Arg Asn

<210> 263
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v22 ECD

<400> 263
 Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln
 1 5 10 15
 Val Thr Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln
 20 25 30
 Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg
 35 40 45
 His Gly Glu Ser Gly Ser Met Ala Val Phe His Lys Thr Gln Gly Pro
 50 55 60
 Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly
 65 70 75 80
 Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu
 85 90 95
 Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser
 100 105 110
 Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr
 115 120 125
 Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala
 130 135 140
 Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His
 145 150 155 160
 Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu
 165 170 175
 Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser
 180 185 190
 Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe
 195 200 205
 Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro
 210 215 220
 Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn
 225 230 235 240
 Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly
 245 250 255
 Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala
 260 265 270
 Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr
 275 280 285
 Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu
 290 295 300
 Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile
 305 310 315 320
 Ser Arg Asn

<210> 264
 <211> 116
 <212> PRT
 <213> Artificial Sequence

761612000240SeqList

<220>

<223> CD155 v1 IgV

<400> 264

```

Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Ser Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Ser Ser Tyr Ser
50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
85      90      95
Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
100      105      110
Asp Ile Trp Leu
115

```

<210> 265

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> CD155 v2 IgV

<400> 265

```

Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Ser Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
85      90      95
Asn Tyr Thr Cys Pro Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
100      105      110
Asp Ile Trp Leu
115

```

<210> 266

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> CD155 v3 IgV

<400> 266

```

Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Pro Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
20      25      30
Met Glu Val Thr His Val Ser Gln Pro Thr Trp Ala Arg His Gly Glu
35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80

```

761612000240SeqList
 Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu Asp Glu Gly
 85 90
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 267
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v4 IgV

<400> 267
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Pro Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Val Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 268
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v5 IgV

<400> 268
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Leu Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Val Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 269
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>

761612000240SeqList

<223> CD155 v6 IgV

<400> 269

```

Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Ser Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
      20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
      35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
      50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
      85      90      95
Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
      100      105      110
Asp Ile Trp Leu
      115

```

<210> 270

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> CD155 v7 IgV

<400> 270

```

Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
      20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
      35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
      50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
      85      90      95
Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
      100      105      110
Asp Ile Trp Leu
      115

```

<210> 271

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> CD155 v8 IgV

<400> 271

```

Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
      20      25      30
Met Glu Val Thr His Val Pro Gln Leu Thr Trp Ala Arg His Gly Glu
      35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
      50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly

```

761612000240SeqList

Asn Tyr Thr Cys 85
 100 Leu Phe Val Thr Phe 90
 105 Pro Gln Gly Ser Arg 95
 Asp Ile Trp Leu 110
 115 Ser Val

<210> 272
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v9 IgV

<400> 272
 Pro Gly Thr Glu Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Cys Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 273
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v10 IgV

<400> 273
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Asp Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 274
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v11 IgV

761612000240SeqList

```

<400> 274
Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Ser Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
      20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
      35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
      50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Pro Gly Leu Arg Val Glu Asp Glu Gly
      85      90      95
Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
      100      105      110
Asp Ile Trp Leu
      115

```

```

<210> 275
<211> 116
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD155 v12 IgV

```

```

<400> 275
Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
      20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
      35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
      50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
      85      90      95
Asn Tyr Thr Cys Leu Phe Val Thr Leu Pro Gln Gly Ser Arg Ser Val
      100      105      110
Asp Ile Trp Leu
      115

```

```

<210> 276
<211> 116
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD155 v13 IgV

```

```

<400> 276
Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Ser Gly
1      5      10      15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
      20      25      30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
      35      40      45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
      50      55      60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65      70      75      80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
      85      90      95

```


761612000240SeqList

Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 277
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v14 IgV

<400> 277
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Ala Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 278
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v15 IgV

<400> 278
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Thr Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Ser Gly Leu His Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 279
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v16 IgV

761612000240SeqList

<400> 279
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Ser Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Cys Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 280
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v17 IgV

<400> 280
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Pro Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Val Glu Pro
 65 70 75 80
 Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
 100 105 110
 Asp Ile Trp Leu
 115

<210> 281
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v18 IgV

<400> 281
 Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Pro Gly
 1 5 10 15
 Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
 20 25 30
 Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
 35 40 45
 Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
 50 55 60
 Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
 65 70 75 80
 Arg Asn Ala Ser Pro Arg Met Phe Gly Leu Arg Val Glu Asp Glu Gly
 85 90 95
 Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val

Asp Ile Trp Leu 100 105 110
115

<210> 282
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> CD155 v19 IgV

<400> 282
Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln Val Pro Gly
1 5 10 15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
20 25 30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
35 40 45
Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
50 55 60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65 70 75 80
Arg Asn Ala Ser Leu Arg Met Phe Gly Leu His Val Glu Asp Glu Gly
85 90 95
Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
100 105 110
Asp Ile Trp Leu
115

<210> 283
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> CD155 v20 IgV

<400> 283
Pro Gly Thr Gly Asp Val Val Val Gln Glu Pro Thr Gln Val Ser Gly
1 5 10 15
Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln Val Pro Asn
20 25 30
Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg His Gly Glu
35 40 45
Ser Gly Ser Met Val Val Phe His Gln Thr Gln Gly Pro Ser Tyr Ser
50 55 60
Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly Ala Glu Leu
65 70 75 80
Arg Asn Ala Ser Leu Arg Met Ser Gly Leu Arg Val Glu Asp Glu Gly
85 90 95
Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser Arg Ser Val
100 105 110
Asp Ile Trp Leu
115

<210> 284
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> CD155 v21 IgV

<400> 284

761612000240SeqList

Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln	Val	Thr	Gly
1				5				10					15		
Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln	Val	Pro	Asn
			20					25					30		
Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg	His	Gly	Glu
		35					40					45			
Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro	Ser	Tyr	Ser
	50					55				60					
Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly	Ala	Glu	Leu
65					70					75					80
Arg	Asn	Ala	Ser	Leu	Arg	Met	Ser	Gly	Leu	Arg	Val	Glu	Asp	Glu	Gly
				85				90						95	
Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser	Arg	Ser	Ala
			100					105					110		
Asp	Ile	Trp	Leu												
			115												

<210> 285
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD155 v22 IgV

<400> 285

Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln	Val	Thr	Gly
1				5				10					15		
Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln	Val	Pro	Asn
			20					25					30		
Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg	His	Gly	Glu
		35					40					45			
Ser	Gly	Ser	Met	Ala	Val	Phe	His	Lys	Thr	Gln	Gly	Pro	Ser	Tyr	Ser
	50					55				60					
Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly	Ala	Glu	Leu
65					70					75					80
Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly	Leu	Arg	Val	Glu	Asp	Glu	Gly
				85				90						95	
Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser	Arg	Ser	Val
			100					105					110		
Asp	Ile	Trp	Leu												
			115												

<210> 286
 <211> 125
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> CD112 IgV

<400> 286

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20						25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85				90						95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala

761612000240SeqList

Thr Phe Pro¹⁰⁰ Lys Gly Ser Val Arg¹⁰⁵ Gly Met Thr Trp Leu¹¹⁰
¹¹⁵ ¹²⁰ ¹²⁵

<210> 287
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v1 ECD

<400> 287
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Asp Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 288
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v2 ECD

<400> 288
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 Page 151

761612000240SeqList

```

1      5      10      15
Gly Thr Ala Glu Leu Pro Cys His Leu Pro Pro Val Pro Gly Leu
20      25      30
His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Gly
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Gly
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Ser Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115      120      125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
130      135      140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145      150      155      160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
165      170      175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
180      185      190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
195      200      205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
210      215      220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225      230      235      240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
245      250      255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
260      265      270
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
275      280      285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
290      295      300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305      310      315      320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
325

```

<210> 289
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v3 ECD

```

<400> 289
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Pro
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115      120      125

```

761612000240SeqList

Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
130	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
			275				280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 290
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v4 ECD

<400> 290

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Val	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ile
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser

761612000240SeqList

Asn	Pro	Glu	Pro	245	Thr	Gly	Tyr	Asp	Trp	250	Ser	Thr	Thr	Ser	Gly	255	Thr	Phe
			260	Val	Ala	Gln	Gly	265	Ser	Gln	Leu	Val	Ile	His	270	Ala	Val	
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val			
	290					295					300							
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn			
305					310					315					320			
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly										
				325														

<210> 291
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v5 ECD

<400> 291

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly			
1				5					10					15				
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Pro	Ser	Val	Pro	Gly	Leu				
			20					25					30					
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His			
		35					40					45						
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser			
	50					55					60							
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser			
65					70					75				80				
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu			
			85						90					95				
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val			
			100					105					110					
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile			
		115					120					125						
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln			
	130					135					140							
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro			
145					150					155				160				
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr			
			165						170					175				
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe			
			180					185					190					
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys			
		195					200					205						
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu			
	210					215					220							
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn			
225					230					235				240				
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser			
				245					250					255				
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe			
			260					265					270					
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val			
		275					280						285					
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val			
	290					295					300							
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn			
305					310					315					320			
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly										
				325														

<210> 292
 <211> 329

761612000240SeqList

<212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v6 ECD

<400> 292
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ala Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Asn Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Ala Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 293
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v7 ECD

<400> 293
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60

761612000240SeqList

Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Phe	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155				160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225				230						235				240	
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315				320	
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 294
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v8 ECD

<400> 294

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Trp	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	Tyr
		35					40					45			
Gln	Asn	Val	Ala	Ala	Ser	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Phe	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155				160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe

761612000240SeqList

Thr	Leu	Val	180	Pro	Ser	Gly	Arg	Ala	185	Asp	Gly	Val	Thr	Val	190	Thr	Cys	Lys
Val	Glu	His	195	Glu	Ser	Phe	Glu	200	Glu	Pro	Ala	Leu	Ile	Pro	205	Val	Thr	Leu
Ser	Val	Arg	210	Tyr	Pro	Pro	Glu	215	Val	Ser	Ile	Ser	Gly	Tyr	220	Asp	Asp	Asn
225	Trp	Tyr	Leu	Gly	Arg	230	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	235	Val	Arg	Ser
Asn	Pro	Glu	Pro	245	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	250	Thr	Phe	
Pro	Thr	Ser	260	Ala	Val	Ala	Gln	Gly	265	Ser	Gln	Leu	Val	Ile	270	His	Ala	Val
Asp	Ser	275	Leu	Phe	Asn	Thr	Thr	280	Phe	Val	Cys	Thr	Val	285	Thr	Asn	Ala	Val
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	300	Asn		
305	Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly	315								
						325												

<210> 295
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v9 ECD

<400> 295

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Trp	Gly	Gln	Leu	Gly
1	Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
		50				55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Arg	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Phe	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
		130				135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
		210				215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225	Trp	Tyr	Leu	Gly	Arg	230	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val
					245						250				255
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275				280						285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
		290				295					300				

761612000240SeqList

Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 296
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v10 ECD

<400> 296

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20						25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Ser	Phe	Pro	Lys	Gly	Tyr	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
			245						250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 297
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v11 ECD

<400> 297

761612000240SeqList

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Tyr	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 298
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v12 ECD

<400> 298

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Ile	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Tyr	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile

761612000240SeqList

Ala	Lys	115	Pro	Lys	Asn	Gln	Ala	120	Glu	Ala	Gln	Lys	Val	125	Thr	Phe	Ser	Gln
130	Pro	Thr	Thr	Val	Ala	135	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro		
145	Arg	Ile	Ser	Trp	150	Leu	Ser	Ser	Leu	Asp	155	Trp	Glu	Ala	Lys	Glu	Thr	
Gln	Val	Ser	Gly	165	Thr	Leu	Ala	Gly	Thr	170	Val	Thr	Val	Thr	Ser	Arg	Phe	
Thr	Leu	Val	180	Pro	Ser	Gly	Arg	Ala	185	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys	
Val	Glu	His	Glu	Ser	Phe	Glu	200	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu		
210	Val	Arg	Tyr	Pro	Pro	215	Glu	Val	Ser	Ile	Ser	220	Gly	Tyr	Asp	Asp	Asn	
225	Trp	Tyr	Leu	Gly	Arg	230	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser	
Asn	Pro	Glu	Pro	245	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe		
Pro	Thr	Ser	260	Ala	Val	Ala	Gln	Gly	265	Ser	Gln	Leu	Val	Ile	His	Ala	Val	
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val			
290	Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn		
305	Thr	Ala	Gly	Ala	Gly	310	Ala	Thr	Gly	Gly	315							
				325														

<210> 299
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v13 ECD

<400> 299

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1	Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly
			20						25				30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40				45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50				55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Ile	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Phe	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230				235						240

761612000240SeqList

Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 300
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v14 ECD

<400> 300

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Thr	Pro
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Tyr	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 301

761612000240SeqList

<211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v15 ECD

<400> 301
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Ser Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 302
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v16 ECD

<400> 302
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 Page 162

761612000240SeqList

```

50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115      120      125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
130      135      140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145      150      155      160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
165      170      175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
180      185      190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
195      200      205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
210      215      220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225      230      235      240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
245      250      255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
260      265      270
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
275      280      285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
290      295      300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305      310      315      320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
325

```

<210> 303
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v17 ECD

```

<400> 303
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Ser Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115      120      125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
130      135      140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145      150      155      160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
165      170      175

```

761612000240SeqList

Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 304
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v18 ECD

<400> 304

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Ser	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20						25				30			
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Ser	His
		35				40					45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120				125				
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155					160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val

761612000240SeqList

290	Gly	Met	Gly	Arg	Ala	Glu	295	Gln	Val	Ile	Phe	Val	300	Arg	Glu	Thr	Pro	Asn
305	Thr	Ala	Gly	Ala	Gly	Ala	310	Thr	Gly	Gly		315						320
					325													

<210> 305
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v19 ECD

<400> 305

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10				15		
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Pro	Pro	Val	Pro	Gly	Leu	
			20					25				30			
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Ser	Asp	Ala	Pro	Ala	Asn	His
		35					40				45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	His	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105				110			
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155				160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170				175		
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235				240	
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
			245						250				255		
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 306
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v20 ECD

761612000240SeqList

```

<400> 306
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Leu Pro Val Pro Gly Pro
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Ser Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100     105
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115     120     125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
130     135     140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145     150     155     160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
165     170     175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
180     185     190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
195     200     205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
210     215     220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225     230     235     240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
245     250     255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
260     265     270
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
275     280     285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
290     295     300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305     310     315     320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
325

```

```

<210> 307
<211> 329
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v21 ECD

```

```

<400> 307
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Asp Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100     105     110

```

761612000240SeqList

Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225				230						235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 308
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v22 ECD

<400> 308

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Pro	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Tyr	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn

761612000240SeqList

225	Trp	Tyr	Leu	Gly	Arg	230	Thr	Asp	Ala	Thr	Leu	235	Ser	Cys	Asp	Val	Arg	240	Ser
					245	Thr	Gly	Tyr	Asp	Trp	250	Ser	Thr	Thr	Ser	Gly	255	Thr	Phe
Asn	Pro	Glu	Pro	Thr	260	Val	Ala	Gln	Gly	265	Ser	Gln	Leu	Val	Ile	270	His	Ala	Val
					275	Asp	Ser	Leu	Phe	280	Asn	Thr	Thr	Val	285	Thr	Asn	Ala	Val
290	Gly	Met	Gly	Arg	Ala	295	Glu	Gln	Val	Ile	Phe	300	Val	Arg	Glu	Thr	Pro	Asn	
305	Thr	Ala	Gly	Ala	Gly	310	Ala	Thr	Gly	Gly		315						320	
					325														

<210> 309
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v23 ECD

<400> 309

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Pro
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Ser	Asp	Ala	Pro	Ala	Asn	His
		35					40				45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Ala	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
				100				105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
				260					265					270	
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
				275					280				285		
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

761612000240SeqList

<210> 310
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v24 ECD

<400> 310
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ser Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Ser Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Ile Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 311
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v25 ECD

<400> 311
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Lys His
 35 40 45

761612000240SeqList

Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
50	55									60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
		130				135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 312
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v26 ECD

<400> 312

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Tyr	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
		130				135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr

761612000240SeqList

Gln	Val	Ser	Gly	165	Thr	Leu	Ala	Gly	170	Thr	Val	Thr	Ser	175	Arg	Phe
Thr	Leu	Val	Pro	180	Ser	Gly	Arg	Ala	185	Asp	Gly	Val	Thr	Val	190	Thr
Val	Glu	His	Glu	195	Ser	Phe	Glu	200	Glu	Pro	Ala	Leu	Ile	205	Pro	Val
Ser	Val	Arg	Tyr	210	Pro	Pro	Glu	215	Val	Ser	Ile	Ser	Gly	220	Tyr	Asp
225	Trp	Tyr	Leu	Gly	230	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	235	Asp	Val
Asn	Pro	Glu	Pro	245	Thr	Gly	Tyr	Asp	Trp	250	Ser	Thr	Thr	Ser	Gly	255
Pro	Thr	Ser	Ala	260	Val	Ala	Gln	Gly	265	Ser	Gln	Leu	Val	Ile	270	His
Asp	Ser	Leu	Phe	275	Asn	Thr	Thr	Phe	280	Val	Cys	Thr	Val	285	Thr	Asn
Gly	Met	Gly	Arg	290	Ala	Glu	Gln	Val	295	Ile	Phe	Val	300	Arg	Glu	Thr
305	Thr	Ala	Gly	Ala	310	Gly	Ala	Thr	Gly	Gly	315					320
				325												

<210> 313
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v27 ECD

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1	Gly	Thr	Val	Glu	5	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	15
				20					25					30	
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50				55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Arg	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Gly	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Ser	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155					160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230				235					240	
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	265	Ser	Thr	Thr	Ser	Gly	Thr
			260										270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			

761612000240SeqList

Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 314
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v28 ECD

<400> 314

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Lys	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Leu	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185						190	
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 315
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v29 ECD

761612000240SeqList

```

<400> 315
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1 5 10 15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20 25 30
His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35 40 45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50 55 60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65 70 75 80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85 90 95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100 105 110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115 120 125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
130 135 140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145 150 155 160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
165 170 175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
180 185 190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
195 200 205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
210 215 220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225 230 235 240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
245 250 255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
260 265 270
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
275 280 285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
290 295 300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305 310 315 320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
325

```

```

<210> 316
<211> 329
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v30 ECD

```

```

<400> 316
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1 5 10 15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20 25 30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35 40 45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50 55 60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65 70 75 80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Val Leu
85 90 95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val

```

761612000240SeqList

Thr	Phe	Pro	100	Lys	Gly	Ser	Val	Arg	105	Gly	Met	Thr	Trp	Leu	110	Arg	Val	Ile
Ala	Lys	Pro	115	Lys	Asn	Gln	Ala	Glu	120	Ala	Gln	Lys	Val	Thr	125	Phe	Ser	Gln
Asp	Pro	Thr	130	Thr	Val	Ala	135	Leu	Cys	Ile	Ser	Lys	Glu	Gly	140	Arg	Pro	Pro
145	Ala	Arg	Ile	Ser	Trp	150	Leu	Ser	Ser	Leu	Asp	155	Trp	Glu	Ala	Lys	Glu	160
Gln	Val	Ser	165	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	175	Arg	Phe	
Thr	Leu	Val	180	Pro	Ser	Gly	Arg	Ala	185	Asp	Gly	Val	Thr	Val	190	Thr	Cys	Lys
Val	Glu	His	195	Glu	Ser	Phe	Glu	200	Pro	Ala	Leu	Ile	205	Pro	Val	Thr	Leu	
Ser	Val	Arg	210	Tyr	Pro	Pro	Glu	215	Val	Ser	Ile	Ser	Gly	Tyr	220	Asp	Asp	Asn
225	Trp	Tyr	Leu	Gly	Arg	230	Thr	Asp	Ala	Thr	Leu	Ser	235	Cys	Asp	Val	Arg	240
Trp	Tyr	Leu	Gly	Arg	245	Thr	Asp	Ala	Thr	Leu	Ser	Cys	250	Asp	Val	Arg	Ser	
Asn	Pro	Glu	Pro	260	Thr	Gly	Tyr	Asp	Trp	265	Ser	Thr	Thr	Ser	Gly	270	Thr	Phe
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	285	His	Ala	Val		
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	290	Asn	Ala	Val		
Gly	Met	Gly	Arg	Ala	Glu	310	Gln	Val	Ile	Phe	Val	Arg	315	Glu	Thr	Pro	Asn	320
305	Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly									
				325														

<210> 317
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v31 ECD

<400> 317

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Trp	Gly	Gln	Leu	Gly
1	Gly	Thr	Val	5	Leu	Pro	Cys	His	10	Leu	Pro	Pro	Val	15	Gly
				20					25				30		Leu
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
				35				40				45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
				50		55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
			115				120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
			130			135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155					160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170				175		
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
			195				200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	220	Pro	Val	Leu
			210			215									

761612000240SeqList

Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 318
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v32 ECD

<400> 318

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Trp	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Ser	Pro	Val	Pro	Gly	Leu
		20						25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35				40					45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85					90					95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
		100					105						110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155					160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
		180						185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

761612000240SeqList

<210> 319
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v33 ECD

<400> 319
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Met Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 320
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v34 ECD

<400> 320
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 Page 176

761612000240SeqList

Gln	Asn	35	Val	Ala	Ala	Phe	His	40	Pro	Lys	Met	Gly	Pro	45	Ser	Phe	Pro	Ser
50	50						55						60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser			
65					70							75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu			
				85					90					95				
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val			
			100					105					110					
Thr	Phe	Pro	Lys	Gly	Thr	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile			
		115					120					125						
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln			
130						135					140							
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro			
145					150					155					160			
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr			
			165						170					175				
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe			
			180					185					190					
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys			
		195					200					205						
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu			
210						215					220							
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn			
225				230					235						240			
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser			
			245						250				255					
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe			
		260						265					270					
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val			
		275					280					285						
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val			
290					295						300							
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn			
305				310						315					320			
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly										
				325														

<210> 321
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v35 ECD

<400> 321

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10				15		
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20					25					30			
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35				40					45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
50					55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65				70					75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85					90					95		
His	Gly	Leu	Thr	Ala	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
		100					105					110			
Thr	Phe	Ser	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120				125				
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
130					135					140					
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145				150					155					160	

761612000240SeqList

Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225				230					235						240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
			245						250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 322
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v36 ECD

<400> 322

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	Arg	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Asn	Trp	Gln	Arg	Pro	Gly	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50				55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225				230					235						240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
			245						250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val

761612000240SeqList

Asp	Ser	275	Leu	Phe	Asn	Thr	Thr	280	Phe	Val	Cys	Thr	Val	285	Thr	Asn	Ala	Val
	290						295						300					
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn			
305					310					315					320			
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly										
				325														

<210> 323
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v37 ECD

<400> 323

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20						25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 324
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>

761612000240SeqList

<223> CD112 v38 ECD

<400> 324

Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ala Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 325

<211> 329

<212> PRT

<213> Artificial Sequence

<220>

<223> CD112 v39 ECD

<400> 325

Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95

761612000240SeqList

His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Thr	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225				230					235						240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
			245						250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 326
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v40 ECD

<400> 326

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Trp	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20						25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75					80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
		100						105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Ile	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150					155					160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu

761612000240SeqList

210	Ser	Val	Arg	Tyr	Pro	215	Glu	Val	Ser	Ile	220	Gly	Tyr	Asp	Asp	Asn
225	Trp	Tyr	Leu	Gly	Arg	230	Thr	Asp	Ala	Thr	235	Ser	Cys	Asp	Val	Arg
					245	Thr	Gly	Tyr	Asp	Trp	250	Ser	Thr	Thr	Ser	Gly
	Asn	Pro	Glu	Pro	260	Thr	Gly	Tyr	Asp	Trp	265	Ser	Thr	Thr	Ser	Gly
	Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
	Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305	Thr	Ala	Gly	Ala	Gly	310	Ala	Thr	Gly	Gly	315					320
					325											

<210> 327
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v41 ECD

<400> 327

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1	Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly
				20					25					30	
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50				55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Lys	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Tyr	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130				135						140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155					160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
			195				200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210				215						220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

761612000240SeqList

<210> 328
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v42 ECD

<400> 328
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Trp Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Ser Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Thr Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 329
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v43 ECD

<400> 329
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Ser Val Pro Gly Leu
 20 25 30

761612000240SeqList

His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40				45				
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155					160	
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
				165					170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
			180					185					190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210					215					220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230				235					240	
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
				245					250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
			260					265					270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290					295					300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315				320	
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly							
				325											

<210> 330
 <211> 329
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v44 ECD

<400> 330

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10				15		
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Ser	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55				60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75					80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Arg	Asp	Ala	Thr	Leu	Ala	Leu
				85					90				95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120					125			
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130					135					140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro

761612000240SeqList

```

145      150      155      160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
      165      170      175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
      180      185      190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
      195      200      205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
      210      215      220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225      230      235      240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
      245      250      255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
      260      265      270
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
      275      280      285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
      290      295      300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305      310      315      320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
      325

```

```

<210> 331
<211> 329
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v45 ECD

```

```

<400> 331
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Val Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Ala Pro Val Pro Gly Leu
      20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
      35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
      50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
      85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
      100      105      110
Thr Phe Pro Lys Gly Thr Val Arg Gly Met Thr Trp Leu Arg Val Ile
      115      120      125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
      130      135      140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145      150      155      160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
      165      170      175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
      180      185      190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
      195      200      205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
      210      215      220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225      230      235      240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
      245      250      255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
      260      265      270

```

761612000240SeqList
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
275 280 285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
290 295 300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305 310 315 320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
325

<210> 332
<211> 329
<212> PRT
<213> Artificial Sequence

<220>
<223> CD112 v46 ECD

<400> 332
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1 5 10 15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20 25 30
His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35 40 45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50 55 60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65 70 75 80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85 90 95
His Gly Leu Thr Val Glu Asp Glu Gly Tyr Tyr Ile Cys Glu Phe Val
100 105 110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
115 120 125
Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
130 135 140
Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
145 150 155 160
Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
165 170 175
Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
180 185 190
Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
195 200 205
Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
210 215 220
Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
225 230 235 240
Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
245 250 255
Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
260 265 270
Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
275 280 285
Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
290 295 300
Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
305 310 315 320
Thr Ala Gly Ala Gly Ala Thr Gly Gly
325

<210> 333
<211> 329
<212> PRT
<213> Artificial Sequence

761612000240SeqList

<220>

<223> CD112 v47 ECD

<400> 333

Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Leu Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Met Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Met Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile
 115 120 125
 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln
 130 135 140
 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro
 145 150 155 160
 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr
 165 170 175
 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe
 180 185 190
 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys
 195 200 205
 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu
 210 215 220
 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn
 225 230 235 240
 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser
 245 250 255
 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe
 260 265 270
 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val
 275 280 285
 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val
 290 295 300
 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn
 305 310 315 320
 Thr Ala Gly Ala Gly Ala Thr Gly Gly
 325

<210> 334

<211> 125

<212> PRT

<213> Artificial Sequence

<220>

<223> CD112 v1 IgV

<400> 334

Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu

761612000240SeqList

His Gly Leu Thr⁸⁵ Val Glu Asp Glu Gly⁹⁰ Asn Tyr Thr Cys Glu⁹⁵ Phe Val
 Thr Phe Pro¹⁰⁰ Lys Asp Ser Val Arg¹⁰⁵ Gly Met Thr Trp Leu¹¹⁰
 Thr Phe Pro¹¹⁵ Lys Asp Ser Val Arg¹²⁰ Gly Met Thr Trp Leu¹²⁵

<210> 335
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v2 IgV

<400> 335
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Ala Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Gly
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Gly
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Ser Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 336
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v3 IgV

<400> 336
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Pro
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 337
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v4 IgV

761612000240SeqList

```

<400> 337
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Val Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ile
100     105     110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
115     120     125

```

```

<210> 338
<211> 125
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v5 IgV

```

```

<400> 338
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Ser Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100     105     110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
115     120     125

```

```

<210> 339
<211> 125
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v6 IgV

```

```

<400> 339
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Ala Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Asn Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95

```

761612000240SeqList
 His Gly Leu Thr Ala Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 340
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v7 IgV

<400> 340
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala
 100 105 110
 Thr Phe Pro Lys Gly Phe Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 341
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v8 IgV

<400> 341
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Trp Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn Tyr
 35 40 45
 Gln Asn Val Ala Ala Ser His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala
 100 105 110
 Thr Phe Pro Lys Gly Phe Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 342
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v9 IgV

761612000240SeqList

```

<400> 342
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Trp Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Arg Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala
100     105     110
Thr Phe Pro Lys Gly Phe Val Arg Gly Met Thr Trp Leu
115     120     125

```

```

<210> 343
<211> 125
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v10 IgV

```

```

<400> 343
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala
100     105     110
Ser Phe Pro Lys Gly Tyr Val Arg Gly Met Thr Trp Leu
115     120     125

```

```

<210> 344
<211> 125
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> CD112 v11 IgV

```

```

<400> 344
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala
100     105     110

```

761612000240SeqList

Thr Phe Pro Lys Gly Tyr Val Arg Gly Met Thr Trp Leu
 100 105 110
 115 120 125

<210> 345
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v12 IgV

<400> 345
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Ile Tyr Thr Cys Glu Phe Ala
 100 105 110
 Thr Phe Pro Lys Gly Tyr Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 346
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v13 IgV

<400> 346
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Ile Tyr Thr Cys Glu Phe Ala
 100 105 110
 Thr Phe Pro Lys Gly Phe Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 347
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v14 IgV

<400> 347

761612000240SeqList

Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Thr Pro
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala
 100 105 110
 Thr Phe Pro Lys Gly Tyr Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 348
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v15 IgV

<400> 348
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Ser Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 349
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v16 IgV

<400> 349
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
 100 105 110

761612000240SeqList

Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 350
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v17 IgV

<400> 350
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Ser Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 351
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v18 IgV

<400> 351
 Gln Asp Val Arg Val Gln Val Leu Ser Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Ser His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 352
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v19 IgV

<400> 352
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly

761612000240SeqList

```

1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Ser Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys His Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
115      120      125

```

<210> 353
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v20 IgV

```

<400> 353
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Leu Pro Val Pro Gly Pro
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Ser Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
115      120      125

```

<210> 354
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v21 IgV

```

<400> 354
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1      5      10      15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20      25      30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35      40      45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50      55      60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65      70      75      80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85      90      95
His Asp Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100      105      110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu

```

115

<210> 355
<211> 125
<212> PRT
<213> Artificial Sequence

<220>
<223> CD112 v22 IgV

<400> 355
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1 5 10 15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
20 25 30
His Ile Pro Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
35 40 45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50 55 60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65 70 75 80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85 90 95
His Gly Leu Thr Val Glu Asp Glu Gly Tyr Tyr Thr Cys Glu Phe Val
100 105 110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
115 120 125

<210> 356
<211> 125
<212> PRT
<213> Artificial Sequence

<220>
<223> CD112 v23 IgV

<400> 356
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1 5 10 15
Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Pro
20 25 30
Tyr Ile Ser Leu Val Thr Trp Gln Arg Ser Asp Ala Pro Ala Asn His
35 40 45
Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
50 55 60
Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
65 70 75 80
Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
85 90 95
His Gly Leu Ala Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
100 105 110
Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
115 120 125

<210> 357
<211> 125
<212> PRT
<213> Artificial Sequence

<220>
<223> CD112 v24 IgV

<400> 357
Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
1 5 10 15

761612000240SeqList

Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Ser	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Ser	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
		50				55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Ile	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 358
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v25 IgV

<400> 358

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10				15		
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Lys	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
		50				55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 359
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v26 IgV

<400> 359

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10				15		
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
		50				55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Tyr	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

761612000240SeqList

<210> 360
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v27 IgV

<400> 360
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Arg Gln Ser
 65 70 75 80
 Thr Gly Gln Gly Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Ser Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 361
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v28 IgV

<400> 361
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Lys His
 35 40 45
 Gln Asn Val Ala Ala Leu His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 362
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v29 IgV

<400> 362
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu

761612000240SeqList

<210> 365
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v32 IgV

<400> 365
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Trp Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ser Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 366
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v33 IgV

<400> 366
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Met Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 367
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v34 IgV

<400> 367
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30

761612000240SeqList

His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Thr	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 368
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v35 IgV

<400> 368

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Ala	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Ser	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 369
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v36 IgV

<400> 369

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	Arg	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Asn	Trp	Gln	Arg	Pro	Gly	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
				85					90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

761612000240SeqList

<210> 370
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v37 IgV

<400> 370
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 371
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v38 IgV

<400> 371
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ala Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 372
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v39 IgV

<400> 372
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His

761612000240SeqList

<211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v42 IgV

<400> 375
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Trp Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ser Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Thr Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 376
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v43 IgV

<400> 376
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Ser Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 377
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v44 IgV

<400> 377
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Ser Pro Val Pro Gly Leu
 20 25 30
 Tyr Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45

761612000240SeqList

Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Arg	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 378
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v45 IgV

<400> 378

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Val	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Ala	Pro	Val	Pro	Gly	Leu
			20					25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Thr	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 379
 <211> 125
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v46 IgV

<400> 379

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
			20					25					30		
His	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50					55					60				
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70					75				80	
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85						90					95	
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Tyr	Tyr	Ile	Cys	Glu	Phe	Val
			100					105					110		
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu			
		115					120					125			

<210> 380
 <211> 125

761612000240SeqList

<212> PRT
 <213> Artificial Sequence

<220>
 <223> CD112 v47 IgV

<400> 380
 Gln Asp Val Arg Val Gln Val Leu Pro Glu Val Arg Gly Gln Leu Gly
 1 5 10 15
 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu
 20 25 30
 His Ile Ser Leu Val Thr Trp Gln Arg Pro Asp Ala Pro Ala Asn His
 35 40 45
 Gln Asn Val Ala Ala Phe His Leu Lys Met Gly Pro Ser Phe Pro Ser
 50 55 60
 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Met Ser Ala Lys Gln Ser
 65 70 75 80
 Thr Gly Gln Asp Thr Glu Ala Glu Leu Gln Asp Ala Thr Leu Ala Leu
 85 90 95
 His Gly Leu Thr Met Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Val
 100 105 110
 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu
 115 120 125

<210> 381
 <211> 254
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD80-TIP I67T/L70Q/A91G/T120S

<400> 381
 Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu Ser Cys
 1 5 10 15
 Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile Tyr Trp
 20 25 30
 Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp Met Asn
 35 40 45
 Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr Asn Asn
 50 55 60
 Leu Ser Thr Val Ile Gln Ala Leu Arg Pro Ser Asp Glu Gly Thr Tyr
 65 70 75 80
 Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Gly Phe Lys Arg Glu His
 85 90 95
 Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr Pro Ser
 100 105 110
 Ile Ser Asp Phe Glu Ile Pro Ser Ser Asn Ile Arg Arg Ile Ile Cys
 115 120 125
 Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu Glu Asn
 130 135 140
 Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp Pro Glu
 145 150 155 160
 Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met Thr Thr
 165 170 175
 Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg Val Asn
 180 185 190
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205
 Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe
 210 215 220
 Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg
 225 230 235 240
 Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val
 245 250

761612000240SeqList

<210> 382
 <211> 867
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD80-TIP I67T/L70Q/A91G/T120S

<400> 382
 atggggccaca cacggaggca gggaacatca ccatccaagt gtccatacct caatttcttt 60
 cagctcttgg tgctggctgg tctttctcac ttctgttcag gtgttatcca cgtgaccaag 120
 gaagtgaag aagtggcaac gctgtcctgt ggtcacaatg tttctgttga agagctggca 180
 caaacctgca tctactggca aaaggagaag aaaatgggtgc tgactatgat gtctggggac 240
 atgaatatat ggcccagta caagaaccgg accatctttg atatcactaa taacctctcc 300
 acagtgatcc aagctctgcg cccatctgac gagggcacat acgagtgtgt tgttctgaag 360
 tatgaaaaag acggcttcaa gcgggaacac ctggctgaag tgacgttatc agtcaaagct 420
 gacttccta cacctagtat atctgacttt gaaattccat cttctaatat tagaaggata 480
 atttgctcaa cctctggagg ttttccagag cctcacctct cctggttgga aaatggagaa 540
 gaattaaatg ccatcaacac aacagtttcc caagatcctg aaactgagct ctatgctgtt 600
 agcagcaaac tggatttcaa tatgacaacc aaccacagct tcatgtgtct catcaagtat 660
 ggacatttaa gagtgaatca gaccttcaac tgggaatacaa ccaagcaaga gcattttcct 720
 gataacctgc tcccatcctg ggccattacc ttaatctcag taaatggaat ttttgtgata 780
 tgctgcctga cctactgctt tgccccaaga tgcagagaga gaaggaggaa tgagagattg 840
 agaagggaaa gtgtacgccc tgtataa 867

<210> 383
 <211> 284
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ICOSL-TIP N52H/I143T

<400> 383
 Asp Thr Gln Glu Lys Glu Val Arg Ala Met Val Gly Ser Asp Val Glu
 1 5 10 15
 Leu Ser Cys Ala Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn Asp Val
 20 25 30
 Tyr Val Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr Tyr His
 35 40 45
 Ile Pro Gln His Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr Arg Asn
 50 55 60
 Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe Ser Leu
 65 70 75 80
 Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His Cys Leu
 85 90 95
 Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val Glu Val
 100 105 110
 Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val Ser Ala Pro
 115 120 125
 His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr Cys Thr Ser Thr Asn
 130 135 140
 Gly Tyr Pro Arg Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp Asn Ser
 145 150 155 160
 Leu Leu Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn Met Arg
 165 170 175
 Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr Pro Ser
 180 185 190
 Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Asn Leu
 195 200 205
 Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp Lys Ile
 210 215 220
 Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr Trp Ser
 225 230 235 240
 Ile Leu Ala Val Leu Cys Leu Leu Val Val Val Ala Val Ala Ile Gly
 245 250 255
 Trp Val Cys Arg Asp Arg Cys Leu Gln His Ser Tyr Ala Gly Ala Trp

761612000240SeqList

Ala Val Ser Pro Glu Thr Glu Leu Thr Gly His Val
 260 265 270
 275 280

<210> 384
 <211> 909
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> ICOSL-TIP N52H/I143T

<400> 384
 atgaggctgg gcagtcctgg actgctcttc ctgctcttca gcagccttcg agctgatact 60
 caggagaagg aagtcagagc gatggtaggc agcgacgtgg agctcagctg cgcttgccct 120
 gaaggaagcc gttttgattt aaatgatgtt tacgtatatt ggcaaaccag tgagtcgaaa 180
 accgtggtga cctaccacat cccacagcac agctccttgg aaaacgtgga cagccgctac 240
 cggaaccgag ccctgatgtc accggccggc atgctgcggg gcgacttctc cctgcgcttg 300
 ttcaacgtca cccccagga cgagcagaag ttctactgcc tgggtgttgag ccaatccctg 360
 ggattccagg aggtttttgag cgttgaggtt acactgcatg tggcagcaaa cttcagcgtg 420
 cccgtcgtca gcgccccca cagccccctc caggatgagc tcaccttcac gtgtacatcc 480
 accaacggct accccaggcc caacgtgtac tggatcaata agacggacaa cagcctgctg 540
 gaccaggctc tgcagaatga caccgtcttc ttgaacatgc ggggcttgta tgacgtgggtc 600
 agcgtgctga ggatcgcacg gacccccagc gtgaacattg gctgctgcat agagaacgtg 660
 cttctgcagc agaacctgac tgtcggcagc cagacaggaa atgacatcgg agagagagac 720
 aagatcacag agaatccagt cagtaccggc gagaaaaacg cggccacgtg gagcatcctg 780
 gctgtcctgt gcctgcttgt ggtcgtggcg gtggccatag gctgggtgtg cagggaccga 840
 tgcctccaac acagctatgc aggtgcctgg gctgtgagtc cggagacaga gctcactggc 900
 cacgtttga 909

<210> 385
 <211> 248
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Anti-CD19 scFv

<400> 385
 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
 85 90 95
 Thr Phe Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr Ser Gly
 100 105 110
 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys
 115 120 125
 Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser
 130 135 140
 Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser
 145 150 155 160
 Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile
 165 170 175
 Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu
 180 185 190
 Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn
 195 200 205
 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr

761612000240SeqList

210
 Tyr Tyr Gly Gly Ser Tyr 215
 225 230 Ala Met Asp Tyr Trp 220 Gly Gln Gly Thr Ser
 Val Thr Val Ser Ser Ala Ala Ala 235 240
 245

<210> 386
 <211> 71
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD8-derived hinge and transmembrane domain

<400> 386
 Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
 1 5 10 15
 Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Ser Arg Pro Ala
 20 25 30
 Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Ser Asp Ile
 35 40 45
 Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser
 50 55 60
 Leu Val Ile Thr Leu Tyr Cys
 65 70

<210> 387
 <211> 112
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CD3zeta intracellular signaling domain

<400> 387
 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 1 5 10 15
 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
 20 25 30
 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
 35 40 45
 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
 50 55 60
 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
 65 70 75 80
 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
 85 90 95
 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 100 105 110

<210> 388
 <211> 1356
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> AntiCD19x8z chimeric antigen receptor

<400> 388
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccggacatcc agatgacaca gactacatcc tccctgtctg cctctctggg agacagagtc 120
 accatcagtt gcagggcaag tcaggacatt agtaaatatt taaattggta tcagcagaaa 180
 ccagatggaa ctgttaaact cctgatctac catacatcaa gattacactc aggagtccca 240
 tcaagggtca gtggcagtgg gtctggaaca gattattctc tcaccattag caacctggag 300
 caagaagata ttgccactta cttttgccaa cagggttaata cgcttcgta cacgttcgga 360

ggggggacta	agttggaat	aacaggctcc	acctctggat	ccggcaagcc	cggatctggc	420
gagggatcca	ccaagggcga	ggtgaaactg	caggagtcag	gacctggcct	ggtggcgccc	480
tcacagagcc	tgtccgtcac	atgcactgtc	tcaggggtct	cattaccgga	ctatggtgta	540
agctggattc	gccagccttc	acgaaatgggt	ctggagtggc	tgggagtaat	atggggtagt	600
gaaccacat	actataatc	agcttcaaa	tcagactga	ccatcatcaa	ggacaactcc	660
aagagccaag	ttttcttaaa	aatgaacagt	ctgcaaatga	atgacacagc	catttactac	720
tgtgccaac	attattacta	cggtggtagc	tatgctatgg	actactgggg	tcaaggaacc	780
tcagtcaccg	tctcctcagc	ggccgcaaag	cccaccacga	cgccagcgcc	gcgaccacca	840
acaccggcgc	ccaccatcgc	gtcgcagccc	ctgtccctcg	gcccagaggg	gagccggcca	900
gcggcggggg	gcgcagtgca	cacgaggggg	ctggactctg	ccagtgatat	ctacactctgg	960
gcgcccctgg	cgggactctg	tggggtcctt	ctcctgtcac	tggttatcac	cctttactgc	1020
agagtgaagt	tcagcaggag	cgcagacgcc	cccgcgtacc	agcagggcca	gaaccagctc	1080
tataacgagc	tcaatctagg	acgaagagag	gagtacgatg	ttttggacaa	gagacgtggc	1140
cgggaccctg	agatgggggg	aaagccgaga	aggaagaacc	ctcaggaagg	cctgtacaat	1200
gaactgcaga	aagataaagt	ggcggaggcc	tacagtgaga	ttgggatgaa	aggcgagcgc	1260
cggaggggca	aggggcacga	tggcctttac	cagggtctca	gtacagccac	caaggacacc	1320
tacgacgccc	ttcacatgca	ggccctgccc	cctcgc			1356

```
<210> 389
<211> 63
<212> DNA
<213> Artificial Sequence
```

$\langle 220 \rangle$
 $\langle 223 \rangle$ T2A

```
<400> 389
ggcagtggcg agggcagagg aagtctgcta acatgcggtg acgtcgagga gaatcctggc 60
cca 63
```

<210>	390
<211>	21
<212>	PRT
<213>	Artificial Sequence

$\langle 220 \rangle$
 $\langle 223 \rangle$ T2A

<400> 390
Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu
1 5 10 15
Glu Asn Pro Gly Pro
20

```
<210> 391
<211> 867
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> CD80
```

<400>	391					
atggggccaca	cacggaggga	gggaacatca	ccatccaagt	gtccatacct	caattttcttt	60
cagctcttgg	tgctggctgg	tctttctcac	ttctgttcag	gtgttatcca	cgtgaccaag	120
gaagtgaaag	aagtggcaac	gctgtcctgt	ggtcacaatg	tttctgttga	agagctggga	180
caaactcgca	tctactggca	aaaggagaag	aaaattggtc	tgactatgat	gtctggggac	240
atgaatatat	ggcccagata	caagaaccgg	accatctttg	atatacctaa	taacctctcc	300
attgtgatcc	tggtctctgc	cccattctgc	gagggcacat	acgagtgtgt	tgttctgaag	360
tatgaaaaag	acgctttcaa	gcgggaacac	ctggctgaag	tgacgttatc	agtcaaagct	420
gacttcccta	cacctagtat	atctgacttt	gaaattccaa	cttctaatat	tagaaggata	480
atttgtctca	cctctggagg	ttttccagag	cctcacctct	cctggttgga	aaatggagaa	540
gaattaaatg	ccatcaaac	aacagttttc	caagatcctg	aaactgagct	ctatgctgtt	600
agcagcaaac	tggatttcaa	tatgacaacc	aaccacagct	tcattgttct	catcaagtat	660

761612000240SeqList

ggacatttaa	gagtgaatca	gaccttcaac	tggaatacaa	ccaagcaaga	gcatttttct	720
gataacctgc	tcccatcctg	ggccattacc	ttaatctcag	taaatggaat	ttttgtgata	780
tgctgcctga	cctactgctt	tgccccaaga	tgccagagaga	gaaggaggaa	tgagagattg	840
agaagggaaa	gtgtacgccc	tgtataa				867

<210> 392
 <211> 909
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> ICOSL

<400> 392						
atgctggctgg	gcagtcctgg	actgctcttc	ctgctcttca	gcagccttcg	agctgatact	60
caggagaagg	aagtcagagc	gatggtaggc	agcgacgtgg	agctcagctg	cgcttgccct	120
gaaggaagcc	gttttgattt	aaatgatgtt	tacgtatatt	ggcaaaccag	tgagtcgaaa	180
accgtgggtga	cctaccacat	cccacagaac	agctccttgg	aaaacgtgga	cagccgctac	240
cggaaccgag	ccctgatgtc	accggccggc	atgctgcggg	gcgacttctc	cctgcgcttg	300
ttcaacgtca	ccccccagga	cgagcagaag	tttactgccc	tggtgttgag	ccaatccctg	360
ggattccagg	aggttttgag	cgttgaggtt	acactgcatg	tggcagcaaa	cttcagcgtg	420
cccgtcgtca	gcgcccccca	cagcccctcc	caggatgagc	tcaccttcac	gtgtacatcc	480
ataaacggct	accccaggcc	caacgtgtac	tggatcaata	agacggacaa	cagcctgctg	540
gaccaggctc	tgagaatga	caccgtcttc	ttgaacatgc	ggggcttgta	tgacgtggtc	600
agcgtgctga	ggatcgacg	gacccccagc	gtgaacattg	gctgctgcat	agagAACgtg	660
cttctgcagc	agaacctgac	tgtcggcagc	cagacaggaa	atgacatcgg	agagagagac	720
aagatcacag	agaatccagt	cagtaccggc	gagaaaaacg	cggccacgtg	gagcatcctg	780
gctgtcctgt	gcctgcttgt	ggtcgtggcg	gtggccatag	gctgggtgtg	cagggaccga	840
tgctccaac	acagctatgc	aggtgcctgg	gctgtgagtc	cggagacaga	gctcactggc	900
cacgtttga						909

<210> 393
 <211> 254
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD80(B7-1)

<400> 393															
Val	Ile	His	Val	Thr	Lys	Glu	Val	Lys	Glu	Val	Ala	Thr	Leu	Ser	Cys
1				5				10					15		
Gly	His	Asn	Val	Ser	Val	Glu	Glu	Leu	Ala	Gln	Thr	Arg	Ile	Tyr	Trp
			20					25					30		
Gln	Lys	Glu	Lys	Lys	Met	Val	Leu	Thr	Met	Met	Ser	Gly	Asp	Met	Asn
			35				40					45			
Ile	Trp	Pro	Glu	Tyr	Lys	Asn	Arg	Thr	Ile	Phe	Asp	Ile	Thr	Asn	Asn
			50			55				60					
Leu	Ser	Ile	Val	Ile	Leu	Ala	Leu	Arg	Pro	Ser	Asp	Glu	Gly	Thr	Tyr
65					70			75						80	
Glu	Cys	Val	Val	Leu	Lys	Tyr	Glu	Lys	Asp	Ala	Phe	Lys	Arg	Glu	His
			85					90						95	
Leu	Ala	Glu	Val	Thr	Leu	Ser	Val	Lys	Ala	Asp	Phe	Pro	Thr	Pro	Ser
			100				105					110			
Ile	Ser	Asp	Phe	Glu	Ile	Pro	Thr	Ser	Asn	Ile	Arg	Arg	Ile	Ile	Cys
		115				120					125				
Ser	Thr	Ser	Gly	Gly	Phe	Pro	Glu	Pro	His	Leu	Ser	Trp	Leu	Glu	Asn
		130			135					140					
Gly	Glu	Glu	Leu	Asn	Ala	Ile	Asn	Thr	Thr	Val	Ser	Gln	Asp	Pro	Glu
145					150					155				160	
Thr	Glu	Leu	Tyr	Ala	Val	Ser	Ser	Lys	Leu	Asp	Phe	Asn	Met	Thr	Thr
			165					170						175	
Asn	His	Ser	Phe	Met	Cys	Leu	Ile	Lys	Tyr	Gly	His	Leu	Arg	Val	Asn
			180				185					190			

761612000240SeqList
 Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro Asp Asn
 195 200 205
 Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe
 210 215 220
 Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg
 225 230 235 240
 Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val
 245 250

<210> 394
 <211> 306
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD86(B7-2)

<400> 394
 Ala Pro Leu Lys Ile Gln Ala Tyr Phe Asn Glu Thr Ala Asp Leu Pro
 1 5 10 15
 Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val Val
 20 25 30
 Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu Gly
 35 40 45
 Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr Ser
 50 55 60
 Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile Lys
 65 70 75 80
 Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr Gly
 85 90 95
 Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala Asn
 100 105 110
 Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn Val
 115 120 125
 Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro Lys
 130 135 140
 Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Glu Tyr Asp
 145 150 155 160
 Gly Val Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp Val
 165 170 175
 Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met Thr
 180 185 190
 Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser Pro
 195 200 205
 Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile Pro
 210 215 220
 Trp Ile Thr Ala Val Leu Pro Thr Val Ile Ile Cys Val Met Val Phe
 225 230 235 240
 Cys Leu Ile Leu Trp Lys Trp Lys Lys Lys Arg Pro Arg Asn Ser
 245 250 255
 Tyr Lys Cys Gly Thr Asn Thr Met Glu Arg Glu Glu Ser Glu Gln Thr
 260 265 270
 Lys Lys Arg Glu Lys Ile His Ile Pro Glu Arg Ser Asp Glu Ala Gln
 275 280 285
 Arg Val Phe Lys Ser Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp Thr
 290 295 300
 Cys Phe
 305

<210> 395
 <211> 272
 <212> PRT
 <213> Homo sapiens

<220>

761612000240SeqList

<221> MISC_FEATURE

<223> Mature CD274 (PD-L1, B7-H1)

<400> 395

```

Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser
1      5      10      15
Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu Asp Leu
20      25      30
Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile Ile Gln
35      40      45
Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser Tyr Arg
50      55      60
Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn Ala Ala
65      70      75      80
Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr Arg Cys
85      90      95
Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys Val
100      105      110
Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro
115      120      125
Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr Pro Lys
130      135      140
Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly Lys
145      150      155      160
Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val Thr
165      170      175
Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys Thr
180      185      190
Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val Ile
195      200      205
Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His Leu Val
210      215      220
Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr Phe Ile
225      230      235      240
Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys Gly Ile
245      250      255
Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu Glu Thr
260      265      270

```

<210> 396

<211> 254

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Mature PDCD1LG2(PD-L2, CD273)

<400> 396

```

Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile Glu His Gly
1      5      10      15
Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser His Val Asn
20      25      30
Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn Asp Thr Ser
35      40      45
Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu Pro Leu Gly
50      55      60
Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp Glu Gly Gln
65      70      75      80
Tyr Gln Cys Ile Ile Tyr Gly Val Ala Trp Asp Tyr Lys Tyr Leu
85      90      95
Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr His Ile Leu
100      105      110
Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln Ala Thr Gly
115      120      125
Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val Pro Ala Asn
130      135      140

```

761612000240SeqList

Thr	Ser	His	Ser	Arg	Thr	Pro	Glu	Gly	Leu	Tyr	Gln	Val	Thr	Ser	Val
145					150					155					160
Leu	Arg	Leu	Lys	Pro	Pro	Gly	Arg	Asn	Phe	Ser	Cys	Val	Phe	Trp	
				165				170							175
Asn	Thr	His	Val	Arg	Glu	Leu	Thr	Leu	Ala	Ser	Ile	Asp	Leu	Gln	Ser
			180					185					190		
Gln	Met	Glu	Pro	Arg	Thr	His	Pro	Thr	Trp	Leu	Leu	His	Ile	Phe	Ile
		195					200					205			
Pro	Phe	Cys	Ile	Ile	Ala	Phe	Ile	Phe	Ile	Ala	Thr	Val	Ile	Ala	Leu
	210					215					220				
Arg	Lys	Gln	Leu	Cys	Gln	Lys	Leu	Tyr	Ser	Ser	Lys	Asp	Thr	Thr	Lys
225					230					235					240
Arg	Pro	Val	Thr	Thr	Thr	Lys	Arg	Glu	Val	Asn	Ser	Ala	Ile		
				245					250						

<210> 397
 <211> 284
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature ICOSLG(B7RP1, CD275, ICOSL, B7-H2)

<400> 397

Asp	Thr	Gln	Glu	Lys	Glu	Val	Arg	Ala	Met	Val	Gly	Ser	Asp	Val	Glu
1				5					10					15	
Leu	Ser	Cys	Ala	Cys	Pro	Glu	Gly	Ser	Arg	Phe	Asp	Leu	Asn	Asp	Val
			20					25					30		
Tyr	Val	Tyr	Trp	Gln	Thr	Ser	Glu	Ser	Lys	Thr	Val	Val	Thr	Tyr	His
		35					40					45			
Ile	Pro	Gln	Asn	Ser	Ser	Leu	Glu	Asn	Val	Asp	Ser	Arg	Tyr	Arg	Asn
	50					55				60					
Arg	Ala	Leu	Met	Ser	Pro	Ala	Gly	Met	Leu	Arg	Gly	Asp	Phe	Ser	Leu
65					70				75						80
Arg	Leu	Phe	Asn	Val	Thr	Pro	Gln	Asp	Glu	Gln	Lys	Phe	His	Cys	Leu
			85					90						95	
Val	Leu	Ser	Gln	Ser	Leu	Gly	Phe	Gln	Glu	Val	Leu	Ser	Val	Glu	Val
			100					105					110		
Thr	Leu	His	Val	Ala	Ala	Asn	Phe	Ser	Val	Pro	Val	Val	Ser	Ala	Pro
		115					120					125			
His	Ser	Pro	Ser	Gln	Asp	Glu	Leu	Thr	Phe	Thr	Cys	Thr	Ser	Ile	Asn
	130					135					140				
Gly	Tyr	Pro	Arg	Pro	Asn	Val	Tyr	Trp	Ile	Asn	Lys	Thr	Asp	Asn	Ser
145					150					155					160
Leu	Leu	Asp	Gln	Ala	Leu	Gln	Asn	Asp	Thr	Val	Phe	Leu	Asn	Met	Arg
				165					170					175	
Gly	Leu	Tyr	Asp	Val	Val	Ser	Val	Leu	Arg	Ile	Ala	Arg	Thr	Pro	Ser
			180					185					190		
Val	Asn	Ile	Gly	Cys	Cys	Ile	Glu	Asn	Val	Leu	Leu	Gln	Gln	Asn	Leu
		195					200					205			
Thr	Val	Gly	Ser	Gln	Thr	Gly	Asn	Asp	Ile	Gly	Glu	Arg	Asp	Lys	Ile
	210					215					220				
Thr	Glu	Asn	Pro	Val	Ser	Thr	Gly	Glu	Lys	Asn	Ala	Ala	Thr	Trp	Ser
225					230					235					240
Ile	Leu	Ala	Val	Leu	Cys	Leu	Leu	Val	Val	Val	Ala	Val	Ala	Ile	Gly
				245					250					255	
Trp	Val	Cys	Arg	Asp	Arg	Cys	Leu	Gln	His	Ser	Tyr	Ala	Gly	Ala	Trp
			260				265						270		
Ala	Val	Ser	Pro	Glu	Thr	Glu	Leu	Thr	Gly	His	Val				
		275					280								

<210> 398
 <211> 506
 <212> PRT
 <213> Homo sapiens

761612000240SeqList

<220>

<221> MISC_FEATURE

<223> Mature CD276(B7-H3)

<400> 398

```

Leu Glu Val Gln Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr
1      5      10      15
Asp Ala Thr Leu Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu
20      25      30
Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu Val
35      40      45
His Ser Phe Ala Glu Gly Gln Asp Gln Gly Ser Ala Tyr Ala Asn Arg
50      55      60
Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg
65      70      75      80
Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr Cys Phe Val
85      90      95
Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln Val Ala Ala
100     105     110
Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg
115     120     125
Pro Gly Asp Thr Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro
130     135     140
Glu Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly
145     150     155     160
Asn Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val
165     170     175
His Ser Ile Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys
180     185     190
Leu Val Arg Asn Pro Val Leu Gln Asp Ala His Ser Ser Val Thr
195     200     205
Ile Thr Pro Gln Arg Ser Pro Thr Gly Ala Val Glu Val Gln Val Pro
210     215     220
Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr Leu Arg Cys
225     230     235     240
Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn Leu Ile
245     250     255
Trp Gln Leu Thr Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly
260     265     270
Arg Asp Gln Gly Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp
275     280     285
Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg Val
290     295     300
Ala Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe Gly
305     310     315     320
Ser Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro Ser
325     330     335
Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr Val Thr
340     345     350
Ile Thr Cys Ser Ser Tyr Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp
355     360     365
Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln
370     375     380
Met Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val
385     390     395     400
Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val
405     410     415
Leu Gln Gln Asp Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro Met
420     425     430
Thr Phe Pro Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys
435     440     445
Leu Ile Ala Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile
450     455     460
Lys Gln Ser Cys Glu Glu Glu Asn Ala Gly Ala Glu Asp Gln Asp Gly
465     470     475     480
Glu Gly Glu Gly Ser Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp
485     490     495

```

761612000240SeqList
 Ser Lys Glu Asp Asp Gly Gln Glu Ile Ala
 500 505

<210> 399
 <211> 258
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature VTCN1(B7-H4)

<400> 399
 Leu Ile Ile Gly Phe Gly Ile Ser Gly Arg His Ser Ile Thr Val Thr
 1 5 10 15
 Thr Val Ala Ser Ala Gly Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys
 20 25 30
 Thr Phe Glu Pro Asp Ile Lys Leu Ser Asp Ile Val Ile Gln Trp Leu
 35 40 45
 Lys Glu Gly Val Leu Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp
 50 55 60
 Glu Leu Ser Glu Gln Asp Glu Met Phe Arg Gly Arg Thr Ala Val Phe
 65 70 75 80
 Ala Asp Gln Val Ile Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val
 85 90 95
 Gln Leu Thr Asp Ala Gly Thr Tyr Lys Cys Tyr Ile Ile Thr Ser Lys
 100 105 110
 Gly Lys Gly Asn Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser Met
 115 120 125
 Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu Thr Leu Arg Cys
 130 135 140
 Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val Trp Ala Ser Gln
 145 150 155 160
 Val Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe Glu
 165 170 175
 Leu Asn Ser Glu Asn Val Thr Met Lys Val Val Ser Val Leu Tyr Asn
 180 185 190
 Val Thr Ile Asn Asn Thr Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala
 195 200 205
 Lys Ala Thr Gly Asp Ile Lys Val Thr Glu Ser Glu Ile Lys Arg Arg
 210 215 220
 Ser His Leu Gln Leu Leu Asn Ser Lys Ala Ser Leu Cys Val Ser Ser
 225 230 235 240
 Phe Phe Ala Ile Ser Trp Ala Leu Leu Pro Leu Ser Pro Tyr Leu Met
 245 250 255
 Leu Lys

<210> 400
 <211> 202
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD28

<400> 400
 Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr Asp Asn
 1 5 10 15
 Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser Arg Glu
 20 25 30
 Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu Val Cys
 35 40 45
 Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser Lys Thr
 50 55 60

761612000240SeqList

Gly	Phe	Asn	Cys	Asp	Gly	Lys	Leu	Gly	Asn	Glu	Ser	Val	Thr	Phe	Tyr
65					70				75						80
Leu	Gln	Asn	Leu	Tyr	Val	Asn	Gln	Thr	Asp	Ile	Tyr	Phe	Cys	Lys	Ile
				85					90					95	
Glu	Val	Met	Tyr	Pro	Pro	Pro	Tyr	Leu	Asp	Asn	Glu	Lys	Ser	Asn	Gly
			100					105					110		
Thr	Ile	Ile	His	Val	Lys	Gly	Lys	His	Leu	Cys	Pro	Ser	Pro	Leu	Phe
		115					120					125			
Pro	Gly	Pro	Ser	Lys	Pro	Phe	Trp	Val	Leu	Val	Val	Val	Gly	Gly	Val
	130					135					140				
Leu	Ala	Cys	Tyr	Ser	Leu	Leu	Val	Thr	Val	Ala	Phe	Ile	Ile	Phe	Trp
145					150					155					160
Val	Arg	Ser	Lys	Arg	Ser	Arg	Leu	Leu	His	Ser	Asp	Tyr	Met	Asn	Met
				165					170					175	
Thr	Pro	Arg	Arg	Pro	Gly	Pro	Thr	Arg	Lys	His	Tyr	Gln	Pro	Tyr	Ala
			180					185					190		
Pro	Pro	Arg	Asp	Phe	Ala	Ala	Tyr	Arg	Ser						
		195					200								

<210> 401
 <211> 188
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CTLA4

<400> 401

Lys	Ala	Met	His	Val	Ala	Gln	Pro	Ala	Val	Val	Leu	Ala	Ser	Ser	Arg
1				5					10					15	
Gly	Ile	Ala	Ser	Phe	Val	Cys	Glu	Tyr	Ala	Ser	Pro	Gly	Lys	Ala	Thr
			20					25					30		
Glu	Val	Arg	Val	Thr	Val	Leu	Arg	Gln	Ala	Asp	Ser	Gln	Val	Thr	Glu
		35					40					45			
Val	Cys	Ala	Ala	Thr	Tyr	Met	Met	Gly	Asn	Glu	Leu	Thr	Phe	Leu	Asp
	50					55					60				
Asp	Ser	Ile	Cys	Thr	Gly	Thr	Ser	Ser	Gly	Asn	Gln	Val	Asn	Leu	Thr
65					70				75					80	
Ile	Gln	Gly	Leu	Arg	Ala	Met	Asp	Thr	Gly	Leu	Tyr	Ile	Cys	Lys	Val
			85						90					95	
Glu	Leu	Met	Tyr	Pro	Pro	Pro	Tyr	Tyr	Leu	Gly	Ile	Gly	Asn	Gly	Thr
		100						105					110		
Gln	Ile	Tyr	Val	Ile	Asp	Pro	Glu	Pro	Cys	Pro	Asp	Ser	Asp	Phe	Leu
		115					120					125			
Leu	Trp	Ile	Leu	Ala	Ala	Val	Ser	Ser	Gly	Leu	Phe	Phe	Tyr	Ser	Phe
	130					135					140				
Leu	Leu	Thr	Ala	Val	Ser	Leu	Ser	Lys	Met	Leu	Lys	Lys	Arg	Ser	Pro
145					150					155					160
Leu	Thr	Thr	Gly	Val	Tyr	Val	Lys	Met	Pro	Pro	Thr	Glu	Pro	Glu	Cys
			165						170					175	
Glu	Lys	Gln	Phe	Gln	Pro	Tyr	Phe	Ile	Pro	Ile	Asn				
			180					185							

<210> 402
 <211> 268
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature PDCD1(PD-1)

<400> 402

Pro	Gly	Trp	Phe	Leu	Asp	Ser	Pro	Asp	Arg	Pro	Trp	Asn	Pro	Pro	Thr
1				5					10					15	

761612000240SeqList

Phe	Ser	Pro	Ala	Leu	Leu	Val	Val	Thr	Glu	Gly	Asp	Asn	Ala	Thr	Phe
			20					25					30		
Thr	Cys	Ser	Phe	Ser	Asn	Thr	Ser	Glu	Ser	Phe	Val	Leu	Asn	Trp	Tyr
		35					40					45			
Arg	Met	Ser	Pro	Ser	Asn	Gln	Thr	Asp	Lys	Leu	Ala	Ala	Phe	Pro	Glu
	50				55						60				
Asp	Arg	Ser	Gln	Pro	Gly	Gln	Asp	Cys	Arg	Phe	Arg	Val	Thr	Gln	Leu
65					70					75					80
Pro	Asn	Gly	Arg	Asp	Phe	His	Met	Ser	Val	Val	Arg	Ala	Arg	Arg	Asn
				85					90					95	
Asp	Ser	Gly	Thr	Tyr	Leu	Cys	Gly	Ala	Ile	Ser	Leu	Ala	Pro	Lys	Ala
			100					105					110		
Gln	Ile	Lys	Glu	Ser	Leu	Arg	Ala	Glu	Leu	Arg	Val	Thr	Glu	Arg	Arg
		115						120				125			
Ala	Glu	Val	Pro	Thr	Ala	His	Pro	Ser	Pro	Ser	Pro	Arg	Pro	Ala	Gly
	130					135						140			
Gln	Phe	Gln	Thr	Leu	Val	Val	Gly	Val	Val	Gly	Gly	Leu	Leu	Gly	Ser
145					150					155					160
Leu	Val	Leu	Leu	Val	Trp	Val	Leu	Ala	Val	Ile	Cys	Ser	Arg	Ala	Ala
				165					170					175	
Arg	Gly	Thr	Ile	Gly	Ala	Arg	Arg	Thr	Gly	Gln	Pro	Leu	Lys	Glu	Asp
			180					185					190		
Pro	Ser	Ala	Val	Pro	Val	Phe	Ser	Val	Asp	Tyr	Gly	Glu	Leu	Asp	Phe
		195					200					205			
Gln	Trp	Arg	Glu	Lys	Thr	Pro	Glu	Pro	Pro	Val	Pro	Cys	Val	Pro	Glu
	210					215					220				
Gln	Thr	Glu	Tyr	Ala	Thr	Ile	Val	Phe	Pro	Ser	Gly	Met	Gly	Thr	Ser
225					230					235					240
Ser	Pro	Ala	Arg	Arg	Gly	Ser	Ala	Asp	Gly	Pro	Arg	Ser	Ala	Gln	Pro
				245					250					255	
Leu	Arg	Pro	Glu	Asp	Gly	His	Cys	Ser	Trp	Pro	Leu				
			260					265							

<210> 403
 <211> 179
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature ICOS

<400> 403

Glu	Ile	Asn	Gly	Ser	Ala	Asn	Tyr	Glu	Met	Phe	Ile	Phe	His	Asn	Gly
1				5				10						15	
Gly	Val	Gln	Ile	Leu	Cys	Lys	Tyr	Pro	Asp	Ile	Val	Gln	Gln	Phe	Lys
			20					25					30		
Met	Gln	Leu	Leu	Lys	Gly	Gly	Gln	Ile	Leu	Cys	Asp	Leu	Thr	Lys	Thr
		35				40						45			
Lys	Gly	Ser	Gly	Asn	Thr	Val	Ser	Ile	Lys	Ser	Leu	Lys	Phe	Cys	His
	50				55						60				
Ser	Gln	Leu	Ser	Asn	Asn	Ser	Val	Ser	Phe	Phe	Leu	Tyr	Asn	Leu	Asp
65				70						75				80	
His	Ser	His	Ala	Asn	Tyr	Tyr	Phe	Cys	Asn	Leu	Ser	Ile	Phe	Asp	Pro
				85					90					95	
Pro	Pro	Phe	Lys	Val	Thr	Leu	Thr	Gly	Gly	Tyr	Leu	His	Ile	Tyr	Glu
			100					105					110		
Ser	Gln	Leu	Cys	Cys	Gln	Leu	Lys	Phe	Trp	Leu	Pro	Ile	Gly	Cys	Ala
		115					120					125			
Ala	Phe	Val	Val	Val	Cys	Ile	Leu	Gly	Cys	Ile	Leu	Ile	Cys	Trp	Leu
	130					135					140				
Thr	Lys	Lys	Lys	Tyr	Ser	Ser	Ser	Val	His	Asp	Pro	Asn	Gly	Glu	Tyr
145					150					155					160
Met	Phe	Met	Arg	Ala	Val	Asn	Thr	Ala	Lys	Lys	Ser	Arg	Leu	Thr	Asp
				165					170					175	
Val	Thr	Leu													

761612000240SeqList

<210> 404
 <211> 259
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature BTLA(CD272)

<400> 404
 Lys Glu Ser Cys Asp Val Gln Leu Tyr Ile Lys Arg Gln Ser Glu His
 1 5 10 15
 Ser Ile Leu Ala Gly Asp Pro Phe Glu Leu Glu Cys Pro Val Lys Tyr
 20 25 30
 Cys Ala Asn Arg Pro His Val Thr Trp Cys Lys Leu Asn Gly Thr Thr
 35 40 45
 Cys Val Lys Leu Glu Asp Arg Gln Thr Ser Trp Lys Glu Glu Lys Asn
 50 55 60
 Ile Ser Phe Phe Ile Leu His Phe Glu Pro Val Leu Pro Asn Asp Asn
 65 70 75 80
 Gly Ser Tyr Arg Cys Ser Ala Asn Phe Gln Ser Asn Leu Ile Glu Ser
 85 90 95
 His Ser Thr Thr Leu Tyr Val Thr Asp Val Lys Ser Ala Ser Glu Arg
 100 105 110
 Pro Ser Lys Asp Glu Met Ala Ser Arg Pro Trp Leu Leu Tyr Arg Leu
 115 120 125
 Leu Pro Leu Gly Gly Leu Pro Leu Leu Ile Thr Thr Cys Phe Cys Leu
 130 135 140
 Phe Cys Cys Leu Arg Arg His Gln Gly Lys Gln Asn Glu Leu Ser Asp
 145 150 155 160
 Thr Ala Gly Arg Glu Ile Asn Leu Val Asp Ala His Leu Lys Ser Glu
 165 170 175
 Gln Thr Glu Ala Ser Thr Arg Gln Asn Ser Gln Val Leu Leu Ser Glu
 180 185 190
 Thr Gly Ile Tyr Asp Asn Asp Pro Asp Leu Cys Phe Arg Met Gln Glu
 195 200 205
 Gly Ser Glu Val Tyr Ser Asn Pro Cys Leu Glu Glu Asn Lys Pro Gly
 210 215 220
 Ile Val Tyr Ala Ser Leu Asn His Ser Val Ile Gly Pro Asn Ser Arg
 225 230 235 240
 Leu Ala Arg Asn Val Lys Glu Ala Pro Thr Glu Tyr Ala Ser Ile Cys
 245 250 255
 Val Arg Ser

<210> 405
 <211> 433
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD4

<400> 405
 Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
 1 5 10 15
 Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
 20 25 30
 Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
 35 40 45
 Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
 50 55 60
 Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
 65 70 75 80

761612000240SeqList

Thr	Tyr	Ile	Cys	Glu	Val	Glu	Asp	Gln	Lys	Glu	Glu	Val	Gln	Leu	Leu
				85					90					95	
Val	Phe	Gly	Leu	Thr	Ala	Asn	Ser	Asp	Thr	His	Leu	Leu	Gln	Gly	Gln
			100					105					110		
Ser	Leu	Thr	Leu	Thr	Leu	Glu	Ser	Pro	Pro	Gly	Ser	Ser	Pro	Ser	Val
		115					120					125			
Gln	Cys	Arg	Ser	Pro	Arg	Gly	Lys	Asn	Ile	Gln	Gly	Gly	Lys	Thr	Leu
	130					135					140				
Ser	Val	Ser	Gln	Leu	Glu	Leu	Gln	Asp	Ser	Gly	Thr	Trp	Thr	Cys	Thr
145					150					155					160
Val	Leu	Gln	Asn	Gln	Lys	Lys	Val	Glu	Phe	Lys	Ile	Asp	Ile	Val	Val
			165						170					175	
Leu	Ala	Phe	Gln	Lys	Ala	Ser	Ser	Ile	Val	Tyr	Lys	Lys	Glu	Gly	Glu
			180					185					190		
Gln	Val	Glu	Phe	Ser	Phe	Pro	Leu	Ala	Phe	Thr	Val	Glu	Lys	Leu	Thr
		195					200					205			
Gly	Ser	Gly	Glu	Leu	Trp	Trp	Gln	Ala	Glu	Arg	Ala	Ser	Ser	Ser	Lys
	210				215					220					
Ser	Trp	Ile	Thr	Phe	Asp	Leu	Lys	Asn	Lys	Glu	Val	Ser	Val	Lys	Arg
225					230					235					240
Val	Thr	Gln	Asp	Pro	Lys	Leu	Gln	Met	Gly	Lys	Lys	Leu	Pro	Leu	His
			245						250					255	
Leu	Thr	Leu	Pro	Gln	Ala	Leu	Pro	Gln	Tyr	Ala	Gly	Ser	Gly	Asn	Leu
			260					265					270		
Thr	Leu	Ala	Leu	Glu	Ala	Lys	Thr	Gly	Lys	Leu	His	Gln	Glu	Val	Asn
	275						280					285			
Leu	Val	Val	Met	Arg	Ala	Thr	Gln	Leu	Gln	Lys	Asn	Leu	Thr	Cys	Glu
	290					295					300				
Val	Trp	Gly	Pro	Thr	Ser	Pro	Lys	Leu	Met	Leu	Ser	Leu	Lys	Leu	Glu
305					310				315						320
Asn	Lys	Glu	Ala	Lys	Val	Ser	Lys	Arg	Glu	Lys	Ala	Val	Trp	Val	Leu
			325						330					335	
Asn	Pro	Glu	Ala	Gly	Met	Trp	Gln	Cys	Leu	Leu	Ser	Asp	Ser	Gly	Gln
			340					345					350		
Val	Leu	Leu	Glu	Ser	Asn	Ile	Lys	Val	Leu	Pro	Thr	Trp	Ser	Thr	Pro
		355					360					365			
Val	Gln	Pro	Met	Ala	Leu	Ile	Val	Leu	Gly	Gly	Val	Ala	Gly	Leu	Leu
	370					375					380				
Leu	Phe	Ile	Gly	Leu	Gly	Ile	Phe	Phe	Cys	Val	Arg	Cys	Arg	His	Arg
385					390					395					400
Arg	Arg	Gln	Ala	Glu	Arg	Met	Ser	Gln	Ile	Lys	Arg	Leu	Leu	Ser	Glu
			405						410					415	
Lys	Lys	Thr	Cys	Gln	Cys	Pro	His	Arg	Phe	Gln	Lys	Thr	Cys	Ser	Pro
			420					425					430		

Ile

<210> 406
 <211> 214
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD8A(CD8-alpha)

<400> 406

Ser	Gln	Phe	Arg	Val	Ser	Pro	Leu	Asp	Arg	Thr	Trp	Asn	Leu	Gly	Glu
1				5				10						15	
Thr	Val	Glu	Leu	Lys	Cys	Gln	Val	Leu	Ser	Asn	Pro	Thr	Ser	Gly	
			20					25				30			
Cys	Ser	Trp	Leu	Phe	Gln	Pro	Arg	Gly	Ala	Ala	Ala	Ser	Pro	Thr	Phe
		35					40					45			
Leu	Leu	Tyr	Leu	Ser	Gln	Asn	Lys	Pro	Lys	Ala	Ala	Glu	Gly	Leu	Asp
	50					55					60				
Thr	Gln	Arg	Phe	Ser	Gly	Lys	Arg	Leu	Gly	Asp	Thr	Phe	Val	Leu	Thr
65					70					75					80

761612000240SeqList

Leu	Ser	Asp	Phe	Arg	Arg	Glu	Asn	Glu	Gly	Tyr	Tyr	Phe	Cys	Ser	Ala
				85					90					95	
Leu	Ser	Asn	Ser	Ile	Met	Tyr	Phe	Ser	His	Phe	Val	Pro	Val	Phe	Leu
			100					105					110		
Pro	Ala	Lys	Pro	Thr	Thr	Thr	Pro	Ala	Pro	Arg	Pro	Pro	Thr	Pro	Ala
		115					120					125			
Pro	Thr	Ile	Ala	Ser	Gln	Pro	Leu	Ser	Leu	Arg	Pro	Glu	Ala	Cys	Arg
	130					135					140				
Pro	Ala	Ala	Gly	Gly	Ala	Val	His	Thr	Arg	Gly	Leu	Asp	Phe	Ala	Cys
145					150					155					160
Asp	Ile	Tyr	Ile	Trp	Ala	Pro	Leu	Ala	Gly	Thr	Cys	Gly	Val	Leu	Leu
			165						170					175	
Leu	Ser	Leu	Val	Ile	Thr	Leu	Tyr	Cys	Asn	His	Arg	Asn	Arg	Arg	Arg
			180					185					190		
Val	Cys	Lys	Cys	Pro	Arg	Pro	Val	Val	Lys	Ser	Gly	Asp	Lys	Pro	Ser
		195					200					205			
Leu	Ser	Ala	Arg	Tyr	Val										
															210

<210> 407
 <211> 189
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD8B(CD8-beta)

<400> 407

Leu	Gln	Gln	Thr	Pro	Ala	Tyr	Ile	Lys	Val	Gln	Thr	Asn	Lys	Met	Val
1				5					10					15	
Met	Leu	Ser	Cys	Glu	Ala	Lys	Ile	Ser	Leu	Ser	Asn	Met	Arg	Ile	Tyr
			20					25					30		
Trp	Leu	Arg	Gln	Arg	Gln	Ala	Pro	Ser	Ser	Asp	Ser	His	His	Glu	Phe
		35					40					45			
Leu	Ala	Leu	Trp	Asp	Ser	Ala	Lys	Gly	Thr	Ile	His	Gly	Glu	Glu	Val
	50					55					60				
Glu	Gln	Glu	Lys	Ile	Ala	Val	Phe	Arg	Asp	Ala	Ser	Arg	Phe	Ile	Leu
65				70					75						80
Asn	Leu	Thr	Ser	Val	Lys	Pro	Glu	Asp	Ser	Gly	Ile	Tyr	Phe	Cys	Met
			85					90						95	
Ile	Val	Gly	Ser	Pro	Glu	Leu	Thr	Phe	Gly	Lys	Gly	Thr	Gln	Leu	Ser
			100					105					110		
Val	Val	Asp	Phe	Leu	Pro	Thr	Thr	Ala	Gln	Pro	Thr	Lys	Lys	Ser	Thr
		115				120						125			
Leu	Lys	Lys	Arg	Val	Cys	Arg	Leu	Pro	Arg	Pro	Glu	Thr	Gln	Lys	Gly
	130					135					140				
Pro	Leu	Cys	Ser	Pro	Ile	Thr	Leu	Gly	Leu	Leu	Val	Ala	Gly	Val	Leu
145					150					155					160
Val	Leu	Leu	Val	Ser	Leu	Gly	Val	Ala	Ile	His	Leu	Cys	Cys	Arg	Arg
			165					170						175	
Arg	Arg	Ala	Arg	Leu	Arg	Phe	Met	Lys	Gln	Phe	Tyr	Lys			
			180					185							

<210> 408
 <211> 497
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature LAG3

<400> 408

Val	Pro	Val	Val	Trp	Ala	Gln	Glu	Gly	Ala	Pro	Ala	Gln	Leu	Pro	Cys
1				5					10					15	

761612000240SeqList

Ser	Pro	Thr	Ile	Pro	Leu	Gln	Asp	Leu	Ser	Leu	Leu	Arg	Arg	Ala	Gly
			20					25					30		
Val	Thr	Trp	Gln	His	Gln	Pro	Asp	Ser	Gly	Pro	Pro	Ala	Ala	Ala	Pro
		35					40					45			
Gly	His	Pro	Leu	Ala	Pro	Gly	Pro	His	Pro	Ala	Ala	Pro	Ser	Ser	Trp
	50					55					60				
Gly	Pro	Arg	Pro	Arg	Arg	Tyr	Thr	Val	Leu	Ser	Val	Gly	Pro	Gly	Gly
65					70					75				80	
Leu	Arg	Ser	Gly	Arg	Leu	Pro	Leu	Gln	Pro	Arg	Val	Gln	Leu	Asp	Glu
				85					90					95	
Arg	Gly	Arg	Gln	Arg	Gly	Asp	Phe	Ser	Leu	Trp	Leu	Arg	Pro	Ala	Arg
			100					105					110		
Arg	Ala	Asp	Ala	Gly	Glu	Tyr	Arg	Ala	Ala	Val	His	Leu	Arg	Asp	Arg
		115					120					125			
Ala	Leu	Ser	Cys	Arg	Leu	Arg	Leu	Arg	Leu	Gly	Gln	Ala	Ser	Met	Thr
	130					135					140				
Ala	Ser	Pro	Pro	Gly	Ser	Leu	Arg	Ala	Ser	Asp	Trp	Val	Ile	Leu	Asn
145					150					155					160
Cys	Ser	Phe	Ser	Arg	Pro	Asp	Arg	Pro	Ala	Ser	Val	His	Trp	Phe	Arg
				165					170					175	
Asn	Arg	Gly	Gln	Gly	Arg	Val	Pro	Val	Arg	Glu	Ser	Pro	His	His	His
			180					185					190		
Leu	Ala	Glu	Ser	Phe	Leu	Phe	Leu	Pro	Gln	Val	Ser	Pro	Met	Asp	Ser
		195				200						205			
Gly	Pro	Trp	Gly	Cys	Ile	Leu	Thr	Tyr	Arg	Asp	Gly	Phe	Asn	Val	Ser
	210					215					220				
Ile	Met	Tyr	Asn	Leu	Thr	Val	Leu	Gly	Leu	Glu	Pro	Pro	Thr	Pro	Leu
225					230					235					240
Thr	Val	Tyr	Ala	Gly	Ala	Gly	Ser	Arg	Val	Gly	Leu	Pro	Cys	Arg	Leu
				245					250					255	
Pro	Ala	Gly	Val	Gly	Thr	Arg	Ser	Phe	Leu	Thr	Ala	Lys	Trp	Thr	Pro
			260					265					270		
Pro	Gly	Gly	Gly	Pro	Asp	Leu	Leu	Val	Thr	Gly	Asp	Asn	Gly	Asp	Phe
		275				280						285			
Thr	Leu	Arg	Leu	Glu	Asp	Val	Ser	Gln	Ala	Gln	Ala	Gly	Thr	Tyr	Thr
	290					295					300				
Cys	His	Ile	His	Leu	Gln	Glu	Gln	Gln	Leu	Asn	Ala	Thr	Val	Thr	Leu
305					310					315					320
Ala	Ile	Ile	Thr	Val	Thr	Pro	Lys	Ser	Phe	Gly	Ser	Pro	Gly	Ser	Leu
				325					330					335	
Gly	Lys	Leu	Leu	Cys	Glu	Val	Thr	Pro	Val	Ser	Gly	Gln	Glu	Arg	Phe
			340					345					350		
Val	Trp	Ser	Ser	Leu	Asp	Thr	Pro	Ser	Gln	Arg	Ser	Phe	Ser	Gly	Pro
		355					360					365			
Trp	Leu	Glu	Ala	Gln	Glu	Ala	Gln	Leu	Leu	Ser	Gln	Pro	Trp	Gln	Cys
	370					375					380				
Gln	Leu	Tyr	Gln	Gly	Glu	Arg	Leu	Leu	Gly	Ala	Ala	Val	Tyr	Phe	Thr
385					390					395					400
Glu	Leu	Ser	Ser	Pro	Gly	Ala	Gln	Arg	Ser	Gly	Arg	Ala	Pro	Gly	Ala
				405					410					415	
Leu	Pro	Ala	Gly	His	Leu	Leu	Leu	Phe	Leu	Ile	Leu	Gly	Val	Leu	Ser
			420					425					430		
Leu	Leu	Leu	Leu	Val	Thr	Gly	Ala	Phe	Gly	Phe	His	Leu	Trp	Arg	Arg
		435					440					445			
Gln	Trp	Arg	Pro	Arg	Arg	Phe	Ser	Ala	Leu	Glu	Gln	Gly	Ile	His	Pro
	450					455					460				
Pro	Gln	Ala	Gln	Ser	Lys	Ile	Glu	Glu	Leu	Glu	Gln	Glu	Pro	Glu	Pro
465					470					475					480
Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Pro	Glu	Gln
				485					490					495	
Leu															

<210> 409
 <211> 280
 <212> PRT
 <213> Homo sapiens

761612000240SeqList

<220>
 <221> MISC_FEATURE
 <223> Mature HAVCR2(TIM-3)

<400> 409
 Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr Leu Pro
 1 5 10 15
 Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp
 20 25 30
 Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val Leu Arg
 35 40 45
 Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp Leu Asn
 50 55 60
 Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn Val Thr
 65 70 75 80
 Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro Gly Ile
 85 90 95
 Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys Pro Ala Lys
 100 105 110
 Val Thr Pro Ala Pro Thr Arg Gln Arg Asp Phe Thr Ala Ala Phe Pro
 115 120 125
 Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala Glu Thr Gln Thr Leu
 130 135 140
 Gly Ser Leu Pro Asp Ile Asn Leu Thr Gln Ile Ser Thr Leu Ala Asn
 145 150 155 160
 Glu Leu Arg Asp Ser Arg Leu Ala Asn Asp Leu Arg Asp Ser Gly Ala
 165 170 175
 Thr Ile Arg Ile Gly Ile Tyr Ile Gly Ala Gly Ile Cys Ala Gly Leu
 180 185 190
 Ala Leu Ala Leu Ile Phe Gly Ala Leu Ile Phe Lys Trp Tyr Ser His
 195 200 205
 Ser Lys Glu Lys Ile Gln Asn Leu Ser Leu Ile Ser Leu Ala Asn Leu
 210 215 220
 Pro Pro Ser Gly Leu Ala Asn Ala Val Ala Glu Gly Ile Arg Ser Glu
 225 230 235 240
 Glu Asn Ile Tyr Thr Ile Glu Glu Asn Val Tyr Glu Val Glu Glu Pro
 245 250 255
 Asn Glu Tyr Tyr Cys Tyr Val Ser Ser Arg Gln Gln Pro Ser Gln Pro
 260 265 270
 Leu Gly Cys Arg Phe Ala Met Pro
 275 280

<210> 410
 <211> 492
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CEACAM1

<400> 410
 Gln Leu Thr Thr Glu Ser Met Pro Phe Asn Val Ala Glu Gly Lys Glu
 1 5 10 15
 Val Leu Leu Leu Val His Asn Leu Pro Gln Gln Leu Phe Gly Tyr Ser
 20 25 30
 Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Val Gly Tyr
 35 40 45
 Ala Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Asn Ser Gly Arg
 50 55 60
 Glu Thr Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Val Thr Gln
 65 70 75 80
 Asn Asp Thr Gly Phe Tyr Thr Leu Gln Val Ile Lys Ser Asp Leu Val
 85 90 95
 Asn Glu Glu Ala Thr Gly Gln Phe His Val Tyr Pro Glu Leu Pro Lys
 100 105 110

761612000240SeqList

Pro	Ser	Ile	Ser	Ser	Asn	Asn	Ser	Asn	Pro	Val	Glu	Asp	Lys	Asp	Ala
		115					120					125			
Val	Ala	Phe	Thr	Cys	Glu	Pro	Glu	Thr	Gln	Asp	Thr	Thr	Tyr	Leu	Trp
	130					135					140				
Trp	Ile	Asn	Asn	Gln	Ser	Leu	Pro	Val	Ser	Pro	Arg	Leu	Gln	Leu	Ser
145					150					155					160
Asn	Gly	Asn	Arg	Thr	Leu	Thr	Leu	Leu	Ser	Val	Thr	Arg	Asn	Asp	Thr
				165					170					175	
Gly	Pro	Tyr	Glu	Cys	Glu	Ile	Gln	Asn	Pro	Val	Ser	Ala	Asn	Arg	Ser
			180					185					190		
Asp	Pro	Val	Thr	Leu	Asn	Val	Thr	Tyr	Gly	Pro	Asp	Thr	Pro	Thr	Ile
		195					200					205			
Ser	Pro	Ser	Asp	Thr	Tyr	Tyr	Arg	Pro	Gly	Ala	Asn	Leu	Ser	Leu	Ser
	210					215					220				
Cys	Tyr	Ala	Ala	Ser	Asn	Pro	Pro	Ala	Gln	Tyr	Ser	Trp	Leu	Ile	Asn
225					230					235					240
Gly	Thr	Phe	Gln	Gln	Ser	Thr	Gln	Glu	Leu	Phe	Ile	Pro	Asn	Ile	Thr
			245						250					255	
Val	Asn	Asn	Ser	Gly	Ser	Tyr	Thr	Cys	His	Ala	Asn	Asn	Ser	Val	Thr
			260					265					270		
Gly	Cys	Asn	Arg	Thr	Thr	Val	Lys	Thr	Ile	Ile	Val	Thr	Glu	Leu	Ser
		275					280					285			
Pro	Val	Val	Ala	Lys	Pro	Gln	Ile	Lys	Ala	Ser	Lys	Thr	Thr	Val	Thr
	290					295					300				
Gly	Asp	Lys	Asp	Ser	Val	Asn	Leu	Thr	Cys	Ser	Thr	Asn	Asp	Thr	Gly
305					310					315					320
Ile	Ser	Ile	Arg	Trp	Phe	Phe	Lys	Asn	Gln	Ser	Leu	Pro	Ser	Ser	Glu
			325						330					335	
Arg	Met	Lys	Leu	Ser	Gln	Gly	Asn	Thr	Thr	Leu	Ser	Ile	Asn	Pro	Val
			340					345					350		
Lys	Arg	Glu	Asp	Ala	Gly	Thr	Tyr	Trp	Cys	Glu	Val	Phe	Asn	Pro	Ile
		355					360					365			
Ser	Lys	Asn	Gln	Ser	Asp	Pro	Ile	Met	Leu	Asn	Val	Asn	Tyr	Asn	Ala
	370					375					380				
Leu	Pro	Gln	Glu	Asn	Gly	Leu	Ser	Pro	Gly	Ala	Ile	Ala	Gly	Ile	Val
385					390					395					400
Ile	Gly	Val	Val	Ala	Leu	Val	Ala	Leu	Ile	Ala	Val	Ala	Leu	Ala	Cys
			405						410					415	
Phe	Leu	His	Phe	Gly	Lys	Thr	Gly	Arg	Ala	Ser	Asp	Gln	Arg	Asp	Leu
			420					425					430		
Thr	Glu	His	Lys	Pro	Ser	Val	Ser	Asn	His	Thr	Gln	Asp	His	Ser	Asn
		435					440					445			
Asp	Pro	Pro	Asn	Lys	Met	Asn	Glu	Val	Thr	Tyr	Ser	Thr	Leu	Asn	Phe
	450					455					460				
Glu	Ala	Gln	Gln	Pro	Thr	Gln	Pro	Thr	Ser	Ala	Ser	Pro	Ser	Leu	Thr
465					470					475					480
Ala	Thr	Glu	Ile	Ile	Tyr	Ser	Glu	Val	Lys	Lys	Gln				
			485						490						

<210> 411
 <211> 222
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature TIGIT

<400> 411

Met	Thr	Gly	Thr	Ile	Glu	Thr	Thr	Gly	Asn	Ile	Ser	Ala	Glu	Lys	Gly
1				5				10					15		
Gly	Ser	Ile	Ile	Leu	Gln	Cys	His	Leu	Ser	Ser	Thr	Thr	Ala	Gln	Val
			20					25					30		
Thr	Gln	Val	Asn	Trp	Glu	Gln	Gln	Asp	Gln	Leu	Leu	Ala	Ile	Cys	Asn
		35				40						45			
Ala	Asp	Leu	Gly	Trp	His	Ile	Ser	Pro	Ser	Phe	Lys	Asp	Arg	Val	Ala
50					55						60				

761612000240SeqList

Pro	Gly	Pro	Gly	Leu	Gly	Leu	Thr	Leu	Gln	Ser	Leu	Thr	Val	Asn	Asp
65					70				75					80	
Thr	Gly	Glu	Tyr	Phe	Cys	Ile	Tyr	His	Thr	Tyr	Pro	Asp	Gly	Thr	Tyr
				85					90					95	
Thr	Gly	Arg	Ile	Phe	Leu	Glu	Val	Leu	Glu	Ser	Ser	Val	Ala	Glu	His
			100					105					110		
Gly	Ala	Arg	Phe	Gln	Ile	Pro	Leu	Leu	Gly	Ala	Met	Ala	Ala	Thr	Leu
		115					120					125			
Val	Val	Ile	Cys	Thr	Ala	Val	Ile	Val	Val	Val	Ala	Leu	Thr	Arg	Lys
	130					135					140				
Lys	Lys	Ala	Leu	Arg	Ile	His	Ser	Val	Glu	Gly	Asp	Leu	Arg	Arg	Lys
145					150					155					160
Ser	Ala	Gly	Gln	Glu	Glu	Trp	Ser	Pro	Ser	Ala	Pro	Ser	Pro	Pro	Gly
				165					170					175	
Ser	Cys	Val	Gln	Ala	Glu	Ala	Ala	Pro	Ala	Gly	Leu	Cys	Gly	Glu	Gln
			180					185					190		
Arg	Gly	Glu	Asp	Cys	Ala	Glu	Leu	His	Asp	Tyr	Phe	Asn	Val	Leu	Ser
		195					200					205			
Tyr	Arg	Ser	Leu	Gly	Asn	Cys	Ser	Phe	Phe	Thr	Glu	Thr	Gly		
	210					215					220				

<210> 412
 <211> 397
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature PVR(CD155)

<400> 412

Trp	Pro	Pro	Pro	Gly	Thr	Gly	Asp	Val	Val	Val	Gln	Ala	Pro	Thr	Gln
1				5					10					15	
Val	Pro	Gly	Phe	Leu	Gly	Asp	Ser	Val	Thr	Leu	Pro	Cys	Tyr	Leu	Gln
			20					25					30		
Val	Pro	Asn	Met	Glu	Val	Thr	His	Val	Ser	Gln	Leu	Thr	Trp	Ala	Arg
		35					40					45			
His	Gly	Glu	Ser	Gly	Ser	Met	Ala	Val	Phe	His	Gln	Thr	Gln	Gly	Pro
	50					55					60				
Ser	Tyr	Ser	Glu	Ser	Lys	Arg	Leu	Glu	Phe	Val	Ala	Ala	Arg	Leu	Gly
65					70				75					80	
Ala	Glu	Leu	Arg	Asn	Ala	Ser	Leu	Arg	Met	Phe	Gly	Leu	Arg	Val	Glu
				85					90					95	
Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Leu	Phe	Val	Thr	Phe	Pro	Gln	Gly	Ser
			100					105					110		
Arg	Ser	Val	Asp	Ile	Trp	Leu	Arg	Val	Leu	Ala	Lys	Pro	Gln	Asn	Thr
		115					120					125			
Ala	Glu	Val	Gln	Lys	Val	Gln	Leu	Thr	Gly	Glu	Pro	Val	Pro	Met	Ala
	130					135					140				
Arg	Cys	Val	Ser	Thr	Gly	Gly	Arg	Pro	Pro	Ala	Gln	Ile	Thr	Trp	His
145					150					155					160
Ser	Asp	Leu	Gly	Gly	Met	Pro	Asn	Thr	Ser	Gln	Val	Pro	Gly	Phe	Leu
				165					170					175	
Ser	Gly	Thr	Val	Thr	Val	Thr	Ser	Leu	Trp	Ile	Leu	Val	Pro	Ser	Ser
			180					185					190		
Gln	Val	Asp	Gly	Lys	Asn	Val	Thr	Cys	Lys	Val	Glu	His	Glu	Ser	Phe
		195					200					205			
Glu	Lys	Pro	Gln	Leu	Leu	Thr	Val	Asn	Leu	Thr	Val	Tyr	Tyr	Pro	Pro
	210					215					220				
Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asn	Asn	Trp	Tyr	Leu	Gly	Gln	Asn
225					230					235					240
Glu	Ala	Thr	Leu	Thr	Cys	Asp	Ala	Arg	Ser	Asn	Pro	Glu	Pro	Thr	Gly
				245					250					255	
Tyr	Asn	Trp	Ser	Thr	Thr	Met	Gly	Pro	Leu	Pro	Pro	Phe	Ala	Val	Ala
			260					265					270		
Gln	Gly	Ala	Gln	Leu	Leu	Ile	Arg	Pro	Val	Asp	Lys	Pro	Ile	Asn	Thr
		275					280					285			

761612000240SeqList

Thr	Leu	Ile	Cys	Asn	Val	Thr	Asn	Ala	Leu	Gly	Ala	Arg	Gln	Ala	Glu
290						295					300				
Leu	Thr	Val	Gln	Val	Lys	Glu	Gly	Pro	Pro	Ser	Glu	His	Ser	Gly	Ile
305					310					315					320
Ser	Arg	Asn	Ala	Ile	Ile	Phe	Leu	Val	Leu	Gly	Ile	Leu	Val	Phe	Leu
				325					330					335	
Ile	Leu	Leu	Gly	Ile	Gly	Ile	Tyr	Phe	Tyr	Trp	Ser	Lys	Cys	Ser	Arg
			340					345					350		
Glu	Val	Leu	Trp	His	Cys	His	Leu	Cys	Pro	Ser	Ser	Thr	Glu	His	Ala
		355					360					365			
Ser	Ala	Ser	Ala	Asn	Gly	His	Val	Ser	Tyr	Ser	Ala	Val	Ser	Arg	Glu
	370					375					380				
Asn	Ser	Ser	Ser	Gln	Asp	Pro	Gln	Thr	Glu	Gly	Thr	Arg			
385					390					395					

<210> 413
 <211> 507
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature PVRL2(CD112)

<400> 413

Gln	Asp	Val	Arg	Val	Gln	Val	Leu	Pro	Glu	Val	Arg	Gly	Gln	Leu	Gly
1				5					10					15	
Gly	Thr	Val	Glu	Leu	Pro	Cys	His	Leu	Leu	Pro	Pro	Val	Pro	Gly	Leu
		20						25					30		
Tyr	Ile	Ser	Leu	Val	Thr	Trp	Gln	Arg	Pro	Asp	Ala	Pro	Ala	Asn	His
		35					40					45			
Gln	Asn	Val	Ala	Ala	Phe	His	Pro	Lys	Met	Gly	Pro	Ser	Phe	Pro	Ser
	50				55					60					
Pro	Lys	Pro	Gly	Ser	Glu	Arg	Leu	Ser	Phe	Val	Ser	Ala	Lys	Gln	Ser
65					70				75						80
Thr	Gly	Gln	Asp	Thr	Glu	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Leu	Ala	Leu
			85					90					95		
His	Gly	Leu	Thr	Val	Glu	Asp	Glu	Gly	Asn	Tyr	Thr	Cys	Glu	Phe	Ala
		100					105					110			
Thr	Phe	Pro	Lys	Gly	Ser	Val	Arg	Gly	Met	Thr	Trp	Leu	Arg	Val	Ile
		115					120				125				
Ala	Lys	Pro	Lys	Asn	Gln	Ala	Glu	Ala	Gln	Lys	Val	Thr	Phe	Ser	Gln
	130				135						140				
Asp	Pro	Thr	Thr	Val	Ala	Leu	Cys	Ile	Ser	Lys	Glu	Gly	Arg	Pro	Pro
145					150				155						160
Ala	Arg	Ile	Ser	Trp	Leu	Ser	Ser	Leu	Asp	Trp	Glu	Ala	Lys	Glu	Thr
			165						170					175	
Gln	Val	Ser	Gly	Thr	Leu	Ala	Gly	Thr	Val	Thr	Val	Thr	Ser	Arg	Phe
		180					185						190		
Thr	Leu	Val	Pro	Ser	Gly	Arg	Ala	Asp	Gly	Val	Thr	Val	Thr	Cys	Lys
		195					200					205			
Val	Glu	His	Glu	Ser	Phe	Glu	Glu	Pro	Ala	Leu	Ile	Pro	Val	Thr	Leu
	210				215						220				
Ser	Val	Arg	Tyr	Pro	Pro	Glu	Val	Ser	Ile	Ser	Gly	Tyr	Asp	Asp	Asn
225					230					235					240
Trp	Tyr	Leu	Gly	Arg	Thr	Asp	Ala	Thr	Leu	Ser	Cys	Asp	Val	Arg	Ser
			245						250					255	
Asn	Pro	Glu	Pro	Thr	Gly	Tyr	Asp	Trp	Ser	Thr	Thr	Ser	Gly	Thr	Phe
		260					265						270		
Pro	Thr	Ser	Ala	Val	Ala	Gln	Gly	Ser	Gln	Leu	Val	Ile	His	Ala	Val
		275					280					285			
Asp	Ser	Leu	Phe	Asn	Thr	Thr	Phe	Val	Cys	Thr	Val	Thr	Asn	Ala	Val
	290				295						300				
Gly	Met	Gly	Arg	Ala	Glu	Gln	Val	Ile	Phe	Val	Arg	Glu	Thr	Pro	Asn
305					310					315					320
Thr	Ala	Gly	Ala	Gly	Ala	Thr	Gly	Gly	Ile	Ile	Gly	Gly	Ile	Ile	Ala
				325					330					335	

761612000240SeqList

Ala	Ile	Ile	Ala	Thr	Ala	Val	Ala	Ala	Thr	Gly	Ile	Leu	Ile	Cys	Arg
			340					345					350		
Gln	Gln	Arg	Lys	Glu	Gln	Thr	Leu	Gln	Gly	Ala	Glu	Glu	Asp	Glu	Asp
		355					360					365			
Leu	Glu	Gly	Pro	Pro	Ser	Tyr	Lys	Pro	Pro	Thr	Pro	Lys	Ala	Lys	Leu
	370					375					380				
Glu	Ala	Gln	Glu	Met	Pro	Ser	Gln	Leu	Phe	Thr	Leu	Gly	Ala	Ser	Glu
	385				390					395					400
His	Ser	Pro	Leu	Lys	Thr	Pro	Tyr	Phe	Asp	Ala	Gly	Ala	Ser	Cys	Thr
				405					410					415	
Glu	Gln	Glu	Met	Pro	Arg	Tyr	His	Glu	Leu	Pro	Thr	Leu	Glu	Glu	Arg
			420					425					430		
Ser	Gly	Pro	Leu	His	Pro	Gly	Ala	Thr	Ser	Leu	Gly	Ser	Pro	Ile	Pro
		435					440					445			
Val	Pro	Pro	Gly	Pro	Pro	Ala	Val	Glu	Asp	Val	Ser	Leu	Asp	Leu	Glu
	450					455				460					
Asp	Glu	Glu	Gly	Glu	Glu	Glu	Glu	Glu	Tyr	Leu	Asp	Lys	Ile	Asn	Pro
	465				470					475					480
Ile	Tyr	Asp	Ala	Leu	Ser	Tyr	Ser	Ser	Pro	Ser	Asp	Ser	Tyr	Gln	Gly
				485					490					495	
Lys	Gly	Phe	Val	Met	Ser	Arg	Ala	Met	Tyr	Val					
			500					505							

<210> 414
 <211> 318
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD226

<400> 414

Glu	Glu	Val	Leu	Trp	His	Thr	Ser	Val	Pro	Phe	Ala	Glu	Asn	Met	Ser
1			5					10						15	
Leu	Glu	Cys	Val	Tyr	Pro	Ser	Met	Gly	Ile	Leu	Thr	Gln	Val	Glu	Trp
			20					25					30		
Phe	Lys	Ile	Gly	Thr	Gln	Gln	Asp	Ser	Ile	Ala	Ile	Phe	Ser	Pro	Thr
		35					40					45			
His	Gly	Met	Val	Ile	Arg	Lys	Pro	Tyr	Ala	Glu	Arg	Val	Tyr	Phe	Leu
	50					55					60				
Asn	Ser	Thr	Met	Ala	Ser	Asn	Asn	Met	Thr	Leu	Phe	Phe	Arg	Asn	Ala
	65				70					75				80	
Ser	Glu	Asp	Asp	Val	Gly	Tyr	Tyr	Ser	Cys	Ser	Leu	Tyr	Thr	Tyr	Pro
			85					90						95	
Gln	Gly	Thr	Trp	Gln	Lys	Val	Ile	Gln	Val	Val	Gln	Ser	Asp	Ser	Phe
			100					105					110		
Glu	Ala	Ala	Val	Pro	Ser	Asn	Ser	His	Ile	Val	Ser	Glu	Pro	Gly	Lys
		115					120					125			
Asn	Val	Thr	Leu	Thr	Cys	Gln	Pro	Gln	Met	Thr	Trp	Pro	Val	Gln	Ala
	130					135					140				
Val	Arg	Trp	Glu	Lys	Ile	Gln	Pro	Arg	Gln	Ile	Asp	Leu	Leu	Thr	Tyr
	145				150					155					160
Cys	Asn	Leu	Val	His	Gly	Arg	Asn	Phe	Thr	Ser	Lys	Phe	Pro	Arg	Gln
				165					170					175	
Ile	Val	Ser	Asn	Cys	Ser	His	Gly	Arg	Trp	Ser	Val	Ile	Val	Ile	Pro
			180					185					190		
Asp	Val	Thr	Val	Ser	Asp	Ser	Gly	Leu	Tyr	Arg	Cys	Tyr	Leu	Gln	Ala
		195					200					205			
Ser	Ala	Gly	Glu	Asn	Glu	Thr	Phe	Val	Met	Arg	Leu	Thr	Val	Ala	Glu
	210					215					220				
Gly	Lys	Thr	Asp	Asn	Gln	Tyr	Thr	Leu	Phe	Val	Ala	Gly	Gly	Thr	Val
	225				230					235					240
Leu	Leu	Leu	Leu	Phe	Val	Ile	Ser	Ile	Thr	Thr	Ile	Ile	Val	Ile	Phe
				245					250					255	
Leu	Asn	Arg	Arg	Arg	Arg	Arg	Glu	Arg	Asp	Leu	Phe	Thr	Glu	Ser	
			260					265					270		

761612000240SeqList
 Trp Asp Thr Gln Lys Ala Pro Asn Asn Tyr Arg Ser Pro Ile Ser Thr
 275 280 285
 Ser Gln Pro Thr Asn Gln Ser Met Asp Asp Thr Arg Glu Asp Ile Tyr
 290 295 300
 Val Asn Tyr Pro Thr Phe Ser Arg Arg Pro Lys Thr Arg Val
 305 310 315

<210> 415
 <211> 327
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD2

<400> 415
 Lys Glu Ile Thr Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp
 1 5 10 15
 Ile Asn Leu Asp Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp
 20 25 30
 Ile Lys Trp Glu Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg
 35 40 45
 Lys Glu Lys Glu Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys
 50 55 60
 Asn Gly Thr Leu Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile
 65 70 75 80
 Tyr Lys Val Ser Ile Tyr Asp Thr Lys Gly Lys Asn Val Leu Glu Lys
 85 90 95
 Ile Phe Asp Leu Lys Ile Gln Glu Arg Val Ser Lys Pro Lys Ile Ser
 100 105 110
 Trp Thr Cys Ile Asn Thr Thr Leu Thr Cys Glu Val Met Asn Gly Thr
 115 120 125
 Asp Pro Glu Leu Asn Leu Tyr Gln Asp Gly Lys His Leu Lys Leu Ser
 130 135 140
 Gln Arg Val Ile Thr His Lys Trp Thr Thr Ser Leu Ser Ala Lys Phe
 145 150 155 160
 Lys Cys Thr Ala Gly Asn Lys Val Ser Lys Glu Ser Ser Val Glu Pro
 165 170 175
 Val Ser Cys Pro Glu Lys Gly Leu Asp Ile Tyr Leu Ile Ile Gly Ile
 180 185 190
 Cys Gly Gly Gly Ser Leu Leu Met Val Phe Val Ala Leu Leu Val Phe
 195 200 205
 Tyr Ile Thr Lys Arg Lys Lys Gln Arg Ser Arg Arg Asn Asp Glu Glu
 210 215 220
 Leu Glu Thr Arg Ala His Arg Val Ala Thr Glu Glu Arg Gly Arg Lys
 225 230 235 240
 Pro His Gln Ile Pro Ala Ser Thr Pro Gln Asn Pro Ala Thr Ser Gln
 245 250 255
 His Pro Pro Pro Pro Pro Gly His Arg Ser Gln Ala Pro Ser His Arg
 260 265 270
 Pro Pro Pro Pro Gly His Arg Val Gln His Gln Pro Gln Lys Arg Pro
 275 280 285
 Pro Ala Pro Ser Gly Thr Gln Val His Gln Gln Lys Gly Pro Pro Leu
 290 295 300
 Pro Arg Pro Arg Val Gln Pro Lys Pro Pro His Gly Ala Ala Glu Asn
 305 310 315 320
 Ser Leu Ser Pro Ser Ser Asn
 325

<210> 416
 <211> 154
 <212> PRT
 <213> Homo sapiens

<220>

761612000240SeqList

<221> MISC_FEATURE

<223> Mature CD160

<400> 416

```

Ile Asn Ile Thr Ser Ser Ala Ser Gln Glu Gly Thr Arg Leu Asn Leu
1      5      10      15
Ile Cys Thr Val Trp His Lys Lys Glu Ala Glu Gly Phe Val Val
20      25      30
Phe Leu Cys Lys Asp Arg Ser Gly Asp Cys Ser Pro Glu Thr Ser Leu
35      40      45
Lys Gln Leu Arg Leu Lys Arg Asp Pro Gly Ile Asp Gly Val Gly Glu
50      55      60
Ile Ser Ser Gln Leu Met Phe Thr Ile Ser Gln Val Thr Pro Leu His
65      70      75      80
Ser Gly Thr Tyr Gln Cys Cys Ala Arg Ser Gln Lys Ser Gly Ile Arg
85      90      95
Leu Gln Gly His Phe Phe Ser Ile Leu Phe Thr Glu Thr Gly Asn Tyr
100      105      110
Thr Val Thr Gly Leu Lys Gln Arg Gln His Leu Glu Phe Ser His Asn
115      120      125
Glu Gly Thr Leu Ser Ser Gly Phe Leu Gln Glu Lys Val Trp Val Met
130      135      140
Leu Val Thr Ser Leu Val Ala Leu Gln Ala
145      150

```

<210> 417

<211> 248

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Mature CD200

<400> 417

```

Gln Val Gln Val Val Thr Gln Asp Glu Arg Glu Gln Leu Tyr Thr Pro
1      5      10      15
Ala Ser Leu Lys Cys Ser Leu Gln Asn Ala Gln Glu Ala Leu Ile Val
20      25      30
Thr Trp Gln Lys Lys Lys Ala Val Ser Pro Glu Asn Met Val Thr Phe
35      40      45
Ser Glu Asn His Gly Val Val Ile Gln Pro Ala Tyr Lys Asp Lys Ile
50      55      60
Asn Ile Thr Gln Leu Gly Leu Gln Asn Ser Thr Ile Thr Phe Trp Asn
65      70      75      80
Ile Thr Leu Glu Asp Glu Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe
85      90      95
Gly Phe Gly Lys Ile Ser Gly Thr Ala Cys Leu Thr Val Tyr Val Gln
100      105      110
Pro Ile Val Ser Leu His Tyr Lys Phe Ser Glu Asp His Leu Asn Ile
115      120      125
Thr Cys Ser Ala Thr Ala Arg Pro Ala Pro Met Val Phe Trp Lys Val
130      135      140
Pro Arg Ser Gly Ile Glu Asn Ser Thr Val Thr Leu Ser His Pro Asn
145      150      155      160
Gly Thr Thr Ser Val Thr Ser Ile Leu His Ile Lys Asp Pro Lys Asn
165      170      175
Gln Val Gly Lys Glu Val Ile Cys Gln Val Leu His Leu Gly Thr Val
180      185      190
Thr Asp Phe Lys Gln Thr Val Asn Lys Gly Tyr Trp Phe Ser Val Pro
195      200      205
Leu Leu Leu Ser Ile Val Ser Leu Val Ile Leu Leu Val Leu Ile Ser
210      215      220
Ile Leu Leu Tyr Trp Lys Arg His Arg Asn Gln Asp Arg Gly Glu Leu
225      230      235      240
Ser Gln Gly Val Gln Lys Met Thr
245

```

761612000240SeqList

<210> 418
 <211> 297
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature CD200R1(CD200R)

<400> 418
 Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val Leu Ala Glu
 1 5 10 15
 Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala Val Leu Cys
 20 25 30
 Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr Trp Glu Ile
 35 40 45
 Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Arg Lys Glu Thr
 50 55 60
 Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile Thr Trp Val
 65 70 75 80
 Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Pro Val Ala Ile
 85 90 95
 Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro Asp Gly Asn
 100 105 110
 Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro Glu Val Thr
 115 120 125
 Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala Val Ala Gly
 130 135 140
 Lys Pro Ala Ala Gln Ile Ser Trp Ile Pro Glu Gly Asp Cys Ala Thr
 145 150 155 160
 Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys Ser Thr Cys
 165 170 175
 His Trp Glu Val His Asn Val Ser Thr Val Thr Cys His Val Ser His
 180 185 190
 Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro Val Pro Gly
 195 200 205
 Ala Lys Lys Ser Ala Lys Leu Tyr Ile Pro Tyr Ile Ile Leu Thr Ile
 210 215 220
 Ile Ile Leu Thr Ile Val Gly Phe Ile Trp Leu Leu Lys Val Asn Gly
 225 230 235 240
 Cys Arg Lys Tyr Lys Leu Asn Lys Thr Glu Ser Thr Pro Val Val Glu
 245 250 255
 Glu Asp Glu Met Gln Pro Tyr Ala Ser Tyr Thr Glu Lys Asn Asn Pro
 260 265 270
 Leu Tyr Asp Thr Thr Asn Lys Val Lys Ala Ser Glu Ala Leu Gln Ser
 275 280 285
 Glu Val Asp Thr Asp Leu His Thr Leu
 290 295

<210> 419
 <211> 183
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Mature NC R3 (NKp30)

<400> 419
 Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
 1 5 10 15
 Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
 20 25 30
 Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
 35 40 45

761612000240SeqList

Arg	Asn	Gly	Thr	Pro	Glu	Phe	Arg	Gly	Arg	Leu	Ala	Pro	Leu	Ala	Ser
	50					55					60				
Ser	Arg	Phe	Leu	His	Asp	His	Gln	Ala	Glu	Leu	His	Ile	Arg	Asp	Val
65					70					75					80
Arg	Gly	His	Asp	Ala	Ser	Ile	Tyr	Val	Cys	Arg	Val	Glu	Val	Leu	Gly
			85						90					95	
Leu	Gly	Val	Gly	Thr	Gly	Asn	Gly	Thr	Arg	Leu	Val	Val	Glu	Lys	Glu
			100					105					110		
His	Pro	Gln	Leu	Gly	Ala	Gly	Thr	Val	Leu	Leu	Leu	Arg	Ala	Gly	Phe
		115					120					125			
Tyr	Ala	Val	Ser	Phe	Leu	Ser	Val	Ala	Val	Gly	Ser	Thr	Val	Tyr	Tyr
	130					135					140				
Gln	Gly	Lys	Cys	Leu	Thr	Trp	Lys	Gly	Pro	Arg	Arg	Gln	Leu	Pro	Ala
145					150					155					160
Val	Val	Pro	Ala	Pro	Leu	Pro	Pro	Pro	Cys	Gly	Ser	Ser	Ala	His	Leu
				165					170					175	
Leu	Pro	Pro	Val	Pro	Gly	Gly									
			180												